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The Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) variant 
surface antigens, encoded by the var gene family, play a crucial role in malaria 
pathogenesis through mediating immunomodulation and host cell adhesion. Var 
genes can be sub-grouped according to genetic or functional features. This thesis 
examined var gene transcription of conserved groups of var genes in the context of 
clinical malaria disease manifestation in African field isolates.  
  
Analysis of var gene transcription in 26 P. falciparum field isolates from Malian 
children revealed that field isolates from children with cerebral malaria show 
significantly higher transcription of group A var genes than the field isolates from 
children with equally high parasite burdens but no symptoms or signs of severe 
malaria (hyperparasitaemia). These results suggest that group A var genes are 
important determinants of parasite virulence and strengthen the growing body of 
evidence associating group A var expression with severe disease in children.   
  
Analysis of var gene transcription in six P. falciparum placental malaria field 
isolates showed that var2csa was transcribed in all placental malaria field isolates, 
but not in 10 childhood isolates examined. This finding, also reported in other recent 
and subsequent studies, suggests that var2csa expression is a critical factor in the 
onset of clinical malaria disease in pregnant women.  
 
Examination of type 3 var gene transcription in laboratory and field isolates 
established that these var genes were commonly transcribed in blood-stage parasites, 
III 
and sequence analysis of the transcribed domains confirmed a very high level of 
conservation across this var gene sub-family.  
  
Finally, rosetting is a property of some group A PfEMP1 and is associated with 
disease severity in African childhood malaria. Certain glycoconjugate compounds 
can disrupt rosetting, possibly due to the functional similarities of interactions 
between rosetting PfEMP1 and host rosetting ligands. A non-toxic compound 
(curdlan sulfate) was found to be effective at disrupting rosettes in all 18 rosetting 
field isolates examined, showing potential for use in treatment of severe malaria due 
to rosetting P. falciparum isolates.  
  
The findings presented in this thesis expand current knowledge of the role and 
significance of var genes/PfEMP1 in P. falciparum malaria disease pathogenesis. 
The work demonstrates the importance of continued research on var genes/PfEMP1 
in further understanding this complex parasite, and ultimately in combating this 
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1.1 P. falciparum malaria general background
1.1.1 Global burden of P. falciparum malaria
Plasmodia are members of the apicomplexan parasite family of eukaryotic protozoa.
Four Plasmodia infect humans, P. vivax, P. ovale, P. malariae and P. falciparum, the
last of which causes the majority of malaria cases worldwide (Fig. 1.1). Of these at
least 90% occur in sub-Saharan Africa, where there are an estimated 200 million
clinical events and 1-5 million deaths per year, predominantly in children under 5
years of age (Snow et al. 1999; Breman 2001; Snow et al. 2005). Clinical immunity to
malaria disease symptoms in malaria endemic areas is achieved by adulthood, though
an asymptomatic infection can persist throughout life.
Fig.1.1. Global burden of malaria map. P. falciparum endemicity map taken from
Snow et al. (2005). Childhood infection prevalence: light green, <10%; medium
green, 11% to 50%; dark green, >50%; yellow, unclassified; grey areas are outside the
limit of transmission.
3
1.1.2 P. falciparum lifecycle
P. falciparum has a compex lifecycle, dependent on transmission via an invertebrate
host, the anopheles mosquito. An infection starts during a mosquito bite as sporozoite-
stage parasites from the mosquito salivary gland are delivered into the blood. The free
sporozoites travel in the blood circulation until they reach the liver to which they
adhere using surface adhesive proteins circumsporozoite protein (CSP) and
thrombospondin-related adhesive protein (TRAP) (Robson et al. 1995; Pradel et al.
2004). The sporozoites then glide across the liver sinusoidal cells, passing through
Kupffer cells, the macrophages of the liver (Frevert et al. 2005). They traverse several
hepatocyes, before settling within a particular hepatocyte for differentiation and
mitotic replication (Tarun et al. 2006). After approximately 6 days, thousands of new
parasites, merozoites, have been created. These are released into the circulation as the
hepatocyte ruptures (Frevert et al. 2005; Tarun et al. 2006).
The erythrocytic cycle of asexual development (reviewed in(Bannister et al. 2000)
now begins. The free merozoites attach to the surface of an erythrocyte, usually to
separate erythrocytes, though multiply-infected cells are also seen (Deans et al. 2006).
The attached merozoite reorientates so that the apical end can form a tight junction
with the erythrocyte. An actin-myosin motor complex then pulls the merozoite inside
the erythrocyte (Keeley and Soldati 2004).
The merozoite is now contained within the parasitophorous vacuole, which is then
released into the erythrocyte cytoplasm through the proteolytic shedding of surface
proteins by subtilase and transmembrane rhomboid proteases (Harris et al. 2005;
O'Donnell et al. 2006). Invasion processes are complex with a high level of
4
redundancy in the pathways and the exact combination of parasite receptors and host
ligands used varies considerably between different laboratory and field isolates
(Cowman and Crabb 2006; Nery et al. 2006; Cortes et al. 2007; Deans et al. 2007).
Merozoite surface protein 1 (MSP-1) and apical membrane protein 1 (AMA-1) appear
to be essential (O'Donnell et al. 2000; Triglia et al. 2000). Antibodies to MSP-1 and
AMA-1 interfere with invasion, and both proteins are vaccine candidates (Cavanagh
et al. 2004; Malkin et al. 2005; Malkin et al. 2007). Proteins containing Duffy
binding-like (DBL) domains, including EBA-175, EBA-140 and EBA-181, are also
involved, and are linked to the actin-myosin motor via a TRAP homolog (Baum et al.
2006). These bind erythrocyte ligands glycophorin A, glycophorin C and sialic acid
on the erythrocyte (Orlandi et al. 1992; Duraisingh et al. 2003; Maier et al. 2003;
Cowman and Crabb 2006). The interaction between EBA-175 and glycophorin A is
the dominant chymotrypsin-resistant invasion pathway in P. falciparum (Duraisingh
et al. 2003).
The newly internalised parasite adopts a cup-shaped ring-like morphology (Aikawa et
al. 1967), and is thus known as a ring stage trophozoite, commonly referred to simply
as a ring. As the ring stage parasite matures it becomes larger, more rounded and
increasingly complex. The endoplasmic reticulum and Golgi increase in size
reflecting the high level of protein production. Approximately 16 hours post-invasion,
parasite-derived proteins begin to be exported to the erythrocyte surface, often via
Maurer’s clefts, membranous structures in the erythrocyte cytosol (Atkinson et al.
1988; Haeggstrom et al. 2004; Knuepfer et al. 2005). Many proteins destined for the
erythrocyte membrane, including PfEMP1, are deposited in knobs (Baruch et al.
1995; Horrocks et al. 2005). These are protrusions of the erythrocyte surface, several
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thousand of which appear 16-18 hours post invasion, and are structurally maintained
by internal parasite-derived proteins such as knob-associated histidine-rich protein
(Gruenberg et al. 1983; Rug et al. 2006). Once on the erythrocyte membrane, the
surface proteins perform the dual function of adhesion and sequestration of infected
erythrocytes, and antigenic variation for immune evasion. There is also an increase in
the rigidity of the erythrocyte containing the mature trophozoite (Suwanarusk et al.
2004).
Repetitive cycles of nuclear division and parasite multiplication commence in the
trophozoite stage, resulting in the creation of 16-20 new merozoites encased within
the parasitophorous vacuole membrane of the parasite, now referred to as a schizont.
These nonmotile merozoites are disseminated by an explosive rupture of the schizont,
and are released for a new cycle of invasion (Glushakova et al. 2005).
The whole erythrocytic cycle takes approximately 48 hours. This stage is responsible
for the disease pathology of malaria. Repeated cycles of erythrocyte invasion,
intracellular maturation, schizogeny, erythrocyte rupture and merozoite release take
their toll, causing anaemia and inflammatory responses. In addition, the adhesive
properties of infected erythrocytes including sequestration within the body and other
adhesion-mediated phenomena are associated with disease pathogenesis (discussed in
section 1.3).
To complete the life cycle, a proportion of parasites must be taken up into a mosquito,
and for this purpose a small proportion of merozoites differentiate into sexual stage
parasites called gametocytes upon erythrocyte invasion, rather than into further
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asexual trophozoites. Commitment to gametocytogenesis is thought to occur at the
previous invasion cycle as all gametocytes from a particular schizont are male or
female (Smith et al. 2000c). A stressed environment within the host is thought to
trigger gametocytogenesis, which can be stimulated by culturing in partially spent
media after a sudden increase in haematocrit in vitro (Carter et al. 1993; Sharp et al.
2006). These gametocytes can be readily taken up into the mosquito through the blood
meal during feeding. Once inside the mosquito midgut, female gametocytes are
fertilised by male gametocytes after DNA replication and exflagellation, forming a
zygote. Triggers for gametocyte activation include a drop in temperature, or presence
of xanthurenic acid (Muhia et al. 2001). Differentiation of the zygote occurs, resulting
in a motile ookinete, which migrates through the midgut wall to settle on the basal
lamina and form an oocyst. Here extensive replication occurs, producing 2000-8000
haploid nuclei after 12-18 days, which are released as sporozoites into the haemocoel
as the oocyst bursts (Sinden 2002). The sporozoites migrate to the salivary glands of
the mosquito, where they are prepared for invasion the next time the mosquito bites.
The P. falciparum life cycle is summarised in Fig. 1.2.
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Fig. 1.2. Plasmodium falciparum life cycle. Reproduced from Center for Disease
Control & Prevention Division of Parasitic Diseases Parasite Image Library
http://www.dpd.cdc.gov/dpdx/HTML/Image_Library.htm. A human host is inoculated
with sporozoites during an Anopheles mosquito bite (1). The sporozoites reach the
liver (2) where they mature into liver stage schizonts (3). Rupture of this schizont
results in the release of merozoites into the bloodstream (4), completing the exo-
erythrocytic cycle (A). These infect new erythrocytes (5), entering the erythrocytic
cycle (B). Ring stage trophozoite parasites mature to pigmented trophozoites, and
then to schizonts, which rupture (6) releasing merozoites for another round of asexual
propagation. A proportion of the merozoites enter the sexual stage, forming
gametocytes (7) which can be taken up by the mosquito (8). Within the mosquito the
sporogenic cycle (C) occurs. Male gametocytes exflagellate and enter female
gametocytes (9) forming a zygote. The zygote become motile and elongated, now an
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ookinete (10), and invades the midwall gut of the mosquito for maturation into an
oocyst (11). Growth and rupture of the oocyst results in release of sporozoites (12)
which are deposited in the salivary gland of the mosquito.
1.1.3 Antigenic variation
The ability to evade the host immune system is crucial for the survival of the
parasites. Certain parasite-derived proteins must be inserted into the erythrocyte
membrane to enable processes such as sequestration to avoid clearance by the spleen.
This causes parasite-derived proteins to be exposed to the extracellular environment
and thus to be vulnerable to antibody-mediated immunity. To avoid providing
consistent targets for the host immune system, the P. falciparum genome encodes
several large hypervariable polymorphic gene families called the variant surface
antigens (VSA). Each member of a VSA family can be expressed individually and
function independently but can become replaced by a novel VSA variant before a
successful antibody response can be elicited. Cross-reactivity of antibodies between
members of the hypervariable gene families is low to avoid recognition by any
previously induced antibodies within the host, and exposed proteins are under a high
level of divergent evolution (Hughes and Hughes 1995; Bockhorst et al. 2007).
However, certain functional or structural constraints result in a number of shared
epitopes (Joergensen et al. 2006) which eventually allows the host to develop
protective immunity to clinical disease. Expression of these polymorphic gene
families can be simplified as waves of expression of different members of the family
over the course of an infection. Switching occurs before an immune response builds
up, each time keeping one step ahead of the immune system (Fig. 1.3), although in a
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natural infection the dynamics of immune response and VSA expression may become
more complex.
Fig. 1.3. Simplified schematic diagram of the theory of antigenic variation. VSA are
expressed for a limited period and then switched to a new variant prior to a successful
immune response. Waves of different VSA variants are indicated by colour. Different
switching rates result in different duration of expression for the different variants.
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1.2 PfEMP1 and var genes
1.2.1 PfEMP1 repertoire
The most well-studied P. falciparum VSA family involved in antigenic variation is
the polymorphic var gene family which encodes the Plasmodium falciparum
erythrocyte membrane protein 1 family (PfEMP1) (Biggs et al. 1991; Baruch et al.
1995; Smith et al. 1995; Su et al. 1995).  Each parasite has a diverse repertoire of 50-
60 var genes, and a correspondingly diverse array of PfEMP1 molecules (Gardner et
al. 2002; Kraemer et al. 2007). Only one PfEMP1 variant is displayed on the host
erythrocyte surface in a single cell cycle, and this is controlled at the level of var gene
transcription (Smith et al. 1995; Scherf et al. 1998). However, PfEMP1 expression
can be switched at each reinvasion cycle during an infection to avoid host recognition
(Roberts et al. 1992; Chen et al. 1998b; Gatton et al. 2003). The genomic var gene
repertoire of different isolates is thought to be largely non-overlapping, apart from a
small number of well-conserved subfamilies, var1csa, var2csa and the type 3 var
genes. However, estimations of the extent of global var gene diversity are confused
by different levels of conservation and recombination in var genes in different
geographic areas (Fowler et al. 2002; Tami et al. 2003; Albrecht et al. 2006; Barry et
al. 2007). Other multigene families involved in antigenic variation in P. falciparum
include rifins (Petter et al. 2007) and the smaller gene families of stevors and Pfmc-
2TM (Lavazec et al. 2007).
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1.2.2 Var gene structure
Var genes have 2 exons separated by a 0.8-1.2 kb intron (Fig. 1.4) (Su et al. 1995).
The extracellular portion of PfEMP1 molecules is encoded by the highly polymorphic
exon 1 (4-10 kb). This extracellular domain comprises several domains: an N-terminal
segment, cysteine-rich interdomain region (CIDR), constant 2 (C2) domains and
Duffy-binding-like (DBL) domains, named because of their homology to the duffy
binding protein of P. vivax. DBL domains can be subclassified by consensus motifs
into 5 well-defined groups (DBLα-ε), plus a sixth heterogeneous group, DBL-X
(Smith et al. 2000; Gardner et al. 2002).
Var genes sequenced to date have between 2 and 7 DBL domains and up to 2 CIDR
domains (Gardner et al. 2002; Kraemer et al. 2007). DBLα domains are always N-
terminal, and occur in most known var gene types. There are two forms of DBLα
domain, DBLα1 and DBLα0 (also sometimes just called DBLα). These are defined
by presence/absence of three conserved cysteines, and conserved hydrophobic
residues summarised in Fig. 1.5. (Kraemer and Smith 2003; Lavstsen et al. 2003;
Robinson et al. 2003). There are three main CIDR types, α , β , and γ . CIDR α
domains are further classified as CIDRα, which always occur in tandem with DBLα0
domains, or CIDRα1, which always occur with DBLα1 domains, though a DBLα1
domain can occur without a CIDRα1 domain (Robinson et al. 2003; Kraemer et al.
2007). The tandem pairing of DBLβ2-C2 is also well conserved.
The central region of the intron is AT-rich and contains a bi-directional promoter
which produces a ‘sterile’ (untranslated) transcript (Calderwood et al. 2003). The
conserved intracellular acidic terminal sequence and the transmembrane domain are
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encoded by the highly conserved exon 2 (1.5 kb). The relationship between var genes
and PfEMP1 is summarised in Fig. 1.4.
Fig. 1.4. Var gene/PfEMP1 structure. Var gene exon 1 encodes DBL and CIDR
domains; exon 2 encodes transmembrane region (TM) and acidic terminal sequence
(ATS). The var gene promoter (grey) and intronic promoter (diagonal stripes) are
indicated.
EXON 1
α       CIDR         β           δ           TM              ATS




Fig. 1.5. Consensus residue features of the DBL_0 and DBLα1 subtype, adapted from
Robinson et al. (2003), showing results from a multiple alignment of 57 DBL_0 and
nine DBL_1 subtype sequences from the 3D7 genome and other parasite genotypes.
The entire DBLα domain is included. The 80% consensus for each type is shown with
conserved residues indicated by capital letters of the single amino acid code. Residues
that were conserved for similar amino acid character are indicated as: c, charge: D, E,
H, K, R; +, positive: H, K, R; h, hydrophobic: A, C, F, I, L, M, V, W, Y; p, polar: C,
D, E, H, K, N, Q, R, S, T; s, small: A, C, D, G, N, P, S, T, V; u, tiny: A, G, S; b, big:
E, K, R, I, L, N, S, Y, W. Within the alignment, periods represent positions that were
not conserved and dashes (–) indicate gaps that were introduced to maintain the
alignment. Shaded residues were highly discriminatory and present in at least 80% of
one type of sequences but absent or present in less than 5% of the other type.
Previously defined DBL homology blocks defined by Smith et al., 2000 are overlined
and labelled A to J.  Block arrows show the tag section of DBLα amplified by the
Taylor primers discussed in chapter 3 (Taylor et al. 2000a; Bull et al. 2005a). Stars
show the two cysteines within this block that can be used to classify amplified













Many of the var genes of sequenced laboratory isolates are situated close to the
telomeres, often in tandem with another var gene or with a rif gene, the rest being
centromerically located (Gardner et al. 2002; Kraemer et al. 2007). Var genes have
been classified into three major groups (A, B and C) and two intermediate groups
(B/A and B/C), defined by the gene’s position and orientation within the chromosome
(Voss et al. 2000; Gardner et al. 2002; Vazquez-Macias et al. 2002; Kraemer and
Smith 2003; Lavstsen et al. 2003), summarised in Table 1.1. The groupings are based
on the 3D7 var gene repertoire, but the same groupings are observed in var genes
from the recently sequenced P. falciparum isolates HB3 and IT (Kraemer et al. 2007)
and the group classification is applicable to all var genes. Group A, B and C var genes
can be found in P. reichenowi, which diverged from P. falciparum approximately 5-7
million years ago (Escalante et al. 1995; Trimnell et al. 2006), suggesting an ancient
origin for the var gene groups.
Group A var genes are subtelomeric and transcribed towards the telomere. They have
a semi-conserved upstream sequence (UpsA) and typically encode large PfEMP1 with
four or more DBL domains. They contain an N-terminal DBLα1 domain (Kraemer
and Smith 2003; Lavstsen et al. 2003; Robinson et al. 2003). The group A var gene
group includes members of the conserved var gene family var1csa (PFE1640w in
3D7). Var1csa var genes have an “UpsA2” upstream sequence, which is a variation
on the UspA sequence with unique 60 bp and 150 bp repeated motifs, and was
formerly referred to as UpsD (Vazquez-Macias et al. 2002; Kraemer and Smith 2003;
Lavstsen et al. 2003; Kraemer et al. 2007). The UpsA2 upstream sequence has only
been seen in one non-var1csa var gene, found in HB3 (Kraemer et al. 2007). A
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var1csa homologue is present in most strains of P. falciparum (Rowe et al. 2002a;
Salanti et al. 2002; Kyes et al. 2003; Winter et al. 2003), and forms a highly
conserved var gene family. In laboratory strain 3D7 var1csa is a pseudogene due to a
truncation, and it lacks the exon 2 (Gardner et al. 2002; Rowe et al. 2002a). The type
3 var genes are also group A var genes, see section 1.2.4.
Group B var genes are also mostly telomerically located, but have a different
upstream sequence type (UpsB) and are transcribed towards the centromere. Group
B/A genes have an UpsB upstream region with an N-terminal DBLα0 domain, or a
hybrid DBLα0/α1 domain that is DBLα0-like at the N-terminus, but DBLα1-like in
the expressed sequence tag region (such as PF08_0140 and MAL6P1.316 in 3D7) and
have a group A-type complex domain structure. Essentially they are group B var
genes that have group A var gene-like characteristics. The precise definition of these
B/A var genes is currently under debate, and as more var gene sequences are
available for examination (Kraemer et al. 2007).
Group C var genes are centromeric and have a third upstream sequence type (UpsC).
Group B and C var genes tend to be shorter, with two DBL domains and two CIDR
domains, and their DBLα domain is of the DBLα0 type. Group B and C var genes are
similar in architecture, mostly type 1 (DBLα-CIDRα-DBLδ-CIDR“not-α” (usually
β or γ)-ATS) in HB3 and 3D7 (Gardner et al. 2002; Kraemer et al. 2007). Group B/C
var genes resemble group C genes in chromosomal location, but have an UpsB
upstream region.
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A conserved var gene family, var2csa (PFL0030c in 3D7), has a distinct upstream
region  (UpsE) which has with little similarity to Ups A, B or C sequences (Kraemer
and Smith 2003; Lavstsen et al. 2003; Kraemer et al. 2007). Most strains have a
var2csa homologue (Trimnell et al. 2006), which is central to sequestration in the
placenta during infection of pregnant women (more detail in section 1.4.5).





































B UpsB 21 2-3 Subtelomeric Centromeric DBLα0 4
B/C UpsB 10 2-3 Central Telomeric DBLα0 4
C UpsC 13 2-3 Central Telomeric DBLα0 4
var2csa UpsE 1 6 Subtelomeric Telomeric None -
Table 1.1. Characteristics of P. falciparum var gene groups. Type 3 var gene family
and the var1csa var gene homologues are indicated as conserved subgroups of group
A var genes. DBLα var1csa: var1csa homologues have a conserved DBLα1  domain
(Rowe et al. 2002a). DBLαtype3: type 3 var  genes have a semi-conserved DBLα1
domain (see chapter 5).
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1.2.4 Type 3 var  genes
The type 3 genes are the smallest var genes and are highly conserved (Gardner et al.
2002; Trimnell et al. 2006). The extracellular portion has only two DBL domains: N-
terminal DBLα domain, followed by a DBLε domain (Smith et al. 2000; Gardner et
al. 2002). They are the only genes in 3D7 apart from PFL0030c (var2csa) not to have
a CIDR domain. Their high sequence conservation indicates that recombination is
restricted to within the type 3 var gene family. Of the few P. falciparum strains
studied so far, most have 1-2 type 3 var gene homologues, though HB3 has none and
3D7 has 3 (Gardner et al. 2002; Trimnell et al. 2006). The type 3 var genes in 3D7,
pfa0015c, pfi1820w and mal6p1.314 (renamed pff0020c), are telomerically located
and transcribed towards the telomere in 3D7. The upstream region is UpsA-type and
there are no distinguishing features to the type 3 upstream region (Trimnell et al.
2006). They also have group A type ATS domain and 3’ downstream untranslated
region. They are thus classified as group A var genes even though other group A var
genes are longer with a more complex domain structure (Gardner et al. 2002;
Kraemer and Smith 2003) as shown in Fig. 1.6. More detail on the type 3 var genes
and PfEMP1 is given in chapter 5.
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Fig. 1.6. Domain structure of Group A var genes of 3D7 (adapted from Lavstsen et al.
2003). The three type 3 var from 3D7 are indicated. DBLζ are a subset of DBLX.
The DBLα of the type 3 var genes is DBLα1-type, consistent with other group A var
genes. The first portion of type 3 DBLα1 domains is indistinguishable from that of
other DBLα1 domains. However, the type 3 DBLα1 domain sequence then diverges
after around 480 nucleotides from other group A DBLα1 domains, and all known
type 3 DBLα domains end in a highly conserved sequence. The DBLε domains of
type 3 var genes are also very highly conserved (further details in chapter 5).
The type 3 var genes probably originated after the split from P. reichenowi, which
does not appear to contain a type 3 var gene homologue (Trimnell et al. 2006). This
may indicate specificity for infection of humans rather than other primates. Little has
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protein expression timing or prevalence in P. falciaprum laboratory strains or field
isolates.
1.2.5 Var gene recombination
Recombination of var genes occurs within and between isolates. It is thought to occur
during sexual stage development within the mosquito, and probably also during
mitosis within the asexual cell cycle (Freitas-Junior et al. 2000; Taylor et al. 2000b).
Small or large recombination events can occur, which contribute to the mosaic-nature
of var genes, and play a role in var gene evolution (Ward et al. 1999; Freitas-Junior et
al. 2000; Kaestli et al. 2004; Bull et al. 2005a; Trimnell et al. 2006; Barry et al. 2007;
Kraemer et al. 2007). Telomeric clustering is believed to facilitate recombination
between var genes, which preferentially occurs between var genes with a similar
upstream region and orientation (Kraemer and Smith 2003). Thus, group B and C var
genes appear to recombine separately from the group A var genes. The three
laboratory strains sequenced to date indicate that the distinct var gene groups are of
similar proportions in all in P. falciparum isolates (Gardner et al. 2002; Kraemer et al.
2007). As with the type 3 var gene family, conserved gene families var1csa and
var2csa also recombine separately from other var genes (Kraemer et al. 2007). This
has allowed them to be maintained in most P. falciparum genomes since evolutionary
separation from P. reichenowi, which also contained a var1csa and a var2csa
homologue (Trimnell et al. 2006).
Genes arise through gene duplication and diversifying selection. There are two sets of
duplicated genes in 3D7, PFD1235w and MAL8P1.207.
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1.2.6 Timing of var gene expression
Var genes cluster in telomeric “bouquets”, caused by crosslinking of telomeres at the
nuclear periphery (Freitas-Junior et al. 2000; Marty et al. 2006). Expression is
controlled by a mutually exclusive expression, so that only one PfEMP1 is expressed
during each asexual growth cycle (Smith et al. 1995; Scherf et al. 1998; Dzikowski et
al. 2006).
Var gene transcripts are detectable by RT-PCR during ring and trophozoite stage,
though the single full length var gene transcript is often only detectable by Northern
blot at ring stage, up to 20 hr post invasion (Chen et al. 1998b; Scherf et al. 1998;
Kyes et al. 2000; Kyes et al. 2003; Dahlback et al. 2007). The same var gene
transcripts can be detected by RT-PCR at ring and trophozoite stage of parasite
growth in vitro and in infected human volunteers (Peters et al. 2002; Dahlback et al.
2007). The var1csa gene is transcribed later, present only at trophozoite stage (Kyes
et al. 2003) and may not be counted in the mutually exclusive expression system, as it
appears to be constitutively expressed in many field isolates (Winter et al. 2003).
Var1csa can be transcribed in 3D7 even though it is a pseudogene and so cannot
produce functional PfEMP1 (Kyes et al. 2003; Kyes et al. 2007). Some studies have
reported multiple var gene transcripts within a single parasite (Duffy et al. 2002),
though it is hard to distinguish between var genes from different parasites, and this
phenomenon is controversial. No data on timing of transcription or protein expression
of the type 3 var genes has been published to date.
Gametocytes also express PfEMP1 early in development (stages I and II) and
commonly express UpsC var genes (Sharp et al. 2006). Whether this is a switch on
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commitment to gametocytogenesis, or a reflection of UpsC var-expressing parasites
being more likely to undergo gametocytogenesis is unclear. Gametocytes sequester
specifically in spleen and bone marrow (Smalley 1976; Rogers et al. 2000), but it is
unclear whether this sequestration is PfEMP1-mediated. As gametocytes are the
transmitted form of the parasite, the molecules causing sequestration and
gametocytogenesis may be involved in determining transmission rates and parasite
virulence.
1.2.7 Activation and silencing of var genes
DNA rearrangement is not required for var gene activation, which is controlled by an
in situ gene activation, causing trancription initiation via RNA polymerase II (Kyes et
al. 2007). Physical movement of var genes to a distinct location along the nuclear
periphery may be required for expression (Ralph et al. 2005).
It appears to be crucial for the parasite to only express one var gene at a time, thus
requiring the remaining var genes to be transcriptionally silent. For example,
silencing of the remaining var genes is crucial for maintaining the reserve var
repertoire for immune evasion. Perhaps suprprisingly, the activity of the intronic
promoter located between the two var gene exons (Fig. 1.4) has been shown to be
required for a var gene to remain silenced, though the precise role of the promoter or
“sterile” transcript is not yet understood (Deitsch 2001; Calderwood et al. 2003;
Frank et al. 2006). The late transcription pattern seen for var1csa, may be due to lack
of a regulatory intronic promoter (Gardner et al. 2002; Winter et al. 2003).
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Chromatin modifications, including methylation and acetylation of histones, appear to
be involved in var gene silencing, though this is not yet fully understood. Histone
acetylation is controlled by a homologue of the yeast Sir2 (silent information
regulator), called PfSir2 (Duraisingh et al. 2005; Freitas-Junior et al. 2005). PfSir2
co-localises with telomeric bouquets, binding to transcriptionally repressed
chromosomes, and disruption of PfSir2 results in aberrant var gene transcription of
certain var genes (Duraisingh et al. 2005). The methylation state of particular
histones, such as histone H3 at lysine K9, is also involved in transcription control
(Chookajorn et al. 2007). Recently, histone methylation has also been shown to be
involved in the “memory” process by which new ring stage parasites are able to re-
express the var gene which was expressed by the parent parasite at the previous
invasion cycle (Lopez-Rubio et al. 2007).
However, var genes can be active in an otherwise transcriptionally silent region of the
chromosome, and in tandem with silent var or rif genes (Ralph et al. 2005; Marty et
al. 2006). Silencing of var genes thus appears to be controlled independently for each
individual gene rather than simply packaging vast swathes of chromatin into a
generally repressed state.
1.2.8 Var gene switching
Var genes need to switch fast enough to evade host immune response without running
out of novel PfEMP1 variants before uptake by mosquito. The order of var gene
expression is complex; there is no predetermined order of var gene expression, but the
expression order does not appear to be entirely random. Var genes have a range of
switching rates, though switching rate is an intrinsic property of each particular var
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gene (Horrocks et al. 2004b). Estimates of switching rates vary from 2% per
generation in vitro (Roberts et al. 1992) up to 16% in vivo (Peters et al. 2002), though
the rate differs for different var genes (Horrocks et al. 2004a). In one study, Ups C
(centromeric) var showed slower “off rates” than group A var genes and were thus
transcribed for longer in culture (Dzikowski et al. 2006). The different var gene
groups appear to be controlled separately. For example, silencing of UpsA and E
genes is dependent on the histone deacetylase activity of Pfsir2, whereas Ups B and C
genes remained silenced after Pfsir2 knock out (Duraisingh et al. 2005). This may be
a mechanism directing var gene choice in response to a particular situation, though
this is not fully understood.
Recent computer modelling of var gene expression switching in culture has suggested
that var genes may use intermediate var genes during switching. This is the “single to
many to single” hypothesis” (A. Serazin and C. Newbold personal communication)
and comes from observations of cultures expressing a predominant var gene
activating transcription of several different var genes which are all rapidly silenced
again as the culture as a whole switches to expression of a second predominant var
gene. It is possible different switching mechanisms are utilised by different var genes
in different situations.
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1.3 P. falciparum and adhesion
1.3.1 P. falciparum adhesion phenotypes
P. falciparum has the unique property of adhesion among human-infective Plasmodia.
The major role for adhesion in P. falciparum is sequestering to avoid host clearance
by the spleen (Chotivanich et al. 2002). This leads to adhesion phenotypes associating
with pathology and virulence (Fig. 1.7).
Fig. 1.7. Common host ligands P. falciparum infected erythrocytes and associated
adhesion phenotypes.
PfEMP1 mediates adhesion of P. falciparum infected erythrocytes. Export into knobs
allows efficient adhesion of the PfEMP1 to its various ligands (Baruch et al. 1995;
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Crabb et al. 1997; Horrocks et al. 2005). PfEMP1 are sensitive to cleavage by trypsin,
and trypsinisation of infected erythrocytes correlates with decreased cytoadherence
properties (Leech et al. 1984).
1.3.2 PfEMP1-mediated adhesion phenotypes: cytoadhesion
Many host ligands are potential adhesion sites for PfEMP1-mediated sequestration, as
detailed in Table 1.2.
CD36 is an endothelial scavenger receptor, present on the peripheral vasculature
endothelium, on many components of the blood, including monocytes, platelets and
erythrocytes, and in organs such as liver and spleen, but is not present on cerebral
endothelium (Turner et al. 1994; Serghides et al. 2003). CD36 can act as a ligand for
infected erythrocytes (Handunnetti et al. 1992; Udomsangpetch et al. 1997; Urban et
al. 1999; Heddini et al. 2001; Pain et al. 2001; Robinson et al. 2003) and binding to
CD36 is the major adhesion phenotype for infected erythrocytes. Affinity for CD36 is
a property of group B, C or B/C PfEMP1 via the CIDRα domain and the majority of
PfEMP1 (49/60 in 3D7) bind to the CD36 (Robinson et al. 2003). However, CD36-
binding appears to mediate sequestration of infected erythrocytes away from vital
organs such as the brain, and adhesion to CD36 is inversely associated with severe
malaria (Rogerson et al. 1999; Serghides et al. 2003).
CSA is a clinically important ligand for cytoadhesion, in the specific case of placental
malaria, where CSA on the placenta offers a novel ligand for sequestration of infected
erythrocytes (Fried and Duffy 1996; Reeder et al. 2000). Hyaluronic acid (Beeson and
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Brown 2004) and IgM binding (Creasey et al. 2003) have also been associated with
placental parasites (see section 1.4.4 and chapter 4 for more detail).
Intracellular adhesion molecule 1 (ICAM-1) is another clinically important adhesion
phenotype of P. falciparum field isolates. Upregulation of ICAM-1 has been reported
during P. falciparum cerebral malaria (Turner et al. 1994; Silamut et al. 1999), and as
such sequestration via ICAM-1 has been associated with cerebral malaria. However,
ICAM-1 upregulation is not seen in all cerebral malaria patients and can occur prior to
parasitisation of the cerebral microvasculature, and has even be reported to occur in
infected individuals without cerebral sequestration (Brown et al. 1999; Silamut et al.
1999). Adhesion to ICAM-1, via a tandem pairing of DBLβ and C2 domains, can be
selected for in vitro and has been observed in field isolates (Smith et al. 2000a;
Chattopadhyay et al. 2004; Springer et al. 2004). E-selectin has also been reported to
be upregulated in cerebral endothelium during parasite sequestration, but affinity for
E-selectin in field isolates of laboratory strains has not been commonly reported and
consistent link with cerebral malaria is unconfirmed (Turner et al. 1994; Silamut et al.
1999).
Adhesion can be a cooperative process. For example, P-selectin can mediate
temporary adhesion, which allows rolling across endothelium and platelets, promoting
firm adhesion through other ligands such as CD36 (Roberts et al. 1985; Senczuk et al.
2001). Adhesion to ICAM and CD36 also appears to be synergistic (McCormick et al.
1997).
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Other host ligands that may support cytoadhesion include vascular cell adhesion
molecule (VCAM), thrombospondin and platelet endothelial cell adhesion
molecule (PECAM-1). Affinity to multiple ligands is correlated with malaria
severity in P. falciparum field isolates (Heddini et al. 2001). Adhesion to complement
receptor 1 (CR1) (Rowe et al. 1997), ABO blood sugars (Carlson and Wahlgren 1992;
Barragan et al. 2000), and heparan sulfate (Ockenhouse et al. 1992) on uninfected
erythrocytes can mediate binding to uninfected erythrocytes, in a process called
rosetting (see section 1.3.3).
A link between the cytoadhesion properties of the expressed PfEMP1 of an isolate
and clinical disease is logical. Parasites from different organs within a patient show
differential var gene expression (Montgomery et al. 2007), despite reports suggesting
sequestered masses are genotypically identical (Dembo et al. 2006; Montgomery et
al. 2006) suggesting a link between PfEMP1 (or other VSA) and site of cytoadhesion.
In addition, parasites from cerebral malaria field isolates do not tend to be genetically
more similar to each other than those causing uncomplicated malaria (Ferreira et al.































































































































































Table 1.2. Host ligands supporting adhesion of P. falciparum infected erythrocytes:
CD36, intracellular adhesion molecule 1 ICAM-1, chondroitin sulphate A CSA,
hyaluronic acid HA, IgG, IgM, complement receptor 1 CR1, ABO Blood sugars,
Heparan sulfate, E-selectin, vascular cell adhesion molecule VCAM, thrombospondin,
P-selectin and platelet endothelial cell adhesion molecule PECAM-1.
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1.3.3 PfEMP1-mediated adhesion phenotypes: rosetting
Rosetting is the spontaneous binding of an infected erythroctye to uninfected
erythrocytes (Fig. 1.8).
Fig. 1.8. Rosetting. A) Photograph showing a rosetting-TM284 infected erythrocyte.
B) Schematic diagram representing a pigmented trophozoite-infected erythrocyte
adhering to 3 uninfected erythrocytes.
All known human-infective Plasmodia can rosette (Udomsanpetch et al. 1995;
Angus et al. 1996; Lowe et al. 1998), and rosettes have also been seen in rodent
malaria strains including P. chabaudi (Mackinnon et al. 2002). Rosettes can be seen
in the peripheral blood of patients infected with P. vivax (Chotivanich et al. 1998),
but only very rarely in the peripheral blood of patients infected with P. falciparum as
the mature stages are usually sequestered. In P. falciparum field isolate samples
taken from peripheral blood, the ring stage parasites must be cultured in vitro to
trophozoite stage to see rosettes form. The rosette frequency (RF) is the percentage
of infected erythrocytes binding to 2 or more uninfected erythrocytes. The
combination of sequestration and rosetting in P. falciparum field isolates may cause
obstruction of the microvasculature (Kaul et al. 1991), which may contribute to the
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association between rosetting and severe malaria (Carlson et al. 1990; Rowe et al.
1995; Rowe et al. 2002c).
Rosetting is a strain-specific property (Wahlgren et al. 1990). Rosetting isolates are
relatively uncommon, though an estimated 25-50% of severe malaria isolates have a
high rosette frequency (RF > 30%) (Rowe 2005). PfEMP1 is the major ligand for
rosetting (Rowe et al. 1997; Chen et al. 1998a). A well-characterised rosetting
interaction involves adhesion between the DBLα1 domain from R29R+var1 of
parasite clone R29, and CR1 on the uninfected erythrocyte surface (Rowe et al.
1997; Rowe et al. 2000; Mayor et al. 2005). Other erythrocyte ligands can also
support rosetting including heparan sulfate-like molecules (Carlson et al. 1992) and
ABO blood group antigens (Carlson and Wahlgren 1992; Chen et al. 1998a;
Barragan et al. 2000). CD36 binding parasites do not usually support rosetting,
except in the case of Malayan Camp (Handunnetti et al. 1992). Many diverse
PfEMP1 support rosetting, and rosetting PfEMP1 can be considered a functional
subgroup of PfEMP1, but no single consensus ‘rosetting motif’ has so far been
identified by comparisons of different rosetting PfEMP1 (Normark et al. 2007).
Rosetting PfEMP1 have been reported that include a DBLα1 domain (e.g. Rowe et
al. 1997), or a DBLα0 domain (Chen et al. 1998a), though recent evidence from
numerous laboratory isolates strongly suggests that most rosetting PfEMP1 gene are
group A PfEMP1, and that group B and C PfEMP1 rarely support rosetting (J.A.
Rowe, unpublished data).
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The physical properties of the rosetting interactions allow certain molecules to
effectively disrupt rosetting on a wide range of field and laboratory P. falciparum
isolates. These molecules include glycoconjugate compounds such as heparin and
fucoidan (Carlson et al. 1992; Rowe et al. 1994). However, their high anticoagulant
activity induces bleeding (Munir et al. 1980; Rampengan 1991; Carlson et al. 1992),
which prevents their use as rosetting-inhibiting drugs in the treatment of severe
malaria (WHO 2000). Identification of effective rosette-inhibiting drugs without
harmful side effects such as high anticoagulant activity would offer potential
therapeutic benefit for severe clinical symptoms caused by rosette P. falciparum
isolates.
It remains unclear what the advantage (if any) of rosetting is for the parasite. It does
not appear to be linked with increased merozoite invasion (Deans and Rowe 2006). It
may be a form of immune evasion, for example protecting the infected erythrocyte
from the innate immune systems by preventing contact-dependent activation of
natural killer cells (Artavanis-Tsakonas et al. 2003), or acting as a cloak to reduce
phagocytosis by macrophages or neutrophils. It may be a by-product of evolution of
adhesive phenotypes “intended” for sequestration, for example to endothelium. It
remains possible that rosetting is an in vitro artefact.
1.3.4 PfEMP1-mediated adhesion phenotypes: platelet mediated
clumping
CD36 binding also mediates platelet-mediated clumping (PMC), whereby platelets
adhere to infected erythrocytes, bridging them together and causing them to clump
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(Pain et al. 2001). Not all CD36-binding parasites support PMC in culture, and any
additional interactions between the infected erythrocyte and the platelets are
unknown at present.  PMC is associated with high parasitaemia (Arman et al. 2007).
Higher PMC levels are seen in patients with severe malaria (Pain et al. 2001), though
as this category often has a high parasitaemia, PMC may not be associated with
virulence per se (Arman et al. 2007). PMC is not usually seen in rosetting parasites,
as the two binding mechanisms are both PfEMP1-mediated and appear to be
mutually exclusive. The relevance and function of PMC in vivo remains unclear.
1.3.5 PfEMP1-mediated immunomodulation
Sequestration and associated adhesion phenotypes may not be the only active reason
for affinity for host molecules; PfEMP1-mediated adhesion to cells of the immune
system has been reported to cause modulation of the immune response. Binding of
infected erythrocytes to dendritic cells halts dendritic cell maturation, prevents up-
regulation of MHC class II molecules, inhibits T cell activation, and causes a switch
in cytokine production towards immunosuppressive cytokine release (Urban et al.
1999; Urban et al. 2001). This interaction appears to be via CD36 (McGilvray et al.
2000; Urban et al. 2001), and is probably mediated by the CIDR domains of group B
or C PfEMP1. Whether other domains from group A PfEMP1 can also fulfil this
function is unclear. Binding to natural killer NK cells is contact dependent and can
be mediated through PfEMP1 (Artavanis-Tsakonas et al. 2003; Baratin et al. 2007).
Binding of infected cells to immune cells thus appears to be a parasite-driven attempt
to halt an inflammatory immune response. However, in some studies, activation of
dendritic cells due to P. falciparum infection, for example during schizont rupture, is
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reported to stimulate an immune response (Pichyangkul et al. 2004). The stimulation
and suppression of the immune system during a malaria infection is complex, and is
probably dependent on previous malaria exposure, host genotypic factors and the
infective parasite strain.
P. falciparum malaria disease manifestation
1.4.1 P. falciparum malaria disease manifestation in African children
P. falciparum malaria is the major cause of malaria disease in young children in
endemic areas. Malaria disease is characterised by periodic fevers, with an asexual
parasitaemia detectable by Giemsa staining of the peripheral blood. P. falciparum
disease is heterogeneous, differing markedly from infection to infection and a variety
of other symptoms commonly accompanies this classic fever. The range of clinical
manifestations, from fever to increasingly severe complications, is outlined in Fig.
1.9 and Table 1.3. “Severe malaria” broadly refers to fever with at least one severe
clinical complication due to P. falciparum infection. In Africa, severe anaemia is
common in the youngest children (under 2 years old), with seizures and cerebral
malaria predominating in slightly older children (Newton et al. 2000). In areas of
lower transmission such as South East Asia, severe disease is commonly seen in
adults, and multi-organ failure is the most common severe disease manifestation.
In malaria-endemic high transmission areas such as across sub-Saharan Africa,
immunity to clinical disease is achieved by 5 years of age, followed by increased
immunity to infection (Snow 1999; Breman 2001; Snow et al. 2005). Total immunity
is not usually achieved, and an asymptomatic low parasitaemia is prevalent in
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malaria-endemic communities, and is required to maintain the immunity to clinical
disease. Severe malaria occurs in those with little previous exposure to malaria, and
thus predominantly in young children in malaria endemic areas, but also in travellers,
and in returning migrants. At present, development of these severe complications
remains hard to predict, and the contribution of parasite genetic factors or virulence
factors in the onset of severe complications is an area of great interest.
Fig. 1.9. Increasing severity of symptoms due to P. falciparum malaria.
Defining criteria of severe disease
1. Cerebral Malaria Unrousable coma
2. Severe normocytic anaemia Haematocrit < 15% or Hb < 5 g/dl
3. Renal failure Urine output < 400 ml in 24 hr
4. Pulmonary failure/oedema
5. Hypoglycaemia Blood glucose < 40 mg/dl
6. Circulatory collapse, shock Systolic blood pressure < 50 mm Hg
7. Spontaneous bleeding E.g. from gums, nose, GI tract
8. Repeated generalized convulsions > 2 convulsions within 24 hr
9. Acidaemia Arterial pH < 7.25
10. Acidosis Plasma bicarbonate < 15 mmol/litre
11. Malaria haemoglobinuria
Other manifestations
1. Imparied consciousness but rousable
2. Prostration, extreme weakness
3. Hyperparasitaemia > 10% erythrocytes infected
4. Jaundice Serum bilirubin > 3.0 mg/dl
5. Hyperpyrexia Rectal temperature > 40°C.
Table 1.3. Severe malaria manifestions and complications of P. falciparum malaria
in children. Adapted from World Health Organisation (2000).
Fever       jaundice  respiratory seizures severe multi-organ  coma
headache                  distress                  anaemia   failure DEATH
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1.4.2 Definitions of clinical childhood disease used in this analysis
i) Cerebral malaria
An unrousable coma (Blantyre coma score ≤  2) in the presence of asexual
parasitaemia, where all other causes of encephalopathy are excluded, defines cerebral
malaria (WHO 2000). There are approximately half a million cases of cerebral
malaria in African children every year, of which 10-30% are fatal and the pathology
is associated with sequestration of parasitized erythrocytes in the cerebral
microvasculature (MacPherson et al. 1985; White 1987; Brewster et al. 1990;
Berendt et al. 1994a; Newton et al. 1998; Silamut et al. 1999). Sequestration is due
to adhesion of infected erythrocytes to the cerebral microvasculature and mature
trophozoites and schizonts are often seen at high concentration within the brain
capillaries (MacPherson et al. 1985). In addition, due to the tightly packed nature of
infected erythrocytes (in some areas of brain capillaries 100% erythrocytes can be
infected), some young ring stage parasites can also become trapped within some
vessels (Silamut et al. 1999). The coma is rapidly reversible, and only an estimated
7-12% patients are left with permanent neurological impairments. In these cases
neural damage is possibly due to relatively rare development of focal lesions, or ring
haemorrhages, within the cerebral hemisphere (Brewster et al. 1990; Newton et al.
1998). Widespread ischaemic damage appears to be avoided as the “sequestered”
erythrocytes are not entirely static; the microvasculature obstruction is caused by
“sludging” of a mass of infected cells which allows very slight oxygenation of the
cerebral endothelium (White 1987). There is usually an absence of platelets and
minimal fibrin deposition associated with the coma and large cerebral haemorrhages
are uncommon (White 1987). Levels of inflammatory cytokines such as TNFα are
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higher in cerebral malaria cases than uncomplicated cases in some studies, though
the involvement of cytokines is inconsistent between reports, and immune damage is
probably not significant in disease pathology in all cases (Kwiatkowski et al. 1990;
Day et al. 1999; Newton et al. 2000). However, an increase in permeability of the
blood brain barrier, due to activation of endothelial cells and activation of
perivascular macrophages, may contribute to disease pathology in some cerebral
malaria patients (Brown et al. 1999).
ii) Uncomplicated malaria
P. falciparum parasitaemia and fever with no signs or symptoms of severe disease
(such as prostration, impaired consciousness or repeated convulsions, see Table 1.3),
is defined as uncomplicated malaria. This condition is rarely fatal and recovery is
rapid. This is a commonly used non-severe disease category in disease-association
studies (Kirchgatter and Portillo Hdel 2002; Bull et al. 2005a; Kaestli et al. 2006;
Rottmann et al. 2006).
iii) Hyperparasitaemia
If the parasite density of uncomplicated malaria (parasitaemia and fever with no
signs or symptoms of severe disease) exceeds 500,000 parasites per microlitre of
blood, the patient is classed as having hyperparasitaemia. This parasite density is
equivalent to approximately 10% parasitaemia. Such an enormous parasite burden
may be expected to cause severe disease manifestation, as severe malaria
complications are associated with a high parasitaemia (WHO 2000; Rowe et al.
2002b). In Asia parasitaemia is directly correlated with severity and risk of death.
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However, in Africa the prognosis for patients with hyperparasitaemia but no other
symptoms of severe malaria is good (Lyke et al. 2003). Thus while high parasitaemia
is associated with severe disease, hyperparasitaemia alone in Africa can be regarded
as a form of uncomplicated malaria; perhaps such a high parasitaemia without other
signs of severe disease indicates particularly non-virulent parasites. A comparison of
cerebral and hyperparasitaemia patients is a more accurate comparison of parasite
virulence than cerebral versus uncomplicated malaria, as there is no significant
difference in parasitaemia. In this study uncomplicated malaria was thus defined as
parasitaemia < 500,000 parasites/µl blood.
1.4.3 PfEMP1 and severe malaria in children
As PfEMP1 family proteins are surface exposed, and involved in
immunomodulation, sequestration, and other adhesive phenotypes such as rosetting,
they are prime candidates for involvement in disease manifestation.
Severe malaria has previously been associated with expression of a restricted and
antigenically conserved subset of variant surface antigens (VSA) through field
isolate agglutination studies (Bull et al. 1999; Bull et al. 2000; Nielsen et al. 2002).
These reveal that VSA from isolates from patients with severe malaria (VSA severe
malaria; VSASM) are commonly recognised by sera from semi-immune individuals.
PfEMP1 associated with severe disease thus appear to be preferentially expressed in
a naïve individual, thus being common targets for protective immunity. Increasing
levels of VSA-specific antibodies are thought to then modulate the VSA repertoire
available for expression in a semi-immune host.
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This VSASM hypothesis was used to model severe malaria-phenotype parasites in a
laboratory strain in vitro, by using bead-selection of parasites with sera from semi-
immune children, and thus selecting for parasites expressing VSA that are commonly
recognised (Jensen et al. 2004). Selecting 3D7 parasites in this fashion resulted in
upregulation of many group A var genes, and downregulation of certain group C
genes, suggesting an association of group A var genes and severe disease (Jensen et
al. 2004). The pattern of var gene upregulation after selection on sera was similar to
the level of upregulation seen after infection of volunteers with NF54 parasites
(genotypically identical to 3D7), such that group A and B/A var genes expanded
relatively quickly, and groups B, C, and B/C tended to be downregulated during the
infection (Lavstsen et al. 2005).
Recent field isolate studies have so far failed to show a consistent link between var
gene group and disease outcome, and data from different studies are conflicting, in
part due to differences in disease classification and methods of analysis.
In Brazil, DBLα domains lacking 1-2 conserved cysteine residues (DBLα1 domains;
probably group A PfEMP1) were more frequently expressed in patients with severe
malaria than with uncomplicated malaria (Kirchgatter and Portillo Hdel 2002). Field
isolates from Tanzania showed an upregulation of group A and B var gene
transcription in severe malaria field isolates (Rottmann et al. 2006), while in Papua
New Guinea, expression of group B var genes were associated with clinical malaria,
both severe and mild (Kaestli et al. 2006). However, in Kenya no significant
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association was found between var gene group and disease category, using DBLα
domain sequence type as a marker of var gene group (Bull et al. 2005a). Thus there
is a trend for group A PfEMP1 to be associated with severe malaria, and group C
with asymptomatic parasitaemia. However, differences in the parasitaemia of the
asymptomatic parasitaemia or “mild” disease field isolates with the severe malaria
category make true associations with parasite virulence hard to determine. The
diverse range of symptoms grouped in the different “severe malaria’ categories
confound the data making comparisons between studies difficult. In addition, disease
manifestation differs between countries. For example, in South East Asia, multi-
organ failure is relatively common, whereas cerebral malaria is not, and rosetting is
not associated with severe disease (al-Yaman et al. 1995), possibly due to high
prevalence of CR1 deficiency (Cockburn et al. 2004). PfEMP1 involvement in Asia
may therefore be different from in Africa, where the association between rosetting
and severe malaria is significant, and cerebral malaria is a common severe
complication (Carlson et al. 1990; Rowe et al. 1995; Rowe et al. 2002c).
A consistent and compelling link between var group expression between in vivo P.
falciparum infection and clinical disease manifestation has not previously been
shown.
1.4.4 P. falciparum placental malaria
In malaria-endemic areas adults are usually clinically immune to malaria. However,
pregnant women once again become susceptible to the disease, which is
characterised by an accumulation of mature-stage erythrocytes in the placenta
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(Beeson and Brown 2002). 50 million pregnancies are exposed to malaria each year
(Steketee et al. 2001) and placental malaria is a major cause of infant morbidity and
mortality, reduced birth weight and severe maternal anaemia, especially common in
first pregnancies (Brabin et al. 1993). Pregnancy-associated immunosuppression was
originally blamed for the susceptibility of pregnant women to the disease. However,
it is now believed that the placenta provides a new niche for parasitic survival, which
may be exploited by parasites that can display particular surface antigens. This is
thought to be possible due to the presence of the glycosaminoglycan chondroitin
sulfate A (CSA) displayed via the proteoglycan thrombomodulin on the
syncytiotrophoblast cells of the placenta, which can act as a receptor for infected
erythrocytes (Fried and Duffy 1996; Reeder et al. 2000). Infected placenta were
observed to have higher CSA levels than uninfected, suggesting CSA-upregulation
may occur, or that placenta with higher CSA levels are more likely to become
infected (Muthusamy et al. 2007).
Resistance to placental malaria increases with gravidity alongside an increase in IgG
which recognise erythrocytes displaying CSA-binding surface antigens (Fried et al.
1998; Ricke et al. 2000; Staalsoe et al. 2004). These antibodies also correlate with
improved birth outcome (Duffy and Fried 2003; Staalsoe et al. 2004).  Moreover,
these antibodies recognise infected erythrocytes from different continents, suggesting
there is a common mechanism for protection against placental malaria worldwide
(Fried et al. 1998).
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There has also been some evidence to suggest that other host molecules such as
hyaluronic acid (HA) binding may also be an important placental receptor (Beeson
and Brown 2004), though CSA is thought to be the major placental sequestration
receptor (Fried et al. 2006; Muthusamy et al. 2007). Malaria during pregnancy thus
comes about due to the placenta providing a new niche for parasitic survival, which
may be exploited by the parasite by using a distinct repertoire of placenta-specific
surface antigens.
1.4.5 PfEMP1 and placental malaria
The main candidates for binding to CSA are PfEMP1. Various DBLγ domains have
been associated with CSA binding in placental isolates, and common DBLγ domain
sequences have previously been reported within populations of pregnant women in
Cameroon, Gabon and Kenya (Khattab et al. 2001; Fried and Duffy 2002; Khattab et
al. 2003). Three main subfamilies of potential placenta-specific CSA-binding
PfEMP1 have been identified: var1csa family (Buffet et al. 1999) (also called
FCR3varCSA), var2csa (Salanti et al. 2003), and also the CS2var gene (Reeder et
al. 1999), (reviewed in Rowe  et al. 2004). Var1csa, is highly conserved (Rowe et al.
2002a; Salanti et al. 2002; Winter et al. 2003), and was initially a promising
candidate for mediating CSA-binding, as antibodies raised to the DBL3γ domain
were able to recognise many infected erythrocytes from CSA-binding parasite lines
(Lekana Douki et al. 2002; Costa et al. 2003). However, transcription of var1csa
(Fried and Duffy 2002; Winter et al. 2003) and CS2var (Duffy et al. 2006a) were not
found to be consistently up-regulated in pregnancy-associated malaria, and CS2var is
not well conserved between strains.
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There is now strong evidence for var2csa playing a major role in placental malaria.
Var2csa is expressed on the surface of CSA-selected parasites (Salanti et al. 2004)
and directly binds CSA though its DBL3X domain, which is closely related to the 67
amino acid minimal CSA-binding region portion of FCR3-CSA DBL3-γ (Gamain et
al. 2004; Gamain et al. 2005). VAR2CSA is consistently upregulated in laboratory
isolates after selection for CSA-affinity, and VAR2CSA knock-out disrupts CSA-
affinity (Salanti et al. 2003; Viebig et al. 2007). Interestingly, VAR2CSA does not
contain a DBLγ domain (Gardner et al. 2002) which was surprising given the
association of both VAR2CSA and DBLγ domains with placental malaria, though
this can partially be explained by cross-reacting epitopes between VAR1CSA
DBL3γ and VAR2CSA DBL3X (Bir et al. 2006).
A var2csa homologue has been identified in most strains and field isolates of P.
falciparum; two var2csa homologues were found in HB3 (Trimnell et al. 2006;
Kraemer et al. 2007).
The DBL6ε domain of VAR2CSA also binds non-specific IgM (Semblat et al.
2006), consistent with nonspecific IgM binding having a role in placental malaria
(Flick et al. 2001; Creasey et al. 2003).
VAR2CSA is recognised by endemic plasma in a sex-specific and parity-dependent
manner (Salanti et al. 2004) and var2csa transcription was detected in infected
erythrocytes specifically from pregnant women from Senegal (Tuikue Ndam et al.
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2005). Anti-VAR2CSA antibodies are present in pregnant women from East and
West Africa (Salanti et al. 2004; Tuikue Ndam et al. 2006). Despite the antigenic
variation between VAR2CSA from different isolates, these antibodies appear to be
cross-reactive to different polymorphic versions of VAR2CSA, though are not
always able to inhibit binding of diverse VAR2CSA to CSA (Beeson et al. 2006).
Literature to date thus consistently indicates an important role for VAR2CSA in
placental malaria. However, there remains a lack of evidence of var2csa expression
directly from field isolates, rather than from CSA-binding laboratory isolates. It is
also unclear to what extent other PfEMP1 play a role in placental malaria. Field
isolate data on relevance of var2csa in placental malaria is very important as var2csa
is of great interest as a vaccine candidate against placental malaria.
1.5 Aims of the thesis
The general aim of the thesis was to investigate the role of conserved PfEMP1
subgroups as virulence factors in clinical disease in African field isolates from
children (Mali and Kenya) and pregnant women (Malawi).
In the case of childhood disease, two approaches were taken to investigate PfEMP1
as a virulence factor. Firstly, transcribed var genes in childhood malaria field isolates
from Mali were examined. Var gene groups were determined using DBLα domain
transcript sequences as an indicator of var gene group of the transcribed var genes.
The hypothesis was that there would be a difference in the pattern of transcription of
var genes between the three clinical groups. It was hypothesised that there would be
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a relatively higher level of group A var gene transcription in the cerebral malaria
isolates compared to the hyperparasitaemia and uncomplicated malaria isolates,
extrapolating from the in vitro work of Jensen et al (2004). The type 3 var gene
family were not included in this analysis due to the primers used, and so were
investigated separately in laboratory strains and field isolates. As they are also group
A var, albeit atypically short and conserved, expression of type 3 var genes was also
hypothesised to be different in the three clinical categories, with an expected
association with cerebral malaria.
Secondly, a major contribution of PfEMP1 in severe disease in Africa is the binding
of uninfected erythrocytes causing rosettes. Rosetting PfEMP1 form a functional
subgroup of PfEMP1; they are predominantly group A (Rowe, JA, personal
communication), and are possibly structurally conserved due to similar interactions
with rosetting ligands. I spent two months in Kilifi, Kenya, examining rosetting field
isolates. Unfortunately, there was insufficient material available to examine the
expressed var genes responsible for rosetting in these field isolates. However, as well
as understanding the molecular mechanism of rosetting, development of non-toxic
compounds for rosette disruption is an important area of research. Attempts to
identify rosette-disrupting compounds for auxiliary treatment of severe malaria
complications caused by rosetting P. falciparum isolates have so far been troubled by
the high anti-coagulant activity of candidate molecules. I was able to test the ability
of a sulfated glycoconjugate compound, curdlan sulfate, to disrupt rosettes in a group
rosetting P. falciparum field isolates.
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In addition to work on childhood malaria isolates from Mali and Kenya, I also
examined var gene transcription in a group of placental field isolates from Malawi.
Specifically, I investigated transcription of DBLγ domains, and a well conserved var
gene, var2csa . The hypothesis was that var2csa would be specifically and
consistently transcribed in the placental isolates, but not in a comparison group of
childhood malaria isolates, and that there might also be some differences in the
sequence of DBLγ domain transcripts from placental and childhood malaria isolates.
My four results chapters address the following specific aims:
1. To compare var gene transcription in childhood malaria field isolates in
three strictly defined clinical manifestation groups. DBLα domain
transcripts, as indicators of var gene group, were analysed to test the
hypothesis that a subset of var may influence clinical disease.
2. To analyse var gene transcription in placental malaria field isolates,
investigating the involvement of a specific var gene, var2csa, and of
conserved DBLγ domains in malaria during pregnancy.
3. To study var gene transcription and protein expression of the unusual,
small and highly conserved type 3 var gene family.
4. To assess the anti-rosetting potential of a sulfated glycoconjugate
compound, curdlan sulfate, on rosetting P. falciparum field isolates, as a






2.1. Aim of chapter
This chapter describes general materials and methods that are relevant to more than
one chapter of the whole thesis. Further detail of specific materials and methods used
within each individual chapter is given within that chapter.
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2.3 Field isolate collection
2.3.1 Mali childhood malaria field isolates
Childhood malaria samples were collected as part of, and a gift from, the Bandiagara
Malaria Project case-control study of severe malaria that has been described in detail
previously (Lyke et al. 2003; Lyke et al. 2004).  Blood samples were collected from
children with malaria after informed consent from parents or guardians, and all
protocols received institutional review board approval. Isolates were obtained from
26 patients with strictly defined disease criteria from the following 3 disease
categories:
i) Cerebral malaria (9 isolates): Unrousable coma (Blantyre coma score ≤ 2) in the
presence of asexual parasitaemia where other obvious causes of encephalopathy are
excluded (WHO 2000).
ii) Uncomplicated malaria (9 isolates): P. falciparum parasitaemia and fever with
no signs or symptoms of severe disease (such as prostration, impaired consciousness
or repeated convulsions, see Table 1.3, introduction). In this study uncomplicated
malaria patients were defined as having <500,000 parasites per microlitre of blood
(approximately 10% parasitaemia), due to the hyperparasitaemia category (see
below).
iii) Hyperparasitaemia (8 isolates): As uncomplicated but malaria parasite density
exceeds 500,000 parasites per microlitre of blood.
The original isolate numbers were changed in the thesis for clarity. Appendix 1
provides a key for isolate reference numbers, and other isolate details.
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2.3.2. Parasite cryopreservation of Mali field isolates
Parasites were prepared for freezing in Mali for long term storage in liquid nitrogen
(Rowe, JA, Edinburgh). 1 volume glycerolyte (42.25% w/v glycerol, 0.1 M sodium
lactate, 4 mM potassium chloride, 0.1 M sodium dihydrogen phosphate, pH 6.8) was
added dropwise to 3 volumes packed cells, allowing cells to equilibrate osmotically
for 5 minutes (min) at room temperature (RT) before dropwise addition of a further 4
volumes glycerolyte. Samples were incubated at –70ºC overnight (o/n) before
storage in liquid nitrogen. A blood spot from each isolate was made on 3MM
Whatman paper for genomic DNA extraction (see section 2.3.11). Frozen isolate
samples and blood spots were then shipped to Edinburgh. Subsequent thawing of
cryopreserved field isolate cultures was carried out by A. Raza, Edinburgh. Cells
were thawed at 37ºC in a water bath, and 200 µl 12% NaCl was added dropwise over
5 min. After a further 5 min, 5 ml 1.8% NaCl was added dropwise, with gentle
agitation of the cells, followed by 5 ml 0.9% NaCl with 0.2% glucose solution. Cells
were then washed twice in incomplete RMPI: RPMI1640 medium (Invitrogen),
supplemented with 25 mM HEPES, 20 mM glucose, 2 mM glutamine, 25 µg/ml
gentamycin and 750 µl NaOH.
2.3.3 Mali field isolate maturation to pigmented-trophozoite stage
Field isolate ring stage parasite were cultured for 8–24 hours (hr) in complete RPMI:
RPMI1640 medium (Invitrogen), supplemented with 25 mM HEPES, 20 mM
glucose, 2 mM glutamine, 25 µg/ml gentamycin and 750 µl NaOH with 10% pooled
normal human serum (Scottish Blood Transfusion Service, Edinburgh, UK). Flasks
were gassed with 96% nitrogen, 3% carbon dioxide and 1% oxygen. The maturity of
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the culture was regularly assessed by Giesma staining, until morphologically
equivalent to 16-20 hr post-invasion in a laboratory strain.
2.3.4 Giemsa staining of thin blood smears
Approximately 10 µ l of the culture at 20% haematocrit was placed onto a
microscope slide and spread thinly with a clean microscope slide. Thin blood smears
were air-dried, fixed with 100% methanol for 20 sec and air-dried again.  Slides were
immersed in 10% Giemsa stain solution (BDH) diluted in Giemsa buffer (prepared
using Giemsa buffer tablets; BDH) for 15 min.  Slides were then washed thoroughly
with tap water and air-dried for light miscroscopy using a 40x and 100x objective
lens under immersion oil (BDH).
2.3.5 Trizol treatment of parasites for RNA extraction
Parasites were pelleted (2000 rpm, 4 min), and as much supernatant as possible was
aspirated away. Trizol reagent (Gibco) was warmed to room temperature, and 10
volumes of Trizol reagent was added to 1 volume packed cells. Cells were left at RT
for 5 min, then stored at -70˚C.
2.3.6 Malawi placental field isolates
Mature sequestered placental parasites from pregnant women from Malawi were
collected directly from P. falciparum-infected placenta on delivery, and stored
immediately in Trizol before shipment to UK (gift from Stephen J. Rogerson). These




Parasites in Trizol reagent were thawed on ice. Two volumes chloroform were added
per volume packed cells. The tube was shaken vigorously for 15 sec then left at RT
for 3 min. The aqueous layer was separated from the phenol-chloroform phase by
centrifugation (4000 rpm, 45 min, 4˚C). This upper aqueous layer was removed into
a fresh tube and the RNA was precipitated by incubating with 0.5 ml isopropanol per
ml of Trizol (RT, 10 min) before centrifugation to pellet the RNA (4000 rpm, 30
min, 4˚C). RNA was washed in 1 ml 70% ethanol prepared with DEPC-H20 and
precipitated again (4000 rpm, 10 min, 4˚C). The RNA pellet was air dried at RT for
10 min, redisolved in DEPC-H20 (60˚C, 10 min) and stored at –70˚C. DEPC-H20 was
prepared by addition of 0.1% DEPC (diethyl pyrocarbonate) to high grade Millipore
water overnight (o/n) at 37˚C then autoclaved to destroy the DEPC. Gloves were
always worn and filter tips used when handling RNA.
2.4.2 DNase treatment
Any contaminating genomic (g) DNA in the RNA preparation was removed by
treatment with 1.5 units DNase (Gibco) for 30 min at RT. 1.5 µl of 25 mM EDTA
(10 min, 65 ˚C) was added to inactivate the DNase enzyme.
2.4.3 cDNA preparation
cDNA was then prepared using Superscript III First Strand Synthesis (Invitrogen)
according to the manufacturer’s instructions. 50 ng random hexamers, 1 nmol dNTP
and 2 µl DEPC-H20 was added to approximately 1 µg RNA. This was mixed gently,
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and heated to 65ºC for 5 min. The mixture was left on ice for 2 min to cool. The
mixture was split into two tubes: “Plus RT” (RT: reverse transcriptase) and “RT
Contol” (to detect gDNA contamination in the RT-PCR reaction). 4 µl of 5x first
strand synthesis buffer, 0.4 µmol DTT, 100 nmol MgCl2 and 1 µl DEPC-H20 was
added to each, mixed gently and incubated (25˚C, 2 min). 0.5 µl Superscript III
reverse transcriptase (RT) was added to each plus RT tube, or 0.5µl DEPC-H20
added to control tubes. These were incubated at 25˚C for 10 min, 50˚C for 50 min
and 85˚C for 15 min. The cDNA was then stored at –20˚C until use. cDNA from
laboratory isolates (except 3D7) was a gift from JA Rowe.
2.4.4 PCR (polymerase chain reaction)
All PCR and RT-PCR reactions were carried out using amplitaq gold with 10x PCR
Gold buffer (Promega) or Platinum taq and Platinum taq buffer (Invitrogen), with
separate addition of MgCl2 and dNTP as detailed in appropriate chapters. All PCR
and RT-PCR reactions were performed in sterile 0.5 ml eppendorf tubes on a PCT-
100 Peltier thermal cycler PCR machine (MJ Research). Primer sequences and
amplification conditions are detailed in each chapter. For RT-PCR, samples without
RT were used in all reactions to exclude gDNA contamination. A positive control
(3D7 cDNA for RT-PCR and 3D7 gDNA for PCR, unless stated otherwise) and
negative control (distilled water) were used in all PCR and RT-PCR reactions.
2.4.5 Agarose gel electrophoresis
All PCR and RT-PCR were examined by agarose gel eletrophoresis. Unless
otherwise stated, 5 µl of PCR or RT-PCR products was loaded onto a 1.5% agarose
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gel, prepared using 1.5 g electrophoresis grade agarose (Invitrogen), 10 ml UltraPure
10xTBE (1M Tris, 0.9 M Boric acid and 0.01M EDTA, Invitrogen) and 90 ml
distilled water. DNA ladder, φX174 RF DNA/Hae fragments (Invitrogen), λ
DNA/HinDIII fragments (Invitrogen), or 100 bp DNA ladder (Invitrogen), was also
loaded. Gels were run at 80 V for 45-60 min. After 25 min running time the gel was
removed and stained in 0.5 µg/ml Ethidium Bromide (EtBr) for 5 min, before
replacing in the gel tray for the remaining 20-40 min electrophoresis. DNA products
were visualised under UV.
2.4.6 PCR/RT-PCR product purification
If only one band of the correct size was seen after agarose gel electrophoresis of a
sample of the PCR/RT-PCR products, the rest of the reaction was purified using a
QIAquick PCR Purification Kit (Qiagen). 5 volumes buffer PB was added to the
PCR/RT-PCR products to promote binding to a QIAquick spin column. Non-bound
liquid, salts and primers were washed through the column by spinning on a bench-
top centrifuge (13,000 rpm, 1 min) and discarded. 750 µl wash buffer was added to
the column to wash remaining impurities from the column upon spinning (13,000
rpm, 1 min). The flow-through was discarded and the column spun again to remove
any residual ethanol. PCR/RT-PCR products were then collected in a fresh tube after
addition of 50 µl elution buffer (10 mM Tris-Cl, pH 8.5) to the column and a final
spin (13,000 rpm, 1 min).
If more than one band was seen, or primer dimers were also seen, PCR/RT-PCR
products were purified using a QIAgen Gel Extraction Kit (Qiagen). A section of the
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gel containing the correct PCR product was excised and melted in 3 volumes buffer
QG Melted agarose, and then added to a spin column. Non-bound liquid, salts and
primers were washed through the column by spinning on a bench-top centrifuge
(13,000 rpm, 1 min) and discarded. Washing with wash buffer and elution was as for
QIAquick PCR Purification Kit (Qiagen), described above.
2.4.7 Ligation and cloning
7 µ l purified PCR product was ligated into 1 µl PCR II TA cloning vector (TA
cloning kit, Invitrogen) using 4 units T4 DNA ligase and 1 µl ligation buffer (all
from TA cloning kit, Invitrogen) o/n at 14°C. The resulting plasmids were used to
transform One Shot TOP10F competent cells (Invitrogen). 2 µl ligated plasmid was
mixed slowly into one vial of One Shot TOP10F competent cells, and the cells were
incubated on ice for 30 min. Cells were heat shocked (30 sec, 42°C) followed by 2
min incubation on ice. Transformed cells were recovered in SOC media (Invitrogen),
at 37°C for 1 hr with shaking. Plates prepared with Luria Bertani (LB) agar (Sigma)
with 50 µl/ml ampicillin were covered in 40 µl each of 20 µg/ml X-gal and 20 µg/ml
IPTG for blue/white screening. Transformed cells were plated out onto the LB agar
plates and incubated o/n at 37°C. White colonies indicate an insert has disrupted the
lacZ locus, whereas blue colonies indicate a re-ligated non-recombinant plasmid as
the lacZ gene is active. Individual white colonies were selected for overnight culture
in LB (Sigma) with 50 µl/ml ampicillin at 37°C.
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2.4.8 Plasmid extraction
Plasmids were extracted from overnight cultures using a miniprep kit (Qiagen).
Bacterial cells from overnight growth from individual plate colonies were pelleted
(13,000 rpm, 3 min) and resuspended in 250 µl buffer P1. Cells were lysed 250 µl P2
buffer, and neutralised in 350 µl N3 buffer. Bacterial cell debris was removed by
centrifugation (13,000 rpm, 10 min), and the supernatant containing the plasmid
applied to a spin column. Spinning (13,000 rpm, 1 min) allowed non-bound liquid or
remaining salts to flow through the column while the plasmid remained bound.
Plasmids were washed in 750 µl wash buffer (13,000 rpm, 1 min). The flow-through
was discarded and the column spun again to remove any residual ethanol. Plasmids
were then collected in a fresh tube after addition of 50 µl elution buffer (10 mM Tris-
Cl, pH 8.5) to the column and a final spin (13,000 rpm, 1 min).
2.4.9 EcoRI restriction enzyme digestion of plasmids
5 µ l of the plasmid extraction in elution buffer was digested with 5 unit EcoRI
(Promega) in a 10 µl reaction, containing 1 µl buffer H (Promega) and 0.2 5 µl BSA
(Promega), which was incubated at 37°C for 1.5-2 hr. 5 µl of the digested plasmid
preparation was visualised on a 1.5% agarose gel, prepared using 1.5 g
electrophoresis grade agarose (Invitrogen), 10 ml UltraPure 10xTBE (1M Tris, 0.9 M
Boric acid and 0.01M EDTA, Invitrogen) and 90 ml distilled water. Gels were run at
80 V for 45-60 min. After 25 min running time the gel was removed and stained in
EtBr (0.5 µg/ml) for 5 min, before replacing in the gel tray for the remaining 20-40
min electrophoresis. DNA products were visualised under UV.
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2.4.10 Sequencing
Plasmids containing an insert were sequenced. 5 µl of BigDye terminator reaction
mix (Applied Biosciences) and 1.6 pmol sequencing vector VR1
(AGATGCATGCTCGAG CGG) or VF1 (ACGTCGGATCCACTAGTA) was added
to 5 µl of the miniprep plasmid preparation containing an insert. The mix was
incubated for 25 cycles of 96°C for 30 sec, 50°C for 15 sec and 60°C for 4 min in
sterile 0.2 ml eppendorf strips on a PCT-100 Peltier thermal cycler PCR machine
(MJ Research). Sequencing was carried out by the University of Edinburgh School
of Biological Sciences Sequencing Service.
2.4.11 DNA extraction
For genotyping, parasite DNA was extracted from blood spots on filter paper using
chelex-100 extraction (Plowe et al. 1995). A small square of blood spot filter paper
was soaked in 0.5x saponin in PBS o/n at 37 ºC. This was centrifuged (6000 rpm, 3
min) and the liquid removed. The filter paper was washed with fresh 1x PBS and re-
pelleted (6000 rpm, 3 min). The liquid was removed as this contains haem and other
debris. 50 µl chelex suspension and 100 µl DEPC-H20 was added. This was boiled
(100ºC) for 8 min. The upper layer, above the chelex suspension contains the gDNA.
Genomic DNA is also present in the RNA extract before DNase1 treatment. An
aliquot of RNA was used for PCR of gDNA for PCR of upstream regions.
2.4.12 Genotyping
The minimum number of genotypes per isolate was estimated by genotyping PCR
with primers to the size-variant genes MSP1 and MSP2 (Ranford-Cartwright et al.
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1993). Each PCR was nested. Primer sequences for MSP1 outer PCR: O1
(CACATGAAAGTTATCAAGAACTTGTC) and O2 (GTACGTCTAATT
CATTTGCACG). Primer sequences for MSP1 inner PCR: N1
(GCAGTATTGACAGGTTATGG) and N2 (GATTGAAAGGTATTTGAC). Primer
sequences for MSP2 outer PCR: S2 (GAGGGATGTTGCTGCTCCACAG) and S3
(GAAGGTAATTAAAACATTGTC). Primer sequences for MSP2 inner PCR: S1
(GAGTATAAGGAGAAGTATG) and S4 (CTAGAACCATGCATATGTCC). All
PCR reactions included 5 µl 10x PCR Gold buffer, 25 pmol each of forward and
reverse primers and 0.2 µl Amplitaq Gold polymerase with a final concentration
1.875 mM MgCl2, and 1.25 mM of each dNTP, and the volume adjusted to 50 µl
after addition of template DNA. For outer PCRs, the DNA template was 5 µl chelex
extracted gDNA. For inner (nested) PCRs, the DNA template was 3 µl of the outer
PCR product. MSP1 outer and inner PCR cycle conditions were 94ºC 5 min, then 30
cycles of 94ºC for 25 sec, 50ºC for 35 sec, 68ºC for 90 sec, followed by a 10 min
extension at 68ºC and cooling to 4ºC. MSP2 outer and inner PCR cycle conditions
were 94ºC 5 min, then 30 cycles of 94ºC for 5 sec, 50ºC for 15 sec, 65ºC for 1 min,
followed by a 10 min extension at 65ºC and cooling to 4ºC. PCR products were run
8% on Novex Pre-cast TBE Polyacrylamide gels (Invitrogen) at 200 V, 1 hr. with
Novex TBE Running buffer (Invitrogen). Gels were soaked in EtBr (0.5 µg/ml) and
visualised under UV.
2.5 Sequence analysis
2.5.1 Grouping of sequences into contigs
Sequences were analysed using Lasergene software (DNAstar, Inc). Contigs were
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created with a minimum percentage match of 95% to classify sequences for each
isolate using SeqMan (DNAstar, Inc). Nucleotide sequences were translated into
amino acid sequence using EditSeq (DNAstar, Inc). Protein sequences were aligned
using the ClustalW method within MegAlign (DNAstar, Inc) and the alignment
converted into a nucleotide alignment with Tranalign (http://bioweb.pasteur.fr/
docs/EMBOSS/tranalign.html). Phenograms were then created from nucleotide or
amino acids sequences within MegAlign (DNAstar, Inc). The sequences were also
aligned using Muscle (Edgar, et al, 2004) for creation of the network (Graham Stone,
Appendix 2). All phenograms are intended to give a measure of sequence similarity
rather than to suggest evolutionary descent.
2.5.2 Homology searches
Homology searches were performed using nucleotide-nucleotide BLAST search of
the NCBI database (http://www.ncbi.nlm.nih.gov/BLAST). Default parameters were
used, apart from restricting the taxon to P. falciparum (taxon 5833). The Sanger P.
falciparum Blast server http://www.sanger.ac.uk/cgibin/blast/submitblast/
p_falciparum, Plasmodb Plasmodium genome resource http://www.plasmodb.org/
plasmo/home.jsp and the Broad Institute HB3 and Dd2 sequencing data
http://www.broad.mit.edu were also used.
2.5.3 Amino acid sequence identity analysis
Each set of sequenced domains (DBLα in chapter 3, DBLγ/var2csa DBL3X in
chapter 4 and type 3 DBLα and DBLε in chapter 5) were aligned at the amino acids
level using clustal W within Megalign (DNAstar, Inc). The percentage sequence
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identity was recorded into a table. The sequence identity figures within the table
were colour-coded into the following groups; 0-30, 30-39.9, 40-49.9, 50-59.9, 60-
69.9 70-99.9 and 100% amino acid identity. Sequences were split into various sub-
categories, such as disease manifestation, or DBLα0 versus DBLα1, and the figures
were repeated. This provided a pictorial illustration of general trends of the level
sequence similarities between and within the different groups of var gene domains.
Histograms and box plots of percentage sequence identity were then created in
Statview, using the amino acid identity data from MegAlign (2.5.3).
2.6 Long term culture and manipulation of P. falciparum
2.6.1 Culture procedures
All processes were carried out in a laminar flow hood, which was regularly cleaned
with detergent and 70% ethanol. Aseptic techniques were used throughout, and all
plastics and slides used in the handling of parasites were decontaminated with 1%
virkon (Alpha Labs). Parasites were cultured in complete RPMI: RPMI1640 medium
(Invitrogen) containing 25 mM HEPES, supplemented with 20 mM glucose, 2 mM
glutamine, 25 µg/ml gentamycin and 750 µl 1M NaOH with 10% pooled normal
human serum (Scottish blood Transfusion service, Edinburgh, UK). Flasks were
gassed with 96% nitrogen, 3% carbon dioxide and 1% oxygen.  Cultures were
maintained at 1-10% parasitaemia by addition of fresh group O blood cells
approximately every 48 hours as appropriate. Blood was prepared firstly through
removal of white blood cells and buffy coat by centrifugation (4000 rpm, 15 min)
and washing twice in incomplete RPMI: RPMI1640 medium (Invitrogen) containing
25 mM HEPES, supplemented with 20 mM glucose, 2 mM glutamine, 25 µg/ml
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gentamycin and 750 µl 1M NaOH, before resuspension at 50% haematocrit in
incomplete RMPI. Blood was stored at 37ºC until required and was used for up to 10
days. Cultures were maintained at 2% haematocrit at 37ºC in complete RPMI and
were regularly assessed by Giemsa stained thin films (section 2.2.4). This culture
method is standard (Trager and Jensen 1976). Preparation for long-term storage in
liquid nitrogen was carried out as outlined in section 2.2.2 on cryopreservation.
2.6.2 Sorbitol synchronization of P. falciparum infected erythrocytes
Cultures were regularly synchronised using sorbitol (Sigma) to lyse the mature
stages by osmotic lysis (Lambros and Vanderberg 1979). Parasites younger than 20
hr post invasion are resistant to sorbitol lysis as they are impermeable to sorbitol.
Thus sorbitol treatment leaves only ring stage parasites in the culture. Parasite
cultures were pelleted (2000 rpm, 4 min). Culture medium was removed and the cell
pellet resuspended in 5 ml of 5% (w/v) D-sorbitol (Sigma) and incubated at 37˚C for
15 min.   Cells were then pelleted again (2000 rpm, 4 min), and washed twice with
10 ml of RPMI 1640 medium and returned to standard culture conditions.
2.6.3 Enrichment of pigmented trophozoite and schizont infected
erythrocytes
Pigmented trophozoite and schizont stages were enriched by gradient separation
using using Percoll (colloidal silica particles coated with polyvinylpyrrolidone)
which creates smooth, isometric gradients (Sigma, UK). Cell cultures were pelleted
(2000 rpm, 4 min) and resuspended in a 5 ml of RPMI 1640 medium without serum,
and carefully layered on top of 5 ml 30% percoll in a 15 ml falcon tube. The tube
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was centrifuged (4000 rpm, 15 min). Pigmented trophozoite and schizont infected
erythrocytes form a clear layer above the sediment of uninfected and ring stage
parasite infected erythroctyes, which fall to the bottom of the tube.  The upper layer
containing pigmented trophozoite and schizont infected erythrocytes was transferred
to a fresh tube, washed twice with 10 ml of RPMI-1640 and re-pelleted (2000 rpm, 4
min), and returned to standard culture condition with fresh complete RPMI and
washed group O erythrocytes.
2.6.4 Enrichment of rosetting pigmented trophozoite and schizont
infected erythrocytes
Pigmented trophozoite infected erythrocyte cultures were selected for high rosetting
parasites by gradient separation using using Percoll (Sigma, UK). Cell cultures were
pelleted (15 min, 4000 rpm) and resuspended in a 5 ml of RPMI 1640 medium
without serum, and carefully layered on top of 5 ml 30% percoll in a 15 ml falcon
tube. The tube was centrifuged (5 min, 1800 rpm). Non-rosetting pigmented
trophozoite infected erythrocytes form a clear layer above the sediment of uninfected
and rosetting pigmented trophozoite stage infected erythroctyes, which fall to the
bottom of the tube.  The upper layer containing pigmented trophozoite and schizont
infected erythrocytes was removed by aspiration. The lower layer of rosetting and
non-infected erythrocytes was washed twice with 10 ml of RPMI-1640, re-pelleted
(2000 rpm, 4 min), and returned to standard culture condition with fresh complete
RPMI and washed group O erythrocytes.
2.6.5 Gametocyte preparation
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Gametocytogenesis was induced in a culture of 6% rings, by increasing the
haematocrit to 5% and incubating in partially spent complete RPMI media (2:3 ratio
fresh:used complete RPMI) followed by incubating at 37 ºC for 32 hr. After 32 hr the
media was changed for fresh complete RPMI.  The media was changed again after a
further 48 hr. After a further 24 hr, gametocyes were present at 0.5-1% at stage II-IV
by microscopy. Gametocytes were purified using a gradient of percoll (52.5%, 45%,
and 30% percoll in incomplete RPMI) in a 15 ml corex glass tube, which was spun at
10,000 rpm, 10 min, RT. Gametocytes form a separate layer above the uninfected
cells and ring stage-infected erythrocytes, and the fraction containing the
gametocytes was collected. Most schizont and pigmented trophozoite-infected
erythrocytes also form a separate layer from the gametocytes. Remaining schizont
and pigmented trophozoite-infected erythrocytes in the gametocyte fraction were
destroyed by sorbitol lysis. Trizol was added to the gametocye preparation and RNA
extracted as section 2.2.5.
2.6.6 Laboratory isolates used in this study
Laboratory strains are single genotype parasite clonal populations, which have been
adapted to culture in vitro. For the majority of P. falciparum laboratory strain
analysis, strain 3D7 was used as it has been fully sequenced and annotated, available
from http://www.plasmodb.org. All other P. falciparum strains used are listed (Table
2.2). Isogenic strains are indicated.
Strain Origin











Malayan Camp Thai-Malaysian border
Dd2 Indochina
7G8 Brazil
Muz12 Papua New Guinea
Table 2.2. Laboratory strains used in this thesis and worldwide origin (Mu et al.
2005). a3D7 and NF45 are isogenic. b FCR3, IT, R29, A1R, Palo Alto and TM267 are
also isogenic.
2.7 Statistical methods
Stastistical analysis was done with StatView 5.0.1 software. Student’s t-tests were
used to compare normally distributed data from two groups with roughly equal
variance, including parasitaemia of isolates and age of patients at time of the
infection. ANOVA were also used to back up t-test results when multiple t-tests were
used to compare different data sets from a single experiment. Chi-squared tests were
used to compare distribution of observed data compared to a null hypothesis, such as
DBLα1/DBLα0 expression.  Kruskal Wallis (non-parametric) tests were used to




Var gene transcription and
childhood malaria disease
manifestation
Some of the results presented in this chapter were published as
Kyriacou, HM et al. (2006). Differential var gene transcription in Plasmodium
falciparum isolates from patients with cerebral malaria compared to
hyperparasitaemia. Molecular and Biochemical Parasitology 150(2):211-8.
66
3.1 Abstract
P. falciparum  field isolates from Mali were used to test the hypothesis that
transcription of a subset of the total var gene repertoire was associated with severe
clinical disease outcome. Using DBLα domain as an indicator of var gene group, an
association was found between group A v a r gene transcription and disease
manifestation. Children with cerebral malaria disease (coma) showed significantly
higher levels of group A var gene transcription than a control group of children with
equally high parasite burden but no signs or symptoms of severe disease. This
provides evidence for the importance of expressed PfEMP1 in disease pathogenesis.
The link demonstrated here between DBLα1-type DBLα domains and severe disease
also has potential implications in future drug and vaccine design, for example
suggesting that DBLα1 rather than DBLα0 may provide a better target for vaccine
development to tackle severe malaria disease.
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3.2 Introduction
3.2.1 P. falciparum  severe disease in Africa
Children under 5 years old in sub-Saharan Africa bear the majority of disease and
mortality due to P. falciparum malaria infection (WHO 2000), and many distinct
severe disease syndromes can develop upon infection (discussed in chapter 1).
Cerebral malaria, coma due exclusively to P. falciparum infection associated with
sequestration of parasitized erythrocytes in the cerebral microvasculature, is a
relatively common severe disease manifestation in Africa, occurring in
approximately half a million children per year with a 10-30% mortality (MacPherson
et al. 1985; White 1987; Brewster et al. 1990; Berendt et al. 1994a; Newton et al.
1998; Silamut et al. 1999). During the rainy season in malaria-endemic areas, over
70% of children can be infected with an asymptomatic parasitaemia (Bejon et al.
2007). Malaria fever without severe complications is defined as “uncomplicated”
malaria disease, and is commonly used as a control population for severe disease-
association studies (Kirchgatter and Portillo Hdel 2002; Bull et al. 2005a; Kaestli et
al. 2006; Rottmann et al. 2006). In addition, some children in Africa have been
observed to withstand a surprisingly high parasitaemia (10% erythrocytes infected),
with no severe disease complications. This condition is rare in low transmission
areas such as Asia or South America, where disease severity is linked more directly
with parasitaemia. Parasite isolates from these children provide a good control group
for a study of parasite virulence in severe clinical disease isolates, with any effect of
parasitaemia being removed.
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3.2.2 PfEMP1 and severe disease
The surface-exposed multigene polymorphic PfEMP1 protein family, encoded by var
genes mediate immunomodulation, sequestration, and other adhesive phenotypes,
and are key candidates for modulating pathology of an infection. PfEMP1 are
classified into three main groups A-C and two intermediate groups B/A and B/C (see
chapter 1). This classification is based on chromosomal position, direction of
transcription, and the upstream region of the var genes, and so potentially separates
genes on the basis of different promoter regions. The classification also splits genes
into two broad groups. Group A and B/A tend to have a complex domain structure
with 4-7 DBL domains and a CIDRα1 domain which does not have affinity for
CD36 (Robinson et al. 2003). Group B, C or B/C PfEMP1 in general are shorter
commonly with only 2 DBL domains and 2 CIDR domains, including a CIDRα
which typically has affinity for CD36 (Gardner et al. 2002; Robinson et al. 2003;
Kraemer et al. 2007).
Restricted and antigenically conserved subsets of variant surface antigens (VSA)
have previously been associated with severe disease through field isolate
agglutination studies, termed VSA “severe malaria”, VSASM (Bull et al. 1999; Bull
et al. 2000; Nielsen et al. 2002). PfEMP1 family variants are obvious targets for
investigation of this observation.
A link between group A PfEMP1 and severe disease was suggested by Jensen et al
(2004) through transcription analysis of severe malaria-phenotype parasites produced
by bead selection of parasites on sera from semi-immune children. A link between
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group A var gene expression and severe disease was also indicated by a small field
isolate study in Brazil (Kirchgatter and Portillo Hdel 2002), though other studies in
Papua New Guinea, Tanzania and Kenya have shown conflicting results (Bull et al.
2005a; Kaestli et al. 2006; Rottmann et al. 2006). These differences may be partly
explained by differences in disease classification and methods of analysis, as well as
differences in disease manifestation (see introduction for more detail). This study set
out to examine var gene transcription in three carefully defined disease manifestation
groups.
3.2.3 Var gene DBLα domain analysis
The PfEMP1 DBLα domain is the most well conserved DBL domain type. Almost
all sequenced var genes to date contain a DBLα domain, including 59 of the 60 3D7
var genes, the exception being members of the var2csa family (Gardner et al. 2002).
Two relatively conserved sections flanking a 400 bp highly polymorphic stretch
allowed primers to be designed to recognise and amplify most DBLα domains
through polymerase chain reaction (PCR) (Taylor et al. 2000a; Bull et al. 2005a). In
3D7, 56/59 DBLα domains are recognised by these primers with an unbiased
distribution. Unfortunately, type 3 var genes cannot be amplified by these primers as
the reverse primer site is not recognised (see chapter 5). Reverse transcriptase (RT)-
PCR of these primers on RNA from an isolate should amplify all of the non-type 3
DBLα domain transcripts present.
PfEMP1 domain sequences can be aligned and compared phylogenetically, using a
phylogenetic tree building progam (Smith et al. 2000b; Kraemer and Smith 2003;
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Lavstsen et al. 2003). DBLα sequences can also be split into the two groups DBLα0
and DBLα1, on the basis of 2 conserved cysteines in the amplified tag (Table 1.1,
introduction). In addition, domains can be further sub-classified into 6 DBLα groups
(Table 3.1, Fig. 3.1) (Bull et al. 2005a; Bull et al. 2007).
Group Cysteines
in tag
PoLV1 PoLV2 DBLα type
1 2 MFK* Non-*REY DBLα1
2 2 Non-MFK* *REY DBLα1
3 2 Non-MFK* Non-*REY DBLα1
4 4 ND Non-*REY DBLα0
5 4 ND *REY DBLα0
6 ≠ 2 or 4 ND ND -
Table 3.1. DBLα group definitions from Bull et al. (2005). PoLV; position of limited
variation. *Any amino acid. ND: Not defined at this position. Group 6 includes
DBLα0 and DBLα1 domains.
In addition, the upstream region sequence can be used to identify var gene group (see
section 3.5.5). The three methods of var gene analysis/classification used in this
chapter are represented in Fig. 3.1.
71
Fig. 3.1. The three methods of var gene analysis/classification. Green: DBLα
sequence analysis from PCR using degenarate primers DBLαAF’ and DBLαBR
(Taylor et al. 2000a; Bull et al. 2005a) to amplify a variable section of the DBLα
domain. Blue: DBLα sequence grouping into DBLα groups 1-6 using positions of
limited variation (PoLV) (Bull et al. 2005a; Bull et al. 2007). PoLV1-4 are indicated
within the DBLαAF’ and DBLαBR amplicon; adapted from Bull et al. (2007). Red:
Upstream sequence analysis from PCR of upstream region (UpsA, UpsB or UpsC)
from PCR using a generic upstream region forward primer and DBLα domain-
specific reverse primer; more detail given in section 3.5.5.
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3.2.4 Var gene analysis: DBLα domains as indicator of var gene group
The 3D7 genome and the recently sequenced HB3 and IT genomes provide data on
common var gene structures, allowing assumptions to be made about the architecture
of a var gene on the basis of DBL domains present (Gardner et al. 2002; Kraemer et
al. 2007). In this chapter, analysis of DBLα domain sequence, and subsequent
classification of the domains into DBLα1 domain or DBLα0 domain, allows
assumptions to be made on the group of var gene transcribed, and thus PfEMP1
group expressed. Presence of a DBLα1 domain indicates a group A or B/A PfEMP1.
Conversely, presence of a DBLα0 domain indicates a group B, C or B/C PfEMP1,
see chapter 1 for more details.
3.3 Aim of chapter
Variable surface antigens are prime candidates for influencing the pathogenesis of
infection, as they mediate immuno-modulation and sequestering within the host. This
chapter focuses on a var gene transcription profiling study of P. falciparum
childhood malaria field isolates, with the aim of indentifying if there was a link
between expressed var gene group and disease manifestation.
3.4 Materials and methods
Materials and methods that are specific to chapter 3 are listed below. General
materials and methods and a list of suppliers are given in chapter 2.
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3.4.1 Field isolate collection
Childhood malaria samples from cerebral malaria (9), uncomplicated malaria (9) and
hyperparasitaemia (8) were collected as part of, and a gift from, the Bandiagara
Malaria Project case-control study of severe malaria (Lyke et al. 2003; Lyke et al.
2004) as described in chapter 2. Cerebral malaria is defined as unrousable coma
(Blantyre coma score ≤ 2) in the presence of asexual parasitaemia where all other
causes of encephalopathy are excluded (WHO 2000). Uncomplicated malaria and
hyperparasitaemia are both defined as P. falciparum parasitaemia and fever with no
signs or symptoms of severe disease (such as prostration, impaired consciousness or
repeated convulsions, see Table 1.3, introduction). However, hyperparasitaemia is
additionally defined as parasite density exceeding 500,000 parasites per microlitre of
blood (approximately 10% parasitaemia), thus in this study uncomplicated malaria
patients were defined as having <500,000 parasites per microlitre of blood.
Parasites were cryopreserved in Mali, thawed in Edinburgh, and cultured for 8-24 hr,
to early pigmented trophozoite stage as described in chapter 2. RNA was extracted
and cDNA prepared as described in chapter 2.
3.4.2 RT-PCR conditions
Reverse-transcriptase (RT)-PCR was used to amplify a region of 300-400 bp of the
v a r  DBLα  domain using unbiased degenerate primers DBLα AF’
GCACG(A/C)AGTTT(C/T)GC and DBLαBR GCCCATTC(G/C)TCGAACCA
(Taylor et al. 2000a; Bull et al. 2005a). These primers are capable of amplifying the
entire var gene repertoire of 3D7 apart from the strain-transcending var2CSA gene
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implicated in malaria in pregnancy as this gene has no DBLα domain (detailed
discussion in chapter 4), and the ‘type 3’ var gene family members, which have
atypical DBLα1 domains, of which there are three in 3D7 (detailed discussion in
chapter 5). Amplification used 5 µ l 10x PCR Gold buffer, 25 pmol each of
DBLαAF’ and DBLαBR primers and 0.2 µl Amplitaq Gold polymerase with a final
concentration 2 mM MgCl2, and 1.25 mM of each dNTP, and the volume adjusted to
50 µl after addition of 2 µl cDNA (or distilled water). Amplification conditions were
as described (Taylor et al. 2000a; Bull et al. 2005a) with a hot start (95˚C, 5 min)
followed by 35 cycles of 95˚C, 20 sec; 42˚C, 20 sec; 60˚C, 1 min. Samples without
RT were used in all reactions to exclude gDNA contamination. 2 µl 3D7 cDNA was
used as a positive control, and distilled water as a negative control.
See chapter 2 for details of ligation, cloning, transformation, and sequencing of RT-
PCR products. In brief, RT-PCR products were visualised by electrophoresis on
1.5% agarose gels. RT-PCR products were purified and ligated into PCR II TA
cloning vector (Invitrogen) and ligated plasmids were used to transform E. coli.
Transform E. coli was grown overnight under ampicillin selection and blue/white
colony screening. Individual colonies were selected for overnight growth and the
plasmids extracted for sequencing. Presence of an insert in the extracted plasmid
preparations was verified by EcoRI restriction digestion prior to sequencing.
Sequencing was carried out by the University of Edinburgh School of Biological
Sciences Sequencing Service.
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3.4.3 Transcript sequence analysis
Transcript sequences from each isolate were grouped into contigs of >95%
nucleotide identity using the SeqMan programme within the DNAstar software
package. Consensus sequences from each isolate were defined as sequence A, B, C
etc from that isolate as EditSeq files (DNAstar software package), and protein
sequences were obtained by translating the DNA sequences using the Editseq
translation function. Nucleotide and protein sequences were then compared within
and between isolates using MegAlign (DNAstar software package). Alignments and
phenograms were produced using the clustal W alignment programme within
MegAlign, using default settings. Sequence distances were calculated using
MegAlign, and colour-coded in Excel into the following groups; 0-30, 30-39.9, 40-
49.9, 50-59.9, 60-69.9, 70-99.9 and 100% amino acid identity for production of
sequence distance figures. Homology searches were performed using nucleotide-
nucleotide BLAST search of the NCBI database (http://www.ncbi.nlm.nih.
gov/BLAST). Pie charts were created in Excel. Phenograms were laid out in Adobe
Illustrator. Histograms and boxplots were created in Statview.
3.4.4 Var gene upstream region PCR
Upstream PCRs were carried out on gDNA with each of 4 upstream primers, UpsA
TATTYHATKTATTAYATTTGTTGTA, UpsB GTTAGAACATTTAAAATTATA,
UpsC1 AVAGAWATATGRTAGATAYAG and UpsC2 ACAAACATAGTGAC
TACC based on sequences from 3D7, and a gene-specific reverse primer (Table 3.2)
for each isolate dominant var gene DBLα domain, and for laboratory isolates Palo
Alto, TM180 and A1R. Amplification used 5 µl 10x PCR Gold buffer, 25 pmol of an
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upstream primer, 25 pmol of a downstream primer and 0.2 µl Amplitaq Gold
polymerase with a final concentration 2 mM MgCl2, and 1.25 mM of each dNTP,
and the volume adjusted to 50 µl after addition of 0.5 µl gDNA from the RNA
preparation (or distilled water). Amplification conditions were 35 cycles of 94˚C, 5
sec; 46˚C, 15 sec; 60˚C, 2 min. 0.25 µl gDNA (3D7 unless otherwise stated) was
used as a positive control, and distilled water as a negative control. RT-PCR products
were obtained for 22 isolates. The remaining 4 isolates (Hyp6, HYP8, U1 and U4)
were not studied due to lack of parasite material. PCR product were purified, ligated
into PCR II vector (Invotrogen) and used to transform E. coli for colony picking,
plasmid extraction and sequencing as described chapter 2. The upstream sequence of
the predominant var gene from 9 isolates was studied.  The remaining upstream
sequences were not obtained due to problems with cross-reactivity of the “specific”




Upstream PCR domain specific reverse
primer sequence
CM1 CM1A CTT ACT TTA GGT AGT GG
CM2 CM2A AAC AAT CGT TGT ATT ACT CGC
CM3 CM3A TTT GAA TGG GCT TGA TTT
CM4 CM4A TGT ATT AGT CGA AGA TGT TCC
CM5 CM5A ATG AAT TCC CCT GTT GTT
CM6 CM6A ACC ATC ATA ATC ACT TAT TTG
CM7 CM7A AAC TCC ATT TGG TTT ATA TAC
CM8 CM8A CTT GAC TTG TAA AAA CAT CAC
CM9 CM9A CAC CAT TTT TAT CTT GGT
HYP1 HYP1A TTT TTC AGT CCA ACT ATC GTT
HYP2 HYP2A TTT CCA CCA TTT TTA TCT TGG
HYP3 HYP3A TTT CAC ATA TTT AGC TAC TCC
HYP4 HYP4A TTG GTC TCT ATT AGC GTT
HYP5 HYP5A GTC CTT CGT CAA ATC ACC
HYP6 HYP6A ND




U2 U2A TCT AGC CAT AGA TGG ACT TTC
U3 U3A ACC ATC ATA ATC ACT TAT TTG
U4 U4A ND
U5 U5A GAA TAT ATA TCA CCT TGC TCT
U6 U6A CCT TTG GAG CTT  TG
U7 U7A TTT TTG TCA TTG TCA TTG TAG
U8 U8A CTG CTA GCC TGT TGT CGT
U9 U9A TTG AGC ATC TTT TAG CTT GTT
Palo Alto PARvar1 GTT CTT GTA CTT TAG GTG A
TM180 TM180var1 TAA ATT GGT AAG AAC GGC TCC TTG
A1R A1Rvar1 CAT TCT TCC CTC TCG T
Table 3.2. Reverse primer sequences for upstream regions PCR for the predominant
gene from each isolate. ND: Not designed due to lack of parasite material.
3.4.5 Statistical analysis
Statistical analysis was done with StatView 5.0.1 software. Student’s t-tests were
used to compare normally distributed data from two groups with roughly equal
variance (patient age, isolate parasitaemia, number of genotypes in each isolate).
Kruskal Wallis (non-parametric) tests were used to compare non-normal data (isolate
rosette frequency and transcription frequency of the six DBLα groups in the different
clinical categories). Chi-squared tests were used to compare distribution of observed
data with a null hypothesis, such as DBLα1/DBLα0 expression levels. Fisher’s
Exact Test was used to compare the predominant gene per isolate for
DBLα1/DBLα0 type. A 3x6 contingency table was used to compare the number of
transcripts classified into the 6 DBLα domains groups proposed by Bull et al. (2005)
in each clinical manifestation group. Correlations between DBLα1 % and age,
parasitaemia and rosette frequency were assessed by Spearman Rank correlation.
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3.5. Results 1: DBLα domain transcription analysis in Malian childhood
field isolates
3.5.1 Malian childhood malaria field isolate details
Field isolates were obtained from 26 children with strictly defined conditions of
uncomplicated (9) or cerebral malaria (9), or hyperparasitaemia (8) from Bandiagara,
Mali, as part of a case-control trial study (Lyke et al. 2003; Lyke et al. 2004). The
aim of the study was to examine var gene transcription within these isolates, using
degenerate primers to DBLα domains to amplify DBLα domain transcripts by RT-
PCR.
Before this was done it was important to assess the 26 field isolates to check that
there were no significant differences in age and parasitaemia between the groups
which may influence the data. No significant difference in patient age was seen
across the three clinical categories (Fig. 3.2A, Table 3.3; t-test, p > 0.45), probably
due to age matching in the study group from which these isolates were taken.
Cerebral and hyperparasitaemia isolates did not differ significantly in parasitaemia
(t-test, p = 0.83). Both had significantly higher parasitaemia than the uncomplicated
isolates (Fig. 3.2B, Table 3.3; p > 0.001).
In addition to age and parasitaemia, data on the rosette frequency and level of
platelet-mediated clumping within each isolate was also available. Cerebral isolates
showed significantly higher rosette frequency than both other categories (Fig. 3.2C,
Table 3.3; p = 0.03), as expected in isolates from Africa (Carlson et al. 1990; Rowe
et al. 1995; Rowe et al. 2002b). Only 4 isolates showed platelet-mediated clumping
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(PMC; Fig. 3.2D), including the only cerebral isolate in which there were no rosettes,
CM8 (PMC 53%, RF 0). Low PMC levels meant that comparison of the disease
categories was not significant, though the data has been analysed elsewhere, showing
an association between parasitaemia and PMC levels, though not with disease
severity per se (Arman et al, 2007).
Furthermore, field isolates can comprise multiple infections. To assess the number of
genotypically distinct infecting parasite strain within each isolate, the number of
distinct genotypes in each isolate was estimated by PCR of size-variant genotype
markers MSP1 and MSP2 (see materials and methods). Multiple distinct genotypes
were present in many isolates (range 1-5, Table 3.4). There was no significant
difference in number of genotypes between the three clinical categories (t-tests, p >
0.48, Table 3.3).
This data is also shown in Appendix 1, which shows a table of all data regarding the
Mali childhood isolates discussed in the thesis.
80
Fig. 3.2. Individual isolate details for the 26 Malian childhood P. falciparum malaria
field isolates studied showing A) age, B) parasitaemia, C) rosette frequency (RF;
percentage of infected erythrocytes bound by ≥ 2 uninfected erythrocytes) and D)
platelet-mediated clumping frequency (PMC; percentage of infected erythrocytes
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Uncomplicated 45.8 ± 28.0 3.3 ± 1.5 8.0 : 0, 15.8 2.4 (1-4)
Hyperparasitaemia 42.5 ± 16.9 11.9 ± 3.9 9.5 : 0, 18.0 2.6 (1-4)




P values P > 0.45b P = 0.83 H:C c
P < 0.001
U:C/H
P = 0.03 d P > 0.48 e
Table 3.3. Combined data from all isolates within each disease category
a% of mature-stage infected erythrocytes that bind 2 or more uninfected erythrocytes.
bUncomplicated:cerebral p = 0.46, uncomplicated:hyperparasitaemia p = 0.72,
cerebral:hyperparasitaemia p = 0.68, t-test.
c H: hyperparasitaemia; C: cerebral malaria; U: uncomplicated malaria. t-test.
dKruskal Wallis test.
eUncomplicated:cerebral p = 0.72, uncomplicated:hyperparasitaemia p = 0.72,
cerebral:hyperparasitaemia p = 0.49, t-test.
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Uncomplicated isolates Cerebral isolates Hyperparasitaemia isolates
Isolate Genotypes Isolate Genotypes Isolate Genotypes
U1 4 CM1 1 HYP1 4
U2 3 CM2 3 HYP2 3
U3 3 CM3 3 HYP3 1
U4 3 CM4 5 HYP4 2
U5 3 CM5 1 HYP5 3
U6 1 CM6 3 HYP6 3
U7 3 CM7 1 HYP7 3
U8 1 CM8 1 HYP8 2
U9 1 CM9 2    
Range 1 to 4 Range 1 to 5 Range 1 to 4
Mean 2.4 Mean 2.2 Mean 2.6
Table 3.4. Estimated number of distinct genotypes present per isolate for each isolate
on the basis of PCR of size-variant markers MSP1 and MSP2.
3.5.2 DBLα RT-PCR technique
The aim of this chapter was to investigate the transcribed var genes in Malian P.
falciparum malaria field isolate by examining the sequence and relative frequency of
transcribed DBLα domains by RT-PCR. There was not enough parasite material to
perform real-time RT-PCR for quantitative analysis of the DBLα domain transcripts
in each isolate, so RT-PCR was quantified by colony analysis.
RNA was extracted from the 26 field isolates, and cDNA was prepared. DBLα
transcripts were amplified from cDNA by RT-PCR using degenerate primers to
DBLα domains (Taylor et al. 2000a; Bull et al. 2005a). An aliquot of products from
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each RT-PCR reaction was visualised on a 1.5% agarose gel. Fig. 3.3 shows a
representative gel; the amplified DBLα RT-PCR products from isolates HYP1,
HYP3 and HYP5 are seen as bands of approximately 400 bp. Multiple bands can be
seen, representing multiple DBLα domain transcripts of slightly different length.
Fig. 3.3. Representative gel of DBLα domain RT-PCR products from Mali field
isolates. RT-PCR products from amplification of DBLα domains from cDNA from
Mali field isolates HYP1, HYP3 and HYP5, with primers DBLαAF’ and DBLαBR,
were visualised by electrophoretic separation on a 1.5% agarose gel. Reverse
transcriptase negative cDNA preparation control (CTL) for each isolate reveal PCR
products from gDNA contamination, and are next to the cDNA amplification for
each isolate. These lanes remain blank indicating there is no gDNA contamination in
the cDNA preparation. 3D7 cDNA was used for a positive control, and distilled
water as a negative control for the PCR reaction. DNA ladder was φX174 RF
DNA/Hae fragments (Invitrogen).
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These DBLα RT-PCR products were then purified and ligated into plasmids. These
recombinant plasmids were used to transform E. coli, which were plated onto LB
agar/ampicillin plates and grown up overnight at 37°C. Ampicillin in the plates
selected for growth of transformed bacteria, and blue-white screening allowed
bacterial colonies containing a recombinant plasmid to be selected. 14-19 white
bacterial colonies were selected for expansion in LB broth at 37°C, and after
approximately 18 hours a number of recombinant plasmids from colonies from each
RT-PCR were extracted using a QIAgen miniprep kit. The presence of an insert of
the correct length was confirmed by enzymatic digestion of the multiple cloning site
using restriction enzyme EcoRI of a sample of each extracted plasmid. Digested
plasmids were visualised on 1.5% agarose gels, and plasmids containing an insert
were marked by presence of an approximately 400 bp band. Fig. 3.4 shows a typical
gel.
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Fig. 3.4. A typical 1.5% agarose gel of EcoRI digests products of plasmids extracted
from a set of minipreps. Plasmid preparations were digested in EcoRI for 1.5-2 hr at
37ºC. In this case 8 minipreps from 3 isolates HYP1, HYP2 and HYP3 are shown, all





The inserted DBLα domain tags in purified plasmids from each isolate RT-PCR
transformation were sequenced, using a primer site just upstream of the multiple
cloning site on the vector.
The RT-PCR colony picking analysis technique described above is summarised in
Fig. 3.5.
Fig. 3.5. Schematic diagram of RT-PCR colony picking analysis technique.
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3.5.3 DBLα RT-PCR validity
In the first instance, I investigated the validity of my approach by sequencing inserts
in 16-17 “blue” colonies derived from each of 3 field isolate. To determine if
sampling a larger number of plasmids would influence the results of the study,
colony picking was repeated, picking 50 further colonies for two of the isolates,
CM7 and CM9 (Fig. 3.6, colony pick repeat column). In addition, to determine
whether the RT-PCR results were representative and repeatable, RT-PCR, cloning
and sequencing was repeated from a separate RT-PCR reaction from the same RNA
extraction from three isolates, CM4, CM7 and CM9 (Fig. 3.6, RT-PCR repeat
column).
In all cases, the same predominant sequence was obtained from the second
amplification, supporting RT-PCR analysis from a lower number of sequences. For
CM9, the same two sequences were obtained in similar ratio in all three analyses
(15:1, 42:8 and 14:1 respectively). For CM4, the dominant domain was seen at a
similar frequency in both RT-PCR (15:1:1 and 12:1), but a different minor sequence
was seen in the second RT-PCR reaction. For CM7, a more complex pattern of gene
expression was seen, with a total of 10 different minor domains obtained, though the
dominant sequence remained consistent, and there was some overlap in the minor
domain transcripts (Fig. 3.6; colours represent the same sequence).
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Fig. 3.6. RT-PCR validation. The pie charts represent the frequency of transcripts
sequenced from miniprep plasmids from three isolates, CM9, CM7 and CM4. For
each isolate the same colour represents the same unique sequence. Left: 16-17
plasmids sequenced from bacteria transformed with ligation products from an RT-
PCR reaction. Middle: a further 50 plasmids were sequenced from the same plate of
bacteria transformed with the ligation products from the original RT-PCR reaction.
Right: 12-15 plasmids were sequenced from bacteria transformed with ligated
plasmids from a new RT-PCR reaction from the orignial cDNA preparation.
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3.5.4 Transcribed DBLα domains in childhood malaria field isolates
Having established that the technique was valid, 14-19 minipreps from plates of
transformed bacteria carrying plasmids representing DBLα var gene transcript from
each of the remaining 23 Malian childhood field isolates were sequenced. Sequences
from each isolate were compared using SeqMan software. Identical or almost
identical sequences from the same isolate (>95% identity) were defined as isolate
sequence A, B, C etc in order of abundance (Genbank accession numbers
DQ367086-DQ367226).
The relative abundance of the different DBLα sequences for each isolate is shown in
Fig. 3.7. Here, pie charts represent the total repertoire of DBLα transcripts detected
by RT-PCR, with the area of the pie slices representing the relative levels of
abundance of each DBLα sequence from colony picking analysis. The number of
colonies picked for plasmid sequencing is also shown.
In addition, DBLα domains can be defined as either DBLα1 or DBLα0 on the basis
of conserved cysteines (DBLα1-like genes have 2 cysteines in the amplified tag, and
DBLα0-like genes have 4 cysteines in the amplified tag; Table 1.1). Sequences are
coloured as DBLα1 (white) or DBLα0 (black) in Fig. 3.7.
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Fig. 3.7. Frequencies of distinct DBLα sequences in each isolate. The pie charts
represent the relative number of different DBLα sequences detected in each isolate
by RT-PCR, cloning and analysis of 14-19 mini-prep clones per isolate. For each
isolate, each pie-slice represents a different sequence, and the size of each pie-slice
represents relative abundance of transcript. Isolate name is in the top left corner of
each box. Bracketed numbers indicate the exact number of mini-prep clones
sequenced for each isolate. Shading indicates DBLα0-like (grey) or DBLα1-like
(white) sequences.
The number of sequences per isolate varied between 1 and 14 (Fig. 3.7). There was
no significant difference in the number of distinct DBLα sequences per isolate
detected in each clinical category (cerebral malaria: median 5, range 1-9;
hyperparasitaemia: median 6.5, range 2-14; uncomplicated malaria: median 4, range
2-10, p = 0.72, Kruskal-Wallis test).
The frequency of DBLα1-like var gene transcripts within each clinical manifestation
group was analysed (Fig. 3.8). There was a highly significant difference in the
frequency of DBLα1-like var gene transcripts within the cerebral malaria isolates
(80.1%) compared to the hyperparasitaemia isolates (25.7%; p < 0.001, Chi-squared
test). 40.5% of the sequences from the uncomplicated malaria patients were DBLα1-
like. The frequency of DBLα1-like var gene transcripts in both cerebral and
hyperparasitaemia was significantly different from in uncomplicated isolates (P <
0.005, Chi-squared test) which showed intermediate DBLα1-like var gene
transcription.
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Fig. 3.8. Percentage of DBLα0 (grey) and DBLα1 (white) transcripts detected across
the 26 Malian field isolates separated by disease category cerebral (C),
hyperparasitaemia (HYP) and uncomplicated malaria (U). *There is a significant
difference in DBLα1 proportion between cerebral and uncomplicated isolates, and
between hyperparasitaemia and uncomplicated isolates (both p < 0.005, Chi-squared
test).   ** There is also a significant difference in DBLα1 proportion between











































If only the predominant gene from each isolate was examined, a marked difference
remained between the cerebral malaria and hyperparasitaemia isolates. The
predominant gene in 8/9 isolates from cerebral malaria patients was DBLα1-like,
whereas the predominant gene in 6/8 hyperparasitaemia isolates was DBLα0-like
(Fig. 3.9, DBLα0- specific cysteines boxed). This difference is significant (Fisher’s
Exact test, p = 0.013). For uncomplicated malaria isolates, the predominant gene was
DBLα1-like in 5/9 isolates and DBLα0-like type in 4/9 isolates, not significantly
different from the cerebral or hyperparasitaemia isolates (U:HYP, P=0.29; U:CM
P=0.13, Fisher’s exact test).
Fig. 3.9. Clustal W alignment of the predominant DBLα domains gene transcript in
P. falciparum isolates CM1-9 from cerebral malaria patients and HYP 1-8 from
hyperparasitaemia patients. The second half of the expressed sequence tag is shown
and the position of the residues that distinguish DBLα0-like domains (cysteines
present) from DBLα1-like domains (cysteines missing) are arrowed, and the cysteine
residues are boxed. Symbols: * indicates conserved residues; : indicates conservative
substitution; . indicates semi-conservative substitution.
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DBLα domains can be separated into 6 groups according to sequence motifs in the
expressed sequence at positions of limited variation as well as the number of cysteine
residues (Bull et al. 2005a), as described in Table 3.1. Group 1 domains have 2
cysteines in the amplified tag and the sequence MFK* at a particular locus defined as
PoLV1. Group 2 domains also have 2 cysteines in the amplified tag and have *REY
at a second locus defined as PoLV2. Group 3 domains contain neither MFK* or
*REY, but also have 2 cysteines in the amplified tag. Group 4 and 5 domains have 4
cysteines in the amplified tag. Group 4 domains do not contain *REY at PoLV2
whereas group 5 domains do.  Group 6 domains have 1,3,5 or more cysteines in the
amplified tag.
Under these definitions, DBLα1 domains are Bull groups 1-3 and DBLα0 domains
are groups 4 and 5. Group 6 are atypical domains with 1, 3, or >5 cysteines in the
amplified tag and can be DBLα1 or DBLα0 domains. Examination of the Mali
sequences classified into these six DBLα domain sequence groups did not reveal any
further differences between the three disease categories (Fig. 3.10). As expected,
most of the genes transcribed in the isolates from cerebral malaria patients are in
groups 1-3 (DBLα1), and isolates from hyperparasitaemia patients mostly transcribe
var genes in groups 4 and 5 (DBLα0). The isolates from uncomplicated malaria
patients show an intermediate pattern with 4 isolates mostly transcribing groups 1-3
(DBLα1) and 5 isolates mostly transcribing groups 4 and 5 (DBLα0). Transcription
frequencies of the six different DBLα groups in the different clinical categories are
significant (P = 0.049, Kruskal Wallis test). A 3x6 contingency table was also used
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to compared the number of transcripts classified into the 6 DBLα groups. For data in
the three clinical groups combined, the distribution of reads in each group is
significantly different (P<0.001). Seven group 6 sequences described by Bull et al
(number of cysteines ≠ 2 or 4) were detected, none of which were transcribed at high
level, and all of which could be classified as either DBLα1 or DBLα0. Neither of the
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B
Fig. 3.10. The transcribed var genes domain sequences from each isolate, and for all
cerebral, hyperparasitaemia and uncomplicated malaria isolate sequences grouped,
were separated into 6 DBLα sequence types (Bull et al. 2005a). Group 1-3 domains
have 2 cysteines in the amplified tag (DBLα1). In addition, group 1 domains have
MFK* at a particular locus defined as PoLV1, group 2 domains have *REY at a
second locus defined as PoLV2 and group 3 domains contain neither MFK* or
*REY. Group 4 and 5 domains have 4 cysteines in the amplified tag (DBLα0).
Group 4 domains do not contain *REY at PoLV2 whereas group 5 domains do.
Group 6 domains have 1,3,5 or more cysteines in the amplified tag. A) Proportion of
transcript in all isolates in the 6 DBLα sequence groups, and combined data for the
three clinical manifestation groups as a bar chart. B) Data for three disease
manifestation groups combined as pie charts.
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3.5.5 Upstream sequence analysis for predominant DBLα domain
transcripts
In the sequenced laboratory strains 3D7, IT and HB3 and in other published var
genes, DBLα1 domains are exclusively seen in group A or B/A var genes while
DBLα0 domains are found in group B, C or B/C var genes (Gardner et al. 2002;
Lavstsen et al. 2003; Kraemer et al. 2007). Thus, DBLα(0/1) domain sequences are
indicators of var gene group. The association of DBLα1 domain transcription with
cerebral malaria described above could be simplified as an association between
transcription of group A or B/A var with cerebral malaria. To validate using
DBLα(0/1) domain to denote groups of transcribed var genes, the different var gene
group upstream region sequences were examined.
Degenerate primers were designed to recognise type A, B or C upstream regions,
using an alignment of published upstream sequences, to allow classification of the
upstream regions of the detected DBLα domains sequences by PCR. These were
designed to amplify the specific upstream regions from laboratory isolate gDNA (gift
from A Raza and JA Rowe) when paired with a gene-specific reverse primer (Fig.
3.11). These primers successfully amplified the upstream region of a specific var
gene from gDNA from three parasite strains PAR+, TM180 and AIR only when the
appropriate upstream group primer  (Ups A, B or C) was used (Fig. 3.12).
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Fig. 3.11. Strategy for specific amplification of transcribed DBLα  domain for
gDNA. Degenerate primers recognising Ups A, B and C regions were used in PCR
reactions with a specific primer to the domain of interest. Only the reaction with the
appropriate upstream region primer resulted in PCR product, which was then
sequenced to verify amplification of the correct DBLα domain and to obtain
upstream sequence data.
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Fig. 3.12. PCR gel showing domain amplification of Ups A, B and C upstream
regions. Specific primers to var genes PARvar1 (Strain: It/Palo Alto [PAR+]; UpsA),
TM180var1 (Strain TM180; UpsB) and A1Rvar1 (Strain A1R; UpsC) were used
with specific primers for UpsA, UpsB and two different UpsC primers C1 and C2,
and with the appropriate gDNA. PCR product is only seen with the expected
upstream primer. DNA ladder was λ DNA/HinDIII fragments (Invitrogen).
Specific primers to the dominant DBLα domain sequence tag from the field isolate
were designed (Table 3.2). These specific primers were used with each of the
upstream primers to amplify the upstream region of the predominant domains in each
isolate. PCR product was obtained and fully sequenced from nine isolates. This gave
the expected result that all of the examined field isolate var genes with DBLα1
domains had UpsA-type or UpsB-type upstream regions whereas all of the field
isolate var genes with DBLα0 domains had UpsB-type or UpsC-type upstream
regions as is seen in 3D7 laboratory strain (Lavstsen et al. 2003). Upstream sequence
group and predicted var gene groups are shown in Table 3.5. Other domains could
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not be sequenced due to cross recognition of other DBL domains with the “specific”
primer, or lack of parasite material.
Manifestation Domain DBLα1/0 Ups
sequence
P r e d i c t e d  Var
group
CM2A DBLα1 A A
CM3A DBLα1 A A
CM6A DBLα1 A A
Cerebral
Malaria
CM8A DBLα1 A A
HYP1A DBLα0 B B
HYP4A DBLα1 B B/A
Hyperparasitaemia
HYP5A DBLα0 B B
U2A DBLα0 C CUncomplicated
Malaria U8A DBLα0 B B
Table 3.5. Ups sequence and predicted var groups for the dominant domain in 9
isolates with successful upstream region. Upstream regions were amplified with
specific primers for UpsA, UpsB and UpsC upstream regions and a reverse gene
specific primer for the predominant DBLα gene for each isolate.
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3.5.6 Phylogenic analysis of DBLα domain transcripts
The association between disease phenotype and var gene expression was explored by
mapping symptoms across a phylogeny of the DBLα sequences. A phenogram was
created from a clustal W alignment of protein sequences. Phenograms depict genetic
relationships without assumptions of evolutionary history. EBA175 was added as a
root, as it is a common ancestor of DBL domains, and forms a clear outgroup
(Adams et al. 1992). For reference, a selection of DBLα sequences from the three
major groups A, B and C from the fully sequenced P. falciparum laboratory clone
3D7 (Gardner et al. 2002) were included, plus four 3D7 genes with intermediate
characteristics (B/A or B/C) (Fig. 3.13).
There is a pronounced split as DBLα1-like form a separate clade from DBLα0-like
sequences in the phenogram. All sequences above the node where the two clades
split (marked *, Fig. 3.13) are DBLα0-like and all below are DBLα1-like. The
DBLα0-like upper clade is comb-like, indicating a high level of recombination or an
explosive gene duplication event of these sequences. The DBLα1-like lower clade
has a more complex branch structure, suggesting more directed evolution.
The phenogram was also coloured according to the 6 DBLα groups classified by
Bull et al (2005), Fig. 3.14. Group 4 and 5 sequences cluster separately from groups
1-3. Group 2 sequences form an outgroup of DBLα1 sequences, in general clustering
separately from group 1 and 3 sequences. There is no obvious pattern to the position




Fig. 3.13.  Phenogram produced from an amino acid alignment using Clustal W, and
the tree-building program in MegAlign (DNA star lasergene software). Sequences
transcribed by isolates from African children with cerebral malaria (CM, red),
hyperparasitaemia (HYP, blue), and uncomplicated malaria (U, green) are compared
to a selection of var genes from the laboratory clone 3D7.  For the 3D7 genes, the
gene name is preceded by A, B, C, BA or BC to indicate the group to which the gene
belongs. The sequences fall into 2 major clades, which split at the asterisked node (*)
with the DBLα1-like sequences in the higher clade and the DBLα0-like sequences
lie in the lower clade. For the predominant gene from 9 of the Malian isolates, the
var gene upstream region was determined by PCR and is indicated after the
appropriate domain (UpsA, UpsB or UpsC). Bootstrap values were calculated by












Fig. 3.14.  Phenogram was produced as for Fig. 3.13. Amino acid sequences were
alignmened in Clustal W, and the phenogram was created tree-building program in
MegAlign (DNA star lasergene software). Sequences transcribed by isolates from
African children with cerebral malaria (CM), hyperparasitaemia (HYP), and
uncomplicated malaria (U) are compared to a selection of var genes from the
laboratory clone 3D7.  For the 3D7 genes, the gene name is preceded by A, B, C, BA
or BC to indicate the group to which the gene belongs. The sequences fall into 2
major clades, which split at the asterisked node (*) with the DBLα1-like sequences
in the higher clade and the DBLα0-like sequences lie in the lower clade. For the
predominant gene from 9 of the Malian isolates, the var gene upstream region was
determined by PCR and is indicated after the appropriate domain (UpsA, UpsB or
UpsC). Sequences are coloured according to the DBLα group classification of Bull
et al. 2005: DBLα1 groups: group 1: red, group 2: purple, group 3: pink. : DBLα0
groups: group 4: dark blue, group 2: light blue. Group 6 sequences are in grey.
Bootstrap values were calculated by Graham Stone through 1000 repeat iterations of
the tree and superimposed onto the phenogram.
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The phenogram successfully separates the domains on the basis of sequence.
However, recombination can generate conflicting signals during the process of tree-
building, potentially causing a significant source of error (Huson and Bryant 2006).
Phylogenetic networks take recombination into account better than traditional
phenogram building algorithms. As var genes are subject to a high level of
recombination (Freitas-Junior et al. 2000; Taylor et al. 2000b; Kraemer et al. 2007) a
network was considered more accurate. A network (Appendix 2) was created by Dr
Graham Stone (University of Edinburgh) to replace the phenogram. The network was
produced from an initial Clustal W alignment of the amino acid sequences, converted
to a nucleotide alignment. The network (Appendix 2) recapitulates the split of
DBLα1 versus DBLα0 sequences seen in the phylogenetic tree. Sequences from the
cerebral malaria patients (red in network; Appendix 2) are significantly concentrated
into a ‘cerebral malaria clade’ (P < 0.001, chi-squared test), while sequences from
the hyperparasitaemia patients (blue) are significantly concentrated in a
‘hyperparasitaeima clade’ (P < 0.025, chi-squared test). Sequences from the
uncomplicated malaria patients (green) showed no bias in distribution between the
two main clades of the network.
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3.6 Results 2: Sequence conservation between var gene DBLα domain
transcripts
3.6.1 Sequence identity between DBLα domain transcripts
Identical sequences from different isolates (branch length zero in Fig. 3.13, or
parallel branches in network, Appendix 2) were rare, reflecting minimal overlap in
var gene repertoires between isolates. Only 12 of the 142 unique sequence tags were
present as identical or almost identical (>95% nucleotide identity) in more than 1
isolate. The mean amino acid sequence identity between sequences was 42.2% (SE
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Fig. 3.15. The percentage amino acid identity between all DBLα transcripts from the
Mali field isolates is displayed as a box plot (showing 10th, 25th, 50th, 75th and 90th
percentiles; values <10th percentile and >90th plotted separately) and as a histogram.
Amino acid sequences were created from nucleotide sequences in EditSeq, and
percentage identity was calculated using MegAlign. Histograms and box plots of
sequence identity were then created in Statview.
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3.6.2 Sequence identity between var gene DBLα domain transcripts in
disease categories
The level of amino acid identity between different Mali DBLα sequence domain
transcripts in each clinical category was also determined. The mean amino acid
identity between transcripts was surprisingly similar between the three disease
categories. Cerebral isolate transcripts showed mean 42.9% (SE 0.26%), and
hyperparasitaemia isolate transcripts showed mean 42.8% (SE 0.27%). The mean
percentage sequence identity uncomplicated isolate transcripts, 40.9%  (SE 0.27%),
was slightly lower from that of hyperparasitaemia and cerebral isolate transcripts,
and this difference was significant (t-test, p < 0.005). There was no significant
difference in transcript identity between hyperparasitaemia and cerebral isolate
sequences (t-test, p = 0.89). The variance of amino acid identity in the three
categories was similar (SD: cerebral 8.6%, hyperparasiteamia 8.8%, uncomplicated,
8.1%). Fig. 3.16 shows histograms and a box plot of the data.
 The level of amino acid identity between different Mali DBLα sequence domain
transcripts in each clinical category was also illustrated pictorially (Fig. 3.17). Amino
acid identity between 2 domains was colour coded such that darker shading reflects
higher amino acid identity.
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Fig. 3.16. Histograms and box plots (showing 10th, 25th, 50th, 75th and 90th
percentiles; values <10th percentile and >90th plotted separately) of percentage
amino acid identity between cerebral, hyperparasitaemia and uncomplicated malaria
DBLα  transcripts. Sequences transcribed in cerebral, hyperparasitaemia or
uncomplicated malaria isolates were considered separately. Amino acid sequences
were created from nucleotide sequences in EditSeq, and percentage identity was
calculated using MegAlign. Histograms and box plots of identity were then created
in Statview.
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Fig. 3.17. Amino acid sequence distance charts showing percentage amino acid
identity between domains separated by disease classification. Sequences transcribed





separately. Amino acid sequences were created from nucleotide sequences in
EditSeq, and percentage identity was calculated using MegAlign. Darkness of
shading indicates level of identity between domains.
3.6.3 Sequence identity between var gene DBLα domain transcripts in
DBLα(1/0) groups
The sequence identity of the DBLα1-like and DBLα0-like transcripts separately was
also calculated. The mean amino acids identity between DBLα0−like transcripts was
46.0% (SE 0.2%) slightly higher than that for DBLα1-like transcripts 45.6% (SE
0.1%). Though a small difference, because of the large sample size this difference is
significant (t-test, p < 0.005). The standard deviation of the DBLα1 sequences
(10.5%) is much greater than for DBLα0 sequences (5.5%), seen as a broader curve
in the histogram (Fig. 3.18). Both DBLα1 sequences and DBLα0 sequences are
more similar to each other than sequences separated by disease category, due to the
definitions of DBLα1 and DBLα0 sequences. This is equivalent to DBLα1 and
DBLα0 sequences clustering separately on the phenogram (Fig. 3.13) and network
(Appendix 2). Fig. 3.19 shows the results pictorially.
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Fig. 3.18. Histograms and box plot (showing 10th, 25th, 50th, 75th and 90th
percentiles; values <10th percentile and >90th plotted separately) of percentage
amino acid identity between all DBLα0 domain and DBLα1 domain transcripts.
Amino acid sequences were created from nucleotide sequences in EditSeq, and
percentage identity was calculated using MegAlign. Histograms and box plots of
identity were then created in Statview.
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Fig. 3.19. Amino acid sequence distance charts showing percentage amino acid
identity between domains separated by DBLα0/1 classification. Darkness of shading
indicates level of identity between domains. DBLα1 and DBLα0 transcript
sequences were considered separately. Amino acid sequences were created from
nucleotide sequences in EditSeq, and percentage identity was calculated using
MegAlign.
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3.6.4 Evidence for conserved var genes
To examine the extent of conservation of these genes to other published global var
genes, sequences were entered in to NCBI BLAST homology search. Database
matches (> 95% nucleotide identity and > 95% sequence coverage) to the Mali
sequence described in this study as of August 2007 are given in Table 3.6.
The most common sequence found in the Mali sequences (CM6A) was present in 5
isolates (CM6, U3, U5, U9 and HYP2), and was the only var transcript detected in
isolate CM6. Nine further non-var1csa Mali sequences were common to 2 isolates
(>95% identity): CM9A:CM8B (100% identity), CM7A:CM2D (100%),
CM9B:CM7D (100%), U7A:HYP2D (100%), CM2E:CM7F (99%), HYP8E:U2A
(99%), U1B:HYP8G (98%), CM2A:HYP3A (98%), U3D:CM7B (96%). One of
these (CM7D/CM9B) was identical to a DBLα  domain from IT/FCR3 family
laboratory strain family (Accession number DQ408000). This domain belongs to the
PfEMP1 PARvar1, which is responsible for rosetting in the Palo Alto form of this
strain (J.A. Rowe, unpublished data). None of the other 8 sequences found in
multiple isolates in Mali (CM6A group, or the 8 transcripts found in 2 isolates)
showed any highly homologous database matches.
Of the non-var1csa sequences found in multiple isolates, most (7/10) involved
cerebral isolate transcripts, and almost half (4/10) were exclusive to cerebral isolates.
No transcript was exclusive to uncomplicated or hyperparasitaemia isolates. In
addition, of the non-var1csa sequences found in multiple isolates, most (7/10) were
DBLα1-like. The group 4 var (Jensen et al. 2004) were not amplified in any of the
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isolates. A similar proportion of DBLα1/0 sequences had no database matches (35%
DBLα1, 28% DBLα0 sequences).
Seven var1csa homologues were also found; CM8D, HYP3B, U5D, U7B were 3D7
var1csa homologues and CM1G, CM4C, CM5B were FCR3 var1csa homologues, as
shown in Table 3.7.
Mali field isolate DBLα sequences Database matches
(>95% identity, >95% coverage)
Name Accession
Number
Freq. DBLα0/1 Group Accession Number (Origin) Nucleotide
identities (%)
CM1 A DQ367086 6/18 1 2 -
CM1 B DQ367087 4/18 1 3 -
CM1 C DQ367088 3/18 1 1 AM115620 (Kenya)1 336/352 (95%)








CM1 E DQ367090 1/18 0 4 -
CM1 F DQ367091 1/18 0 4 -





















CM1 H DQ367093 1/18 0 5 -
CM2 A DQ367094 7/14 1 2 DQ367144 (HYP3a, Mali)* 333/338 (98%)
CM2 B DQ367095 3/14 0 4 -
CM2 C DQ367096 2/14 1 1 AF221828 (Kenya)9 340/340 (100%)
CM2 D DQ367097 1/14 1 2 DQ367116 (CM7a, Mali)* 358/358 (100%)
CM2 E DQ367098 1/14 1 2 DQ367121 (CM7f, Mali)* 325/329 (98%)
CM3 A DQ367099 10/14 1 1 -






CM3 C DQ367101 1/14 0 4 -
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Mali field isolate DBLα sequences Database matches
(>95% identity, >95% coverage)
Name Accession
Number
Freq. DBLα0/1 Group Accession Number (Origin) Nucleotide
identities (%)
CM3 D DQ367102 1/14 1 3 -
CM4 A DQ367103 15/17 0 4 -
CM4 B DQ367104 1/17 0 4 -





















CM5 A DQ367106 8/18 1 1 -





















CM5 C DQ367108 2/18 1 3 -
CM5 D DQ367109 1/18 0 5 -
CM5 E DQ367110 1/18 0 4 -
CM5 F DQ367111 1/18 0 4 -
CM5 G DQ367112 1/18 0 4 -








CM5 I DQ367114 1/18 0 4 -








CM7 A DQ367116 8/17 1 2 DQ367097 (CM2d, Mali)* 358/358 (100%)
CM7 B DQ367117 2/17 1 6 DQ367198 (U3d, Mali)* 316/329 (96%)
CM7 C DQ367118 2/17 1 2 -




CM7 E DQ367120 1/17 1 2 DQ407961 (TM180, SE Asia)5
DQ407945 (Tm90, SE Asia)
342/343 (99%)
341/343 (99%)
CM7 F DQ367121 1/17 1 2 DQ367098 (CM2e, Mali)* 325/329 (98%)
CM7 G DQ367122 1/17 1 3 AM116525 (Kenya)1 342/343 (99%)
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Mali field isolate DBLα sequences Database matches
(>95% identity, >95% coverage)
Name Accession
Number






CM8 A DQ367123 5/19 1 1 AM115191 (Kenya)1 346/346 (100%)
CM8 B DQ367124 4/19 1 3 DQ367131 (CM9a, Mali)* 373/373 (100%)
CM8 C DQ367125 3/19 1 1 -
CM8 D DQ367126 3/19 1 2 PFE1640w (Var1CSA, 3D7)18
DQ367212 (U5d, Mali)*
DQ367145 (HYP3b, Mali)*


















CM8 E DQ367127 1/19 1 2 -
CM8 F DQ367128 1/19 1 1 -
CM8 G DQ367129 1/19 1 2 AM115921 (Kenya)1 327/329 (99%)
CM8 H DQ367130 1/19 0 6 -
CM9 A DQ367131 15/16 1 3 DQ367124 (CM8b, Mali)* 373/373 (100%)




HYP1 A DQ367133 13/15 0 4 -
HYP1 B DQ367134 1/15 0 4 -
HYP1 C DQ367135 1/15 0 4 -
HYP2 A DQ367136 6/15 0 4 DQ135692 (Zimbabwe)6 335/343 (97%)
HYP2 B DQ367137 3/15 0 4 -
HYP2 C DQ367138 1/15 0 4 -
HYP2 D DQ367139 1/15 0 4 DQ367218 (U7a, Mali)* 415/415 (100%)
HYP2 E DQ367140 1/15 0 4 -
HYP2 F DQ367141 1/15 0 4 -








HYP2 H DQ367143 1/15 0 6 -
HYP3 A DQ367144 3/18 1 2 DQ367094 (CM2a, Mali)* 333/338 (98%)
HYP3 B DQ367145 2/18 1 2 PFE1640w (Var1CSA, 3D7)18
DQ367212 (U5d, Mali)*



















Mali field isolate DBLα sequences Database matches
(>95% identity, >95% coverage)
Name Accession
Number
Freq. DBLα0/1 Group Accession Number (Origin) Nucleotide
identities (%)
…
HYP3 C DQ367146 2/18 0 4 -
HYP3 D DQ367147 1/18 0 4 -
HYP3 E DQ367148 1/18 0 4 -
HYP3 F DQ367149 1/18 0 4 -
HYP3 G DQ367150 1/18 0 4 -
HYP3 H DQ367151 1/18 0 4 -
HYP3 I DQ367152 1/18 0 4 -
HYP3 J DQ367153 1/18 0 4 -
HYP3 K DQ367154 1/18 0 4 -
HYP3 L DQ367155 1/18 0 4 -
HYP3 M DQ367156 1/18 0 4 -
HYP3 N DQ367157 1/18 0 4 -
HYP4 A DQ367158 14/15 1 2 -
HYP4 B DQ367159 1/15 1 2 -
HYP5 A DQ367160 4/15 0 4 -
HYP5 B DQ367161 3/15 1 1 -
HYP5 C DQ367162 3/15 0 4 -








HYP5 E DQ367164 2/15 0 4 -
HYP6 A DQ367165 5/16 0 4 -
HYP6 B DQ367166 3/16 1 1 DQ134477 (PNG)6 337/339 (99%)
HYP6 C DQ367167 2/16 0 4 -
HYP6 D DQ367168 1/16 0 4 -
HYP6 E DQ367169 1/16 0 4 AM115543 (Kenya)1 399/405 (98%)
399/405 (98%)
HYP6 F DQ367170 1/16 0 4 -
HYP6 G DQ367171 1/16 0 4 -
HYP6 H DQ367172 1/16 1 1 -
HYP6 I DQ367173 1/16 0 4 -
HYP7 A DQ367174 15/16 0 5 -
HYP7 B DQ367175 1/16 0 6 -








HYP8 B DQ367177 3/16 0 4 -
HYP8 C DQ367178 2/16 0 4 -
HYP8 D DQ367179 1/16 0 4 -
HYP8 E DQ367180 1/16 0 4 DQ367190 (U2a, Mali)* 411/415 (99%)
HYP8 F DQ367181 1/16 0 4 -
HYP8 G DQ367182 1/16 0 4 DQ367185 (U1b, Mali)* 399/407 (98%)
HYP8 H DQ367183 1/16 0 4 -
U1 A DQ367184 8/15 1 2 -
U1 B DQ367185 3/15 0 6 DQ367182 (HYP8g, Mali)* 399/407 (98%)
U1 C DQ367186 1/15 0 4 -
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Mali field isolate DBLα sequences Database matches
(>95% identity, >95% coverage)
Name Accession
Number
Freq. DBLα0/1 Group Accession Number (Origin) Nucleotide
identities (%)
U1 D DQ367187 1/15 0 4 -
U1 E DQ367188 1/15 1 2 AY462831 (PNG)8 337/344 (97%)
U1 F DQ367189 1/15 0 5 -
U2 A DQ367190 11/15 0 4 DQ367180 (HYP8e, Mali)* 411/415 (99%)
U2 B DQ367191 1/15 0 6 -
U2 C DQ367192 1/15 1 3 -
U2 D DQ367193 1/15 0 5 -
U2 E DQ367194 1/15 0 4 -








U3 B DQ367196 2/17 1 3 -
U3 C DQ367197 2/17 0 6 AY462743 (PNG)8 338/345 (97%)
U3 D DQ367198 1/17 1 2 DQ367117 (CM7b, Mali)* 316/329 (96%)
U4 A DQ367199 6/15 0 4 -
U4 B DQ367200 1/15 0 4 -
U4 C DQ367201 1/15 0 4 -
U4 D DQ367202 1/15 0 4 -
U4 E DQ367203 1/15 0 4 -
U4 F DQ367204 1/15 0 4 -
U4 G DQ367205 1/15 1 3 -
U4 H DQ367206 1/15 0 4 -
U4 I DQ367207 1/15 0 4 DQ135614 (Gabon)6 384/400 (96%)
U4 J DQ367208 1/15 0 4 -
U5 A DQ367209 7/19 1 3 -








U5 C DQ367211 4/19 0 4 -
U5 D DQ367212 1/19 1 2 PFE1640w (Var1CSA, 3D7)18
DQ367145 (HYP3b, Mali)*



















U5 E DQ367213 1/19 0 5 -
U6 A DQ367214 10/19 1 1 -
U6 B DQ367215 7/19 1 1 -
U6 C DQ367216 1/19 1 1 -




U7 A DQ367218 14/15 0 4 DQ367139 (HYP2d, Mali)* 415/415 (100%)
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Mali field isolate DBLα sequences Database matches
(>95% identity, >95% coverage)
Name Accession
Number
Freq. DBLα0/1 Group Accession Number (Origin) Nucleotide
identities (%)





















U8 A DQ367220 17/19 0 4 -
U8 B DQ367221 1/19 0 4 DQ134996 (Gabon)10 372/373 (99%)








U9 A DQ367223 13/16 0 4 -
U9 B DQ367224 1/16 0 4 -








U9 D DQ367226 1/16 0 4 -
Table 3.6. NCBI database homologues for Mali isolate DBLα transcripts described
in this study. Accession number, frequency (number of clones sequenced per isolate
with identical sequence), DBLα0/1 classification and group (Bull et al. 2007) are
given. Up to 10 database matches (>95% identity, >95% sequence coverage,
http://www.ncbi.nlm.nih.gov/BLAST) are also described (accession number, country
of origin, and% nucleotide identity). Multiple database matches from the same strain
or isolate but entered multiply on the NCBI database multiple times are not repeated
in the table.
… more than 10 database matches were found.
- no database matches were found.
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1(Bull et al. 2005a), 2(Fowler et al. 2002), 3(Su et al. 1995), 4 Barry et al. 2005
(unpublished), 5(Trimnell et al. 2006), 6(Barry et al. 2007), 7(Rowe et al. 2002a),
8(Kaestli et al. 2004), 9(Taylor et al. 2000b), 10(Winter et al. 2003), 11(Albrecht et al.
2006), 12(Tami et al. 2003), 13(Salanti et al. 2002), 14(Horrocks et al. 2002), 15(Duffy
et al. 2002), 16(Fernandez et al. 2002), 17Ozarkar, et al unpublished, 18(Hall et al.
2002), 19(Khattab et al. 2003), 20(Kirchgatter et al. 2000), 21(Kraemer et al. 2007),
*this study/(Kyriacou et al. 2006).




CM8D 3D7 var1csa 330/331 (99%)
HYP3B 3D7 var1csa 331/331 (100%)
U5D 3D7 var1csa 331/331 (100%)
U7B 3D7 var1csa 326/331 (98%)
CM1G FCR3 var1csa 321/357 (89%)
CM4C FCR3 var1csa 322/353 (91%)
CM5B FCR3 var1csa 325/353 (92%)
Table 3.7. Details of homology of the Mali isolate DBLα transcripts described in this
study to the two forms of var1csa described in Rowe et al. (2002a). Nucleotide
identity to 3D7 var1csa, PFE1640w, (Hall et al. 2002) or FCR3 var1csa, AJ133811,
(Scherf et al. 1998) is shown.
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 3.7 Results 3: Correlations of DBLα1 domain transcript frequency and
isolate characteristics
3.7.1 DBLα1 domain transcription correlates with high rosetting
Rosette frequency (RF) was significantly higher in the cerebral malaria isolates than
in the hyperparasitaemia or uncomplicated malaria isolates (Table 3.3; p = 0.035), in
agreement with consistent observations that rosetting is a virulence factor in Africa
(Carlson et al. 1990; Rowe et al. 1995; Rowe et al. 2002b). Group A var genes are
associated with rosetting, and var genes responsible for rosetting in 8 rosetting
laboratory isolates (unpublished data, Rowe JA) are all group A with DBLα1
domains that cluster within the ‘cerebral’/DBLα1-like portion of the tree (data not
shown).
In my isolates, DBLα1-like gene expression was also associated with rosetting
(Spearman Rank correlation Rho = 0.52, p = 0.009; Fig. 3.20). This is in accordance
with the association of group A var genes and rosetting (unpublished data, Rowe
JA), and of rosette frequency and malaria severe/cerebral malaria in Africa (Carlson
et al. 1990; Rowe et al. 1995; Rowe et al. 2002b). Colouring the points according to
disease manifestation shows that the correlation is driven by high RF levels in the
cerebral malaria isolates which also have high DBLα1% transciprtion levels (red in
Fig. 3.20), and by low RF levels in the hyperparasitaemia malaria isolates which
showed low DBLα1% transciprtion levels (blue in Fig. 3.20).
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Fig. 3.20. Correlation between isolate rosette frequency (RF) and proportion of
DBLα1-like domain transcripts detected. Spearman Rank correlation: Rho = 0.52, p
= 0.009. Red cirles: cerebral malaria isolates, green squares: uncomplicated malaria
isolates, blue diamonds: hyperparasitaemia isolates.
Splitting the sequences into the DBLα groups 1-5 (Bull et al. 2005a) (there were not
enough group 6 domains to examine) reveals that DBLα1 groups 1 and 3 positively
correlate with rosetting, but only group 1 reaches significance (P < 0.05) (Fig. 3.21).
This is consistent with laboratory rosetting lines that are often groups 1 or 3 (Alex
Rowe, personal communication) although Bull et al. (2005) found group 2 to be
















Fig. 3.21. Spearman Rank correlations between isolate rosette frequency (RF) and
proportion of DBLα group 1-5 domain transcripts detected (Bull et al. 2005a).
Groups 1 and 3 show positive Rho (Spearman Rank correlation) for association with
rosette frequency. *Only group 1 association with rosette frequency is significant
(Rho = 0.394; p = 0.049). There was a tendency for group 4 to be negatively
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3.7.2 DBLα1 domain transcription does not correlate with age
There was no significant correlation of any of the groups with age (Fig. 3.22), though
there was a tendency for Bull group 4 transcripts to be associated with age (Rho =
0.385; p = 0.055, Fig. 3.23). All other groups showed (not significant) negative



















Fig. 3.22. No significant correlation was found between age (months) and proportion
of DBLα1-like domain transcripts detected in the isolate. Spearman Rank
correlation: Rho = -0.30, p = 0.14.
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Fig. 3.23. Spearman Rank correlations between age and proportion of DBLα group
1-5 domain transcripts detected in the isolate (Bull et al. 2005a). No correlation











































































































3.7.3 DBLα1 domain transcription does not correlate with parasitaemia
There was also no significant correlation of any of the groups with parasitaemia (in






















Fig. 3.24. No significant correlation was found between parasitaemia (%) and
proportion of DBLα1-like domain transcripts detected in the isolate. Spearman Rank
correlation: Rho = 0.35, p = 0.18.
129
Fig. 3.25. Spearman Rank correlations between parasitaemia and proportion of
DBLα groups 1-5 transcripts detected in the isolate (Bull et al. 2005a). No





















































































































The major finding presented in this chapter was that a higher level of DBLα1
domain transcription was observed in cerebral malaria isolates compared to
hyperparasitaemia isolates. This indicates an association of group A var transcription
with cerebral malaria, and therefore an association of group A PfEMP1 and malaria
severity. This study of clinical isolates provides evidence to support in vitro work
reporting a link between group A var gene transcription and “severe malaria
phenotype parasites,” parasites selected on semi-immune plasma pools (Jensen et al.
2004). I will recap my findings and then discuss my data in the context of other
relevant studies.
Transcription profiling of 26 Malian field isolates revealed a marked difference in
DBLα(0/1) transcription level in the three disease manifestation groups, with
significantly higher frequency of DBLα1-like domain transcripts detected in cerebral
malaria isolates compared to hyperparasitaemia isolates (P < 0.001, Chi-squared
test). In the majority of cerebral malaria isolates the predominant transcript was
DBLα1-like, significantly different to the hyperparasitaemia group, where the
predominant transcript in the majority of isolates was DBLα0-like (P = 0.013,
Fisher’s Exact test). The majority of isolates possessed multiple genotypes (18/26),
and thus different subpopulations of parasites had different genetic repertoires of var
gene available to express. Expression of different var genes from subpopulations of
parasites from the same genotype was also expected, due to switching of the
expressed var gene. Most isolates (17/26) displayed expression of DBLα1-like and
DBLα0-like domains. Of the remaining isolates, 6 exhibited 100% DBLα1-like
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domain expression (U3, U6, CM6, CM7, CM9 and HYP4) and 3 had 100% DBLα0-
like domain expression (U4, HYP1 and HYP8). No cerebral isolate exhibited 100%
DBLα0-like domain expression. It is tempting to speculate that CM4 may be
particularly susceptible to cerebral malaria, only having 1/17 DBLα1-like sequences.
It is also possible that HYP4 may be protected from the cerebral malaria which might
be expected from 100% DBLα1-like domain expression, for instance by having a
protecting genetic polymorphism.
Younger host age and increased severity of disease has previously been associated
with parasite expression of var sequences which are more frequently recognised by
plasma from semi-immune children (Bull et al. 1999; Bull et al. 2000; Nielsen et al.
2002; Lindenthal et al. 2003). This suggested that var genes associated with severe
disease, and young host age, are more common within a parasite population. This
may suggest certain var genes being more commonly found in the genome of distinct
parasites. Alternatively, certain PfEMP1 may be more frequently expressed, or
commonly elicit a particularly successful immune response. The data in this chapter
show that group A var genes are linked with severe disease, and group A var genes
appear to be more ‘common’ in terms of sequence homology as most transcripts
appearing in multiple isolates were group A. This fits with the hypothesis that
surface antigens involved in severe disease can be recognised by plasma from high
numbers of people within a population (Bull et al. 1999; Bull et al. 2000; Nielsen et
al. 2002; Lindenthal et al. 2003).
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A number of previous studies support the findings reported here. A small Brazilian
study reported a link between severe malaria and expression of genes lacking 1-2
cysteines (those subsequently defined as missing in DBLα1 domains). However,
only eight such sequences in total were found, across only six severe malaria patients
(Kirchgatter and Portillo Hdel 2002). The association of group C var and non-severe
disease was also seen in Tanzania (Rottmann et al. 2006) and Papua New Guinea
(Kaestli et al. 2006), consistent with the data presented in this study. However, in
Tanzania both group A and B were increased in the severe malaria group, and in
Papua New Guinea, only group B was associated with clinical disease. Both studies
used upstream region PCR to define var gene group (Kaestli et al. 2006; Rottmann et
al. 2006). It is possible that some of the group B transcripts associated with severe
malaria are group B/A (UpsB region with group A-like domain structure).
Previous studies used a broad definition of severe disease, grouping patients with
very different severe complications, and presumably very different underlying
pathologies and molecular mechanisms (Kirchgatter and Portillo Hdel 2002; Bull et
al. 2005a; Kaestli et al. 2006; Rottmann et al. 2006). Uncomplicated malaria was
commonly used as the comparison to severe malaria, resulting in studies comparing
groups with disease severity and also highly different parasitaemia. Controlling for
parasite burden by using hyperparasitaemia as the comparative non-severe malaria
group was an important contributing factor to allow a clear result to be found from
this study. Transcription from the uncomplicated malaria isolates showed an
intermediate distribution across the DBLα(0/1) spectrum. However, analysis of the
parasites causing the “uncomplicated” low parasitaemia disease must be treated with
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caution. On presentation at hospital, these patients received treatment and thus it was
not possible to follow disease progression to the natural end point of severe clinical
symptoms, hyperparasitaemia or parasite clearance. The data from this study is
consistent with the uncomplicated isolates representing an earlier time point in
disease pathogenesis, where disease progression may be predestined but not yet
clinically evident.
The success of this study relied on a precise and accurate disease definition for
cerebral malaria of Blantyre score ≤ 2 with an asexual P. falciparum parasitaemia
and no other possible cause of coma. Due to the high prevalence of low level
asymptomatic parasitaemia in the general population, post-autopsy investigation
revealed that P. falciparum was not the genuine cause of coma and/or death in up to
23% of patients diagnosed with cerebral malaria in Malawi (Taylor et al. 2004;
Milner et al. 2005). In this study it was not possible to confirm cerebral diagnosis by
autopsy, and as such it is theoretically possible that some of the cerebral malaria
cases were incorrectly diagnosed. This could explain isolate CM4, unique in the
cerebral malaria group with such a high frequency of DBLα0-like domain
transcription (16/17 sequences). A strict definition of cerebral malaria was used in
diagnosis of the isolates obtained for this study and the clear pattern of gene
expression that emerged suggests that the diagnoses were as accurate as possible,
although problems of misdiagnoses in a small proportion of cases remains a
possibility in studies of field isolate disease manifestation and should be taken into
consideration. This study and other reports (Kurtzhals et al. 2001; Nacher et al.
2001) emphasise the need for strictly defined disease criteria and carefully chosen
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control groups in studies examining the molecular basis for malaria disease outcome.
It is likely that this study was successful due to use of a strictly defined severe
disease category with a precise pathology, and an appropriate control group.
In P. falciparum malaria, mature parasites sequester to avoid splenic clearance
(Chotivanich et al. 2002) and cerebral malaria is characterised by sequestration of
infected erythrocytes in the microvasculature of the brain (Berendt et al. 1994b;
Silamut et al. 1999). Ideally, sequestered parasites, for example from postmortem
brain, would be examined (Taylor et al. 2004; Milner et al. 2005). These parasites
would be mature trophozoites, in contrast to the younger rings found in peripheral
blood. Although once controversial (Chen et al. 1998b; Noviyanti et al. 2001; Duffy
et al. 2002), the recent data strongly indicates that a single var gene is transcribed at
ring stage and this corresponds to the PfEMP1 protein on the surface at trophozoite
stage (Dahlback et al. 2007). This var gene transcript appears to remain present at
high enough concentration for RNA extraction and RT-PCR in the mature
trophozoite, and studies comparing var gene transcription across a cell cycle report
the same var gene transcripts are present in ring and trophozoite parasites for a given
culture (Peters et al. 2002; Montgomery et al. 2007). However, taking the RNA too
late in the cell cycle may result in gaining relatively increased proportions of
var1csa, which is transcribed throughout trophozoite stages (Kyes et al. 2003).  A
detailed study of var gene transcription in laboratory isolate NF54 suggests
collection of parasites for var gene transcription studies at ring stage and pigmented
trophozoite stage provides a good representation of var gene transcription for that
invasion cycle (Dahlback et al. 2007). The report also confirmed that var gene
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transcripts collected at ring stage are reflective of PfMEP1-mediated adhesion
properties of the mature parasite. In this work and other similar studies (e.g.(Bull et
al. 2005b), ring stage parasites were obtained from peripheral blood, carrying the
assumption that the population of peripheral ring parasites directly reflects the
sequestered mature population. Genotypically, peripheral parasites reflect the
sequestered parasites (Dembo et al. 2006; Montgomery et al. 2006).
Sequestered parasite populations in different organs of the same patient show
differential var gene expression, supporting a link between cytoadhesion and
pathology (Montgomery et al. 2007). Although peripheral rings were not directly
examined in this study, the assumption from previous studies is that the peripheral
ring population reflects the sequestered parasite mass, which is then sequestered
upon PfEMP1 expression at maturity in whichever organ best suits its particular
cytoadhesive properties (Dembo et al. 2006; Montgomery et al. 2006). However, an
absolute correlation between var gene transcript range in peripheral rings and
sequestered erythrocyte PfEMP1 remains an assumption.
In addition, within an infection, var gene transcription is highly dynamic (Peters et
al. 2002; Kaestli et al. 2004). Each var gene has its own intrinsic switching rate
(Horrocks et al. 2004b), ranging from <0.025% per generation to at least 16% in
experimentally infected individuals (Peters et al. 2002; Horrocks et al. 2004b). Var
gene switching and silencing is very complex and is controlled at multiple levels.
This involves tight transcriptional control with a silencing role of internal promoters
and epigenetic chromatin modifications (Horrocks et al. 2004b; Duraisingh et al.
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2005; Frank et al. 2006). At present it is not possible to predict the order of var gene
expression as switching is not completely understood, but it is clear that the order of
var gene transcription is far from random. In vitro, telomeric var genes (group A, B
or A/B) have faster “off” rates than centromeric var genes (group C) (Frank et al.
2007). Upon adaptation to culture, parasites from infected individuals rapidly reduce
the relative level of group A var gene transcription compared to group B or C (Peters
et al. 2007). Laboratory strains tend to revert to group C var gene expression during
long term culture (Frank et al. 2007). In contrast to fast “off” rates in vitro, group A
and B genes expand more rapidly than group C genes in experimentally infected
human volunteers (Lavstsen et al. 2005). It is possible that the activation of group A
or B/A requires an additional stimulus from an infection, such as a detection of a
signal from cerebral endothelium. Little is known about transcription factors which
promote var gene activation, but it is possible that differences in the upstream region
of the group A var genes may be involved in selection for group A var gene
expression. For example, the mechanism of silencing appears to be different between
the group A and B or C var genes, as silencing of group A, but not B or C, var genes
is dependent on PfSir2 (Duraisingh et al. 2005).
In many studies (e.g. Kirchgatter et al. 2002), low parasitaemia isolates are cultured
for a few cycles before RNA extraction. Combining the data showing that group A
var genes are more likely to be switched off, and the fact that it is most often the
uncomplicated malaria isolates that show low parasitaemia, suggests an unfair bias in
the reporting of lower group A transcription levels in uncomplicated isolates. In this
study, RNA was collected from all isolates at ring stage and was processed and
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stored immediately. Isolates were not cultured through to the next cell cycle, and so
no var gene switching could occur. However, even taking this extra precaution, the
var gene expressed at collection may have been switched on since development of
severe disease symptoms, and thus the currently expressed var gene may not be
responsible for the clinical condition. Collecting field isolates as close as possible to
onset of clinical symptoms, and avoiding culturing where possible, will increase
confidence of a direct correlation between detected var gene transcription and
disease outcome.
In addition to parasite isolates, the choice of DBLα domain to investigate was
advantageous. Good primers were available (Taylor et al. 2000a; Bull et al. 2005a),
and the vast majority of var genes contain a DBLα domain (Gardner et al. 2002).
Though there was not enough parasite material for quantitative real-time RT-PCR,
the RT-PCR colony picking technique used proved accurate and reproducible and
has been used in many previous studies (e.g. Kirchgatter et al. 2002; Bull et al,
2005). A recent study comparing RT-PCR and real-time RT-PCR of var gene
transcripts found RT-PCR gave very similar results to a real-time RT-PCR, with the
same dominant transcript being detected with both approaches in the majority of
isolates (Gatton et al. 2006). Though a clear distinction in DBLα(0/1) domain
transcription levels between cerebral malaria and hyperparasitaemia isolates was
discovered, the study could be reinforced and strengthened by sequencing more
transcripts per isolate, the inclusion of more isolates from each group, and the
addition of further clinical disease categories.
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The disparity in DBLα (0/1) domain transcription levels between the two isolate
groups suggests there might be a functional difference between DBLα0 and DBLα1
domains. The only known adhesive and well-characterised property of DBLα
domains is rosetting, for example mediated via interaction of a PfEMP1 DBLα1
domain with CR1 on non-infected erythrocytes (Rowe et al. 1997). The association
of rosetting with severe malaria in Mali and group A var genes in this present study
was expected, as rosetting has been repeatedly linked to severe malaria in Africa
(Carlson et al. 1990; Rowe et al. 1995; Bull et al. 2005a; Rowe 2005; Kaestli et al.
2006). In these Malian isolates, DBLα  groups 1 and 3 correlated with rosette
frequency (RF), in contrast to the correlation between DBLα group 2 and RF
reported in a recent Kenyan study (Bull et al. 2005a). This could be a genuine
difference between the Mali and Kenya isolates. Unlike DBLα groups 1 and 3, the
proportion of DBLα group 2 sequences is not significantly different between
cerebral and hyperparasitaemia isolates in this study. Interestingly, a link between
DBLα1 domains in general and rosetting, but not group 2 DBLα domains and
rosetting was also reported in a recent study of Ugandan field isolates (Normark et
al. 2007). The functional significance of this DBLα grouping (1-6) compared to the
broader grouping of DBLα(0/1) remains to be confirmed, though the classification is
a useful tool for DBLα domain analysis. Although results associating sequences
separated into the DBLα groups with RF are conflicting, the association of DBLα1
in general with rosetting is supported in both geographic locations and in laboratory
isolates (Rowe, JA, unpublished data). The association of rosetting and severe
malaria demonstrated in these field isolates, and in many other studies, highlights
rosetting as a key target of clinical intervention to control parasite-mediated
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phenomena associated with severe disease complications (see chapter 6 for
discussion of rosette inhibition in severe malaria).
Though DBLα0 domains have been reported to support rosetting (Chen et al.
1998a), rosetting in laboratory strains appears to be predominantly via DBLα1
domains (Rowe, JA, unpublished data), suggesting that there is a steric restriction on
the conformation of DBLα1 domain that can retain affinity for CR1 or other
rosetting ligands. Perhaps the two extra cysteines found in DBLα0 domains form a
disulfide bond that fundamentally alters the DBLα domain structure. Recent
structural predictions of DBLα domain structure based on the known structures of
EBA175 and P. knowlsei DBLα, suggest that DBLα0 domains have a GAG-binding
motifs, which mimic the carbohydrate-binding pocket of EBA-175 (Tolia et al. 2005;
Singh et al. 2006; Normark et al. 2007). In the DBLα1 domains, some of these GAG
motifs disappear with the loss of the two cysteines, supporting this hypothesis.
Motifs and predicted structural features present in rosetting PfEMP1 include an alpha
helix that appears to be conserved between rosetting PfEMP1 DBLα  domains
(Normark et al. 2007).
Conversely, it may not be the DBLα1 domains per se, but other features of the group
A var genes that is involved in cerebral malaria pathogenesis. Group A and B/A
PfEMP1 are in general larger, with a more complex domain structure than PfEMP1
from group B, C and B/C. The plethora of other domains available in the group A
and B/A PfEMP1 may have clinically relevant binding potential. For example, the
majority of DBLγ domains, some of which were originally implicated in CSA
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binding (see chapter 4) are found in group A or B/A var  (12/14 in 3D7), as are the
majority of DBLε domains (11/12 in 3D7), some of which enable binding to
naturally occurring IgM anibodies (Semblat et al. 2006). There is also evidence that
certain PfEMP1 have affinity for molecules on the cerebral endothelium such as
ICAM1, mediated by a tandem array of DBLβ and C2 domain (Smith et al. 2000a;
Springer et al. 2004). Perhaps surprisingly, ICAM-binding DBLβ/C2 tandem arrays
do not appear to be associated with particular PfEMP1 groups (Smith, JD, personal
communication).
Whilst DBLα1 domain transcripts are indicative of a group A, B/A PfEMP1,
identification of DBLα0 domains is indicative of a group B, C or B/C PfEMP1.
These typically possess a DBLα0-CIDRα type semi-conserved head structure
(Gardner et al. 2002; Kraemer et al. 2007) and are capable of CD36-binding
(Robinson et al. 2003). Though the DBLα0 domain itself does not have affinity for
CD36, its presence suggests expression of PfEMP1 with affinity for CD36.
CD36-binding is the most common known adhesive property of malaria isolates,
with the majority of field isolates having affinity for CD36 (Udomsangpetch et al.
1997). The role of CD36 in malaria pathogenesis is complex (reviewed in(Serghides
et al. 2003) and not fully understood. CD36 is a scavenger receptor expressed on
erythrocytes, platelets, and many other cellular components of the blood, in many
tissues including endothelium and muscle, and on organs such as liver and spleen,
but not on the cerebral endothelium (Turner et al. 1994; Serghides et al. 2003).
CD36-binding is thus associated with sequestration of infected erythrocytes in areas
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such as skin and muscle away from vital organs such as the brain (Serghides et al.
2003). The lack of CD36-binding in infected erythrocytes coated in group A
PfEMP1 may access cerebral endothelium, as they are less likely to be sequestered
elsewhere. Earlier studies reported CD36 binding being associated with non-severe
malaria without reference to PfEMP1 (Rogerson et al. 1999; Traore et al. 2000). It is
tempting to speculate these results came about because of expression of group B, C
or B/C PfEMP1 in these mild malaria patients.
CD36 binding also mediates platelet mediated clumping, a phenomenon originally
associated with severe malaria (Pain et al. 2001). The only isolate with high PMC
was a cerebral malaria isolate (CM8), with high parasitaemia (20%), but with low
group B/C expression (only 1/19 DBLα0-like transcripts). The in vivo relevance of
PMC remains unclear and the phenomenon is now thought to be associated with high
parasitaemia but not severe malaria per se (Arman et al, in press).
Finally, CD36 promotes non-opsonic (non-inflammatory) phagocytic clearance
(McGilvray et al. 2000) and phagocyosis of Plasmodium infected erythrocytes by
human macrophages can by reduced by 50% by blocking CD36-dependent
interactions (Smith et al. 2003). However, CD36-binding parasites are also able to
cause inhibition of dendritic cells (Urban et al. 1999). These data suggest a complex
relationship between CD36-binding and sequestration and immune response. In
general, the data indicate a low immunopathological burden where CD36-binding
parasites dominate. This is a good strategy for a parasite that does not benefit from
host death, and is consistent with the association presented here between group B, C
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or B/C var genes and hyperparasitaemia. However, the extent of CD36-binding in
parasites not expressing a CD36 binding PfEMP1, through other proposed ligands
such as modified band 3, sequestrin and CLAG9, is unclear (Serghides et al. 2003).
There was also no significant correlation of any of the DBLα  groups with
parasitaemia. The lack of association of any group with parasitaemia supports the
idea that a particular var  gene group does not encourage an expansion of
parasitaemia, but the var gene group expressed plays a role in determining whether a
severe clinical manifestation will develop. The lack of association of DBLα group
with parasitaemia is also reflected in the sequences from uncomplicated malaria
patients being distributed across the phenogram and network.
The relative proportion of DBLα1 var genes detected in this study is similar to the
relative proportion of DBLα1 var genes in parasite genomes seen in published
strains and other reports, at around 20-30% (Fowler et al. 2002; Gardner et al. 2002;
Albrecht et al. 2006; Kraemer et al. 2007). If the proportion of DBLα1 var genes in
an isolate is relative stable, as appears to be the case from 3D7, IT and HB3
genomes, this suggests that there is no general bias of expression towards DBLα1 or
DBLα0 var genes, though the gDNA repertoire of DBLα var gene sequences within
these particular isolates would have to be examined to confirm this.
Roughly one third of the transcript sequences were unique with no database matches,
while others showed a high level of conservation. Interestingly, a non-var1csa highly
conserved sequence, CM6A, was found in 5 isolates. Extended sequencing of the
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CM6A domain from the var genes from which these sequences belong would reveal
whether the entire gene is conserved between these isolates, or just the DBLα
domain. It would be interesting to screen for the presence of this domain in other
isolates to identify to what extent this is a strain transcending var gene in addition to
the var1csa, var2csa and type 3 var gene family. Expression of this domain in vitro
would be a useful starting point for the examination of any particular roles for which
this sequence has been conserved, for example through a series of binding studies.
The identification of a domain identical to the DBLα1 of Palo Alto rosetting var
gene PARvar1 in 2 rosetting cerebral malaria isolates (CM7, RF 20% and CM9, RF
41%) is also intriguing, suggesting this may be a conserved rosetting var gene
family. It would be very interesting to examine the prevalence of this gene in other
isolates, and investigate whether the homology to PARvar1 extends throughout the
entire var gene or is confined to the DBLα domain. These domains suggest that
var1csa, var2csa and the type 3 var genes may not be the only var genes which are
common to many different isolates.
The immunity achieved against P. falciparum infection by adulthood in malaria-
endemic areas suggests a finite global diversity of var genes and other VSA, or at
least a high enough level of cross-reactive epitopes for antibody-mediated immunity
(Bull et al. 2000). Certain geographic locations appear have a limited var gene
repertoire with a relatively stable var gene repertoire and considerable interstrain var
gene overlap, including Brazil (Afonso Nogueira et al. 2002; Albrecht et al. 2006)
and West Pacific (Fowler et al. 2006), while data from other areas suggests a lower
sequence overlap globally (Fowler et al. 2002; Bull et al. 2005a; Trimnell et al.
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2006). Though a study of the domains of 3D7 predicts that cross-reactive epitopes
are relatively uncommon, antibodies directed at group A PfEMP1 show higher levels
of cross-reactivity between domains than those directed at group B or C PfEMP1
(Joergensen et al. 2006). This is consistent with my findings that group A var genes
tend to be more common in terms of conserved sequences between isolates and
database matches, and with the original agglutination studies showing high
frequency of recognition of parasites causing severe disease (e.g. (Bull et al. 1999).
The high level of diversifying selection on PfEMP1 (Lavstsen et al. 2003), and
recombination between var genes within and between isolates, will continue to drive
expansion of the global var gene repertoire.
The data presented in this chapter is of relevance to the exploration of PfEMP1 as a
potential vaccine target. For example, as the majority of var genes contain DBLα0
domains these might be considered to provide a more comprehensive or universal
target than DBLα1 domains. However, a DBLα0 domain vaccine, even if it was very
effective at protecting against parasites expressing DBLα0 domains, may select for
parasites expressing DBLα1 domains. In this study, DBLα1 domains are associated
with cerebral malaria, and thus a DBLα0 domain vaccine may have the potential to
select for cerebral malaria-causing PfEMP1-expressing parasites. Thus, a general
DBLα0 domain vaccine would not necessarily be useful in protecting against severe
disease. Analysis of this kind is critical to avoid creation of a vaccine which may
actually be detrimental to those at risk of infection. Secondly, database analysis of
the domains sequenced here highlight the huge global range of DBLα domains. Even
from parasites collected from a small geographic location at a particular time
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relatively little overlap between domains was seen. However, the presence of some
very common DBLα1 domains such as the three described in this chapter could be
exploited. Of course, sequence data is not enough to provide evidence for cross-
reactive epitopes, as cryptic (conformational) epitopes are also possible (Joergensen
et al. 2006).
In conclusion, the data presented in this study show a strong association of group A
var gene transcription and cerebral malaria. This is consistent with previous work,
and provides further evidence for the importance of PfEMP1 in clinical
complications due to P. falciparum infection. The study was successful due to
carefully chosen severe disease criteria and a suitable control group. As with any
multifactorial disease, other factors such as household factors (Mackinnon et al.
2005) as well as polymorphisms in human genes such as CR1 (Cockburn et al. 2004)
or blood group (Rowe et al. 2007) may also affect or modulate parasite virulence.
However, the data strongly suggest that group A PfEMP1 play a critical role in
cerebral malaria pathogenesis. As described, these findings have implications for
future work on vaccine or drug design against PfEMP1, and increase our




Var gene transcription in
placental malaria field
isolates
Some of the results presented in this chapter were published as
Duffy, MF et al. (2006) Transcribed var genes associated with placental
malaria in Malawian women. Infection and Immunity, 74: 4875-4883.
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4.1 Abstract
P. falciparum placental malaria field isolates from Malawi were used to test the
hypothesis that var2csa and/or conserved DBLγ domains are commonly transcribed
in placental malaria field isolates. Var2csa transcription was detected in all placental
isolates examined by RT-PCR, but not in a control group of childhood malaria
isolates also analysed. Many DBLγ domain transcripts were also detected in these
placental and childhood isolates, but no DBLγ domain features were found to be
specific to placental isolates compared to the childhood isolates through phylogenetic
analysis. This data strengthens the growing body of evidence pointing to var2csa as
crucial for placental malaria pathogenesis, and confirms non-var2csa var genes are
also expressed in placental field isolates.
4.2 Introduction
Malaria during pregnancy is the most common manifestation of clinical malaria in
adults in malaria-endemic countries, where adults are typically immune to clinical
disease (Brabin 1993; Brabin et al. 2004). Immunity to clinical disease increases
through childhood with increasing episodes of disease, probably through cross-
reactive immune responses developed from previously employed VSA variants.
Parasite-infected erythrocytes depend on sequestration to avoid clearance in the
spleen (Chotivanich et al. 2002), and once immunity is achieved, parasites have
effectively exhausted the supply of novel sequestration receptors. However, upon
pregnancy, the placenta becomes a novel niche for parasitic sequestration. As
placental sequestration is a novel process in terms of disease episodes for an
individual, adhesion is thought to require fresh VSA variants, which are not
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expressed in malaria in childhood, and to which there is thus no protective immunity
in the first pregnancy. These infected erythrocytes are unusual in their high affinity
for chondroitin sulfate A (CSA). CSA is a sulfated glycosaminoglycan, present on
the intervillous spaces and on syncitiotrophoblasts, which is where placental
adhesion occurs (Achur et al. 2000; Valiyaveettil et al. 2004). Though CSA is also
present on other cell types including cerebral endothelium and erythrocytes, CSA is
not commonly a ligand for infected erythrocytes in non-placental field isolates.
Affinity for CSA has thus provided a starting point for studies on placental malaria-
phenotype parasites, and CSA-binding infected erythrocytes have become
synonymous with placental malaria-type parasites. Though there is evidence that
other adhesion phenotypes also play a minor role in placental sequestration, for
example adhesion to hyaluronic acid (HA) (Beeson et al. 2000), CSA appears to be
the major sequestration receptor in the placenta (Duffy et al. 2006b; Muthusamy et
al. 2007). Some data regarding HA-mediated adhesion has been confused due to the
possibility of contaminating CSA in the HA preparations used (Valiyaveettil et al.
2004; Fried et al. 2006).
As with childhood malaria, the PfEMP1 family are key suspects for mediating
adhesion during pregnancy. PfEMP1 mediating placental adhesion would be
expected to bind CSA, to be transcribed in the majority of placental field isolates and
to be expressed exclusively in placental malaria field isolates (not for example in
childhood malaria isolates). At the time of the study design, the conserved features
which define var gene DBLγ domains were the only var gene sequences associated
with expression in placental malaria (Khattab et al. 2001; Lekana Douki et al. 2002;
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Costa et al. 2003; Khattab et al. 2003). In particular, transcription of well-conserved
gene var1csa which contains 2 DBLγ domains was associated with placental malaria
field isolates and with adhesion to CSA (Buffet et al. 1999; Rowe et al. 2002a;
Gamain et al. 2004). Other DBLγ-containing var genes have been implicated in
placental malaria: CS2var (Reeder et al. 1999) and varPAM732 (Khattab et al. 2001;
Badaut et al. 2007). The pan-reactivity of antibodies to DBLγ-containing var genes
to placental malaria isolate worldwide suggested a small set of epitopes common to
DBLγ domains was responsible for placental sequestration (Lekana Douki et al.
2002; Costa et al. 2003).
It was not logical to suspect all DBLγ domains would be involved in placental
malaria, as DBLγ domain variants are common in the group A PfEMP1 which can be
expressed in childhood malaria. Involvement of var genes in placental malaria which
are also common in childhood infection is inconsistent with the novel placental-
specific var gene hypothesis. It was hypothesised that only a subset of DBLγ
domains may be involved in placental adhesion. The study thus was originally
designed to amplify transcribed DBLγ domains from parasites taken directly from
infected placenta, to explore any association of particular sequences with placental
sequestration in field isolates. However, since the outset of the study two major
advances altered the direction of the chapter.
Firstly, evidence for var1csa involvement in placental malaria was losing
momentum. In 2003, Winter et al. reported that var1csa is commonly expressed in
childhood isolates, and since then many other field isolate studies (including chapter
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3 RT-PCR data) have supported this observation of var1csa expression in children
and men. If var1csa plays a role in placental isolates, it is certainly not the major
contributor.
Secondly, there was increasingly convincing evidence for involvement of another
strain transcending var gene, var2csa, in placental malaria (Salanti et al. 2003;
Salanti et al. 2004). VAR2CSA has since been shown to support adhesion to CSA
through adhesion and knock out studies (Salanti et al. 2003; Salanti et al. 2004;
Gamain et al. 2005; Viebig et al. 2005; Viebig et al. 2007) and to be expressed in
infected erythrocytes in pregnant women from Senegal (Tuikue Ndam et al. 2005).
Conservation of var2csa in the majority of field isolates examined, and in laboratory
strains 3D7, HB3 and IT also suggests a strong selective pressure to retain a var2csa
copy in the genome (Trimnell et al. 2006; Kraemer et al. 2007). The high
conservation of this gene also indicated that it may provide a promising vaccine
candidate, to mimic the natural immunity to placental malaria which increases with
subsequent pregnancies (Fried et al. 1998; Duffy and Fried 2003), if it was proved
that var2csa was essential for, or at least a common contributor to, placental
sequestration.
As it became apparent that VAR2CSA may play a crucial role in placental malaria,
the RT-PCR strategy adopted in this chapter was enhanced to also amplify the
DBL3X domain of var2csa family var genes homologues. The primers still retained
the ability to also amplify any transcribed DBLγ domains, as the primer sites were
designed to recognise an area of homology between var2csa and DBLγ domains in
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general. It was considered important to also detect DBLγ domain-containing
transcribed var genes in the placental isolates firstly as a comparative set of var gene
transcripts to var2csa, and secondly as the extent to which other var genes contribute
to the placental malaria phenotype is still unclear. The panel of field isolates was also
increased to include a range of childhood isolates for comparison.
4.3 Aim of chapter
The aim of this chapter was to test the hypothesis that a conserved var gene, var2csa,
and/or conserved DBLγ domains are commonly and specifically transcribed in
placental malaria field isolates.
4.4 Materials and methods
Materials and methods that are specific to chapter 4 are listed below. General
materials and methods and a list of suppliers are given in chapter 2.
4.4.1 Field isolates
Placental malaria field isolates were obtained from Stephen J. Rogerson, from
Blantyre, Malawi (Chapter 2).
4.4.2 RT-PCR conditions
RT-PCR was used to amplify approximately 500 bp of the var gene DBLγ domains,
using unbiased primers; 1st set (DBLγ  amplification only, designed by S.J.
Rogerson, Melbourne, Australia): D3F (CCTCCWAGRAGAMAAAAATTAT) and
D3R2 (CCATCKNAR AAATTGNGGTY), and second set (DBLγ/var2csaDBL3X
152
amplification) D3F as above and D3R1.2 (ACAAWANTSNTCDBMCCATTC,
designed by J.A. Rowe). Neither of these pairs were nested. Amplification conditions
were a hot start, 95˚C, 5 min, followed by 40 cycles of 95˚C, 20 sec; 42˚C, 30 sec;
60˚C, 30 sec finishing with 60˚C, 10 min. 25 pmol of each primer, 2.5 mM MgCl2
and 0.125 units Platinum taq (Invitrogen) were used in each 50 µl reaction. 2 µl
cDNA or H20, or 0.5 µl gDNA were used in the amplification reaction. Samples
without RT were used in all reactions to exclude DNA contamination.
4.4.3 Primer bias calculation
The instrinsic bias for D3F and D3R1.2 primer pair had previously been calculated
as < 2% for the most frequently detected sequence (S.J. Rogerson, Melbourne). The
instrinsic bias for D3F and D3R1.2 primer pair was calculated using excel
BIOMONDIST as < 2% for the most frequently detected sequence. The most
frequently detected sequence was counted 9 times when only 5 counts would be
expected in 37 minipreps. This is a bias of (9/5)^(1/35) over 35 cycles = 1.017, i.e. a
1.7% bias per cycle.
Details of ligation, cloning, transformation, and sequencing of RT-PCR products are
given in chapter 2. In brief, RT-PCR products were visualised by electrophoresis on
1.5% agarose gels. RT-PCR products were purified and ligated into PCR II TA
cloning vector (Invitrogen) and ligated plasmids were used to transform TOP10F E.
coli. Transformed E. coli was grown overnight under ampicillin selection and
blue/white colony screening. Individual white colonies were selected for overnight
growth and the plasmids extracted for sequencing. Presence of an insert in the
153
extracted was verified by EcoRI restriction digestion prior to sequencing.
Sequencing was carried out by the University of Edinburgh School of Biological
Sciences Sequencing Service (details in chapter 2).
4.4.4 Transcript sequence analysis
Transcripts sequences from each isolate were grouped into contigs of >95%
nucleotide identity using the SeqMan programme within DNAstar software package.
Consensus sequences from each isolate were saved as sequence A, B, C etc from that
isolate as EditSeq files (DNAstar software package), and protein sequences were
obtained by translating the DNA sequences using EditSeq translation function.
Nucleotide and protein sequences were then compared within and between isolates
using MegAlign (DNAstar software package). Alignments and phenograms were
produced using the clustal W alignment programme within MegAlign, using default
settings. Sequence distances were calculated using MegAlign, and colour-coded into
the following groups; 0-30, 30-39.9, 40-49.9, 50-59.9, 60-69.9 70-99.9 and 100%
amino acid identity for production of sequence distance figures. Where nucleotide
identity levels were not normally distributed, a non-parametric test (Mann-Whitney
Test) as used rather than a t-test for comparisons between groups. Homology
searches were performed using nucleotide-nucleotide BLAST search of the NCBI
database (http://www.ncbi.nlm.nih.gov/BLAST). Pie charts were created in Excel.
Phenograms were laid out in Adobe Illustrator.
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4.5 Results 1: Preliminary DBLγ transcription data with primer pair D3F
and D3R2
4.5.1 RT-PCR to amplify transcribed DBLγ domains in placental malaria
isolates
Six placental malaria field isolates (CS294, P132, P134, P136, P143, P154) were
obtained from Queen Elizabeth Central Hospital in Blantyre (gift from Stephen J.
Rogerson). These were mature pigmented trophozoites which had been extracted
directly from placenta and stored immediately in Trizol. Isolates P132, P136, P143
and P154 had previously been genotyped using PCR of size-variant markers (MSP1,
MSP2 and GLURP allelic forms), which revealed that each isolate showed multiple
infections; six different parasite genotypes were detected in isolate P132 and three
were detected in P136, P143 and P154 (Rowe et al. 2002a).  The number of
genotypes for P134 and CS294 was not determined.
RNA extraction from each isolate and cDNA preparation had previously been
performed by Dr JA Rowe (Rowe et al. 2002a). In addition, cDNA from 2 parasite
strains that had previously been panned for affinity to CSA, TM180CSA and
TM284CSA was obtained (gift from Dr JA Rowe).
Degenerate primers to amplify the expressed DBLγ domains by RT-PCR were
designed by Stephen J. Rogerson; Primers: D3F and D3R2. This primer pair
amplifies an approximately 500 bp region of DBLγ domains (Fig. 4.1) and had
previously been tested for unbiased recognition of DBLγ domains (Stephen J.
Rogerson, personal communication). At this stage the importance of VAR2CSA was
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not known, and the focus of research was on involvement of DBLγ domains. Thus
these primers did not recognise the DBLX domain, and so could not amplify var2csa
(Fig. 4.1; see section 4.7 for primers to also amplify var2csa).
Fig. 4.1. Primer pairs to amplify DBLγ domains. A Clustal W aligment of 3D7 DBLγ
domains and 3D7 var2csa DBL3X (PFL0030c3X) created in MegAlign is shown.
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Primers D3F (green), D3R2 (blue) and D3R1.2 (red) are shown. Primer pair
D3F/D3R2 recognises DBLγ domains only. Primer pair D3F/D3R1.2 also recognises
var2csa (PFL0030c3X) see section 4.7.
4.5.2 RT-PCR to amplify transcribed DBLγ domains in placental malaria
isolates: primer pair D3F and D3R2
DBLγ domain RT-PCR with primers D3F and D3R2 was carried out on the 6
placental isolates, and also the two parasite strains selected for CSA-affinity,
TM180CSA and TM284CSA (Fig. 4.2). CS294, P132, P136, P143, P154 and
TM180CSA gave RT-PCR product. P134 and TM284CSA did not give a RT-PCR
product.
Fig. 4.2. 1.5% agarose gel of RT-PCR products from amplification of DBLγ domains
from cDNA from Malawi placental field isolates CS294, P132, P143, P136, P143,
P154, and laboratory strains TM180CSA and TM284CSA with primers D3F and











































performed without reverse transcriptase, is next to the cDNA amplification. These
lanes remain blank indicating there is no gDNA contamination in the cDNA
preparation. A4 gDNA was used for a positive control, and distilled water as a
negative control. DNA ladder was φX174 RF DNA/Hae fragments (Invitrogen).
4.5.3 DBLγ domain transcripts detected by RT-PCR with primers D3F
and D3R2
DBLγ domain RT-PCR products were purified by gel extraction and PCR products
were used to transform E. coli, resulting in plates of colonies carrying plasmids with
inserted copies of the DBLγ domains. A random selection of 12-17 of these colonies
were picked and grown over night in LB broth at 37°C to allow growth and
replication of the bacteria carrying the plasmid. After approximately 18 hours the
recombinant plasmids were extracted. Presence of an insert of the correct length was
confirmed by enzymatic digestion of the multiple cloning site using restriction
enzyme EcoRI of a sample of each extracted plasmid. Digested plasmids were run
out on 1.5% agarose gels, and plasmids containing an insert were marked by
presence of an approximately 500 bp band. Fig. 4.3 shows a typical gel. Two bands
were seen when the insert contained an EcoRI restriction site (GTTAAC, e.g. P143,
digests 2, 4 and 7, Fig. 4.3).
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Fig. 4.3. A typical agarose gel of EcoRI digests products of plasmids extracted from
a set of minipreps. In this case 8 plasmid extractions each from isolates P143 and
P154 are shown, all of which had inserts of approximately 500 bp. DNA ladder was
φX174 RF DNA/Hae fragments (Invitrogen).
The sequences obtained from each parasite isolate were compared for multiple
copies of the same sequence (over 95% sequence identity), and defined as placental
(Pl) var gene A, B, C… from each isolate. Up to five sequences were detected per
isolate though the presence of more var gene transcripts cannot be excluded. Results
were displayed as pie charts to indicate the relative abundance of distinct transcribed
DBLγ domains (Fig. 4.4).
            P143                        P154
1  2  3  4  5  6  7  8  1  2  3  4  5  6  7  8
500 bp
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Fig. 4.4. Frequencies of distinct DBLγ sequences in each isolate. The pie charts
represent the relative number of different DBLα sequences detected in each isolate
by RT-PCR, cloning and analysis of 12-17 mini-prep clones per isolate. Each pie
represents a different isolate, and the size of each pie-slice represents relative
abundance of transcript. Isolate name given in bold and bracketed numbers indicate
the exact number of plasmids sequenced for each isolate. Domains with homology to
var1csa are shaded (3D7 var1csa DBL3γ; yellow. 3D7 var1csa DBL5γ; purple.
FCR3 var1csa DBL3γ; blue).
All of the placental field isolates showed a predominant var gene. The predominant
gene in three of the five isolates (CS294, P132 and P136) was almost identical
(>97% homology). Nucleotide sequence comparisons revealed these sequences were
highly homologous (>92% identity) to the DBL3γ of 3D7 var1csa (yellow in Fig.
4.4). Sequences homolgues to the DBL5γ  of 3D7 var1csa were also seen
(CS294PlvarD, P143PlvarB and P132PlvarB, > 87% homology to 3D7 var1csa
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DBL5γ, purple in Fig. 4.4). The DBL3γ of FCR3 var1csa is slightly different to that
of 3D7 (Rowe et al. 2002a), and the predominant gene of P143 was a FCR3-like
var1csa homologue (97% homology, blue in Fig. 4.4).
Var1csa is a highly conserved sequence (Khattab et al. 2001), and has previously
been reported in many placental isolates worldwide, including from Cameroon (Fried
and Duffy 2002), Kenya (Khattab et al. 2003) and from Gabon (Kyes et al. 2003),
but is also seen in childhood malaria field isolates (Winter et al. 2003, and discussed
in chapter 3). The finding of var1csa in these placental isolates, collected as
trophozoites and schizonts, is unsurprising as var1csa has an unusual transcription
profile, being expressed at trophozoite stage (Kyes et al. 2003), rather than at ring
stage, as for other var genes (Khattab et al. 2001; Salanti et al. 2004).
4.5.4 Sequence similarities between transcripts detected by RT-PCR
with primers D3F and D3R2
Sequence identity between domains was 27.8-100% (mean 47.7%, s.d. 13.6%). Two
sequences P154PlvarA and CS294PlvarB were identical, as were CS294PlvarA and
P132PlvarB the var1csa DBL3γ homogues discussed above.
4.5.5 Phylogenetic analysis of transcript sequences detected by RT-
PCR with primers D3F and D3R2
A phenogram was constructed to compare the DNA sequences from Malawi (red)
and from laboratory CSA-selected strain TM180CSA (blue), with published DBLγ
mRNA sequences from pregnancy-associated malaria in Gabon, Cameroon and
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Kenya, and also with var1csa gene DBL3γ and DBL5γ domains from 3D7 and FCR3
(Beeson et al. 1999; Buffet et al. 1999; Reeder et al. 1999; Reeder et al. 2000;
Khattab et al. 2001; Fried and Duffy 2002; Khattab et al. 2003; Salanti et al. 2003;
Gamain et al. 2005). This was intended to examine the extent of the similarities
between the DNA sequences, rather than to suggest phylogenetic evolution, and to
display how the Malawi sequences were distributed in relation to DBLγ domains
from other placental isolates. The predominantly expressed var gene from each of
the isolates was marked with an arrow (←) (Fig. 4.5).
The Malawi sequences were distributed throughout the extent of the tree. There is no
marked distinction between the different groups of sequences dependent on country
of origin (Fig. 4.5).
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Fig. 4.5. Phenogram displaying transcribed DBLγ domains in P. falciparum placental
field isolates from Malawi (this study; red) amplified with primers D3F and D3R2,
with transcribed DBLγ domains in P. falciparum placental field isolates from
Cameroon (498,482,732 and 720/734), Kenya (Plcx) and Gabon (Gbx). Transcribed
DBLγ domains from CSA-binding laboratory strain TM180CSA (this study: blue)
and the DBLγ domains of var1csa (FCR3 and 3D7; shaded in yellow) and CS2var
(shaded in blue) are also included. The predominant transcript from each Malawi
placental isolate and TM180CSA is marked with an arrow ().
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4.5.6 Limitation of transcription analysis using D3F and D3R2
Literature at the time of this study was emerging which strongly implicated var2csa
as a (if not “the”) major CSA-binding PfEMP1 (Salanti et al. 2003; Salanti et al.
2004; Tuikue Ndam et al. 2005; Viebig et al. 2005; Beeson et al. 2006).
Unfortunately, var2csa could not be amplified with this primer pair, which became
an obvious limitation of the study. The DBL3X domain of var2csa, which has been
shown to support CSA binding (Gamain et al. 2005; Dahlback et al. 2006) has
similarity to a DBLγ domain, and it was possible to design a primer pair to extend
the range of DBL domains amplified to include the var2csa DBL3-X domain,
without losing specificity for PfEMP1 DBLγ domains (section 4.6). It was decided to
proceed with a second primer pair which would include var2csa in the RT-PCR
analysis, rather than to extend the analysis with primer pair D3F and D3R2.
Unfortunately, this meant that DBLγ  domains from non-placental malaria isolates
were not studied with D3F and D3R2.
4.6 Results 2: DBLγ/var2csa transcription analysis using a second set
of primers D3F and D3R1.2
4.6.1 PCR on 3D7 genomic DNA to determine bias of a second set of
primers D3F and D3R1.2
A second set of degenerate primers was designed (Dr JA Rowe) to amplify var2csa
DBL3X domains as well as PfEMP1 DBLγ domains (D3F and D3R1.2; Fig. 4.1 and
4.6).
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Fig. 4.6. Primer sites of D3F and D3R1.2 on a clustal W alignment of 3D7 DBLγ
domains and var2csa DBL3X (PFL0030c 3X).
The degree of bias in this primer pair (D3F and D3R1.2) was determined by
amplification of 3D7 genomic DNA. 3D7 genomic DNA was amplified with D3F
and D3R1.2. The PCR products were cloned and 38 recombinant plasmids were
sequenced. 12/16 gamma domains were represented in the sequences from the
plasmids from 38 minipreps (Fig. 4.7). The primers showed acceptable primer bias
(<2%) of amplification of 3D7 DBLγ domains (Gardner et al. 2002), in line with
other published degenerate primers (Taylor et al. 2000a; Duffy et al. 2006a).
Var2csa (PFL0030c 3X) was amplified with average frequency (Fig. 4.6.)
C C T C C W A G R A G A M A A A A A T T A TD3F
C C T C C T A G A A G A A G G C A A T T G TMAL7P1_4g
C C T C C A A G A A G A C A A A A T T T A TPF07_0050_3g
C C A C C T A G A A G A C A A A A A T T A TPF08_0140_3g
C C T C C A A G A A G A C A A A A G T T A TPF08_0141_3g
C C T C C T A G A A G A C A A A A A T T A TPF11_0008_2g
C C T C C T A G A A G A C A A A A A T T A TPF13_0003_3g
C C A C C A C G A A C A C A A G A A T T A TPFB0010w_2g
C C T C C T A G A A G A C A A A A A T T A TPFD0005w_2g
C C T C C A A G A A G A A T A A A A T T A TPFD1235w_4g 
C C T C C A A G A A G A C A A A A G T T A TPFE1640w_3g 
C C T C C T A G G A G A A A A A A A T T A TPFE1640w_5g 
C C T C C A A G A A G A A T A A A A T T A TPFF0010w_3g
C C T C C T A G A A G A A T A A A A T T A TPFL0020w_3g
C C T C C A A G A A C A C A A A A T T T A TPFL0030c 3X
Amplification of
≈ 500 nt unique DBLγ/X
domain sequence …
G A A T G G K V H G A N S A N T W T T G T  D3R1.2
G A A T G G G G A A A A A T A T T C T G T  MAL7P1_4g
G A A T G G A C T G A C G A G T T T T G T  PF07_0050_3g
G A A T G G G G A G A A G A G T T T T G T  PF08_0140_3g
G A A T G G G G G G A A G A G T T T T G T  PF08_0141_3g
G A A T G G A G T G A T G A A T T T T G T  PF11_0008_2g
G A A T G G A G T G A T G A A T T T T G T  PF13_0003_3g
G A A T G G G G A G A T C A A T T T T G T  PFB0010w_2g
G A A T G G G G A G A A G A G T T T T G C  PFD0005w_2g
G A A T G G A G T G A C G A A T T T T G T  PFD1235w_4g 
G A A T G G T A T G A C G A T T A T T G C  PFE1640w_3g 
G A A T G G G C A G A A G A A T T T T G T  PFE1640w_5g 
G A A T G G G G A G A A G A T T T T T G T  PFF0010w_3g
G A A T G G A G T G A T G A A T T T T G T  PFL0020w_3g
G A A T G G A G C G A A C A G T T T T G T  PFL0030c 3X
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Fig. 4.7. Amplification of 3D7 gDNA using primer pair D3F and D3R1.2. Bars
indicated frequency of amplification of the DBLγ domain/var2csaDBL3X
transcripts. Black line shows expected bionomial distribution of frequencies as a
polynomial trendline. This shows a bias of < 2% for the most frequently detected
sequence.
4.6.2 DBLγ/var2csa DBL3X transcript sequences detected in Malawian
placental malaria field isolates by RT-PCR with primers D3F and D3R1.2
RT-PCR was carried out with the new primer pair D3F amd D3R1.2 for the six
placental isolates CS294, P132, P134, P136, P143, P154. Transcripts from
TM180CSA and TM284 were not amplified as the focus of the study was
transcription in placental isolates not laboratory strains. RT-PCR products were
obtained for all six isolates and were purified, ligated and cloned as before. 11-19
colonies were picked at random for growth overnight in LB broth, and the plasmids



















































































The sequences obtained with primer pair D3F and D3R1.2 from parasite isolates
CS294, P132, P134, P136, P143, P154 were compared for multiple copies of the
same sequence (over 95% sequence identity), and again defined as placental (Pl) var
gene A-H from each isolate. Pie charts were then created to show frequency of
different domains for the D3F/D3R1.2 primer pair (Fig. 4.8). Var1csa was present in
5/6 isolates with these primers (shaded in yellow, Fig. 4.8). All of the parasite
isolates expressed at least one var gene with strong homology to var2csa (shaded in
grey, Fig. 4.8).
Fig. 4.8. Proportions of DBLγ/var2csa domains in 6 placental malaria isolates. Pie
charts represent the relative number of different DBLγ/X sequences as detected by
RT-PCR. Bracketed number is the number of cloned sequences for the isolate, and
the isolate name is shown in bold. Sequences with homology to var2csa are shaded
in grey, and with homology to var1csa in yellow.
167
Some sequences amplified with D3F and D3R2 were amplified again D3F and
D3R1.2 (Fig. 4.9). Where a sequence was amplified that had already been identified
from the first amplification, the original name was kept, e.g. P136PlvarA was
amplified with both primer sets. Though some of the same sequences were amplified,
the predominant transcript with D3F/D3R2 was not predominant when amplified
with D3F/D3R1.2 in any isolate. With these primers, a wider range of domains was
amplified, and a predominant gene was less clear.
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Fig. 4.9. DBLγ/var2csa RT-PCR on placental isolates P132, P134, P136, P143, P154
and CS294. Both amplifications used forward primer D3F. Y-axis shows frequency
of RT-PCR products relating to transcripts A, B, C etc for each isolate with products
with reverse primer D3R2 (striped) and D3R1.2 (black). There was no RT-PCR


































































4.6.3 Phylogenetic analysis of transcript sequences detected by RT-
PCR with primers D3F and D3R1.2
A phenogram was constructed to give an indication of sequence similarity of the var
genes expressed from the difference isolates from the second set of primers, D3F and
D3R1.2 (Fig. 4.10), and together sequences amplified from D3F and D3R2 primer
pair (Fig. 4.11) with the published sequences from Gabon, Cameroon and Kenya,
and also with var1csa DBL3γ and DBL5γ domains from 3D7 and FCR3 and var2csa
DBL3X domain from 3D7 (Beeson et al. 1999; Buffet et al. 1999; Reeder et al.
1999; Reeder et al. 2000; Khattab et al. 2001; Fried and Duffy 2002; Khattab et al.
2003; Salanti et al. 2003; Gamain et al. 2005).
Fig. 4.10 and Fig. 4.11 both highlight the striking clustering of some transcripts from
the placental malaria isolates discussed in this chapter around var2csa DBL3X. Only
sequences from the second set of primers, D3F and D3R1.2 cluster here, due to
primer specificity. The non-var2csa transcripts amplified with D3F and D3R1.2 are
spread evenly throughout the rest of the tree. There was no obvious separation of
transcripts from the two different primer sets, or from the Malawian isolates
examined here compared to the published sequences.
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Fig. 4.10. Phenogram showing expressed DBLγ sequences from P. falciparum isolates
of placental malaria from females in Malawi (red), alongside the DBLγ domains of
var1csa (FCR3varCSA 3/5γ and 3D7Chr5var 3/5γ, yellow), and the DBL-3X domain of





Fig. 4.11. Phenogram displaying transcribed DBLγ domains in P. falciparum
placental field isolates from Malawi (this study) in relation to other DBLγ domains.
Red: transcribed DBLγ domains in P. falciparum placental field isolates from
Malawi amplified with D3F and D3R1.2. Blue: transcribed DBLγ domains in P.
falciparum placental field isolates from Malawi amplified with primers D3F and




DBLγ domains from CSA-binding laboratory strain TM180CSA with primers D3F
and D3R2. Black: transcribed DBLγ domains in P. falciparum placental field isolates
from Cameroon (498,482,732 and 720/734), Kenya (Plcx) and Gabon (Gbx). The
DBLγ domains of var1csa (FCR3 and 3D7; shaded in yellow), the DBLγ domain of
CS2var (shaded in blue) and the DBL3X domain of var2csa (shaded in pink) are also
included.
4.6.4 DBLγ domain RT-PCR of childhood isolates using primers D3F
and D3R1.2
It is not possible to assess whether var2csa transcription is specific for placental
malaria field isolates without comparing the placental transcription pattern to that of
non-pregnant individuals, such as non-pregnant women, men or children. The
childhood malaria samples described in chapter 3 were available and so these were
used for a comparison. RT-PCR, cloning and sequencing were then used to create
transcription profiles for a subset of the childhood isolates examined for DBLα
expression (Chapter 3). Five cerebral and five uncomplicated isolates were chosen at
random.
As with the DBLα domains, a range of transcripts were detected per isolate. There
was no significant difference in the number of sequences detected within the three
disease categories  (Kruskal Wallis test, P=0.48), and a predominant DBLγ domain
was seen in most isolates (Fig. 4.12). Var1csa transcripts were detected in 8/10
childhood isolates; 4/5 cerebral isolates and 4/5 uncomplicated malaria isolates
(yellow in Fig. 4.12). Var2csa transcripts were not detected in any childhood isolate
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Fig. 4.12. Proportions of DBLγ/var2csa domains in 5 isolates from 3 disease
categories; uncomplicated childhood malaria, cerebral childhood malaria, and
placental malaria. Pie charts represent the relative number of different DBLγ/X
sequences as detected by RT-PCR with D3F and D3R1.2. Bracketed number is the
number of cloned sequences for the isolate, and the isolate name is shown in bold.
Sequences with homology to var2csa are shaded in grey, and with homology to
var1csa in yellow.
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A phenogram was constructed, incorporating all sequences amplified from both the
primer pairs from all 16 isolates (Fig. 4.13). There was no difference in distribution
of the cerebral versus uncomplicated malaria DBLγ sequences. However, there was a
very marked clustering of placental sequences around var2csa DBL3X domain, as
var2csa is present at a high abundance in placental isolates from Malawi, but is not
present in any of the childhood isolates from Mali. Using only sequences amplified






Fig. 4.13. Phenogram displaying transcribed DBLγ/var2csa transcripts in P .
falciparum placental field isolates from P. falciparum isolates of childhood cerebral
(purple) and uncomplicated (green) malaria from Mali and from placental isolates
from Malawi (red) amplified with primers D3F and D3R21.2. Transcribed DBLγ
domains in P. falciparum placental field isolates from Cameroon (498,482,732 and
720/734), Kenya (Plcx) and Gabon (Gbx), and from CSA-binding laboratory strain
TM180CSA (blue), the DBLγ domains of var1csa (FCR3 and 3D7; yellow) and
CS2var (blue) and the DBL3X domain of var2csa (pink) are also included. Var2csa
DBL1X and DBL2X are also included for reference, but are in grey as they could not
be amplified by these primers. Phenogram was constructed from a clustal W
alignment of amino acid sequences.
A phenogram only including the childhood DBLγ transcripts amplified from the
second primer pair from all 16 isolates (Fig. 4.14) also shows clearly there was no
difference in distribution of the cerebral versus uncomplicated DBLγ sequences.
Unfortunately there was not enough parasite material to perform real-time RT-PCR
for these samples, which would have been useful to quantify relative amounts of var
gene transcripts detected in these isolates.
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Fig. 4.14. Phenogram displaying transcribed DBLγ/var2csa transcripts in P .
falciparum placental field isolates from P. falciparum isolates of childhood cerebral
(purple) and uncomplicated (green) malaria from Mali amplified with primers D3F
and D3R1.2. Phenogram constructed from a clustal W alignment of amino acid
sequences.
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4.7 DBLγ transcript analysis
4.7.1 Sequence diversity of DBLγ domain transcripts
The level of amino acid identity between different DBLγ sequence domain tags was
calculated. Amino acid identity of the DBLγ transcripts separated by disease
category indicates a significantly higher level of amino acid in the placental malaria
group (median 33.1%) than in childhood malaria (median 30.1% Mann-Whitney Test
<0.001) as shown by box plots and histograms (Fig. 4.15). The level of amino acid
identity between different Malawi DBLγ sequence domain tags was calculated and
also illustrated pictorially (Fig. 4.16). Percentage amino acid identity between 2
DBLγ/var2csa domains is colour coded such that darker shading reflects higher
amino acid identity.
Var2csa homologues are comparatively highly conserved and the var2csa transcripts
amplified in these isolates shared 64-96% nucleotide identity, median 88.3% (Fig.
4.15 and 4.16). Removing the var2csa homologues decreased the similarity between
placental isolates sequences (median 29.5%) though this act did not significantly
change the distribution of sequence identities (Mann-Whitney test, placental “all
sequences” versus placental “non-var2csa sequences”, P=0.358). The was still a
significant difference between placental DBLγ (non-var2csa) and childhood DBLγ
sequences (Mann-Whitney test P=0.019).
Var2csa homologues were significantly more similar to each other than the DBLγ
transcripts from childhood of placental malaria isolates both Mann-Whitney Test
P<0.001).
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Fig. 4.15. Histograms and box plots of percentage amino acid identity between all
DBLγ domain transcripts from placental, childhood, placental (var2csa only) and
placental (non-var2csa only) DBLγ transcripts. Box plots show 10th, 25th, 50th, 75th





Fig. 4.16. Amino acid sequence distance charts showing percentage amino acid
identity between domains for DBLγ/var2csa domains. A) Placental malaria, cerebral
malaria, uncomplicated malaria, and all childhood isolate DBLγ/var2csa sequences.
B) Placental var2csa homologues and non-var2csa homologues separately. Darkness
of shading indicates level of identity between domains.
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Fig. 4.17. Alignment of var2csa in this study and var2csa DBL3X from FCR3 and
3D7, produced from a clustal W alignment of protein sequences.
Fig. 4.17. Alignment of var2csa in this study and var2csa DBL3X from FCR3 and
3D7, produced from a clustal W alignment of protein sequences.
Although relatively highly conserved, the var2csa homologues retain some
polymorphicity. Variability between the var2csa homologues is concentrated
towards the end of the amplified tag, with a relatively more conserved region in the
middle (alignment amino acids 78-122; Fig. 4.17).
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4.7.2 Conservation of DBLγ domain transcripts detected
A BLAST homology search performed for sequences not homologous to var1csa or
var2csa on the NCBI database, indicated no other highly conserved DBLγ were
present (Table 4.1). There is much less similarity between DBLγ domains than
DBLα domains (Table 3.3, chapter 3) though this may reflect the fewer DBLγ
domains on NCBI database, see discussion.
184
DBLγ transcript Database matches
Name Accession
Number
Accession Number Origin Nucleotide
identities (%)
P134varA DQ306273 -












P154varA DQ306293 Placental mRNA, Malawi CS294varB 450/450 (100%)
P154varD
DQ306296




































DBLγ transcript Database matches
Name Accession
Number












CM7B - 3D7 var Pff0010w DBLγ domain3 393/434 (90%)
CM7C - -
CM7D - -





Table 4.1. Homology of Malawi isolate non-vass1csa or var2csa DBLγ transcripts
described in this study compared to sequences on NCBI database. Database matches
> 85% identity, >85% sequence coverage, http://www.ncbi.nlm.nih.gov/BLAST are
also described (accession number, origin, and% nucleotide identity). - no database
matches were found. 1Khattab et al. 2003, 2Kraemer et al. 2007, 3Gardner et al. 2002,
*This study/(Duffy et al. 2006a).
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4.8 Analysis of DBLα domain transcripts detected in placental isolates
P132, P136, P143, P154 and CS294, from Rowe et al. (2002a)
As most DBLγ are from Group A or B/A var (12/15 in 3D7, 12/18 in HB3 and 12/25
in IT) amplification of DBLγ domains in this study was expected to result in
detection predominantly of group A or B/A var gene transcripts. If the 3D7 gene
repertoire is typical, DBLγ domain amplification should detect 91% of non-type 3
group A or B/A var genes, but only 7% of group B, C or B/C var genes. If the HB3
or IT genomes are more typical, more group B,C or B/C var genes would be
amplified by DBLγ domain RT-PCR.
To examine the relative proportions of group A and B/C var expressed in these
isolates, DBLα(0/1) RTPCR transcription data on isolates P132, P136, P143, P154
and CS294, which already been published (Rowe et al. 2002a) was reanalysed. This
paper had used the primers from Taylor et al. (2000a) and the method described in
chapter 3. The DBLα domain transcripts were downloaded from NCBI database and
classified as DBLα0 or DBLα1, on the basis of number of cysteines in the amplified
tag (Table 1.1). Pie charts were created to show the relative proportions of the two
subtypes of DBLα domain (DBLα0 shaded black, DBLα1 in white; Fig. 4.18).
Var1csa homologues are indicated (yellow). This revealed higher DBLα0 than
DBLα1 transcription in these placental isolates. Only 3 non-var1csa DBLα1
transcripts were detected.
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Fig. 4.18. DBLα domain RT-PCR data on isolates P132, P136, P143, P154 and
CS294 taken from Rowe et al. (2002). Pie charts indicate relative abundance of
DBLα domains (DBLα0 grey, DBLα1 white, var1csa homologues in yellow).
4.9 Discussion
The results presented in this chapter highlight the exclusive nature of transcription of
a particular var gene, var2csa, in placental malaria isolates. This study of clinical
isolates supports the growing body of evidence from studies of field and laboratory
strains of P. falciparum advocating VAR2CSA as a major contributor to the
opportunistic placental sequestration that commonly occurs during pregnancy in
malaria-endemic areas. The data obtained will be discussed alongside current
developments concerning the role of VAR2CSA in placental malaria.
In this study, transcription of at least one var2csa homologue was detected by RT-
PCR in all six Malawian placental isolates available, but in none of the 10 Malian
childhood isolates also examined. Other recent studies have also found var2CSA
transcripts to be present in the majority of placental isolates but rarely detected in
childhood or non-placental isolates, confirming this strong association specifically
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with placental malaria (Salanti et al. 2004; Tuikue Ndam et al. 2005; Duffy et al.
2006a; Francis et al. 2007; Fried et al. 2007). Furthermore, VAR2CSA PfEMP1
protein is recognised by natural antibodies from endemic areas in a sex-specific and
parity-dependent manner (Salanti et al. 2003; Salanti et al. 2004; Tuikue Ndam et al.
2006), again emphasising the link between var2csa and pregnancy reported in this
study.
Placental isolates possess a unique binding phenotype with a consistently high
affinity for CSA (Fried and Duffy 1996; Fried et al. 2006; Fried et al. 2007;
Muthusamy et al. 2007). This is consistent with expression of VAR2CSA as
VAR2CSA binds to CSA when expressed on the surface of an infected erythrocyte
and is consistently upregulated in laboratory isolates after selection for CSA-affinity
(Salanti et al. 2003; Avril et al. 2004; Salanti et al. 2004; Gamain et al. 2005; Duffy
et al. 2006b; Beeson et al. 2007a; Francis et al. 2007; Fried et al. 2007). In certain
strains var2csa disruption irreversibly ablates CSA-affinity, suggesting this protein
mediates the majority of CSA-binding (Gamain et al. 2005; Viebig et al. 2005;
Duffy et al. 2006b). Most field isolates are predicted to contain a var2csa homologue
(Trimnell et al. 2006). If all var2csa homologues retain affinity for CSA, then it is
likely that all parasite isolates have the potential to cause placental malaria.
The relative sequence homology between the VAR2CSA DBL3X domains identified
in the placental field isolates in this study was 64-96%, similar to the range of
homology published in Trimnell et al. 2006 (54-94%). Var2csa homologues are
conserved by var gene standards, composed of blocks of highly conserved stretches,
189
separated by regions of high interclonal diversity (Beeson et al. 2006; Duffy et al.
2006a; Trimnell et al. 2006; Barfod et al. 2007; Bockhorst et al. 2007). Presence of a
var2csa homologue in P. reichenowi suggests a strong evolutionary advantage for
CSA-binding ability (Trimnell et al. 2006; Bockhorst et al. 2007). Var2CSA is under
a high level of diversifying selection which appears to be driven by immune pressure
(Dahlback et al. 2006; Barfod et al. 2007; Bockhorst et al. 2007). Whether all of the
VAR2CSA homologues retain CSA-affinity is not obvious from the sequence.
None of the childhood isolates in this study showed evidence of var2csa
transcription, consistent with a role for var2csa specifically in placental malaria. In
other studies, var2csa homologues have infrequently been detected in non-pregnant
individuals (Duffy et al. 2006a; Francis et al. 2007), though these do not always
appear to have the characteristic CSA-binding ability (Fried et al. 2007). Low levels
of antibodies with reactivity to VAR2CSA have also recently been detected in
plasma from some men and children from various malaria-endemic areas (Beeson et
al. 2007b). It may be that these VAR2CSA have a subtly different structure resulting
in a different binding phenotype.
CSA is present in other parts of the body, including on the cerebral vasculature
(Robert et al. 1995). However, VAR2CSA does not appear to be involved in any
other sequestration, such as during cerebral malaria, and var2csa was not seen in
these cerebral malaria isolates. CSA is hugely heterogeneous, composed of tandem
repeats of glucuronic acid and N-acetylgalactosamine-4-sulfate, and subtleties in the
structure of CSA in the placenta may be critical for adhesion here. Infected
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erythrocytes adhere most efficiently to CSA in a low sulfation state, and this form is
common in the intervillous spaces of the placenta (Achur et al. 2000). The origin of
CSA in the placenta is foetal, not maternal (Muthusamy et al. 2007), possibly
presenting a slightly different binding site for PfEMP1 interaction than maternal-
derived CSA, for example on host erythrocytes, and providing the specificity for
CSA-adhesion only in the placenta.
Upregulation of CSA upon infection may also be important; Muthusamy et al.
(2007) observed infected placentas had higher CSA levels than uninfected placentas.
It is also possible that CSA-binding has another function other than as a receptor for
sequestration. For example CSA-binding placental parasites have recently been
shown to escape non-opsonic phagocytosis compared to CD36-binding parasites
(Serghides et al. 2006), though this may be due to loss of CD36-binding rather than
gain of CSA-affinity. As placental CSA may be unique in structure, using placental
cryosections (Avril et al. 2004) rather than bovine CSA (Fried and Duffy 1996;
Ricke et al. 2000) for in vitro adhesion studies may give a more accurate reflection
of clinically important in vivo interactions.
The childhood isolates used for comparison in this study were from Mali not Malawi
and so have a different geographic origin from the placental isolates. However, the
var gene repertoire of isolates in Mali appears to be typical of isolates across Africa
and the world (chapter 3), and var2csa expression is seen in placental malaria
isolates worldwide (Salanti et al. 2003; Avril et al. 2004; Salanti et al. 2004; Gamain
et al. 2005; Duffy et al. 2006a; Beeson et al. 2007a; Francis et al. 2007). Ideally,
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isolates from men or non-pregnant women, matched for age, geographic location and
socioeconomic group would have been used for comparison. It would also have been
interesting to also examine DBLγ transcription in the hyperparasitaemia isolates
described in chapter 3 for comparison.
As var2csa has been associated with placental malaria, this study reveals expression
of a perhaps surprisingly high number of non-var2csa var genes in placental isolates.
The parasites studied were expelled directly from the placenta, raising the question
whether these PfEMP1 were also involved in placental sequestration, alongside
VAR2CSA. If this were the case it might be possible to detect a particularly
“placental” sequence or motif. Antibodies to the DBL3γ  domain of FCR3
VAR1CSA recognise 40-60% of placental isolates and block CSA adhesion,
suggesting cross-reacting DBLγ domain epitopes are commonly expressed in
placental malaria isolates (Lekana Douki et al. 2002; Costa et al. 2003). However,
there was no particular clustering in the phenogram of placental isolate DBLγ
transcript sequences compared to those from childhood malaria isolates.
Furthermore, comparison to sequences on the NCBI database suggested there is not
anything particularly “placental” about the DBLγ transcripts detected in the placental
isolates in this study compared to the overall var gene repertoire. Of the 9 transcripts
with highly homologous database matches, 4 matches were DBLγ transcripts, all
from placental malaria isolates. No database matches to childhood malaria isolate
transcripts were found. However, this may be misleading as DBLγ domains are most
commonly studied in relation to placental malaria, and this may be reflected in the
DBLγ RNA sequences represented in the NCBI database. Alternatively, some var
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gene transcripts detected in these placental isolates may simply be from an incidental
sub-symptomatic chronic infection that had expanded due to pregnancy-associated
immunomodulation (reviewed in(Ndam and Deloron 2007), and have no direct role
in placental sequestration.
The only DBLγ domain transcript seen in multiple isolates was var1csa, detected in
5 of the 6 placental isolates examined here. Var1CSA is commonly detected in
placental isolates including those from Cameroon (Khattab et al. 2001), Kenya
(Fried and Duffy 2002) and Gabon (Khattab et al. 2003), and VAR1CSA can
mediate CSA binding (Buffet et al. 1999; Rowe et al. 2002a; Gamain et al. 2004;
Badaut et al. 2007), though the in vivo relevance of this interaction in infection is
unclear. Var1csa disruption in laboratory strain FCR3 was reported to knock out
CSA-binding (Andrews et al. 2003), but CSA-affinity was regained as the parasite
switched on var2csa (Gamain et al. 2005). The mechanism of VAR1CSA-mediated
binding to CSA appears to be very similar to that of VAR2CSA. The minimal (67
amino acid) region of FCR3 VAR1CSA required for CSA binding has high
homology to the CSA-binding domain of VAR2CSA (Gamain et al. 2004; Gamain et
al. 2005), with cross-reacting epitopes (Bir et al. 2006), suggesting a common
mechanism of adhesion, and overlapping binding sites. It might thus be expected that
var1csa expression in an infection would elicit an antibody response which could be
protective against VAR2CSA subsequent infections. However, as var1csa is
commonly expressed in non-pregnant and childhood isolates (Fried and Duffy 2002;
Rowe et al. 2002a; Winter et al. 2003), including 8/10  childhood isolates in this
study, and incidents of placental malaria are high with estimates of infection in up
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two-thirds of pregnancies in malaria-endemic sub-Saharan countries (Broen et al.
2007), it seems unlikely a protective antibody repertoire is created and maintained.
It is possible the association of var1csa, transcribed at trophozoite stage (Kyes et al.
2003), with placental isolates is a result of studying mature parasites extracted
directly from the placental at delivery in this and many other studies (Khattab et al.
2001; Fried and Duffy 2002; Khattab et al. 2003; Duffy et al. 2006a). To avoid this,
trophozoite parasites could be cultured to ring stage before RNA extraction.
However, culturing risks var gene switching, as discussed in chapter 3. Alternatively,
peripheral ring stage parasites could be studied. Peripheral ring stage parasites
matured in vitro to pigmented-trophozoite stage tend to show the same binding
phenotype as mature trophozoite parasites collected directly from the placenta from
the same isolate (Francis et al. 2007). This suggests the parasites are from the same
population, as observed in comparisons of sequestered and peripheral parasite
populations in childhood isolates (Dembo et al. 2006; Montgomery et al. 2006).
Whichever parasites are studied, it is clear var1csa expression is neither necessary
nor sufficient for placental sequestration of infected erythrocytes.
In addition to var1csa and var2csa, other PfEMP1 are capable of binding to CSA
and may prove to be conserved mediators of placental sequestration. Distinct DBLγ
domains with affinity for CSA have been identified from placental isolates (Khattab
et al. 2001; Khattab et al. 2003), including the semi-conserved varPAM732 which
specifically binds to immobilised CSA (Chia et al. 2005), and to CSA on placental
cryosections (Badaut et al. 2007). CS2var also has affinity for CSA (Reeder et al.
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1999). Expression of CS2var rescued the CSA-binding phenotype of a var2csa
knock-out parasite (Duffy et al. 2006b) and a placental isolate from Malawi
expressed CS2var as the major transcript (Duffy et al. 2006a). However, CS2var is
not commonly conserved between isolates nor expressed at higher levels in placental
isolates compared to non-pregnant hosts, so a crucial role in placental malaria is
unlikely (reviewed in(Rowe and Kyes 2004). Neither CS2var nor varPAM732 DBLγ
domains transcripts were seen in these placental isolates.
As most DBLγ are from group A or B/A var, amplification of DBLγ domains in this
study was expected to result in detection predominantly of group A or B/A var  gene
transcripts. Examining mainly group A and B/A var genes may be a limitation of the
study, as most group B and C var genes would have been overlooked. This prompted
analysis of DBLα(0/1) RTPCR data using the primers described in chapter 3 (data
from Rowe et al. 2002) revealed higher DBLα0 than DBLα1 transcription in these
placental isolates. The low level of transcription of DBLα1 domains in these isolates
is consistent with the association of DBLα1 domains/group A PfEMP1 with severe
childhood disease, and young immunologically naive hosts.
As syncitiotrophoblasts do not express CD36 (Sartelet et al. 2000), and placental
isolates do not tend to show affinity for CD36 (Fried et al. 2007; Muthusamy et al.
2007), group B, C or B/C PfEMP1 expression was not expected. The high frequency
of DBLα0 domains in Rowe et al. 2002 is thus surprising. If the association of DBLγ
and group A (DBLα1 domains) is true for field isolates, the DBLα0 domains
amplified here are unlikely to ‘belong’ to the DBLγ domain transcripts detected in
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this chapter. The high presence of DBLα0 domains suggests even more non-var2csa
var genes are being transcribed in these field isolates than would be predicted from
the DBLγ analysis alone. Unfortunately, these primers cannot recognise var2csa, and
so comparisons of abundance of DBLα(0/1) and var2csa transcription would not be
possible unless quantitative real-time RT-PCR analysis was performed.
Results in chapter 3 showed cerebral isolates expressed a higher proportion of group
A or B/A var genes than uncomplicated isolates. In this analysis, no difference was
seen in the number or clustering of DBLγ/var2csa domain transcripts in the cerebral
and uncomplicated childhood malaria groups. However, there is no data on the
relative levels of transcription in the different isolates. Though a similar level of
diversity of DBLγ transcripts per isolate was detected, this does not necessarily
equate to a similar level of overall DBLγ transcription as non DBLγ-containing var
genes are neglected. This data does not therefore conflict with the results of chapter
3.
Non-var2csa transcripts were found in each placental isolate, with no detectably
“placental” features. There is no reason to assume they have affinity for CSA.
However, they may bring about placental sequestration through other interactions.
Binding to hyaluronic acid has previously been implicated in placental malaria
(Beeson et al. 2000). Although subsequent studies have shown this interaction is not
as important as CSA interaction (Muthusamy et al. 2007), it may still have a minor
role. Binding to IgM is a characteristic of many placental isolates (Creasey et al.
2003), and can be mediated by PfEMP1 including var1CSA and var2csa (Semblat et
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al. 2006). IgG binding may also be involved (Flick et al. 2001). ICAM1 also appears
to be upregulated in placenta upon P. falciparum infection, (Sartelet et al. 2000)
which provide a target for adhesion via certain PfEMP1 (Smith et al. 2000a; Springer
et al. 2004). The complete binding phenotype of placental parasites is probably still
not fully understood.
The clear association of var2csa with placental malaria have inevitably led research
towards the development of a vaccine against placental malaria, though
unfortunately this challenge has so far proved difficult. Assessments of the cross-
reactivity of anti-var2csa protection are conflicting (Elliott et al. 2005; Beeson et al.
2006; Barfod et al. 2007) and the true level of involvement of other PfEMP1, or
other proteins, is unclear. Recently a number of non-PfEMP1 proteins have been
associated with placental malaria (Francis et al. 2007; Fried et al. 2007; Gowda et al.
2007; Mok et al. 2007). If other proteins have the potential to cause placental
sequestration then a placental malaria vaccine directed exclusively at var2csa is
unlikely to be successful.  Seeking to inhibit parasite protein-mediated adhesion to
host cells is not a problem confined to placental malaria. Rosetting, a phenomenon
association with malaria severity in Africa (Carlson et al. 1990; Rowe et al. 1995;
Rowe et al. 2002b) is brought about through interactions via many different PfEMP1
with uninfected erythrocytes. In the case of rosetting, interactions with host
erythrocyte ligands via many different PfEMP1 can be universally inhibited by
certain glycosaminoglycan drugs, rather than trying to target each interaction
independently (Havlik et al. 2005; Kyriacou et al. 2007), see chapter 6 for details of
curdlan sulfate as a rosette inhibiting drug. A similarly broad approach could be
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useful in the case of placental malaria of trying to protect the placenta against a wide
range of different mechanisms of placental-sequestration, rather than focussing on a
single interaction, although this may not be feasible.
In conclusion, the data presented in this chapter are indicative of var2csa being
important in placental malaria, an association which has become increasingly
convincing in the light of recent supporting studies. In the case of placental malaria a
clearer picture of var gene involvement has emerged than in childhood cerebral
malaria, with one specific var gene rather than a whole subgroup being involved.
This reflects a simpler mechanism of sequestration, whereby a single var gene has
high affinity for a novel ligand. It follows that defining conserved sequences that
contribute specifically to placental malaria is pivotal in the development of effective
drugs and vaccines to combat this disease.
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Chapter 5




This chapter examined type 3 var gene transcription in laboratory strains and field
isolates. Type 3 var genes are group A var genes, and it was hypothesised that their
transcription would be associated with cerebral malaria, following the link between
other group A var genes and cerebral malaria discussed in chapter 3. Type 3 var gene
transcripts were detected in the majority (23/26) of field isolates examined, and were
highly conserved. Transcription of the type 3 var genes was not associated with
cerebral malaria, however, there was an increased diversity of transcripts in the
hyperparasitaemia isolates compared to cerebral malaria isolates, possibly suggesting
a higher frequency of type 3 var gene transcription. Phylogenetic analysis of the type
3 var gene sequences obtained revealed 6 highly conserved subgroups of type 3
DBLα domain. Type 3 DBLε domains were highly homologous across the entire
length of the amplified tag. Transcription of type 3 var genes in P. falciparum
laboratory isolates revealed transcription occurs in asexual parasites, in ring stage,
pigmented trophozoite stage and schizont stages, of laboratory isolate 3D7. No
association with binding phenotype in laboratory isolates (rosetting or IgM affinity)




5.2.1 Type 3 var  gene/ PfEMP1 structure
The type 3 var genes are the shortest of the var family, being approximately 4 kb in
length (3.948, 3.984 and 3.978 kb in 3D7). The type 3 var genes thus encode the
smallest PfEMP1 (approximately 153 kDa). Type 3 PfEMP1 have no CIDR domains
and only two extracellular DBL domains; an N-terminal DBLα domain (further
referred to as DBLαtype3), and a membrane-proximal DBLε domain (DBLεtype3) (Fig.
5.1, Fig. 5.2). The DBL domains are followed by a transmembrane region and ATS,
typical for PfEMP1 (Fig. 5.1, Fig. 5.2).
Fig. 5.1. Diagram of type 3 PfEMP1s showing DBLαtype3, DBLεtype3, transmembrane
region (TM) and ATS region. Hatched and striped N-terminal region of DBLαtype3
domains are variable, light grey shaded area of DBLαtype3 and DBLεtype3domains, as










Fig. 5.2. Annotated clustal W alignment of the three 3D7 type 3 PfEMP1 amino acid
sequences showing NTS region, DBLα domain, conserved cysteine-rich region,
DBLε domain, transmembrane (TM) domain and ATS region. Arrows indicate
beginning of each domain type.
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5.2.2 Type 3 var genes are atypical group A var genes
Type 3 var genes are interesting due to their unusual domain structure, containing
only two well-conserved extracellular DBL domains. The data presented in chapter 3
revealed an association between group A var gene transcription and cerebral malaria.
However, transcription of type 3 var genes could not be analysed with the primers
used in chapter 3. Type 3 var genes are group A genes; as well as having a DBLα1-
type DBLα domain, the type 3 var genes have UpsA-type upstream regions and are
telomerically located with transcription towards the telomere in 3D7 (Smith et al.
2000b; Gardner et al. 2002; Kraemer and Smith 2003; Lavstsen et al. 2003).
However, the other group A var genes are characterised by having many
extracellular domains. The type 3 var genes encode atypical group A PfEMP1,
without the complex domain architecture of the other group A PfEMP1. It is possible
that they have different properties to classic group A PfEMP1, and their transcription
may not be associated with severe disease.
5.2.3 Type 3 var gene DBLα1 domains
The nucleotide sequence of first half of the DBLα type3 domains is variable, and
DBLαtype3 domains are indistinguishable from other DBLα1 domains (Fig. 5.3).
However, the DBLαtype3 domains become increasingly similar until the final ≈ 336
nucleotides of each DBLαtype3 domain, which form a highly conserved DBLαtype3-
specific region, and DBLαtype3 cluster separately in a phenogram from other DBLα1
domains (Fig. 5.4).
203
Fig. 5.3. Clustal W amino acid alignment of DBLα1 domains from 3D7. The
consensus sequence from an alignment of the three DBLαtype3 domains in 3D7 is
shown and identical residues shaded. DBLαtype3 domains are indicated (}). Red line
(amino acid 191 in this alignment) indicates the start of the type 3-specific portion.
Fig. 5.4. Phenogram of 3D7 group A DBLα1 domains; DBLαtype3 domains (circled)
cluster separately.
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5.2.4 Type 3 var gene DBLε  domains
Similarly, Type 3 epsilon domains (DBLεtype3) are extremely conserved; the three
DBLεtype3 in 3D7 have only 4 nucleotide differences, and they cluster separately from
other epsilon domains after phylogenetic analysis (Fig. 5.5 and Fig. 5.6).
Fig. 5.5. Clustal W amino acid aligment of all 3D7 epsilon domains; type 3 epsilon
domains indicated (}) Shading indicates DBLεtype3 domain residues.
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Fig. 5.6. Phenogram of 3D7 epsilon domains; DBLεtype3 domains (circled) cluster
separately.
5.2.5 Type 3 var gene intron
Retrieval of data from plasmboDB database revealed Pfa0015c, Pfi1820w and
Mal6P1.314 have introns of 158, 171 and 150 bp respectively. These introns are
much shorter than those of other var genes, which are usually 0.8-1.2 kb (Su et al.
1995). They do not contain the conserved repeat elements which make up the
promoter initiator element, described by Calderwood et al. (2003). Pfi1820w and
Mal6P1.314 do not contain the Inr-like initiator sequence (TCATA). Pfa0015c does
contain this sequence, but as it is not in the correct context within the initiator
element it is unlikely to act as a promoter (Calderwood et al. 2003). This has
implicatons for regulation, as the intron promoter regulates var gene silencing
(Deitsch 2001; Calderwood et al. 2003; Frank et al. 2006).
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5.2.6 Type 3 var gene ATS region
The ATS region of the type 3 var genes in 3D7 cluster with the ATS region of the
other 3D7 group A var genes in a distance tree of the ATS domains by Lavstsen et
al. 2003. Mal6P1.314 and Pfi1820w ATS regions are almost identical and form a
slight outgroup from other group A ATS regions (Lavstsen et al. 2003).
5.2.7 Type 3 var gene transcription
At present there is little published data on type 3 var gene expression in laboratory or
field isolates. Two papers discuss type 3 var gene transcription in relation to disease
severity. Firstly, Jensen et al. (2004) report type 3 var gene transcription (pfa0015c)
at relatively high levels in unselected 3D7, and a decrease in expression after
selection on semi-immune sera. This suggests type 3 PfEMP1 are not associated with
severe disease and are not common targets for an immune response. Secondly,
Rottman et al. (2006) reported a small (non-significant) upregulation of type 3 var
gene transcription in severe malaria compared to uncomplicated or asymptomatic
malaria isolates, but in this study there was an increase in all var gene groups in
severe malaria compared to the control groups, suggesting an increase in overall var
gene transcription in the severe malaria cohort, possibly due to the higher
parasitaemia.
5.2.8 Type 3 var gene/PfEMP1 hypotheses
The intention of the chapter was to examine type 3 var gene transcription in a range
of laboratory and field isolates. Due to the association of group A var gene
transcription with cerebral malaria isolates discussed in chapter 3, it was
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hypothesised that type 3 var gene transcription may be more common in cerebral
malaria isolates than in hyperparasitaemia isolates. However, as type 3 var genes are
not typical group A var genes, the association found between group A var genes and
cerebral malaria disease in chapter 3 could not be extended to the type 3 var genes
without specifically examining this link.
It was thought possible that the timing of expression could be regulated differently to
other var genes due to the small intron and therefore lack of regulatory promoter
(Deitsch 2001; Calderwood et al. 2003; Frank et al. 2006).  It was also thought
possible that the lack of the regulatory promoter may promote type 3 var gene
expression outside the mutually exclusive var gene expression system (Smith et al.
1995; Scherf et al. 1998; Dzikowski et al. 2006), and that type 3 var gene transcripts
could be constitutively expressed.
The high conservation of type 3 PfEMP1 led me to doubt prolonged exposure of type
3 PfEMP1 on the erythrocyte surface, and so an antibody was designed to
specifically recognise type 3 PfEMP1, to allow protease experiments with
immunofluorescence and Western blot to investigate type 3 PfEMP1 expression and
determine whether it is surface expressed.
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5.3 Aim of chapter
In this chapter, transcription of type 3 var genes in P. falciparum laboratory and field
isolates was examined. Data was obtained on the frequency of expression, timing of
expression, and sequence conservation of the type 3 var genes in laboratory strains
and field isolates. In addition, to study protein expression of the type 3 PfEMP1, a
type-3 specific anti-peptide polyclonal antibody was designed and raised in chicken.
This antibody was then used to examine protein expression of type 3 PfEMP1 in P.
falciparum laboratory strain 3D7.
5.4 Materials and methods
Materials and methods that are specific to chapter 5 are listed below. General
materials and methods and a list of suppliers are given in chapter 2.
5.4.1 Type 3 var gene PCR/RT-PCR
Field isolate cDNA prepared as detailed for DBLα analysis was used (see chapter 2
and 3). Laboratory strains used were 3D7, NF54, Dd2, HB3, TM180, TM284,
FCR3/It, 7G8, Muz12, TM267 and Malayan Camp all from JA Rowe/A Raza except
3D7. Type 3 var gene sequence taken from 3D7 were pfa0015c, pfi1820w and
mal6p1.314 (also renamed pff0020c) (Gardner et al. 2002; Hall et al. 2002). Type 3
var gene sequences DQ408041-DQ408070 were taken from Trimnell et al. 2006.
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5.4.2 Type 3 DBLα domain amplification
PCR/RT-PCR was used to amplify a region of the type 3 var gene DBLα domain
using forward primer αAF3_type3F; GCAMGAAGTTTTGC modification of
DBLαAF’ (GCACGMAGTTTYGC) (Bull et al. 2005a) and reverse primer
Type3alphaR1; CAGAAATATTCAG (PCR product 420 bp) or Type3alphaR2
ATATTTCATTGATTGTTTATC (PCR product 580 bp). Amplification used 5 µl
10x PCR Gold buffer, 25 pmol each of DBLαAF’ and DBLαBR primers and 0.2 µl
Amplitaq Gold polymerase with a final concentration 2 mM MgCl2, and 1.25 mM of
each dNTP, and the volume adjusted to 50 µl after addition of 2 µl cDNA, 0.25 µl
gDNA, or distilled water. Amplification conditions were as described for DBLα RT-
PCR (Taylor et al. 2000a; Bull et al. 2005a) with a hot start (95˚C, 5 min) followed
by 35 cycles of 95˚C, 20 sec; 42˚C, 20 sec; 60˚C, 1 min. Samples without RT were
used in all reactions to exclude gDNA contamination.
5.4.3 Type 3 DBLε domain amplification
PCR/RT-PCR was used to amplify a region of 726 bp of the type 3 var gene DBLε
domain using forward primer Type3epsF GACAATAATGGTGTGTTAGTTCCTC
and reverse primer Type3epsR GTATGATGCAGCACATTCCTCA. This pair was
unbiased on 3D7 gDNA. Amplification conditions were as for DBLα domain RT-
PCR; hot start (95˚C, 5 min) followed by 35 cycles of 95˚C, 20 sec; 42˚C, 20 sec;
60˚C, 1 min. Samples without RT were used in all reactions to exclude gDNA
contamination. Amplification conditions and mix were as for type 3 var gene DBLα
domain RT-PCR.
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5.4.4 Tubulin gene amplification
PCR/RT-PCR was used to amplify 389 bp of the 3D7 P. falciparum β-tubulin gene
using forward primer Tub3’ GATCCAAGTGGTACCTAT and reverse primer Tub5’
GGATACTCCTCTCTTAT. Amplification used 5 µl 10x PCR Gold buffer, 25 pmol
each of Tub3’ and Tub5’ primers and 0.2 µl Amplitaq Gold polymerase with a final
concentration of 2.25 mM MgCl2, and 1.25 mM of each dNTP, and the volume
adjusted to 50 µl after addition of 1 µl cDNA, 0.25  µl gDNA, or distilled water.
Amplification conditions were a hot start (95˚C, 5 min) followed by 35 cycles of
95˚C, 10 sec; 50˚C, 15 sec; 62˚C, 1 min. Samples without RT were used in all
reactions to exclude gDNA contamination.
5.4.5 Sequence analysis
See chapter 2 for details of ligation, cloning, transformation, and sequencing of RT-
PCR products. In brief, RT-PCR products were visualised by electrophoresis on
1.5% agarose gels. RT-PCR products were purified and ligated into PCR II TA
cloning vector (Invitrogen) and ligated plasmids were used to transform TOP10F E.
coli. Transformed E. coli was grown overnight under ampicillin selection and
blue/white colony screening. Individual white colonies were selected for overnight
growth and the plasmids extracted for sequencing. Presence of an insert in the
extracted plasmids was verified by EcoRI restriction digestion prior to sequencing.
For Mali isolate gDNA type 3 var gene PCR only, plasmids were sequenced directly
from transformed E. coli colonies. Colonies were grown at 37°C o/n in LB broth
with 8% glycerol. Sequencing was then carried out by the University of Edinburgh
School of Biological Sciences Sequencing Service.
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Transcript sequences from each isolate were grouped into contigs of >95%
nucleotide identity using the SeqMan programme within the DNAstar software
package. Consensus sequences from each isolate were saved as sequence A, B, C etc
from that isolate as EditSeq files (DNAstar software package), and protein sequences
were obtained by translating the DNA sequences using the EditSeq translation
function.
Nucleotide and protein sequences were then compared within and between isolates
using MegAlign (DNAstar software package). Alignments and phenograms were
produced using the clustal W alignment programme within MegAlign, using default
settings. Sequence distances were calculated using MegAlign, and colour-coded into
the following groups; 0-30, 30-39.9, 40-49.9, 50-59.9, 60-69.9 70-99.9 and 100%
amino acid identity for production of sequence distance figures. Homology searches
were performed using nucleotide-nucleotide BLAST search of the NCBI database
(http://www.ncbi.nlm.nih.gov/BLAST). Phenograms were laid out in Adobe
Illustrator.
5.4.6 Northern blot methods
1.2 g of agarose was disolved in 80 ml of distilled water with 10 ml of 10x MOPS
(110 mM MOPS, 25 mM Na-Acetate, 5 mM EDTA pH 7.0) and 3 ml of 37%
formaldehyde. 1 µg RNA, 9 µl formamide, 3 µl formaldehyde (37%), 2 µl 10x
MOPS was heated to 65°C for 5 min and loaded immediately onto the gel with 2 µl
of RNA gel loading buffer (1x MOPS with 0.01% Bromophenol blue, 10% glycerol,
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30% formaldehyde, 3.33% formamide). Millennium Markers (Ambion) were also
loaded.  Gel was run at 150 volts in 1x MOPS running buffer for 90 min. Gel was
stained with final concentration 0.5 µg/ml EtBr in 200 ml of 1x MOPS for 30 min on
shaker at RT and destained twice with water for 30 min on shaker at room
temperature to visualize RNA and photograph markers. To transfer the RNA to
nitrocellulose, the gel was placed on top of a wick of wet MME paper in 10x SSC
(1.5 M NaCl, 0.15 M Tri Sodium Citrate) covering the gel tray. Nylon membrane
(Roche) prewetted in 10x SSC was placed on top of the gel, followed by 2x MME
papers the size of gel prewet in 2x SSC, and then 2 inches of paper towel. A weight
(old catalogue) was placed on top of the assembly. Next day the nylon membrane
was removed and air-dried before cross-linking the RNA by UV (1.2 sec) in a
Stratalinker. PCR for riboprobe used the primers as described in Table 5.1.




















MSP-1 NI N2 MSP-1 60°C
Table 5.1 PCR primers for riboprobe design.
Amplification used 5 µl 10x PCR Gold buffer, 25 pmol each of DBLαAF’ and
DBLαBR primers and 0.2 µl Amplitaq Gold polymerase with a final concentration 2
mM MgCl2, and 1.25 mM of each dNTP, and the volume adjusted to 50 µl after
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addition of 2 µl cDNA, 0.25  µl gDNA, or distilled water. Amplification conditions
were as described for DBLα RT-PCR (Taylor et al. 2000a; Bull et al. 2005a) with a
hot start (95˚C, 5 min) followed by 35 cycles of 95˚C, 20 sec; 42˚C, 20 sec; 60˚C, 1
min. Samples without RT were used in all reactions to exclude gDNA contamination.
PCR products were purified as described in chapter 2 and were cloned into PCR II
vector (Invitrogen) and plasmids obtained by miniprep (QIAgen) and insert size
verified by EcoRI digestion (details in chapter 2).
All materials for riboprobe production and Northern blot analysis were from Roche
(Northern starter kit). For riboprobe transcription and DIG incorporation, 2µl NTP
Mix, 1 µl RNase inhibitor, 2 µl 10xTansription Buffer, 40 units SP6 polymerase and
DTT (final concentration 5 µM) was added to 1 µg template plasmid, and water
added to give a final volume of 20 µl. Mix was incubated at 37°C for 2 hr. 2 µl of
DNaseI was added (37°C, 15 min) to remove any DNA template, and the DNase
reaction stopped by the addition of 2 µl of 200 mM EDTA, pH 8.0. The riboprobe
was precipitated at –70°C for 2 hr, using 2.5 µl of 4 M LiCl and 75 µl of cold 100%
ethanol, pelleted (13,000 rpm, 15 min, at 4°C) and washed with 50 µl 70% cold
ethanol. The RNA pellet was air dried for 10 min and resuspended in 50 µl of DEPC-
H20 with 1 µl  of RNase inhibitor.
Nylon membranes (Roche) were prehybridised in 10 ml hybridisation solution
(Maleic acid buffer: 100 mM Maleic acid, 150mM NaCl, pH 7.5 with DIG Easy Hyb
granules: Roche) for 1 hr at the hybridisation temperature (DBLαtype3, DBLεtype3
and MSP1 probe at 60 ˚C, exon 2 probe at 50˚C). 2 µl probe was boiled in 100 µl
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hybridisation solution for 5 min and added to membrane with fresh hybridisation
solution, and incubated at hybridisation temperature, with rotation, o/n. The
membrane was then washed twice for 30 min at “hyb temp + 5˚C” in 0.2x SSC/0.1%
SDS. Membrane was washed for 1 min in Maleic acid buffer (100 mM Maleic acid,
150mM NaCl, pH 7.5) and blocked for 1 hour in 20 ml Northern blocking buffer (18
ml of Maleic acid buffer with 2 ml of 10% Northern block buffer, Roche).
Membrane was then incubated for 30 min in 20 ml blocking buffer + 2 µl Anti-DIG
antibody (Roche), before two further 15 min washes in Maleic acid buffer with 0.3%
Tween 20. Membrane was soaked for 2 min in Detection buffer (100 mM Tris-HCl,
100 mM NaCl pH 9.5) before incubating with 1 ml CDP-Star (Roche) 5 min, RT.
Membrane was exposed to X-ray film.
5.4.7 Transcription time course
For the time course RT-PCR and for the Northern blots, RNA was extracted from a
fresh culture of laboratory strain 3D7 by chloroform extraction and isopropanol
precipitation as detailed in chapter 2. For the time courses, 200 µl packed cell
volume was extracted for each time point and immediately stored in Trizol at -70˚C,
and the rest of the culture re-gassed and incubated at 37˚C. A Giemsa slide was also
prepared to assess parasite maturity at each time point. RNA extraction and cDNA
preparation for each time point was carried out at the same time.
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5.4.8 DBL domain structural modelling
The published structures of the EBA175 DBL domain (Tolia et al. 2005) and a P.
knowlesi DBL domain  (Singh et al. 2006) were downloaded from the Research
Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank
(http://www.pdb.org), PDB ID 1zrl and 2c6j, for modelling of type 3 protein
structures. The mal6p1.314 DBLα domain amino acid sequence was aligned to the
amino acid sequence of EBA175 and P. knowlesi DBLα by clustal W. The aligned
amino acid sequence was then mapped onto the published structures using Cn3d
structural modelling software (http://www.ncbi.nlm.nih.gov/Structure/CN3D/
cn3d.shtml). Secondary structure colouring shortcuts, and worm and spacefill
rendering shortcuts, were used. Regions of interest were highlighted in the structure
by selection of the corresponding amino acid sequence.
5.4.9 Protean software
Protean/Lasergene software (DNAstar, Inc) was used to analyse features of the
pfa1820w, pfa0015c and mal6P1.314 type 3 var gene DBLα  domain protein
sequences to aid peptide choice. Alpha helical and beta sheet regions were predicted
by Garnier-Robson, Chou-Fasman and Eisenberg plots. These are based on statistical
preferences of different amino acids to have particular secondary structure types in
known protein structures. Kyte-Doolitle plots were used to predict hydrophobicity.
Amino acids are given a hydrophobicity score between -4.6 (hydrophobic) and 4.6
(hydrophilic), and the hydrophobicity plot shows the averaged score over stretches of
9 amino acids. Karplus-Schulz plots show flexible regions based on the
characteristics of neighbouring residues. The Emini plot predicts surface exposure
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probability, based on values of surface accessibility averages over 6 amino acid
stretches. The Jameson-Wolf index predicts antigenicity of a given region, through a
complex algorithm combining hydrophobicity, surface probability, flexibility, and
alpha/beta regions predictions.
5.4.10 Peptide antibody production
Final peptides were chosen after consultation with peptide.design@eurogentec.com.
Peptide synthesis, hen immunization and yolk collection was all performed by
Eurogentec, UK. Briefly, peptides DTDPPVVDYIPQC (peptide 1) and
CNVLNKEIDEMNNQ (peptide 2) were synthesized by solid phase Fmoc chemistry
by Eurogentec, Belgium. Peptides were analysed by MADLI-TOF mass
spectrometry and reversed phase analytical HPLC for weight and purity at
Eurogentec, Belgium. Peptides alone are not immunogenic, thus conjugation to a
carrier is required to elicit an immune response. Keyhole Limpet Hemocyanin (KLH)
carrier was linked to the thiol group of the terminal cysteines of each peptide using
m-Maleimidobenzoyl-N-hydroxysuccinimide ester (MBS). Hens PO41 and PO42
were immunised under the Eurogentec Double XP protocol. Eggs were collected on
days 51-98 after immunisation and pooled as follows: days 51-57, 58-66, 72-78 79-















51 – 57 28/3 – 04/04 48 ml 2.37 mg/ml IgY stored @ -20˚ C
58 – 66 04/04 – 11/04 60 ml 2.32 mg/ml IgY stored @ -20˚ C
66 - 71 11/08 – 18/04 Yolks stored @ -20˚ C
72 - 78 18/04 – 25/04 Yolks stored @ -20˚ C
79 - 85 25/04 – 02/05 100 ml 3.87 mg/ml undetectable Approx 1 mg/ml
86 - 92 02/05 – 09/05 50 ml 3.13 mg/ml IgY stored @ -20˚ C













51 - 57 28/3 – 04/04 60 ml 2.74 mg/ml IgY stored @ -20˚ C
58 - 66 04/04 – 11/04 66 ml 3.12 mg/ml IgY stored @ -20˚ C
66 - 71 11/08 – 18/04 Yolks stored @ -20˚ C
72 - 78 18/04 – 25/04 Yolks stored @ -20˚ C
79 - 85 25/04 – 02/05 100 ml 2.72 mg/ml undetectable Approx 1 mg/ml
86 - 92 02/05 – 09/05 30 ml 2.55 mg/ml IgY stored @ -20˚ C
93 - 98 09/05 – 14/05 Yolks stored @ -20˚ C
Table 5.2. Egg collection and yolk processing schedule.
5.4.11 IgY Extraction
IgY extraction was performed using EggStract kit (Promega, Madison, WI)
according to manufacturer’s guidelines. Yolks were warmed to RT. 3 volumes
precipitation solution A was added slowly and stirred for 5 min to precipitate the
lipids. The mixture was centrifuged (10,000 rpm, 15 min), and the supernatant
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collected into a graduated cylinder through gauze. The supernatant was stirred at RT
while 1/3 volume solution B was added slowly to precipitate the IgY. The mixture
was centrifuged (10,000 rpm, 15 min), and the supernatant discarded. The
precipitated IgY was resuspended in PBS. IgY precipitation was repeated to increase
the purity of extracted IgY. IgY was stored at -20˚C.
5.4.12 Determining IgY concentration
Absorbance at 280 was read on a spectrophotometer. The protein extinction
coefficient of IgY is 13.3. This is the absorbance (A280nm) value for 1% (i.e. 1
g/100ml) solution, measured in a 1 cm cuvette. Thus for concentration at mg/ml (0.1
% solution), absorbance at 280 nm must be divided by 1.33.
5.4.13 IgY affinity purification
A sample of the extracted IgY from immunised hen eggs was affinity-purified
against the peptide using the SulfoLink Immobilization Kit (Pierce, IL, USA),
according to manufacturer instructions.  Briefly, 0.5 mg of each peptide was reduced
using Tris(2-carboxyethyl)phosphine (TCEP) and both peptides immobilized
concurrently on the SulfoLink Resin via the free sulfhydryl groups on the terminal
cysteines. The internal methionine of peptide 2 will also stabilise immobilisation on
the column. Extracted IgY (4-8 mg) was applied to the column. After washing,
bound antibody eluted was in 3 x 2 ml 0.2 M glycine HCl (pH 2.5) and neutralised in
50 µ l 1 M Tris HCl (pH 8.5) per ml elution. The full 6 ml elution was then
concentrated using a vivaspin column (Vivascience, UK), molecular weight cut off
10 kDa, and buffer exchanged into 500 µl PBS containing 0.05% azide. Affinity-
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purified and concentrated antibody was then aliquoted and stored at –20°C. Affinity
purification was also carried out with the two peptides separately.
5.4.14 Enzyme-Linked ImmunoSorbent Assay (ELISA)
Microtest III assay plates (Falcon) were coated 150 ml PBS with 10 µg/ml peptide 1,
10 µg/ml peptide 2, 1% BSA or PBS alone, at 4°C, o/n. Plates were washed three
times with PBS, blocked for 2 hr at 37°C with 150 µl 2% milk with 0.5% Tween 20
and washed three times with PBS before adding primary IgY 1:100 in blocking
solution (150 µl) to each well, for 2 hr at 37°C. Plates were washed a further three
times with PBS, before incubation with 150 µl of peroxidase conjugated goat anti-
chicken IgG diluted 1:1000, 1hr RT, then washed a final 3 times with PBS. For
detection, 100 ml TMB Substrate Reagent (BD OptEIA) was added to each well and
the plate was left to develop for 30 min at RT, in the dark, before the reaction was
stopped with 50 µl 2M H2SO4 per well. Absorbance measurements were made on an
ELISA plate reader at 450 nm. These are shown as mean ± standard error (SE).
5.4.15 Detergent extraction of proteins
Infected erythrocytes (IE) or non-infected erythrocytes were washed twice with PBS.
If trypsinisation was required, cells were incubated with 5 volumes 0.1 or 1 mg/ml
trypsin (Sigma), or mock treated with PBS, for 5 min at RT. Trypsinisation was
stopped by addition of trypsin inhibitor (Sigma) for 5 min at RT. Cells were then
pelleted (4000 rpm, 3 min) and washed in RPMI. All cell preparations were then
lysed on ice with 5 volumes of NETT buffer (150 mM NaCl, 5 mM EDTA, 50 mM
tris pH8.0, 1% triton-X100 (w/v)) plus complete mini protease inhibitor cocktail
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(Roche). Cell lysates were then centrifuged (13,000 rpm, 10 min at 4°C).
Supernatants were removed. These are now referred to as triton-X100 soluble (TS)
fractions. The triton-X100 insoluble pellet was resuspended in a Tris saline (20 mM
tris-HCl pH 8.0, 150 mM HCl, 2% (w/v) SDS) plus complete mini protease inhibitor
cocktail (Roche).  The solubilised TI fraction was repeatedly pipetted and vortexed
to disrupt the parasite DNA. Samples were centrifuged (13,000 rpm, 10 min, RT) to
pellet the remaining insoluble fraction, seen as a brown pigment in the infected
erythrocyte sample.  The soluble TI fractions were removed and transferred to a fresh
tube. All samples were stored at –80°C.
5.4.16 SDS-PAGE
SDS-PAGE was performed using the Novex precast gel system (all reagents from
Invitrogen). Samples were prepared according to the NuPAGE Novex Tri-acetate
mini Gel protocol with NuPAGE LDS sample buffer and NuPAGE reducing agent,
and heated to 70°C for 10 min. Samples were then run on 3-8% Tris-acetate gradient
gels using Tris-acetate SDS running buffer for 1 hr at 150 V. Pre-stained precision
protein molecular weight markers (10-250 kDa; Bio-rad) were used in all gels.
5.4.17 SimplyBlue staining
To visualise all loaded proteins on the acrylamide gel, gels were washed 3x 5 min in
distilled water and then soaked in SimplyBlue safe stain (Invitrogen) for 1 hr, and
destained 1hr to overnight in distilled water.
5.4.18 Western blotting
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Proteins were electrophoretically transferred from SDS-PAGE gels to polyvinylidene
difluoride (PVDF) membrane (Invitrogen) using a NuPAGE transfer buffer
(Invitrogen) (30 V, 1 hr, RT). PVDF membranes were activated in 100% methanol
for 30 sec prior to transfer. Membranes were washed briefly in PBS before
incubating in blocking buffer (PBS/5% milk) for 30-60 min RT with rocking, and
then o/n at 4°C. Membrane was then incubated for 1 hr in primary antibody or sera
was diluted to 1 in 1000 unless otherwise stated in PBS/5% milk with rocking at RT.
Blots were washed 3 x 10 min with PBST (PBS with 0.5% Tween-20). Incubation in
secondary antibody (1 in 1000 HRP-conjugated goat anti-chicken H&L IgY, Abcam)
was for 1 hr. Blots were then washed 2 x 10 min with PBST and 1 x 10 min in PBS
alone prior to visualisation with an enhanced chemiluminescence (ECL) detection kit
(Amersham).  Chemiluminescence was detected using HyperfilmTM ECL
(Amersham).
5.4.19 Immunoflourescence assay (IFA)
For live IFA, cultures at 2% haematocrit were incubated with primary antibody
(chicken pre-immune IgY extract (1:10), rabbit preimmune serum (1:10) or immune
IgY (1:10) in PBS/1%BSA) for 1 hr on ice. Cells were then washed three times in
PBS/1%BSA, and incubated with alexa488-conjugated goat anti-chicken or anti-
rabbit secondary antibody (1:1000) in PBS/1%BSA for 1 hr on ice in the dark. Cells
were washed a further three times in PBS/DAPI/1%BSA and mounted onto a glass
slide with flouromount. Live cells were viewed under fluorescence at 100x
magnification.
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For fixed IFA, P. falciparum cultures were smeared onto slides and fixed with
acetone. Slides were incubated for 1 hour in preimmune IgY, immune IgY extract
affinity purified against peptides 1 and 2 together (both 1:10 in PBS/1% BSA), or
PBS/1%BSA alone. The culture was then washed and the slides were incubated in
alexa 488 conjugated secondary antibody 1:1000 and PBS/DAPI/BSA1% for 1 hour
in the dark. Secondary incubation was washed off and the fixed cells were viewed
under fluorescence at 100x magnification.
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5.5 Results 1: Type 3 var gene analysis
5.5.1 Type 3 var gene DBLα domain amplification: DBLα primer
design 1
To examine whether type 3 var genes were transcribed in laboratory and field
isolates, I designed a type 3-specific primer pair for use in PCR and RT-PCR. The
primers were designed to specifically recognise all type 3 DBLα domains, but not
recognise other DBLα domains or other sequences. The DBLαAF’ forward primer
from the Taylor primer pair described in section 1.3 recognises DBLαtype3 domains,
but the DBLαBR reverse primer does not amplify type 3 var genes. To amplify the
type 3 DBLα domains a new primer pair was designed.
The forward primer was a modification of the DBLαAF’ forward primer from
Taylor et al. (2000a), which had increased specificity for the type 3 group A DBLα
domains (αAF3_type3F; GCAMGAAGTTTTGC modification of DBLαAF’;
GCACGMAGTTTYGC, Fig. 5.7); degeneracy at positions 6 (M) and 12 (Y) is
unnecessary as all known type 3 DBLα domains have an A and T at these positions.
However, degeneracy at position 4 was an improvement, as some type 3 DBLα
domains (4/17 published sequences) have an A rather than a C here.
A reverse primer was designed to specifically amplify the DBLαtype3 domains
(primer: Type3alphaR1; CAGAAATATTCAG). This recognises a conserved section
just before the end of the DBLαtype3 domain, and results in a 420 bp PCR product
(Fig. 5.8).
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Both primer sequences recognised all published type 3 domains, and neither primer
sequence showed homology to any genes other than type 3 var genes (NCBI Blast
database search).
Fig. 5.7. Forward primers for amplification of type 3 DBLα domains. The forward
primer GCAMGAAGTTTTGC (αAF3_type3) is a modification of the generic
forward primer used for DBLα domain amplification in chapter 3 (DBLαAF’
GCACGMAGTTTYGC(Taylor et al. 2000a; Bull et al. 2005a) which is better suited
to amplification of type 3 DBLα  domains. Forward primers αAF3_type3 and
DBLαAF’ are shown with the primer binding sites from published type 3 DBLα
domains from IT, MC, 3D7 and other P. falciparum isolates 713, 7G8, D10, Ecu,
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Fig. 5.8. Alignment of published type 3 var genes from strains 3D7 (mal6p1.314,
pfa0015c and pfi1820w), FCR3 (it4var3), Malayan Camp (mc var5), 713, 7G8, D10,
Ecu, Fab6, M2, M5, V1S, showing primer sites for AF3_type3F (F), Type3alphaR1
(R1) and Type3alphaR2 (R2; (see section 5.5.3).
5.5.2 Testing primer pair AF3_type3F and Type3alphaR1 on 3D7 gDNA
The primer pair AF3_type3F and Type3alphaR1 were tested on 3D7 gDNA.
Amplification resulted in a PCR product of the correct size for type 3 DBLα domain
amplification with this primer pair (420 bp) (Fig. 5.9).
Fig. 5.9. Amplification of type 3 DBLα domains from 3D7 gDNA using primer pair
AF3_type3F and Type3alphaR1. An aliquot (5 µl) of PCR product was run on a
1.5% agarose gel. Distilled water was used as a negative control for the PCR
reaction. DNA ladder was φX174 RF DNA/Hae fragments (Invitrogen).




Products from the PCR of type 3 DBLα domains from 3D7 gDNA using primer pair
AF3_type3F and Type3alphaR1 were purified and ligated into the TA cloning vector
for transformation of E. coli, which were then grown overnight (details in chapter 2).
30 colonies were selected for overnight growth, and the plasmids extracted and an
aliquot digested with EcoRI to verify an insert of the correct length was present (Fig.
5.10).
Fig. 5.10. 1.5% agarose gel of 5 µl of EcoRI digests products of plasmids extracted
from a set of 14 minipreps from RT-PCR of 3D7 gDNA using primer pair
AF3_type3F and Type3alphaR1. DNA ladder was φX174 RF DNA/Hae fragments
(Invitrogen).
Plasmids containing an insert were sequenced to assess the frequency of the three
3D7 DBLα domain amplified by RT-PCR, which was expected to be approximately
even. However, primer validation on 3D7 gDNA showed a bias in recognition of
Pfi1820w and Pfa0015c DBLα domains compared to Mal6P1.314 (Fig. 5.11). This
420 bp
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bias was repeated with a further 21 colonies. This was surprising as the primer sites
showed 100% identity to all 3D7 sequences, and products would be the same length.
The DBLαtype3 domain from the single type 3 var gene from R29/IT strain laboratory
isolate was also successfully amplified using the primer pair AF3_type3F and
Type3alphaR1. No other genes, such as non-type 3 var genes were amplified with
this primer pair.
Fig. 5.11. Pie charts showing relative proportions of DBLα domains from the 3D7
type 3 var genes Pfi1820w, Pfa0015c and Mal6P1.314 after PCR on 3D7 genomic
gDNA with primer pair AF3_type3F and Type3alphaR1.
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5.5.3 Type 3 var gene DBLα domain amplification: DBLα primer
design 2
A new reverse primer was designed to specifically amplify the DBLαtype3 domains in
order to achieve a more even amplification of the 3D7 type 3 DBLα domains. Primer
Type3alphaR2 (ATATTTCATTGATTGTTTATC) recognises the end of the
DBLαtype3 domain, giving a 580 bp PCR product (Fig. 5.12). Type3alphaR2
recognises all published type 3 domains, and does not show homology to any genes
other than type 3 var genes (NCBI Blast database search).
PCR products were obtained from PCR of 3D7 gDNA (Fig. 5.12A). These were
purified, ligated and a random selection of 27 and 22 transformed plasmids
sequenced as for the previous primer pair. Plasmids were digested by EcoRI to
confirm presence of an insert prior to sequencing (Fig. 5.12B).
Fig. 5.12. Amplification of type 3 DBLα domains from 3D7 gDNA using primer
pair AF3_type3F and Type3alphaR2. A) An aliquot (5 µl) of PCR product was run
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on a 1.5% agarose gel. Distilled water was used as a negative control for the PCR
reaction. DNA ladder was φX174 RF DNA/Hae fragments (Invitrogen). B) EcoRI
digests products of plasmids extracted from a set of 18 minipreps from RT-PCR of
3D7 gDNA using primer pair AF3_type3F and Type3alphaR2. DNA ladder was
φX174 RF DNA/Hae fragments (Invitrogen).
This pair was less biased on 3D7 gDNA, recognising all three domains in both sets
of sequencing (Fig. 5.13). The primers were also used to amplify type 3 domains
from NF54, and 18 plasmids were also sequenced from transformed E. coli.
Mal6P1.314 was still amplified less frequently than the other 3D7 type 3 var genes,
however the distribution of the three type 3 DBLα domains was not significantly
different from expected in the two 3D7 amplifications or the NF54 amplification
(Chi-squared P>0.3).
The DBLαtype3 domain from the single type 3 var gene from R29/IT strain laboratory
isolate was also successfully amplified with primer pair AF3_type3F a n d
Type3alphaR2. No other genes, such as non-type 3 var genes were amplified from
3D7, NF54 or R29.
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Fig. 5.13. Pie charts showing relative proportions of DBLα domains from the 3D7
type 3 var genes Pfi1820w, Pfa0015c and Mal6P1.314 after PCR on 3D7 genomic
gDNA with primer pair AF3_type3F and Type3alphaR2.
5.5.4 Type 3 var gene DBLε domain amplification: DBLε primer design
A primer pair was also designed to amplify DBLε type3 domains, Type3epsF
GACAATAATGGTGTGTTAGTTCCTC and type3epsR GTATGATGCAGC
ACATTCCTCA (Fig. 5.14). These primers recognise the published type 3 epsilon
domains and do not recognise any other genes (NCBI database homology search).
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Fig. 5.14. Alignment of published type 3 var genes showing primer sites for
Type3epsF and Type3epsR.
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The primer pair Type3epsF and Type3epsR gave a PCR product of 726 bp when
used with 3D7 gDNA (Fig. 5.15A). The PCR products were purified and ligated into
the topo cloning vector for transformation of E. coli, which were grown overnight.
10 colonies were selected for overnight growth, and the plasmids extracted and an
aliquot digested with EcoRI to verify an insert of the correct length was present (Fig.
5.15B). Type 3 epsilon domains contain an EcoRI site, the PCR product (726 bp) is
seen as two smaller products (399 and 327 bp) after digestion (Fig. 5.15B).
Fig. 5.15. Amplification of type 3 DBLα domains from 3D7 gDNA using primer
pair Type3epsF, and Type3epsR. A) An aliquot (5 µl) of PCR product was run on a
1.5% agarose gel. Distilled water was used as a negative control for the PCR
reaction. B) EcoRI digests products of plasmids extracted from a set of 10 minipreps
from RT-PCR of 3D7 gDNA using primer pair Type3epsF and Type3epsR. DNA
ladders were φX174 RF DNA/Hae fragments (Invitrogen).
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Cloning and sequencing showed they specifically amplified the three DBLε domains
from 3D7, and all three domains could be amplified (ratio 3,3,4, Fig. 5.16). This
distribution of sequences was not significantly different from expected: p > 0.99,
Chi-squared test. The DBLεtype3 domain from the single type 3 var gene from R29/IT






Fig. 5.16. Pie charts showing relative proportions of DBLε domains from the 3D7
type 3 var genes Pfi1820w, Pfa0015c and Mal6P1.314 after PCR on 3D7 genomic
gDNA with primer pair Type3epsF and Type3epsR.
5.5.5 Type 3 var gene PCR from laboratory strains gDNA
Little data on the frequency of type 3 var gene occurring in P. falciparum genomes is
available; at the time of the start of the study only 3D7 had been shown to contain a
type 3 var gene, though subsequent sequencing has revealed a type 3 var gene in IT,
but not in Dd2 or HB3. To assess the prevalence of type 3 var genes in strains other
than 3D7, gDNA from 10 further strains was examined. Genomic DNA was
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available from FCR3, TM267, TM284, Malayan Camp, Dd2, TM180, 7G8, Muz12
and HB3 (gift from JA Rowe/A Raza). Type 3 DBLα domains were amplified by
primer pair AF3_type3F and Type3alphaR2. Type 3 DBLε domain was amplified by
primer pair Type3epsF and Type3epsF. All PCR products were cloned and
sequenced to verify type 3 domains had been amplified. Type 3 alpha and epsilon
domains were amplified from 3D7, TM284, FCR3/IT, TM267 and Malayan Camp,
but not from Dd2, HB3, TM180, 7G8 or Muz12 (Fig. 5.17 and Table 5.3). 7G8 gave
a PCR product with the DBLα  primer pair (AF3_type3F and Type3alphaR2),
however, this was longer than expected for a type 3 var gene DBLα domain and
sequencing proved that this was not a type 3 var gene DBLα domain. A summary of
the type 3 domains detected in the laboratory isolates is given in Table 5.3.
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Fig. 5.17. PCR of type3 domains from lab strains 3D7, Dd2, HB3, TM180, TM284,
FCR3/IT, 7G8, Muz12, TM267, Malayan Camp (MC). Left) Type 3 DBLα domains
were amplified by primer pair AF3_type3F and Type3alphaR2. Right) Type 3 DBLε
domain was amplified by primer pair Type3epsF and Type3epsF. A 5µl aliquot of all
PCR products was run on 1.5% agarose gels. Distilled water was used as a negative
control for the PCR reaction. The DNA ladder was φX174 RF DNA/Hae fragments
(Invitrogen).
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Table 5.3. PCR for type 3 DBLα and DBLε domains was carried out on laboratory
strains 3D7, FCR3/IT, TM267, TM284, Malayan Camp, Dd2, TM180, 7G8, Muz12
and HB3. Tick () indicates a PCR product was obtained, and the sequence was
confirmed as a type 3 domain. Cross () indicates no type 3 PCR product was
obtained, or was not the correct domain (7G8 DBLα).
Therefore 4/9 genetically distinct laboratory strains have a single detectable type 3
var gene (5/10 tested laboratory strains, but TM267 is isogenic with FCR3/IT). The
three type 3 var genes from 3D7 and the one type 3 var gene from FCR3/IT/TM267
have been published and discussed previously, and the sequences amplified here
match these sequences perfectly. The TM284 DBLα domain had not previously been
published. The type 3 DBLε domain amplified from TM284 is identical to the
TM284 type 3 DBLε domain sequence submitted by Trimnell et al. (2006) over the
length of the previously submitted sequence, but the sequence is longer as the PCR
primers used in this chapter are further apart than those used by Trimnell et al.
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(2006). The type 3 var gene from Malayan Camp had also not previously been
published.
Type 3 var gene domains were not found in Dd2 by PCR using these conditions.
Though Trimnell et al. found a type 3 var gene in Dd2 (epsilon domain only),
subsequent publishing of the Dd2 genome sequence suggests Dd2 does not contain a
type 3 var gene. The epsilon domain published as from Dd2 does not correspond
with any contigs from the Dd2 genome published so far by the Broad Institute
Sequencing Program. Trimnell et al. also found an epsilon domain, but not alpha
domain, in TM180. Neither was found in my experiments by PCR. The negative
PCR result for type 3 var gene domains in HB3 here are in agreement with those of
Trimnell et al. and the Broad Institute Sequencing Program,
A type 3 var gene DBLα domain from 7G8 has been published by Trimnell et al.
(2006), accession number DQ408045. A PCR product was detected from
amplification of 7G8 gDNA with primers AF3_type3F and Type3alphaR2 but
agarose gel electrophoresis (Fig. 5.17) suggested this was too long to be a type 3
DBLα domain and sequencing proved this PCR product was not a type 3 var gene,
and was an epsilon domain with 57% identity to the published 7G8 type 3 DBLα
domain. No PCR product was obtained from 7G8 gDNA with the epsilon primer pair
Type3epsF/Type3epsR. Amplification of the DBLα domain was also attempted with
the other primer pair AF3_type3F/Type3alphaR1, but no PCR product was obtained.
These PCR suggest 7G8 does not have a type 3 var gene. The 7G8 sequence
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published in Trimnell et al 2006 is identical to that of another P. falciparum strain
examined in that paper, Fab6.
5.5.6 Type 3 var gene transcription: laboratory strains
Little data is currently available on the transcription of type 3 var genes in laboratory
strains or field isolates. The aim of this section was to assess the frequency of type 3
var gene transcription in the laboratory strains available, and investigate any
association with rosetting and IgM binding. In addition, it was necessary to identify a
laboratory strain which was transcribing a type 3 var gene in order to investigate the
timing of type 3 var gene transcription more precisely.
Early pigmented trophozoite culture cDNA from 7 laboratory strains (3D7, Palo
Alto, TM267, A1R, A4R, R29 and TM284) was available for RT-PCR (gift from JA
Rowe/A Raza). For 5 of the above strains (Palo Alto, TM267, A1R, A4R and R29),
cDNA was also available from cultures that had been selected for high rosette
frequency (> 70% RF). 3D7 could not be selected for high rosetting, but cDNA was
available from parasites selected for IgM binding (Gift from JP Semblat). The
transcription patterns of the above strains are presented below in sections 5.5.5a-d
and summarised in section 5.5.5e.
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5.5.6a Type 3 var gene transcripts are present in rosetting and non-
rosetting TM267
RT-PCR amplified DBLα and DBLε domain transcripts from rosetting (R+) and
non-rosetting (R-) TM267 (Fig. 5.18). This suggests type 3 var gene transcription
does not influence rosetting in TM267.
Fig. 5.18. Type 3 transcripts are present in rosetting and non-rosetting TM267 by
RT-PCR. Type 3 DBLα  domain transcripts were amplified by primer pair
AF3_type3F and Type3alphaR2. Type 3 DBLε domain transcripts were amplified by
primer pair Type3epsF and Type3epsF. PCR show gDNA, rosetting (R+) and non-
rosetting (R-) cDNA, and distilled water as a negative control. A 5 µl aliquot of all
RT-PCR products was run on a 1.5% agarose gel. CTL lanes (without reverse
transcriptase, to control for gDNA contamination) were negative, indicating there
was no gDNA contamination. DNA ladder was 100 bp ladder.
  580 bp 726 bp
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5.5.6b Type 3 var gene transcripts are present in rosetting and non-
rosetting Palo Alto
The Palo Alto DBLεtype3 domain was detected by RT-PCR from this cDNA but the
DBLαtype3 domain could not be amplified with the primer pair AF3_type3F and
Type3alphaR2 (Fig. 5.19A). The DBLα primers recognise perfectly the Palo Alto
DBLαtype3 domain, and amplification of gDNA from the same Palo Alto culture
shows that the alpha domain primers can still bind in this strain. To resolve this,
amplification was carried out using the forward primer alpha primer and reverse
epsilon primer, to span both the alpha and epsilon domain (1672 bp). This
amplification gave PCR product in Palo Alto gDNA and cDNA (R+ and R-).
Sequencing of these PCR/RT-PCR products gave the Palo Alto type 3 DBLα and
DBLε domains separated by the published Palo Alto type 3 interdomain region
(Broad Institute), confirming both DBL domains were linked as expected and were
transcribed (Fig. 5.19B).
The RT-PCR amplification of the type 3 var  gene in rosetting and non-rosetting Palo
Alto suggests that type 3 var gene transcription does not influence rosetting in Palo
Alto, as was seen with TM267. Palo Alto and TM267 are both clones of IT and are
thus genetically identical. In addition, Palo Alto and TM267 express the same
predominant var gene, and are thus essentially identical strains (JA Rowe,
unpublished data). The detection of type 3 var gene transcripts in these two clones of
IT, is consistent with these two strains being transcriptionally very similar.
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Fig. 5.19. Type 3 transcripts are present in rosetting and non-rosetting Palo Alto by
RT-PCR. A) Type 3 DBLα/ε domain amplification from Palo Alto gDNA, and




cDNA from rosetting (R+) and non-rosetting (R-) Palo Alto using primer pair
AF3_type3F and Type3alphaR2, or Type3epsF/R. B) Type 3 DBLα−ε domain
transcripts were amplified from Palo Alto gDNA, and cDNA from rosetting (R+) and
non-rosetting (R-) Palo Alto using primer pair AF3_type3F and Type3epsR. Distilled
water was used as a negative control. A 5 µl aliquot of all RT-PCR products was run
on a 1.5% agarose gel. CTL lanes (without reverse transcriptase, to control for
gDNA contamination) were clean, indicating there was no gDNA contamination.
DNA ladder was φX174 RF DNA/Hae fragments (Invitrogen).
5.5.6c Type 3 var gene transcripts are not present in rosetting or non-
rosetting strains of A1R, A4R, R29 or in TM284
Type 3 var gene transcripts were not detected in either in the rosetting or non-
rosetting subpopulations of the remaining 3 laboratory strains tested (R29, A1R,
A4R; all IT-derived clones). Genomic DNA controls were positive for PCR product
in all cases indicating PCR was successful. A representative gel is given in Fig. 5.20
for R29. The cDNA was a gift from JA Rowe/A Raza and had been used
successfully for non-type 3 var gene RT-PCR (data not shown).
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Fig. 5.20. Type 3 transcripts are not present in rosetting or non-rosetting R29. No
type 3 DBLα/ε domain transcripts were amplified using primer pair AF3_type3F and
Type3alphaR2 or Type3epsF and Type3epsF. Templates used were R29 gDNA, and
cDNA from rosetting (R+) and non-rosetting (R-) R29, each with control (CTL) for
gDNA contamination. A 5 µl sample of all RT-PCR products was run on a 1.5%
agarose gel. Genomic DNA controls were positive for PCR product in all cases
indicating PCR was successful. No cDNA lanes were positive indicating type 3 var
genes were not being transcribed. DNA ladder was φX174 RF DNA/Hae fragments
(Invitrogen).
  580 bp
726 bp
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5.5.6d Type 3 var gene transcripts are present in IgM-binding and non-
IgM binding 3D7
RT-PCR amplified DBLα domain transcripts from IgM-bnding and non-IgM binding
3D7; RT-PCR reaction was carried out by JP Semblat (Fig. 5.21).
Fig. 5.21. Type 3 transcripts are present in IgM-bnding and non-IgM binding 3D7 by
RT-PCR. Type 3 DBLα  domain transcripts were amplified by primer pair
AF3_type3F and Type3alphaR2 by JP Semblat. A 5µl aliquot of all RT-PCR
products was run on 1.5% agarose gels. Distilled water was used as a negative
control for the PCR reaction. DNA ladder was φX174 RF DNA/Hae fragments
(Invitrogen).
RT-PCR products (gift from JP Semblat) were purified, ligated and cloned, and 15 or
16 miniprep plasmid extracts were sequenced. All three versions of the type 3 var
246
gene (pfa0015c, Pfi1820w and Mal6p1.314) DBLαtype3 and DBLεtype3 domains were
amplified by RT-PCR from the 3D7 cDNA. There was a slight bias towards
Pfi1820w, and away from Pfa0015c in the unselected parasites but this change in
distribution was not significant (Chi-squared test, P=0.93, Fig. 5.22).
Fig. 5.22. Type 3 transcripts are present in IgM-bnding and non-IgM binding 3D7 by
RT-PCR. Type 3 DBLα  domain transcripts were amplified by primer pair
AF3_type3F and Type3alphaR2. Pie charts represent distribution of the three 3D7
type 3 DBLα domain transcripts in IgM-binding and non-IgM binding strains from
16/15 purified plasmid extracts.
5.5.6e Type 3 var gene transcription in laboratory strains: summary
These results, summarised in Table 5.4, demonstrate that some but not all strains
express a type 3 var gene, and that this expression is not associated with IgM binding
in 3D7 or rosetting in TM267, Palo Alto, A1R, A4R or R29. RT-PCR results were
the same in rosetting as for the non-rosetting isogenic strains. Amplification across
the whole alpha and epsilon domains together using the forward alpha primer and












Detection of type 3 var gene transcripts in Palo Alto and TM267, but not in other IT-
derived clones (R29, A1R and A4R), suggests that type 3 var genes can be switched
on and off in genetically identical parasites, and are thus not constitutively on as the
lack of an intronic promoter suggested.
RT-PCR RT-PCRNon-rosetting/
Non-IgM binding DBLαtype3 DBLεtype3
Rosetting/
IgM-binding DBLαtype3 DBLεtype3
3D7(IgM-)   3D7(IgM+) 
Palo AltoIT (R-)   Palo AltoIT (R+)  
TM267IT(R-)   TM267IT (R+)  
A1RIT(R-)   A1RIT (R+)  
A4RIT(R-)   A4RIT (R+)  
R29IT(R-)   R29(R+)  
TM284  
Table 5.4. Summary of type 3 RT-PCR results for 7 laboratory P. falciparum strains,
including rosetting (R+) and non-rosetting (R-) subpopulations of Palo Alto, TM267,
A1R, A4R, R29 and IgM binding (IgM+) and non-binding (IgM-) subpopulations of
3D7. Palo Alto, TM267, A1R, A4R, R29 are all IT-derived clones as indicated. In
addition, rosetting Palo Alto and TM267 also express the same predominant non-
type 3 var gene, PARvar1 (JA Rowe, unpublished data).
5.5.7 Type 3 var gene transcription time course in laboratory strain 3D7
The 3D7 laboratory strain consistently expressed type 3 var genes in the above RT-
PCR experiments. Thus, 3D7 was used for investigation of the timing of
transcription of the type 3 var genes. Little data is currently available on timing of
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transcription of type 3 var genes, apart from a report of type 3 var gene transcripts at
“ring; 30 hr post invasion” and “trophozoite/schizont; 36-48 post invasion” 3D7
(Jensen et al. 2004), though relative levels of transcription were not measured. To
examine the timing of transcription of the type 3 var genes, 3D7 parasite schizonts
were purified using a percoll, and were incubated with fresh erythrocytes for 6 hours
for invasion. After 6 hours, the remaining schizonts were destroyed by sorbitol lysis.
RNA was collected from early rings, late rings, trophozoites, schizonts and
gametocytes from a culture of laboratory strain 3D7 (Fig. 5.23). RT-PCR using the
type 3 DBLα  primers AF3_type3F and Type3alphaR2, and DBLε  primers
Type3epsF and Type3epsF, indicated that type 3 var gene transcripts were present at
all asexual cell stages, but were not present in gametocyte RNA (Fig. 5.24). Non-
type 3 DBLα domains were amplified with the DBLαAF’/DBLαBR primers from
Taylor et al. discussed in chapter 3. All 3D7 cultures showed expression of non-type
3 var genes. Tubulin transcripts were present in all samples demonstrating that the
cDNA preparation was successful.
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Fig. 5.23 Synchronised 3D7 culture, showing early rings (0-6 hr post-invasion), late
rings (12-18 hr), pigmented trophozoites (24-30 hr), schizonts (36-42 hr) and
gametocytes (stage II-IV). Parasites were stained with Geimsa. Images taken at 100x
magnification.
Early rings      Late rings
Pigmented trophozoites                             Schizonts
Gametocytes
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Fig. 5.24. RT-PCR analysis for synchronised 3D7 strain parasites for type 3 DBLα
(left) and tubulin (right) was used for amplification for early rings (ER), late rings
(LR), trophozoite (Tr), schizonts (Scz), gametocytes (Gc). CTL (control); no reverse
transcriptase was used, providing a control for gDNA contamination. Amplifications
for type 3 DBLα domains (primers AF3_type3F and Type3alphaR2) and tubulin
(primers tubulin 3’ and tubulin 5’) are shown. A 5 µl sample of all RT-PCR products
was run on a 1.5% agarose gel, and products were visualised under UV after staining
in 0.5 µg/ml EtBr. Genomic DNA controls were positive for PCR product in all
cases indicating PCR was successful. All asexual stages, but not gametocytes, were
positive for type 3 DBLα domain RT-PCR (left). All cDNA lanes were positive for
tubulin RT-PCR (right). DNA ladder was φX174 RF DNA/Hae  fragments
(Invitrogen).
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5.5.8 48 hour type 3 var gene transcription time course in laboratory
strain 3D7
For a more precise analysis of timing of expression, laboratory strain 3D7 parasites
were tightly synchronised by purifying schizonts with percoll, and allowing only 1
hour for invasion of rings, before remaining schizonts were removed by sorbitol
lysis. Parasite samples were taken regularly for RNA extraction and cDNA
preparation until the first new rings were seen 42-43 hours post-invasion (Fig. 5.25).
RT-PCR analysis showed type 3 var gene transcripts were present across all time
points (Fig. 5.26A). This transcription pattern was different from that observed for
the non-type 3 DBLα domains, transcription of which was more easily detectable in
rings than pigmented trophozoites. The strongest RT-PCR product for the non-type 3
DBLα domains was seen at late ring/early trophozoite stage (Fig. 5.26B). RT-PCR
for tubulin (Fig. 5.26C) confirmed cDNA had been made successfully for each RNA
extraction and tubulin transcription increased with maturity of the parasites.
Unfortunately, despite repeated treatment with DNase, and repeated RNA collection
and extraction, genomic DNA contamination remained a problem in these cDNA
preparations (bands in RT-control lanes, Fig, 5.26 right panels).  To resolve this
issue, a fresh time course was undertaken from the same frozen parasite aliquots for
Northern blot analysis.
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Fig. 5.25. Synchronised 3D7 culture for RT-PCR time course. Images taken 4 hr
before percoll treatment (-4 hr), after percoll treatment (0 hr), after 1hr of invasion,
and after a further 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 40 and 42 hr after sorbitol




Fig. 5.26. RT-PCR analysis for synchronised 3D7 strain parasite time course. cDNA
(left panels) or RT control samples (right panels) were used for amplification. Time
points were 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 40 and 42 hr post invasion. 3D7 gDNA
was used as a positive control and distilled water as a negative control. A) Type 3
DBLε var gene transcription: RT-PCR with primers Type3epsF and Type3epsF. B)
Non-type 3 DBLα var transcription: RT-PCR with primers DBLαAF’/DBLαBR
primers (Taylor et al. 2000a; Bull et al. 2005a). C). Tubulin transcription RT-PCR
with primers Tub3’ and Tub5’. DNA ladder was φX174 RF DNA/Hae fragments
(Invitrogen).
5.5.9 Northern blot analysis: probe design
Probes were designed to recognise type 3 DBLα domain, type 3 DBLε  domain,
exon 2 and MSP1. Both type 3 domain probes were designed against pfa0015c. The
type 3 DBLα domain probe spans only the type 3-specific section of the type 3
DBLα domain (Fig. 5.27). The type 3 DBLε domain probe covers the whole of the
type 3 DBLε domain, and the PCR primers Type3epsF/R (section 5.5.3) were used.
The exon 2 probe spans the first 310 nucleotides of the exon 2 of pfa0005w, and has
60.8-100% homology to the exon 2 of 3D7 var genes (mean homology 70.5%, S.D.
10.4%). The MSP probe spans 553 bp of the P. falciparum 3D7 MSP1.
255
Fig. 5.27. Clustal W nucleotide sequence alignment of the DBLα probe sequence
(identical to pfa0015c) with the homologous stretch of the three type 3 DBLα
domains from 3D7. Primers type3probeF (forwards arrow) and Type3alphaR2
(backwards arrow) are indicated. Shading indicates nucleotides identical to the probe
sequence.
PCR products were purified with a spin column and ligated into a PCR II vector. The
vector was used to transform E. coli, and after overnight growth and plasmid
extraction, the insert was sequenced to verify the sequence before probe production.
The insert was then amplified using the specific forward primer and M13R/M13F
primer sites within the vector to assess the direction of the insert (Fig. 5.28). All
inserts were amplified with M13R (Fig. 5.29), and therefore SP6 polymerase was
used for the reverse transcription reaction. SP6 polymerase was used to create a
single stranded RNA complementary to the coding sequence for each insert.
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Digoxigenin (DIG) label was attached to the uracil (dUTP) in the dNTP mix, and
was thus incorporated into the RNA probe. This allows the probe to be detected
using an antibody with affinity for the DIG label, overcoming the need for
radioactivity  (Fig. 5.28).
Fig. 5.28. Schematic of amplification for probe reverse transcription. PCR
amplification using the specific forward primer and M13R/M13F primer sites within
the vector was used to assess the direction of the insert. If the PCR with M13R is
successful (upper panel), the insert is forwards, and thus the SP6 promoter is
required for reverse transcription of the complementary strand with respect to the
coding sequence for the probe. If the PCR with M13F is successful (lower panel),
reverse transcription requires the T7 promoter. Digoxigenin (DIG) is incorporated
into the probe during polymerisation.
PCR insert for probe T7 SP6 M13RM13F



















Fig. 5.29. PCR amplification using the specific forward primer and M13R was
successful for all ligated vectors. Forward primers used were DBLα: type3probeF,
DBLε: Type3epsF, exon2: exon2F, MSP1: N2, water control lane: N2. DBLε PCR
was unsucssessful for the first ligation (left hand panel), and so the ligation was
repeated (right hand panel).
DIG-labelled probes for DBLα, DBLε, Exon2 and MSP1 were diluted to 1:40,
1:400, 1:4000 and 1:40,000, along with a 1:10 dilution series DIG-labelled control
probe for actin (starting concentration 10 ng/µl). 1 µl of each diluted probe was
spotted onto nylon membrane, and fixed with UV. The membrane was washed
briefly in Maleic acid buffer and blocked (1hr) before incubation with anti-DIG























Fig. 5.30. DIG-labelled probes for DBLα, DBLε, Exon2 and MSP1 were diluted to
1:40, 1:400, 1:4000, 1:40,000 and 1:400,000, along with a 1:10 dilution series of a
DIG-labelled control probe for actin (start concentration 10 ng/µl). 1 µ l of each
diluted probe was spotted onto nylon membrane, and fixed with UV. Probes were
then incubated with anti-DIG antibody (CDP-Star), and probe spots visualised after
exposure to X-ray film.
Comparisons to the actin probe of known concentration allowed estimation of the
concentrations of the new probes. Estimated probe concentrations:
DBLα probe: 1:40 dilution ≈ 1 ng/µl ∴ probe 40 µg/ml
DBLε probe: 1:40 dilution ≈ 100 pg/µl ∴ probe 4 µg/ml
Exon 2 probe: 1:400 dilution ≈ 10 ng/µl ∴ probe 4000 µg/ml
MSP1 probe: 1:40 dilution ≈ 5 ng/µl ∴ probe 200 µg/ml
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5.5.10 Northern blot analysis: presence of type 3 var gene transcript in
laboratory strain 3D7
A Northern blot was used to verify the presence of type 3 var gene transcripts in
laboratory strain 3D7. RNA prepared from a 9% mixed stage culture of 3D7 (4%
ring, 4% pigmented trophozoite, 1% schizont). RNA was separated by agarose gel
electrophoresis on a 1.2 % agarose/formamide gel, and the RNA was transferred to
nylon membrane. The membrane was hybridised overnight at a range of
temperatures (60ºC–68ºC) with the type 3 DBLα domain probe. The membrane was
then washed in 0.5x SSC/0.2% SDS (see materials and methods), and was incubated
in blocking buffer before incubation with an anti-DIG secondary antibody, which
binds to the DIG label in the probe. Unbound antibody was washed away with
Maleic acid wash buffer. The membrane was then processed in an X-ray developer.
Hybridisation with the type 3 DBLα domain probe at 60ºC resulted in detection of a
3.98 kb transcript corresponding to a type 3 var gene (Fig. 5.31A). The probe also
cross-reacted strongly to a band at approx 6.5 kb, and faintly to longer var gene
transcripts (> 9 kb). Increasing the stringency of the washing (longer time and a
range of SSC/SDS concentrations) did not reduce the strength of the 6.5 kb band
compared to the 3.98 kb transcript. Hybridisation at higher temperatures resulted in
loss of any recognition of RNA by the probe.
To confirm the 3.98 kb transcript detected with the DBLα probe was a var gene, a
probe generated against var gene exon 2 probe was also used. This generic var gene
exon 2 probe was used to probe fresh nylon membranes from the same RNA
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preparation from the mixed stage 3D7 culture. Hybridisation at 50ºC resulted in
recognition of a type 3 var gene length (3.98 kb) transcript (Fig. 5.31B). Non-type 3
var genes (> 9kb) are also clearly recognised by the generic exon 2 probe. The 6.5 kb
transcript (Band X in Fig. 5.31B) is again recognised, although only very faintly.
Hybridisation at temperatures above 50ºC resulted in loss of transcript recognition.
Hybridisation was attempted with the type 3 epsilon probe with various temperature
and washing conditions, but no DIG labelled probe was ever detected upon
development of the membrane. This may be due to the low concentration of the
probe, or an unsuccessful labelling reaction (faint spots, Fig. 5.30).
A homology search of the 3D7 genome database (http://www.plasmodb.org)
suggests the only gene which was any homology to the probe is var1csa
(PFE1640w); the DBLα probe has 60% homology with nucleotides 8165–8470 of
the 9.45 kb var1csa transcript (Fig. 5.32). This may also be the faint upper band in
Fig. 5.31, but the identity of the 6.5 kb transcript (band X) is unclear.
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A DBLα probe B Exon 2 probe
Fig. 5.31. Northern blot showing RNA from 9% mixed stage 3D7 culture (4% ring,
4% pigmented trophozoite, 1% schizont). RNA was separated by agarose gel
electrophoresis on a 1.2 % agarose gel, and the RNA was transferred to nylon
membrane. A) The membrane was hybridised overnight (60ºC) with a type 3 var
gene DBLα domain probe. RNA corresponding to the type 3 DBLα var transcript
(3.98 kb) is marked with an arrow (). The probe cross reacts strongly to a band at
approx 6.5 kb, and faintly to longer var gene transcripts (> 9 kb). B) The membrane
was hybridised overnight (50ºC) with the var gene exon 2 probe. RNA
corresponding to the type 3 DBLα var transcript (3.98 kb) is marked with an arrow
































Fig. 5.32. Alignment showing the type 3 DBLα probe and the sections of transcripts
recognised by it in 3D7; pfa0015c (nucleotides (nt) 886-1132, 100% homology),
pfi1182w (nt 864-1120, 99.2% homology), mal6p1.314 (685-1141, 97.6%
homology), and var1csa (nt 8165–8470 59.8% homology).
The RNA from the RT-PCR time courses were processed through the Northern blot
analysis method describe above. Unfortunately, this was not successful for DBLα
domain, DBLε domain or exon 2 probes. The MSP1 probe recognised the schizont
extract at 42 hr post invasion only, suggesting the Northern blot method used was
successful (Fig. 5.33). This suggests the gel, transfer and detection procedures were
successful, and the buffers were correctly made. Failure to detect RNA with the other
probes (type 3 DBLα/ε and exon 2) may have been due to the hybridisation or
washing being sub-optimal for the other probes.
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Fig. 5.33 MSP1 Northern blot of 3D7 time course. RNA samples were as Fig. 5.24
early rings (ER), late rings (LR), trophozoite (Tr), schizonts (Scz), gametocytes (Gc).
RNA was separated by agarose gel electrophoresis on a 1.2 % agarose gel, and the
RNA was transferred to nylon membrane. The membrane was hybridised overnight
(60ºC) with the MSP1 probe. RNA corresponding to the MSP1 transcript (5.12 kb) is
marked with an arrow ().
ER     LR     Tr     Sz     Gc
5 kb
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5.5.11 Type 3 var genes in Mali field isolates
The aim of this section was to determine whether type 3 var genes were commonly
transcribed in P. falciparum field isolates, using gDNA and cDNA from the 26 field
isolates from the Mali study sites examined for non-type 3 DBLα transcription
discussed in chapter 3 (Lyke et al. 2004). Data is presented for type 3 var gene
presence in Mali field isolate gDNA (section 5.5.11), type 3 var gene DBLα/ε
domain transcript detection by RT-PCR (sections 5.5.12 and 13 respectively), and
finally a summary of type 3 var genes in the Mali isolates (section 5.5.14). Section
5.5.15 will then discuss the sequences phylogenetically.
5.5.12 PCR of type 3 gDNA var genes from Mali field isolate gDNA
Firstly, type 3 DBLα  domain amplification on gDNA from each isolate was
performed to assess whether type 3 var genes were present in the Mali isolates. PCR
was performed using the alpha domain primer pair AF3_type3F and Type3alphaR2.
Type 3 var gene DBLα domain PCR product was detected in all isolates (Fig. 5.34).
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Fig. 5.34 Type 3 DBLα domains were amplified from gDNA from the 26 Malian
field isolates (9 cerebral malaria, 8 hyperparasitaemia and 9 uncomplicated malaria)
using primer pair AF3_type3F and Type3alphaR2. A 5 µl sample of all RT-PCR
products was run on a 1.5% agarose gel. G: gDNA controls were positive for PCR
product in all cases indicating PCR was successful. H: water control lanes. DNA
ladder was 100 bp  ladder.
For 10 isolates with a good PCR product (HYP1, HYP2,  HYP5, HYP6, HYP7,
CM1, CM4, CM6, U1 and U4) the PCR products were cloned and used to transform
E. coli. The ligated plasmids from 24 colonies were extracted and sequenced from
each of these isolates. The number of distinct (>95% identity) DBLα transcripts per
isolate ranged from 1-4 from 5-22 miniprep plasmid sequences per isolate (Table
5.5).  On average there were 0.86 type 3 DBLα domains per genotype, but more
isolates would need to be studied to confirm these proportions.
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Table 5.5. Table showing the number of distinct DBLα domains detected by PCR of
gDNA using the type 3 alpha domain primer pair AF3_type3F and Type3alphaR2,
with the number of miniprep plasmids sequenced. Also shown is the number of
genotypes detected in these isolates (details in chapter 3), the relative number of type
3 var genes detected per genotype for each isolate, and the average number of
detected DBLα domains per genotype.
5.5.13 Type 3 var gene transcription in Mali field isolates: Type 3 DBLα
domain RT-PCR
Having established that the isolates all appeared to contain type 3 var genes at the
gDNA level, RT-PCR was used to assess how frequently these were transcribed.
Type 3 DBLα  domain RT-PCR using AF3_type3F and Type3alphaR2 was
performed on cDNA from each of the 26 Mali field isolates (prepared in chapter 3).
PCR products were obtained for 15/26 isolates; 8/8 hyperparasitaemia isolates, 3/9















Hyperpara- HYP1 22 2 4 0.50
HYP2 14 3 3 1.00
Sitaemia HYP5 15 3 4 0.75
HYP6 5 2 3 0.67
HYP7 19 2 3 0.67
Cerebral CM1 11 2 1 2.00
Malaria CM4 10 1 5 0.20
CM6 10 3 3 1.00
U1 10 2 4 0.50





were purified, cloned and sequenced, to assess the number of distinct type 3 DBLα
domain transcripts per isolate. There was a significantly higher number of type 3
DBLα domain transcripts seen in the hyperparasitaemia isolates compared to
cerebral malaria isolates (t-test, P=0.003). Table 5.6 shows the number of distinct
type 3 DBLα transcripts detected per isolate.
Type 3 RT-PCRClinical disease
category
Isolate name

































Table 5.6: Presence and number of transcribed type 3 DBLα domains detected by
RT-PCR using primers AF3_type3F and Type3alphaR2 in 8 hyperparasitaemia, 9
cerebral malaria and 9 uncomplicated malaria field isolates, with the number of
minipreps sequenced.
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5.5.14 Type 3 var gene transcription in Mali field isolates: Type 3
DBLε domain RT-PCR
Type 3 DBLε domain transcripts were also amplified by RT-PCR from the same
cDNA preparations, using primers Type3epsF and Type3epsR. PCR products were
obtained for 16/26 isolates; 6/8 hyperparasitaemia isolates, 6/9 cerebral malaria
isolates and 4/9 uncomplicated malaria isolates. As before, the PCR products were
purified, cloned and sequenced, to assess the number of distinct DBLε domain
transcripts detected per isolate, shown in Table 5.7.
Type 3 RT-PCRClinical disease
category
Isolate name


































Table 5.7: Presence and number of transcribed epsilon domains detected by RT-PCR
using primers type 3 DBLα  in 8 hyperparasitaemia, 9 cerebral malaria and 9
uncomplicated malaria field isolates, with the number of minipreps sequenced.
Epsilon domains were very similar (>92% amino acid identity, see section 5.5.15)
and no isolates showed multiple DBLε domain transcripts.
5.5.15 Type 3 var gene transcription in Mali field isolates: Summary
In total, evidence of type 3 var gene transcription was detected in 23/26 isolates; all 8
hyperparasitaemia isolates, 8/9 cerebral isolates and 7/9 uncomplicated isolates
(Table 5.8). The observation of epsilon but not alpha product in 7 isolates, including
5/9 cerebral isolates, was puzzling. RT-PCR was repeated on all of the cerebral
isolates (except CM7 due to cDNA running out) with the first pair of type 3 DBLα
domain primers (αAF3_type3F and Type3alphaR1, section 5.5.1). Only CM1
showed a PCR product with these primers. RT-PCR was also repeated on all of the
cerebral isolates (except CM7 due to cDNA running out) with the forward type 3
DBLα domain primer and reverse epsilon domains primer (αAF3_type3F and Type
3epsR). Again, only CM1 showed a PCR product with these primers. The lack of
product indicates the type 3 DBLα domains are either not present, or at very low
concentration, in the cerebral malaria isolates. The type 3 DBLε domains are more
highly conserved and there is no degeneracy in the forward primer, unlike the
forward primer for the type 3 DBLα domains. Thus it is possible that a very low
level of type 3 var gene transcription would be picked up by the epsilon but not the
alpha domain primers, as the epsilon primers may be a more powerful primer pair
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(see discussion). It is also possible the alpha domain primers could not amplify the













HYP1 1 1 1 4 0
HYP2 2 1 2 3 0.07
HYP3 4 1 4 1 0.28
HYP4 1 0 1 2 1.00
HYP5 2 1 2 3 0.40
HYP6 2 1 2 3 0.25
HYP7 2 1 2 3 0.06
Hyperpara-
sitaemia
HYP8 1 0 1 2 0.00
CM1 1 1 1 1 0.83
CM2 0 1 1 3 0.79
CM3 0 1 1 3 0.93
CM4 0 1 1 5 0.06
CM5 0 1 1 1 0.72
CM6 0 1 1 3 1.00
CM7 2 0 2 1 1.00
CM8 1 1 1 1 0.95
Cerebral
malaria
CM9 0 0 0 2 1.00
U1 2 1 2 4 0.60
U2 0 0 0 3 0.07
U3 0 1 1 3 1.00
U4 1 1 1 3 0.06
U5 2 1 2 3 0.74
U6 1 0 1 1 1.00
U7 0 1 1 3 0.07
U8 3 0 3 1 0.05
Uncomplicat
ed malaria
U9 0 0 0 1 0.06
Table 5.8: Presence and number of transcribed type 3 alpha and epsilon domains
detected by RT-PCR in 8 hyperparasitaemia, 9 cerebral malaria and 9 uncomplicated
malaria field isolates, and the estimated (minimum) repertoire of transcribed type 3
var gene in each isolate. *Genotypes and DBLα1% data was taken from chapter 3.
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There was no significant difference in the proportion of isolates showing type 3 var
gene transcription in the three isolate groups (Chi-squared, p = 0.37). The relative
levels of transcription between isolates cannot be directly compared, as the RT-PCR
was not quantitative. However, there was a significantly higher number of type 3
transcripts seen in the hyperparasitaemia isolates compared to cerebral malaria
isolates (t-test, p = 0.02; Fig. 5.35A). This difference is even greater if only the
number of distinct DBLαtype3 transcripts detected is compared (t-test, p = 0.003). This
is in contrast to the findings of chapter 3 which showed an increase in non-type 3
DBLα1 transcripts in the cerebral versus hyperparasitaemia isolates, and shows an
association between type 3 transcription and non-cerebral malaria.
There was no correlation between number of estimated transcribed type 3 var genes
and DBLα1% as calculated in chapter 3 (Spearman Rank correlation: Rho = -0.03, p
= 0.89; Fig. 5.35B). There was also no correlation between number of estimated
transcribed type 3 var genes and number of genotypes estimated in chapter 3
(Spearman Rank correlation: Rho = 0.18, p = 0.38; Fig. 5.35C).
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B  C
Fig. 5.35. A) Estimated transcribed type 3 var repertoire for the three isolate clinical
categories. Hyperparasitaemia isolates showed significantly higher diversity of type
3 var genes than cerebral malaria isolates (t-test p = 0.02). B) Spearman Rank
correlation DBLα1% and estimated transcribed type 3 repertoire (Rho = -0.03, p =
0.89). C) Spearman Rank correlation number of genotypes and estimated transcribed
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Comparing the estimated number of transcribed and encoded type 3 var genes,
approximately 50-70% percent of the type 3 var genes are transcribed (Table 5.9).
Table 5.9. Table showing the number of distinct DBLα domains detected by PCR of
gDNA using the type 3 alpha domain primer pair AF3_type3F and Type3alphaR2,
with the number distinct DBLα transcripts detected, and estimated number of type 3
var genes transcribed per isolate. The ratio of transcribed:encoded type 3 var genes,
and the average of these for all 10 isolates is given.
The lack of product in CM9, U2 and U9 for alpha and epsilon domain RT-PCR
indicates no, or little, type 3 var gene transcription. It is unlikely the RT-PCR
reaction “failed” due to a poor cDNA preparation, as amplification of non-type 3
DBLα domains had been successful (chapter 3).
The low number of minipreps sequenced per isolate for alpha and epsilon RT-PCR




















type 3 var 
gene
Hyperpara- HYP1 2 1 1 0.50 0.50
sitaemia HYP2 3 2 2 0.67 0.67
HYP5 3 2 2 0.67 0.67
HYP6 2 2 2 1.00 1.00
HYP7 2 2 2 1.00 1.00
Cerebral CM1 2 1 1 0.50 0.50
Malaria CM4 1 0 1 0.00 1.00
CM6 3 0 1 0.00 0.33
U1 2 2 2 1.00 1.00





estimated number of type 3 transcripts in each isolate is included in the table of Mali
isolate data (Appendix 1).
5.5.16 Type 3 var gene diversity in Mali field isolates
The type 3 domains showed a similarly high level of conservation as previously
published type 3 var genes, with amino acid identities of 58.3-100% for the alpha
domains (mean 76.3%, SE 0.4%, SD 0.2%) and 94.2-100% for the epsilon domains
(mean 97.8%, SE 0.3%, SD 0.002%) as shown in Fig. 5.36 (histograms and box plot)
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Fig. 5.36. Box plot (displaying 10th, 25th, 50th, 75th and 90th percentiles; values
<10th percentile and >90th plotted separately) and histograms of percentage amino
acid identity between cerebral, hyperparasitaemia and uncomplicated malaria type 3
DBLα and DBLε domains. Percentage identity was calculated using MegAlign.
Histograms and box plots of identity were then created in Statview. Note the scale
for amino acid identity on the histograms are different.
Type 3 DBLα domains    Type 3 DBLε domains
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Fig. 5.37. Amino acid sequence distance charts showing percentage amino acid
identity between Mali field isolate DBLαtype3 and DBLεtype3 domains. Darkness of
shading indicates level of identity between domains. Amino acid sequences were
created from nucleotide sequences in EditSeq, and percentage identity was calculated
using MegAlign.
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5.5.17 Phylogenetic analysis of DBLα type 3 domains from Mali field
isolates
The DBLαtype3 domains were aligned using clustal W and phenograms were created
(Fig. 5.38). As expected from a subgroup of domains with such high sequence
similarities, the DBLαtype3 domains cluster separately from the non-type 3 DBLα
domains of 3D7 (Fig. 5.38). The DBLαtype3 domains clustered into 6 distinct clades,
representing 6 highly conserved DBLαtype3 domains groups DBLαtype3 A-F of >95%
nucleotide sequence identity (Fig. 5.38). The consensus sequence for these groups
was defined as Type 3 DBLα type3 A-F so homology comparisons to different
sequences could be made. Mal6p1.314 did not fall into one of these groups (nearest
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Fig. 5.38. Phenograms of field isolate Type 3 DBLα domains created from a clustal
W alignment of sequences. Type 3 DBLα  domains from the Mali isolates,
transcribed or gDNA only are included, with 3D7 DBLα1 domains for comparison.
Sequences are grouped into consensus group (>95% identity) A-F. Type 3 DBLα












and D2 are defined as a subset of group D, as the sequences of group D2 fall just
outside the 95% homology cut-off, but are very similar (94% identity) to those of
group D1.
DBLαtype3 were also amplified from gDNA from 6 Kenyan field isolates (gift from
Pete Bull, Kilifi, Kenya), resulting in a further 8 DBLα type3 sequences. It was not
possible to count the number of genotypes within each sample, as only a few
microlitres cDNA was available, however a range of 1-5 is expected from previous
work in this area (Bull et al. 1999). Five of these sequences fell into the strictly
defined 6 subgroups A-F of DBLα type3 (>95% nucleotide sequence identity). In
addition, 9 other sequences from various global locations (Trimnell et al. 2006) also
showed high homology to the defined DBLα type3 subgroups (Fig. 5.39). DBLαtype
group A is particularly highly conserved, with 19 sequences belonging to this group
with >99% homology including sequences from vastly different geographic areas
(East Africa, West Africa and South America), and a further 2 sequences with >95%
homology. One sequence Kilifi gDNA5D was identical to the alpha domain of
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Fig. 5.39. Phenograms of field isolate Type 3 DBLα domains created from a clustal









transcribed or gDNA only are included, with Kenya isolates sequences and other
published type 3 DBLα domain sequences. Sequences are grouped into consensus
group (>95% identity) A-F, including D1 and D2 separately as before.
Type 3 DBLα 
domain group
(>95% indentity)
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V1Sb, SE Asia (100%)
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Table 5.10. Six distinct groups of conserved (>95% identity) DBLαtype3 domains A-F,
showing the percentage identity of each sequence to the group consensus. Mali field
isolate RT-PCR and gDNA sequences, Kilifi gDNA sequences and domains obtained
from the NCBI database. Percentage nucleotide homology the defined DBLαtype
group A-G consensus sequence is given in brackets. D1 and D2 are defined as a
subset of group D, as the sequences of group D2 fall just outside the 95% homology
cut-off, but are very similar (94% identity) to those of group D1. For published
sequences geographic origin is also given.
5.5.18 Phylogenetic analysis of DBLε type 3 domains from Mali field
isolates
The DBLεtype3 domains also cluster separately from non-type 3 domains, forming just
one tight group in the phenogram clearly distinct from the non-type 3 epsilon
domains from 3D7 (Fig. 5.38). As they all show such high homology to each other
they cannot be separated into more distinct subgroups. All type 3 epsilon domains
found on NCBI database showed >97% nucleotide homology to this group. This is
also reflected in the high sequence homology across the whole repertoire of









































Fig. 5.40 Phenogram of field isolate DBLεtype3 domains (bracketed) with 3D7 epsilon
domains for comparison created from a clustal W amino acid alignment. *3D7 type 3





5.6 Results 2: Type 3 PfEMP1 protein analysis
5.6.1 Type 3-specific anti-peptide polyclonal antibody production:
DBLα domain structure
As one hypothesis of this chapter was that there might be an association of type 3
DBLα1 domain expression with cerebral malaria, it was decided to raise an antibody
to the type 3 DBLα domain. This was intended to be a useful tool for confirming
whether the type 3 PfEMP1 is translated, and would be used to determine if the type
3 PfEMP1 were surface exposed, using immunofluorescence, and Western blotting
with protease treatment of the surface exposed proteins using trypsin. In the future, a
type 3 DBLα domain could potentially be used to determine type 3 DBLα1 domain
function; for example if binding assays suggested the type 3 DBLα1 domain had
affinity for certain ligands, the antibody could be used to block binding, and show
specificity of the interaction. It could also be used in culture, for example to
determine whether the type 3 DBLα1 domain has any role in processes such as
invasion, or for selection of type 3 PfEMP1-expressing parasites. These future
experiments are outside the scope of this chapter (see discussion for further details).
The type 3 DBLε domains could also have been chosen as the target of a type 3
specific antibody as they are also very highly conserved. However, as they are more
membrane proximal they might not be as accessible to antibody for example in live
cell immunoflourescence assays.
As described in the introduction, DBLαtype3domains contain a specific and conserved
subdomain, comprising the second half of the domain (Fig. 5.41). Therefore it was
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useful to model the structure of the type 3 specific subdomain to predict any
structural feature which may influence antibody design, and to predict surface
exposed regions.
Fig. 5.41. Alignment of 3D7 group A var gene DBLα domains. Type 3-specific and
conserved region is boxed in red.
The structure of the DBL domains of EBA175 had previously been published (Tolia
et al. 2005). In comparison to EBA175 RII monomer F2 domains (Tolia et al. 2005),
the type three specific portion of a DBLαtype3 domain is equivalent to the F2
subdomain 2. The switch from generic DBLα1 domain to type 3 specific conserved
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part of the DBLα type3 domain occurs between the two subdomains, specifically
between helices T and U as described in Tolia et al. (2005) (Fig. 5.42). This is
equivalent to between subdomains 2 and 3 of the P. knowlesi DBL as defined by
Singh et al. (2006); subdomains 1 and 2 of the P. knowlesi DBL as defined by Singh
are equivalent to the first subdomain of the RII EBA175 monomer F2 DBL domain,
defined by Tolia.
Fig. 5.42. The EBA175 RII monomer F1 (green) and F2 (purple) subdomains
showing alpha helices (rectangles) and disulfide bridges (red lines), adapted from
Tolia et al. (2005). The conserved type 3-specific region corresponds to the second
half of the DBLα domain sequence, corresponding to the second subdomain (circled
in red) within domain F2 (purple) of the eba174 RII monomer (Tolia et al. 2005).
The first subdomain of the F2 DBL domain as defined by Tolia is equivalent to
subdomains 1 and 2 of PkDBL as defined by Singh et al. 2006 and the second Tolia
subdomain is equivalent to Singh subdomain 3.
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To analyse the structure of the type 3-specific DBLα domain sequence more closely,
the structures of EBA175 and the P. knowlesi DBL were downloaded from the
Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank
(http://www.pdb.org). The 3D7 type 3 var gene mal6p1.314 sequence was used in
structural modeling as a representative type 3 DBLα domain. The mal6p1.314 DBLα
domain amino acid sequence was aligned to the amino acid sequence of EBA175 and
P. knowlesi DBLα by clustal W. The aligned amino acid sequence was then mapped
onto the published structures using Cn3d structural modelling software
(http://www.ncbi.nlm.nih.gov/Structure/CN3D/cn3d.shtml). This programme
superimposes aligned amino acids sequences but does not attempt to model novel
structural features, or resolve unaligned sequences. Thus resulting structures are not
definitive, but gross features, such as long alpha helices can be confidently
positioned. The two DBL structures map very closely onto each other using this
technique, showing a high degree of structural identity between these two domains,
suggesting there might be a high structural similarity between other DBL domains.
Structural modelling of the type 3-specific subdomain using published structures of
EBA175 and P. knowlesi DBL (Tolia et al. 2005; Singh et al. 2006) as a scaffold,
suggests the type 3-specific region is a disordered stretch, followed by two long
helices separated by another unstructured region (Fig. 5.43).
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Fig. 5.43. Cn3D generated image of Mal6P.314 amino acid sequences mapped onto
known DBL structures. A and B (upper panel) show Mal6P1.314 mapped onto
EBA175 F2 domain (PDB ID 1ZRL; Tolia et al. 2005). C and D (lower panel) show
Mal6P1.314 mapped onto P. knowlesi DBL structure (PDB ID 2c6j; Singh et al.
2006). A and C (left) show the whole DBLα domain. B and D (right) show only the
type 3 conserved region. Type 3 conserved regions are highlighted in yellow,
showing disordered residues followed by two predicted long alpha helices.
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5.6.2 Type 3-specific anti-peptide polyclonal antibody production:
peptide choice
Peptides for anti-peptide antibodies should be 12-16 amino acids long (advice from
peptide.design@eurogentec.com) with no internal cysteines as these are used for
conjugation to the carrier. For production of an anti-peptide antibody for global
recognition of all type 3 domains, peptides were chosen that are well conserved in all
known type 3 domains but do not occur in other DBLα1 domains or any other
parasite or host proteins. The peptides must also be highly antigenic to increase the
chance of successful and specific antigen production in the host animal.
Protean software analysis was used to aid peptide design (Fig. 5.44). Alpha helical
regions predicted by structural modelling (Fig. 5.43) are also supported by Garnier
Robson analysis (Fig. 5.44). Alpha helical regions suggest a conserved structure, and
thus potentially a conserved structural epitope for antigen recognition. Helical
peptides are good antigenic targets for recognition of proteins in native states, such
as by immunoflourescence, as it is likely that the peptide may also form a helix, and
thus have a similar conformation to the native protein. However, denatured proteins
have lost secondary structure, so antibodies to helices are not necessarily helpful for
recognition of denatured proteins by Western blot analysis.
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After analysis with Protean/Lasergene, and consulation with the company





Kyte-Doolittle plots of these amino acids show the hydrophillicity of the regions is
high, suggesting that these amino acids are probably surface exposed, in agreement
with the Emini surface probability plot (Fig. 5.44). The Jameson-Wolf analysis also
shows high antigenic index for most of this region (Fig. 5.44). These peptides are
shown on an amino acid alignment of type 3 DBLα  domains (Fig. 5.45) and
highlighted in a DBLαtype 3 domain structure model (Fig. 5.46).  Blast search of the
NCBI database suggested these epitopes do not occur in other proteins.
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Fig. 5.44. Analysis of the final 133 amino acids of Mal6p1.314 DBLα domain using
Protean/Lasergene software (DNAstar, Inc), showing predictions of alpha helical and
beta sheet regions (Garnier-Robson, Chou-Fasman and Eisenberg plots),
hydrophobicity (Kyte-Doolitle plot), flexible regions (Karplus-Schulz plot),
antigenicity (Jameson-Wolf index) and surface exposure probability (Emini plot).
Potential peptides for immunisation (DTDPPVVDYIPQ) (CNVLNKEIDEMNNQ)
and (LVSKWKN(E/Q)FDK) are boxed.
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Fig. 5.45. Position of three potential immunogenic peptides (DTDPPVVDYIPQ)
(CNVLNKEIDEMNNQ) and (LVSKWKN(E/Q)FDK) (boxed) on clustal W
alignment of type3 amino acid sequences; mal6p1.314, pfi1820w and pfa0015c from
3D7, pfclin379b05 from Ghanaian clinical isolate (www.sanger.ac.uk), ittype3.pot
from IT/FCR3 strain and mc var5 from Malayan Camp.
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L R W M S E W S E Y F C N V L N K E I D E M N N Q C K D C E M S R R C N D D S E 194 mc var5.prot
G G K C K K C K E Q C Q I F K E L V S K W K N E F D K Q S M K Y K E L Y I K A S Majority
370 380 390 400
G E K C K K C K E Q C Q I F K E L V S K W K N E F D K Q S M K Y K E L Y I K A S 349 Mal6P1.314.prot
G G K C K K C K E Q C Q I F K E L V S K W K N Q F D K Q S M K Y M E L Y N K A S 339 PFI1820w.prot
G E K C K K C K E Q C Q I F K E L V S K W K N Q F D K Q S M K Y M E L Y N K A S 346 PFA0015c.prot
G G K C K K C K E Q C Q I F K E L V S K W K N Q F D K Q S M K Y M E L Y N K A S 91 pfclin379b05.prot
G E K C K K C K E Q C Q I F K E L V S K W K N E F D K Q S M K Y K E L Y I K A S 127 ittype3.prot
G G K C K K C E E Q C Q I F K E L V S K W K N E F D K Q S M K Y K E L Y I K A S 234 mc var5.prot
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    A          B
Fig. 5.46. Cn3D generated worm (A) and spacefill (B) images of Mal6P.314 amino
acid sequences mapped onto the known structure of EBA175 F2 domain (PDB
number 1ZRL) (Tolia et al. 2005). Peptides DTDPPVVDYIPQ (1),
CNVLNKEIDEMNNQ (2) and LVSKWKN(E/Q)FDK (3) are indicated in yellow.
Two peptides are better than one for raising polyclonal antigen as this increases the
immunization success rate of obtaining antibodies that recognize the protein from
75% to 95% (reference http://uk.eurogentec.com). Due to the E/Q discrepancy in the












As described, both peptides are totally conserved in all available published type 3
DBLα domains, including the three from 3D7, and showed no homology to any
other proteins (P. falciparum, human, or otherwise) by NCBI blast homology search.
Both are hydrophilic with a high antigenic index (Jameson-Wolf and Kyte-Doolittle
plots; Fig. 5.44), and are thus likely to be surface exposed with good antigenic
potential. Peptide 2 is likely to resemble native protein secondary structure, as is it
predicted helical by structural modelling and Garnier-Robinson prediction. As such,
antibodies recognising this peptide are likely to recognise native protein such as in
immunoflourescence. Peptide 1 is less likely to resemble native protein conformation
as it is predicted to be disordered by Protean analysis. Antibodies recognising this
epitope will potentially recognise denatured proteins such as in a Western blot. A
terminal cysteine would be added to peptide 1 to facilitate coupling to the carrier
(final sequence DTDPPVVDYIPQ +C).
5.6.3 Preimmune sera analysis
Two host animals were required for immunisation. The more commonly used and
appropriate host species were hen and rabbit. To decide which species would be
used, 5 preimmune hen egg yolks and 5 preimmune rabbit sera were obtained from
Eurogentec (Belgium), and the preimmune antibody repertoire from the animals was
tested for recognition of infected and uninfected red blood cells.
Preimmune hen egg samples from 5 candidate hens were obtained as fresh yolk.
Preimmune hen yolk IgY purification was carried out using the Promega Eggstract
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kit. Extracted IgY concentration (2-4 mg/ml) was within the expected concentration
of IgY from yolk (Eggstract kit manual).
To determine how pure the sample was, the 1 µl (2-4 µg) of the IgY extractions was
run on a reducing SDS-PAGE gel and either stained with SimplyBlue (Fig. 5.47A) or
transferred onto a PVDF membrane and probed with a goat anti-chicken HRP-
conjugated secondary antibody (Fig. 5.47B). The heavy (67 kDa) and light (27 kDa)
IgY chains were detected by SimplyBlue and by goat anti-chicken HRP-conjugated
secondary antibody probing. Fig. 5.47 shows that the purified IgY extract was
successful and was relatively pure.
Fig. 5.47. IgY extractions (PO38-42). A) 1 µl of each IgY extract (2-4 mg/ml) was
run out on a gradient 3-8% reducing tris-acetate SDS-PAGE gel and all proteins
were visualized by staining with SimplyBlue. B) Proteins transferred to PVDF
membrane and detected with an anti-chicken HRP- conjugated secondary antibody
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(1:1000, 1 hr incubation). IgY was visualised using enchanced chemiluminescence
and exposure to X-ray film. The protein ladder was a pre-stained precision protein
molecular weight marker (Bio-Rad).
5.6.4 Preimmune recognition of IE proteins by Western blot
Western blots were used to determine whether the antibodies in the preimmune sera
or yolk extract recognised proteins from infected erythrocytes (IE). Proteins
extracted from an asynchronous culture of 3D7 were run on a 3-8% reducing
acrylamide gel. The proteins were transferred to PVDF membrane. The membrane
was cut into strips for incubation in the sera at 1:100 dilution. The appropriate
secondary antibody (anti-chicken or anti-rabbit) conjugated to HRP was used to
detect primary antibody binding.
Each IgY extract showed some recognition of IE proteins (Fig. 5.48). PO40 IgY
bound the IE proteins the most strongly and PO41 and PO42 showed the least
binding in the 155-270 kDa range. The Western blot was repeated to try to improve
the quality of protein detection but this was not successful. It was decided to rely on
affinity purification to reduce background antibody affinity for IE proteins.
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Fig. 5.48. Western blot of an asynchronous culture of 3D7 (gift from JP Semblat)
using preimmune IgY extracts. Extracted IE proteins were separated by reducing
SDS-PAGE on a 3-8% tris-acetate gel (1 hr, 150 V). Proteins were transferred to
PVDF membrane (1 hr, 30V) and the membrane was cut into strips. Each strip of
membrane was blocked overnight in milk and then incubated in the IgY extract
(PO38-42) at 1:100 dilution for 1 hr. HRP-conjugated anti-chicken secondary
antibody (1:1000, 1 hr incubation) was used to bind IgY. Bands were visualised
using enchanced chemiluminescence and exposure to X-ray film. The protein ladder
was a pre-stained precision protein molecular weight marker (Bio-Rad).
Each preimmune rabbit sera also showed some recognition of IE proteins, with
strong recognition of proteins in the PfEMP1 size  (155-270 kDa) range (Fig. 5.49).
Rabbit S170 showed the lowest levels of host protein recognition. All rabbits serum
recognized proteins around size of known type 3 PfEMP1 (153 kDa), and strong
recognition of proteins around 100 kDa and 250 kDa.
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Fig. 5.49. Western blot of an asynchronous culture of 3D7 (gift from JP Semblat)
using preimmune rabbit sera. Extracted IE proteins were separated by reducing SDS-
PAGE on a 3-8% tris-acetate gel (1 hr, 150 V). Proteins were transferred to PVDF
membrane (1 hr, 30V) and the membrane was cut into strips. Each strip of membrane
was blocked overnight in milk and then incubated in the preimmune rabbit sera
(S166-S170) at 1:100 dilution for 1 hr. HRP-conjugated anti-rabbit secondary
antibody (1:1000, 1 hr incubation) was used to detect bond IgG. Bands were
visualised using enchanced chemiluminescence and exposure to X-ray film. The
























5.6.5 Preimmune recognition of IE proteins on live cells in
immunoflourescence assay (IFA)
Samples of P. falciparum culture were used to assess whether the preimmune sera or
yolk IgY would recognise native proteins in an immunoflourescence assay (IFA). As
many parasite proteins that are exported to the surface of the erythrocyte are seen on
the surface at pigmented trophozoite stage (e.g. PfEMP1), the IFAs were performed
when the culture contained a majority of parasites at the pigmented trophozoite stage
(4%), although some ring stage parasites were also present (1%). As such any
recognition of host erythrocyte proteins, or plasmodium protein on the IE suface at
ring or pigmented trophozoite stage, should be detected.
A TM284 P. falciparum culture (gift from A Raza) was incubated for 1 hour in
preimmune sera (1:10) or preimmune IgY (1:10) in PBS/1% BSA. The IgY was then
washed off and the cells were incubated in alexa 488 conjugated secondary antibody
1:1000 and PBS/DAPI/BSA1% for 1 hour in the dark.  Secondary incubation was
washed off and the live cells were viewed under fluorescence at 100x magnification.
Representative images from each of the IFA are shown in Fig. 5.50 and a summary is
given in Table 5.11. Where recognition occurred, DAPI staining revealed fluorescing
cells were not specifically infected or uninfected.
301
Fig. 5.50. Representative images of immunoflourescence assays (IFA) on TM284
infected IE. Cells at 2% haematocrit and cultures at 4% trophozoite, 1% ring stage.
A) Cells were incubated with chicken pre-immune IgY extract (1:10) and then with
alexa488-conjugated goat anti-chicken secondary antibody (1:1000). B) Cells were
incubated with rabbit preimmune serum (1:10) and then with alexa488-conjugated







PO38 Occasional cells fluoresced strongly plus
occasional speckles in other cells.
PO39 Occasional cells fluoresced strongly plus
moderate speckles in most cells.
PO40 All cells fluoresced strongly.




PO42 Moderate speckling in every cell.
S166 Occasional fluorescence of few speckles
per cell.
S167 No fluorescence.






Chicken control No fluorescence.Secondary
controls Rabbit control No fluorescence.
Table 5.11 Preimmune IFA summary.
5.6.6 Animal choice and justification
Chickens were chosen for immunization. Yolk have more IgY than rabbit sera has
IgG and more yolk volume is received from chicken than sera from rabbits. Thus
chicken immunization provides more antibody per animal. Avian antibody is
expected to be less cross-reactive to mammalian proteins than rabbit antibody.
Although the immunofluorescence data suggested rabbit preimmune sera showed
lower recognition of IE proteins, all rabbit preimmune sera showed a high level of
recognition of proteins around the size of type 3 PfEMP1 (153 kDa).
Chickens SH19 and SH20 were chosen because they showed the lowest levels of
preimmune recognition of infected erythrocyte proteins in Western blot and
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immunofluorescence. This suggested they might yield specific antibody with low
background of non-specific signal. Any remaining non-specific recognition in the
post-immunisation polyclonal antibody mix will be reduced by affinity purification
against the two immunizing peptides.
5.6.7 Generation of affinity-purified polyclonal antibody
Chickens PO41 and PO42 were immunised with peptides DTDPPVVDYIPQC
(peptide 1) and CNVLNKEIDEMNNQ (peptide 2) by Eurogentec (Belgium).
Eggs were collected in weekly batches, and received as fresh pooled yolk. IgY was
extracted from days 51-98 post immunization, and extracted IgY reconstituted in
PBS to the original yolk volume for each weekly pool (Table 5.2). Affinity
purification against a mixture of the two peptides was perfomed using the Sulfolink
technology (Promega) for 4/7 pools. This exploits the free sulfhydryl groups on the
terminal cysteines of the peptides to immobilize the peptides on a SulfoLink Resin
(see Fig. 5.51 and materials and methods). IgY was eluted in 6 ml elution buffer, due
to its low pH, then buffer exchanged into 0.5 ml PBS.
Fig. 5.51. SulfoLink Resin affinity purification method. Diagram taken from
Sulfolink kit 20325 manual, Pierce.
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Affinity-purified IgY from days 79-85 (dates 25/04-02/05) were used in all following
experiments, unless stated otherwise.
5.6.8 Affinity-purified antibody recognises target peptides by ELISA
To determine whether the pre-immune, post-immune and affinity-purified antibodies
had affinity for the peptides, an ELISA was performed.  Peptides were immobilised
onto ELISA plate wells overnight at 4ºC. Antibody was incubated in the plates and
non-bound antibody was removed by washing before incubation with 150 µl of
peroxidase conjugated goat anti-chicken IgG diluted 1:1000, for 1 hour. TMB
Substrate was added to each well and the plate was left to develop for 30 min in the
dark, before the reaction was stopped with sulfuric acid. The concentration of bound
antibody was assessed by absorbance at 450 nm. These are shown as mean ±
standard error (SE), Fig. 5.52.
The ELISA data (Fig. 5.52) showed preimmune sera had low affinity for the
peptides, and immunisation resulted in IgY with affinity for both peptides. The pool
of antibodies from the immune yolks also has increased affinity for BSA and milk
block compared to IgY extracted from the yolks of the hens pre-immunisation.
However, after affinity purification, the resulting antibody pools from both hens had
increased specificity for both peptides, and greatly reduced affinity for BSA and milk
block. Both pools of affinity-purified antibodies had equally high affinity for the 2

















































Fig. 5.52. ELISA showing affinity of preimmune, post immune IgY and affinity-
purified IgY, purified against both peptides simultaneously. Antibody was incubated
in ELISA plate wells coated (overnight at 4ºC) with 10 µg/ml peptide 1, 10 µg/ml
peptide 2, 1% BSA in PBS or PBS alone. Non-bound antibody was removed by
washing before incubation with 150 µl of peroxidase conjugated goat anti-chicken
IgG diluted 1:1000. Detection was measured as absorbance at 450 nm after
incubation with TMB Substrate then sulfuric acid. These are shown as mean ±
standard error (SE).
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5.6.9 Affinity purified antibody recognises band of approximately
150 kDa
To assess whether the antibody recognised type 3 PfEMP1 in a protein extract of
3D7 culture. 6.5 µl of protein extract was separated by denaturing SDS-PAGE on a
3-8% tris-acetate gel, and the proteins were transferred to PVDF membrane. The
membrane was blocked overnight in milk. At the same time, 1:100 dilution of the
immune IgY or affinity purified IgY from chickens PO41 and PO42 was pre-
incubated overnight in blocking buffer with a small strip of PVDF membrane to
remove antibodies that bound non-specifically to the membrane.  The blocked
membrane was incubated for 1 hour with the immune or affinity purified IgY. Non-
bound antibody was then removed by washing, and bound antibody detected by
incubation with secondary HRP-conjugated anti-chicken antibody followed by
enchanced chemiluminescence and exposure to X-ray film.
The pre-purification immune IgY from both chickens showed a high level of non-
specific affinity to many proteins IE proteins (Fig. 5.53) as was predicted by ELISA
(Fig. 5.52). The affinity-purified antibody from hen PO41 did not show any strong
protein recognition; a faint band at approximately 150 kDa may be type 3 PfEMP1.
The affinity-purified antibody from hen PO42 recognised a protein of approximately
150 kDa on SDS-PAGE by Western blot that is specific to infected erythrocytes and
may be type 3 PfEMP1. The three type 3 PfEMP1 in 3D7, Mal6p1.314 (153.3 kDa),
Pfa0015c (153.3 kDa) and pfi1820w (152.0 kDa), are all too close in size to
differentiate these by migration. There is also a strong band at approximately (180
kDa).
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Fig. 5.53. Western blot of an asynchronous culture of 3D7 using immune IgY extract
and affinity-purified IgY from PO41 (left) or PO42 (right). Triton soluble protein
extraction from uninfected erythrocytes (u) and erythrocytes infected with a 10%
mixed stage culture of 3D7 (i) were run on a reducing SDS-PAGE on a 3-8% tris-
acetate gel (1 hr, 150 V). Proteins were transferred to PVDF membrane (1 hr, 30V)
and the membrane was cut into 4 strips. Each strip of membrane was blocked
overnight in milk and then incubated with immune IgY extract or affinity-purified
IgY from PO41 (left) or PO42 (right) at 1:100 dilution for 1 hr and 1 hr secondary
incubation with HRP-conjugated anti-chicken secondary antibody (1:1000). Bands
were visualised using enhanced chemiluminesence and exposure to X-ray film. An
approximately 150 kDa protein, the size of a type 3 PfEMP1, is indicated (arrow).

















PO41 IgY PO42 IgY
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5.6.10 Affinity purification against peptides separately
Affinity purification was also carried out on the two peptides separately for immune
IgY from chicken PO42. Only chicken  PO42 IgY was used as the PO42 IgY affinity
purified against both peptides showed higher recognition of the band of 150 kDa,
which was thought to be the type 3 PfEMP1, than the PO41 IgY affinity purified
against both peptides. Affinity purification was performed as before using Sulfolink
resin affinity purification method. The purified antibody showed recognition of the
appropriate peptide, and low affinity for PBS/BSA (Fig. 5.54). Purification with
peptide 2 and both peptides together were successful, with enriched IgY with affinity
for the appropriate wells. Purificationagainst peptide 1 separately was less





















Fig. 5.54. ELISA showing affinity of post immune non-purified PO42 IgY and PO42
IgY purified with both peptide, or peptides 1 or 2 separately. Antibody was
incubated in ELISA plate wells coated (overnight at 4ºC) with 10 µg/ml peptide 1,
10 µg/ml peptide 2, 1% BSA in PBS or PBS alone. Non-bound antibody was
removed by washing before incubation with 150 µl of peroxidase conjugated goat
anti-chicken IgG diluted 1:1000. Detection was measured as absorbance at 450 nm
after incubation with TMB Substrate then sulfuric acid. These are shown as mean ±
standard error (SE).
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To assess the recognition specificity for IE proteins of the peptide1- and peptide 2-
purified antibodies a Western blot was performed. The 3D7 culture protein extract
used in Fig. 5.53 was separated again by denaturing SDS-PAGE on a 3-8% tris-
acetate gel, and the proteins were transferred to fresh PVDF membrane. The
membrane was blocked overnight in milk. At the same time, 1:100 dilution of
chicken PO42 immune IgY affinity purified against peptide 1 or peptide 2 was pre-
incubated overnight in blocking buffer with a small strip of PVDF membrane to
remove antibodies that bound non-specifically to the membrane.  The blocked
membrane was incubated for 1 hour with the affinity purified IgYs. Non-bound
antibody was then removed by washing, and bound antibody detected by incubation
with secondary HRP-conjugated anti-chicken antibody followed by enchanced
chemiluminescence and exposure to X-ray film (Fig. 5.55).
Antibody purified against both peptides independently recognised a 150 kDa protein
in P. falciparum protein extract but not in the uninfected erythrocyte controls (Fig.
5.55). Antibody affinity purified against peptide 1 showed weak recognition of type
3 protein, and also cross reacted with a host cell-derived protein at 240 and 260 kDa
(possibly spectrin). Antibody affinity purified against peptide 2 gave a much stronger
recognition of the type 3 protein at 150 kDa, but also cross-reacted with a parasite-
derived protein at approx 270 - 300 kDa, possibly non-type3 PfEMP1. Recognition
of the triton-soluble fraction by the antibody purified against both peptides (Fig.
5.53, above) more closely resembles that purified against peptide 2 only. Thus, it is
likely that the majority of IgY in the purified antibody pool recognises peptide 2.
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Fig. 5.55. Triton soluble (TS) and Triton insoluble (TI) protein extractions from
erythrocytes infected with a 6% trophozoite stage culture of 3D7 and uninfected
erythrocytes control were run on a reducing 3-8% tris-acetate gel SDS-PAGE and
proteins were transferred to PVDF membrane. The membrane was blocked overnight
in milk and probed with 1:1000 dilution of PO42 IgY affinity-purified against
peptide 1 (left) or peptide 2 (right). Secondary incubation was with HRP-conjugated
anti-chicken secondary antibody (1:1000). Bands were visualised using enhanced
chemiluminesence and exposure to X-ray film. A protein of the correct size for a
type 3 PfEMP1 (153 kDa) is indicated (arrow). The protein ladder was a pre-stained
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5.6.11 The 150 kDa band detected with the antibody appears to be
trypsin insensitive
The pigmented trophozoite culture was treated with 0.1-1mg/ml trypsin for 5 min,
and then treated with trypsin inhibitor for 5 min, before protein extraction. The 150
kDa band detected with the antibody appears to remain trypsin insensitive, indicating
it may be internal (Fig. 5.56).
In an attempt to verify the trypsin worked, the blot was repeated and probed for non-
type 3 PfEMP1 with an antibody with affinity for the ATS region and complement
receptor 1 which are expected to be trypsin sensitive at >10 µg/ml (Miller et al.
1977; Sharling et al. 2007). Unfortunately the Western blots were unsuccessful due
to high background (PfEMP1 ATS) or no signal (CR1). However, the type 3
antibody cross-reacts with bands in the 270-300 kDa range in the 3D7 triton
insoluble protein extracts which may be non-type 3 PfEMP1. These bands are
reduced on addition of the trypsin at 1 mg/ml  (Fig. 5.56), suggesting that the
trypsinisation was effective.
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Fig. 5.56. Triton soluble (TS) and Triton insoluble (TI) protein extractions from
uninfected erythrocytes (uRBC) and erythrocytes infected with a 6% trophozoite
stage 3D7 culture (3D7) were run on a denaturing SDS-PAGE and probed with
affinity-purified anti-type 3 antibody. Samples marked (+) were incubated with
1mg/ml trypsin for 5 min before protein extraction. The 153 kDa protein is marked
with an arrow. Bands thought to correspond to non-type 3 PfEMP1, which reduce in
intensity after trypsinisation, are indicated (*).The protein ladder was a pre-stained
precision protein molecular weight marker (Bio-Rad).
+    -    +     -      +     -    +    -  1mg/ml trypsin
          TI                       TS










5.6.12 Antibody recognises a protein of 150 kDa in HB3; a strain without
a type 3 PfEMP1
The recent whole genome sequencing of parasite strain HB3 revealed that this strain
was a natural knock-out for the type 3 PfEMP1. This explains “failure” of the type 3
alpha and epsilon PCR in HB3 gDNA in section 5.5.4.
HB3 parasites were cultured and protein samples collected from a culture of 7%
trophozoites. Proteins were loaded on to four reducing 3-8% tris-acetate acrylamide
gels, separated by SDS-PAGE, and transferred to PVDF membrane for Western blot
(3 gels), or stained in SimplyBlue to record total protein loaded (1 gel). The three
PVDF membranes were probed with preimmune IgY, immune IgY affinity purified
against peptide 1, or immune IgY affinity purified against peptide 2. Probing with
immune IgY affinity purified against peptide 2 showed strong recognition of a 150
kDa protein in HB3, as well as in 3D7 rings and pigmented trophozoites (Fig. 5.57).
This suggests the 150 kDa band is specific to infected erythrocytes, but may not be
specific to a type 3 PfEMP1.
In order to see if this cross reactivity was a problem due to using reducing SDS-
PAGE, the Western blot with the same antibody preparation was repeated using
native (non-reducing) gels. No proteins were recognized by the antibody after
membrane were probed with preimmune IgY or immune IgY affinity purified against
peptide 1 or 2.
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Fig. 5.57. Triton soluble (TS) and Triton insoluble (TI) protein extractions from
uninfected erythrocytes (U), HB3 culture 7% trophozoites (ht), 3D7 culture 6% rings
(3r) and 3D7 culture 6% pigmented trophozoites (3t) were loaded onto reducing 3-
8% tris-acetate acrylamide gels, separated by SDS-PAGE, and transferred to PVDF
membrane for Western blot or stained in SimplyBlue (top right) to record total
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protein loaded. Membranes were blocked in 5% milk o/n and probed with
preimmune IgY (top left), immune IgY affinity purified against peptide 1 (bottom
left), or immune IgY affinity purified against peptide 2 (bottom right) for 1 hr. After
washing, secondary incubation was with HRP-conjugated anti-chicken secondary
antibody (1:1000). Bands were visualised using enhanced chemiluminesence and
exposure to X-ray film. A protein of 153 kDa is recognised in all infected
erythrocyte lanes, including HB3, by peptide 2-affinity purified antibody (indicated
with an arrow). The protein ladder was a pre-stained precision protein molecular
weight marker (Bio-Rad).
5.6.13 Antibody recognises a protein on HB3 by fixed IFA
A fixed IFA was used to assess whether the antibody would recognise uninfected
erythrocytes, and erythrocytes infected with 3D7 or HB3. 3D7 and HB3 P .
falciparum cultures were smeared on to a glass slide and fixed with acetone. The
slides were incubated for 1 hour with preimmune IgY or immune IgY (affinity
purified against both peptides) both 1:10 in PBS/1% BSA, or with PBS/1% BSA
alone. Unbound antibody was then washed off and the slides were incubated in alexa
488 conjugated secondary antibody 1:1000 and PBS/DAPI/1%BSA for 1 hour in the
dark. Secondary incubation was washed off and the fixed cells were viewed under
fluorescence at 100x magnification. The IFA on 3D7 revealed the affinity-purified
antibody recognized infected erythrocytes only (Fig. 5.58). However, repeating the
IFA on HB3-infected erythrocytes also resulted in recognition of IE by the affinity-
purified antibody (Fig. 5.58). For both 3D7 and HB3 cultures, uninfected
erythrocytes did not fluoresce with preimmune IgY or PBS/1%BSA alone (Fig.
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5.58). As only infected erythrocytes were recognised by the affinity purified
antibody, the cross reactivity must be to a parasite-derived protein, as seen with the
Western blot (Fig. 5.58). It is likely there is cross reactivity to high molecular weight
PfEMP1, as suggested by faint bands (>250 kDa (*), Fig. 5.56), as well as with the
band of 150 kDa in HB3, which is also likely to exsist in 3D7. All erythrocytes,
infected and uninfected, fluoresced with immune IgY in live IFA (data not shown).
Whether there is any specific recognition of the type 3 PEMP1 in 3D7 is not clear.
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 Fig. 5.58. P. falciparum cultures of 3D7 (6% pigmented trophozoites; upper 3
panels) and HB3 (7% pigmented trophozoites; bottom) were smeared onto slides and
fixed with acetone. Slides were incubated for 1 hour in preimmune IgY, immune IgY
extract affinity purified against peptides 1 and 2 together (all 1:10 in PBS/1% BSA),
or PBS/1%BSA alone. The culture was then washed and the slides were incubated in
alexa 488 conjugated secondary antibody 1:1000 and PBS/DAPI/1/%BSA for 1 hour
in the dark. Secondary incubation was washed off and the fixed cells were viewed
under fluorescence at 100x magnification. Representative images of 3D7 with
preimmune IgY, affinity purified immune IgY extract and PBS/1%BSA alone, and
HB3 with affinity purified immune IgY extract are shown. HB3 did not fluoresce
with preimmune IgY or PBS/1%BSA alone.
5.7  Discussion
This chapter examined the type 3 var genes and PfEMP1 in a range of laboratory and
field isolates. The hypotheses to be examined in this chapter were threefold. Firstly,
that there would be a high level of conservation in all type 3 var genes in laboratory
strains and field isolates, but that the timing of expression may be unusual due to the
lack of a regulatory intronic promoter which controls the silencing of other var genes
(Deitsch 2001; Calderwood et al. 2003; Frank et al. 2006). Secondly that there might
be a link between type 3 var gene transcription and cerebral malaria, due to the
association of group A var transcription with cerebral malaria isolates discussed in
chapter 3. Thirdly, due to the high conservation of type 3 PfEMP1 it was
hypothesised that type 3 PfEMP1 may not be surface exposed, and design of a type
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3-specific antibody was attempted to address this question. The data obtained in
answer to the above hypotheses will be discussed.
PCR of gDNA revealed 4 of the 9 laboratory isolates examined encode a type 3 var
gene. Transcripts were only detected in TM267, Palo Alto and 3D7, suggesting
expression was not constitutive, as had been hypothesised due to the lack of
regulatory intron (Deitsch 2001; Calderwood et al. 2003; Frank et al. 2006). Another
conserved var gene family, var1csa, also lacks the regulatory intron, and appears to
be regulated uniquely, possibly outside of the mutually exclusive var gene promoter
system (Kyes et al. 2003; Winter et al. 2003; Kyes et al. 2007). Transcription of type
3 var genes was not associated with rosetting in TM267 or Palo Alto, or with IgM
binding in 3D7.
RT-PCR data for laboratory strain 3D7 suggests that type 3 var genes are expressed
in both ring and trophozoite stages of erythrocytic development. Northern blot
confirmed the presence of the type 3 var gene transcript in a mixed stage culture, but
due to technical difficulties a precise Northern blot time course could not be
completed. There was no evidence for a unique mechanism of transcriptional control.
No type 3 transcripts were detected in gametocytes, in agreement with a previous
study (Sharp et al. 2006).
The type 3 DBLα domains were omitted in the field isolate transcription profiling
study (chapter 3) as in many similar var gene studies (Fowler et al. 2002; Bull et al.
2005a; Albrecht et al. 2006; Barry et al. 2007; Kraemer et al. 2007), due to disparity
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between type 3 and non-type 3 reverse primer site sequences (Taylor et al. 2000a;
Bull et al. 2005a). Most (23/26) of the field isolates examined in this study show
evidence of type 3 var gene transcription, supporting recent observations that the
vast majority of isolates contain a type 3 var gene (Trimnell et al. 2006). Type 3 var
sequences show an extremely high level of conservation within and between isolates.
The almost total conservation of the second half of DBLα type3 domains suggests a
very particular and conserved function. The first half of the DBLα type3 domain
sequence, though not entirely conserved, appears to be constrained in sequence, and
six conserved subgroups of DBLαtype3 domain (A-F) were defined. This indicates a
functional constraint on the type 3 PfEMP1 alpha domain, and suggests that there
may be a limited repertoire of DBLα type3 sequences. DBLεtype3 domains are also
highly conserved, with nucleotide sequence homology >97% across the whole
domain. DBLεtype3 domains are so similar that different domains from different type 3
var genes may not easily be distinguished, and no isolate showed multiple distinct
epsilon transcripts in the RT-PCR analysis.
The high similarity of DBLεtype3 domain sequences partially explains the discrepancy
between the number of alpha and epsilon domains detected by RT-PCR. However,
why some isolates showed DBLαtype3 domain but not DBLεtype3 domain transcription,
or vice versa, cannot easily be explained. It is formally possible DBLα and DBLε
domains are regulated alternately, though this would be very unusual and
unexpected. Alternatively, it could be a PCR artefact. The most likely explanation is
that there is a very low level of type 3 var gene transcript in these isolates, and the
alpha domain PCR is less powerful than the epsilon domain PCR due to the
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degeneracy of the forward primer, and so cannot efficiently amplify the type 3
DBLα domain transcript by RT-PCR. Type 3 transcription in field isolates could be
studied in more detail, especially where alpha and epsilon data were inconsistent, to
explore this observation more thoroughly.
The second hypothesis, that there would be a strong correlation between type 3
DBLα1 domain transcription and cerebral malaria, did not appear to be true for type
3 DBLα1 domains. Type 3 var gene transcripts were not more commonly detected in
cerebral malaria isolates. Though type 3 var gene DBLε domain transcripts were
detected in 8/9 cerebral isolates, type 3 var gene DBLα domain transcripts could not
be detected, suggesting a low level of transcription. Furthermore, all 8
hyperparasitaemia isolates and 7/9 uncomplicated isolates showed evidence of type 3
var gene DBLε domain transcription, with type 3 var gene DBLα domain transcripts
also detectable in all hyperparasitaemia and 5/7 of these uncomplicated malaria
isolates. The data suggests a correlation between increased diversity of type 3 var
gene transcription with hyperparasitaemia. As the total RT-PCR product was not
quantifiable, it was not possible to directly compare abundance of type 3 transcripts
in different isolates, and so it is not possible to conclude an overall higher level of
type 3 var gene transcription in hyperparasitaemia isolates compared to cerebral
malaria isolates. It is intriguing that the uncomplicated malaria isolates fall between
the hyperparasitaemia and cerebral malaria isolates in the diversity of type 3 var
gene transcripts observed. This is reminiscent of the level of DBLα1 domain
transcription in uncomplicated malaria isolates falling between that of cerebral
malaria isolates and hyperparasitaemia malaria isolates reported in chapter 3. This
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strengthens the observation of a discrepancy in diversity of type 3 var gene
transcripts in the two other groups, as uncomplicated malaria can be considered an
earlier stage in disease progression, before expansion to hyperparasitaemia, or
development of severe symptoms, as discussed in chapter 3.
It is interesting that genes with the same upstream region (group A type 3 var genes
versus group A non-type 3 var genes; both UpsA) appear to be regulated differently
in terms of level of expression in field isolates. It may be possible that parasite
populations in an infection tend to have a certain proportion of parasites activating
group A var gene expression; when this is a non-type 3 group A var gene, severe
symptoms are common, but when this is a type 3 group A var gene, severe
symptoms are less likely, and hyperparasitaemia can develop. There was not a
significant negative correlation between type 3 group A var gene transcript diversity
and non-type 3 DBLα1 domain transcription proportion, though data on absolute
type 3 var gene versus non-type 3 group A transcription level is not available.
This association between the DBLα1-type 3 domain with hyperparasitaemia may
indicate that only DBLα1(non-type3) are involved in severe disease pathology, for
example through processes such as rosetting (Rowe et al. 1995; Russell et al. 2005),
which tend to be mediated through non-type 3 DBLα1 domains (Rowe, JA,
unpublished data).  Alternatively, it could be the large variety of domains in the long
and complex group A PfEMP1 that are crucial to disease pathology, rather than the
DBLα1 domain directly. The reduced number of extracellular domains in the type 3
PfEMP1 may result in reduced adhesive potential. This is supported by in vitro data
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that no type 3 var genes were upregulated when parasites were selected for adhesion
to a human bone marrow endothelial cell line (Jensen et al. 2004). Type 3 var gene
transcription was not found to be associated with rosetting or IgM binding in this
study, and the type 3 epsilon domain is not capable of IgM binding (Semblat, JP et
al. in prep). In addition, and unlike many other group A var genes, the type 3 var
genes were not increased in transcription after selection for “severe malaria
phenotype” by affinity for pools of semi immune plasma (Jensen et al. 2004). These
observations suggest that type 3 var genes are not likely to be specifically involved
in severe disease pathogenesis, though very little data on type 3 var transcription in
vivo is available. Parasites from experimentally infected volunteers expressed type 3
var, though transcription levels were low, and tended to decrease with time of
infection, unlike many non-type 3 group A var genes (Lavstsen et al. 2005). In a
subsequent study, type 3 var gene transcription was found to be significantly higher
in severe malaria cases than in asymptomatic malaria, though this increase may
simply reflect the 7 fold higher parasitaemia in the severe malaria group (Rottmann
et al. 2006). It would have been interesting to compare this severe malaria type 3 var
gene transcription to an appropriate hyperparasitaemia patient group with similar
parasitaemia.
The third hypothesis examined type 3 PfEMP1 and possible surface exposure. The
high level of conservation of the type 3 var genes (for example all epsilon domains
share > 97%, and the 6 groups of highly conserved type 3 DBLα domains) appears
to be at odds with its membership of a family of variant surface antigens. Of the two
other well-conserved PfEMP1 families, VAR2CSA is conserved due to a crucial role
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of CSA-binding in placental malaria (discussed in chapter 4), but the role of
VAR1CSA is still uncertain. It is generally believed that conserved proteins are
selected for a particular purpose, thus the conservation and frequency of the type 3
var genes between isolates indicates an important function, although this study
identified 5 laboratory strains in which a type 3 var could not be amplified from
gDNA (Muz12, Dd2, HB3, TM180 or 7G8) suggesting they cannot be essential. The
role of the type 3 var genes cannot be determined without first studying the encoded
proteins. At present there is no published data determining whether the type 3
PfEMP1 are expressed at a protein level, or if they are exported to the infected
erythrocyte surface.  It is conceivable such a conserved var gene family might be a
liability to a strategy of immune evasion; if a copy was commonly expressed on the
surface of every P. falciparum isolate antibodies might be raised which could
recognise all other isolates on subsequent infections. It is possible such a conserved
gene would remain internal.
To attempt to address this possibility, a polyclonal antibody to the type 3 var was
designed and raised in chickens. The DBLαtype3 domain was chosen for antibody
production rather than the DBLεtype3 domain. The type 3-specific portion of the
DBLαtype3 domain is highly conserved and so it was possible to identify type 3-
specific peptide epitopes for immunisation. It would also have been possible to use
peptide epitopes from the epsilon domain to create a type 3 PfEMP1-specific
antibody. However, DBLαtype3 domains also contain a variable region, whereas
DBLεtype3 domains are almost identical across the whole domain. Thus different
DBLαtype3 domains are more likely to have different binding properties than different
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DBLεtype3 domains. In addition, DBLα domains are more N-terminal and thus lie
further away from the erythrocyte surface. Being more exposed they might have an
increased binding potential. DBLα domains which bind host molecules have already
been defined in the case of rosetting (Rowe et al. 1997; Russell et al. 2005), and so
the interaction of conserved DBLαtype3 domains with other proteins is not unlikely.
Thus the binding properties of DBLαtype3 domains appeared to be more interesting to
study than that of DBLεtype3 domains, especially due to the association between non-
type 3 DBLα1 domains and cerebral malaria. Therefore an antibody raised against
the DBLαtype3 domains was considered potentially more useful.
Hens rather than rabbits were chosen for immunisation due to the better pre-immune
sera data for hens, specifically for hens PO41 and PO42. Hen egg yolks also give an
increased yield of antibody compared to rabbit sera. Avian antibodies are also less
likely to cross react with mammalian erythrocyte proteins than rabbit antibodies.
After consultation with Eurogentec, 2 highly conserved type 3-specific peptides were
chosen for immunisation. Structural modelling on EBA175 (Tolia et al. 2005) and P.
knowelsi DBLα (Singh et al. 2006) allowed one helical and one disordered peptide
to be chosen. This was to give a high chance of eliciting specific antibodies to
recognise type 3 PfEMP1 in immunoflouresence (native state) and in Western blot
(denatured state). ELISA confirmed a specific recognition of both peptides with
affinity-purified antisera, though the level of recognition was not very high compared
to non-specific binding to BSA/PBS in the immune serum prior to affinity
purification. Affinity-purification against both peptides together gave a similar
326
affinity profile to antisera purified against peptide 2 only. This suggests peptide 2
elicited a more efficient immune response in the hens. The majority of antibodies in
the resulting affinity-purified antisera thus probably recognise peptide 2.
The affinity-purified anti-peptide antisera recognised a protein of approximately 150
kDa on a Western blot in protein extracts from ring and pigmented trophozoite
stages, indicating that type 3 PfEMP1 (153 kDa) may be recognised by the antibody
at both ring and pigmented trophozoite stage. In general, PfEMP1 are expressed at
ring stage and are packaged in single small vesicles and exported to Maurer’s clefts
under the erythrocyte plasma membrane (Haeggstrom et al. 2004; Knuepfer et al.
2005; Frankland et al. 2006). If type 3 PfEMP1 acted as “normal” they woud be
expected to appear at the erythrocyte surface, usually in knobs approximately 16
hours post-invasion (Horrocks et al. 2005). The mechanism of export of PfEMP1 is
controversial, but appears to involve an N-terminal hydrophobic stretch and a
PEXEL, motif or vacuolar transport signal (VTS), located within the first DBL
domain (Hiller et al. 2004; Marti et al. 2004; Knuepfer et al. 2005). The
PEXEL/VTS are present in the type 3 PfEMP1. This suggests trafficking of type 3
PfEMP1 is, at least in part, through a similar mechanism to other PfEMP1.
There is evidence that at least some type 3 PfEMP1 reaches the surface, as it can be
labelled with sulfo-N-hydroxysuccinimide (NHS)-LC-biotin (Sharling et al. 2007).
Sulfo-NHS-LC-biotin is an ester vitamin that reacts with and labels lysines and the
N-termini of proteins via primary amino groups. Uptake of biotin through the novel
permeation pathway (Baumeister et al. 2003) was prevented using furosemide (Kirk
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et al. 1994; Sharling et al. 2007), thus the biotin labelling was specific to surface-
exposed proteins. Surface proteins were separated by SDS-PAGE and a band of
approximately 150 kDa was detected with HRP-conjugated streptavidin. Detection
using a generic antibody to PfEMP1 ATS region suggested this protein was probably
type 3 PfEMP1, suggesting the type 3 PfEMP1 was on the erythrocyte surface.
Surface-exposed PfEMP1 is sensitive to cleavage by trypsin at concentration 0.1
mg/ml (Leech et al. 1984; Sharling et al. 2004), and trypsinisation results in loss of
PfEMP1-mediated adhesion in trypsin-sensitive PfEMP1 (Nielsen et al. 2007). This
study suggested that 150 kDa band recognised by the type 3 antibody is resistant to
trypsin at 0.1-1 mg/ml. Higher molecular weight proteins (> 270 kDa) in the triton
insoluble fraction which cross reacted with the antibody and are probably non-type 3
PfEMP1, decreased in intensity in the trypsin-treated lanes. This suggests the
trypsinisation was successful. In addition, type 3 PfEMP1 trypsin-insensitivity was
also observed in a study of PfEMP1 biotinylation (Sharling et al. 2007). This
indicates the type 3 PfEMP1 is resistant to trypsin cleavage, or is not exported to the
erythrocyte surface.
If the type 3 PfEMP1 is surface-exposed, an alternative reason for trypsin
insensitivity could be simply its length. The epsilon domain and second half of the
alpha domain of type 3 PfEMP1 may be hidden. EBA175, a dimer of two DBL
domains, has a predicted length of 8.6 nm, extrapolating from a Stoke’s radius of 4.3
nm (Tolia et al. 2005). Thus, the extracellular portion of a type 3 PfEMP1, also
having just two DBL domains, may be expected to have a similar length. The
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glycocalyx, a network of polysaccharides on cellular components of the blood, has a
mean thickness on erythroctyes of 5.9 nm (Linss et al. 1991). Speculatively, this fits
well with the approximately 3/4 of the type 3 PFEMP1 being conserved, possibly
leaving the N-terminal portion of the DBLα domain open to immune pressure and
the resulting diversifying selection.
Unfortunately, these results were all questionable due to the antibody recognising a
band of the same size in HB3, a strain without a type 3 var gene. Whether the
antibody cross react with something in HB3, but also recognises the type 3 PfEMP1
in 3D7 is not clear. If the type 3 PfEMP1 is recognised, as suggested by recognition
of the peptides through ELISA, then the intensity of the Western blot band should
decrease if the type 3 PfEMP1 is sensitive to trypsin, even if the antibody also cross-
reacts with another protein of a similar size. Affinity purifying the antibody against
the type 3 PfEMP1 protein directly might be helpful.
The function of the type 3 PfEMP1 remains unclear. Their conserved sequence
suggests an important function, although their absence in certain strains such as HB3
suggests they are not essential. As they appear to remain internal, a role in
sequestration is unlikely. A role in invasion is possible, as invasion proteins would
be expected only to be surface exposed at merozoite stage, such MSP-1 or AMA-1
(O'Donnell et al. 2000; Triglia et al. 2000). If affinity purification of the antibody
against the type 3 PfEMP1 directly was successful, then future experiments could
help elucidate the function of the type 3 PfEMP1. Using the antibody in a type 3
PfEMP1-expressing culture may reveal a function in processes such as invasion,
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merozoite release or schizont rupture, or in binding phenotypes such as rosetting or
platelet-mediated clumping. Binding-affinity in type 3 PfEMP1-expressing strains
could also be tested through expression of DBLαtype3 domains, or entire type 3
PfEMP1 in in vitro expression systems. Expression could be verified using the
antibody, and type 3 PfEMP1-specific adhesion could be confirmed using additional
antibody to reverse binding. The antibody may also help to address type 3 binding
specificity by inhibiting adhesion of type 3-expressing parasites to ligand-coated
plates.
In conclusion, the experiments outlined in this chapter revealed that type 3 var genes
are commonly transcribed in laboratory strains and field isolates, and are highly
conserved, largely falling into 6 highly conserved groups on the basis of sequence
polymorphism in the first half of the alpha domain. Surprisingly, transcription was
associated with hyperparasitaemia rather than cerebral malaria, as was the case for
other non-type 3 DBLα1 domains in chapter 3, suggesting an altered regulation of
this subpopulation of group A var genes. Unfortunately, attempts to raise an antibody
to investigate type 3 PfEMP1 expression timing and protein location were
unsuccessful due to cross-reactivity of the antibody produced. The type 3 var
genes/PfEMP1 remain an intriguing and highly conserved family, and further
investigation of these var genes/PfEMP1, for example with regard to function, would
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Gene sequence associations with severe malaria disease manifestation, such as the
link between group A var gene transcription cerebral childhood malaria (discussed in
chapter 3) and var2csa transcription placental malaria in pregnant women (discussed
in chapter 4), provide information on the pathogenesis of the disease and offer data
for informed drug and vaccine design to improve medical treatment available to
infected individuals. Vaccines usually target conserved parasite antigens to elicit a
protective immune response and drugs can be designed to disrupt processes
associated with severe disease. The spontaneous binding of infected erythrocytes to
uninfected erythrocytes to form rosettes is a property of some strains of P .
falciparum that is linked to severe complications of malaria. Rosette disrupting drugs
such as heparin and fucoidan have high anticoagulant activity, preventing their use as
treatment, Curdlan sulfate (CRDS) is a sulfated glycoconjugate compound that is
chemically similar to heparin but with much lower anticoagulant activity. CRDS has
previously been shown to have antimalarial activity in vitro and is safe for clinical
use. Previous work in the Rowe laboratory revealed that CRDS significantly
inhibited rosetting in seven P. falciparum laboratory strains. In this chapter the
ability of CRDS to inhibit rosetting in a group of 18 African clinical isolates was
examined. CRDS disrupted rosettes in vitro in all 18 P. falciparum African field
isolates examined. The kinetics of CRDS anti-rosetting action in laboratory strain
Palo Alto was also examined, revealing fast action on rosettes (< 2 min) and
reversibility of rosette disruption. The strong ability to inhibit rosetting suggests that
CRDS has the potential to reduce the severe complications and mortality rates from
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P. falciparum malaria among African children, supporting further clinical trials of
CRDS.
6.2 Introduction
Despite decades of research, malaria still claims an estimated million lives per year
in sub-Saharan Africa, and severe complications such as cerebral malaria remain
relatively common (WHO 2000). Eradication of Plasmodium remains a long-term
goal. Meanwhile, it is crucial to target factors that contribute to severe disease and
reduce clinical complications of malaria. Rosetting, which is estimated to be a factor
in 25-50% of severe malaria cases in sub-Saharan Africa (Rowe 2005), is one
obvious target for therapy to reduce incidents of severe disease.
6.2.1 Molecular basis of rosetting
Rosetting is the spontaneous binding of non-infected erythrocytes by erythrocytes
infected with mature asexual blood stage Plasmodium parasites (reviewed in Rowe
2005). The molecular basis of rosetting centres on PfEMP1, the high-molecular
weight transmembrane protein, encoded by the plasmodium var multigene family,
discussed in chapters 3-5. Rosetting is a strain-specific property (Wahlgren et al.
1990) and it is the N-terminal DBLα domain of a subset of PfEMP1 that mediates
the rosetting interaction (Rowe et al. 1997; Chen et al. 2004). There is little sequence
similarity between rosetting DBLα domains, though sequence analysis suggests the
majority are DBLα1 domains, and that rosetting PfEMP1 are frequently Group A var
genes (J.A.Rowe unpublished data;(Bull et al. 2005a; Kyriacou et al. 2006; Normark
et al. 2007)and as discussed in chapter 3).
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Rosetting is a heterogeneous phenomenon, and a variety of molecules on the
erythrocyte surface may participate in rosette formation, including heparan sulfate
(HS)- like glycosaminoglycans (GAG) (Chen et al. 1998a; Barragan et al. 1999;
Vogt et al. 2003), complement receptor 1 (Rowe et al. 1997), and the trisaccharide
glycan of blood group A antigen (Barragan et al. 2000). CD36, a scavenger receptor
on many host cells including erythrocytes (van Schravendijk et al. 1992), has also
been shown to occasionally support rosetting, acting as the receptor for Malayan
Camp strain rosettes (Handunnetti et al. 1992). Low molecular weight “rosettins”
may also be involved, though there is little data on these (Helmby et al. 1993).
6.2.2 Rosette frequency (RF) is linked to severe disease in African field
isolates
In African P. falciparum malaria field isolates, there is a compelling link between
rosette frequency (RF) and severe disease (Carlson et al. 1990; Rowe et al. 1995),
and higher rosetting was observed in the cerebral malaria compared to
hyperparasitaemia or uncomplicated Malian field isolates discussed in chapter 3.
Rosette-like aggregates have been observed in congested cerebral vessels (Riganti et
al. 1990), but are infrequently reported in cerebral malaria postmortem. Rosettes are
not observed in arterioles (high wall sheer stress), but rapidly reform in the venules
(low wall sheer stress), demonstrating rapid reformation after disruption in an
artificially perfused rat microvasculature model of P. falciparum–infected
erythrocyte sequestration (Kaul et al. 1991).
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However, an association between rosetting and severe malaria disease is not the case
in Asia, where complement receptor 1 (CR1) deficiency is common. CR1 deficient
erythrocytes show reduced RF with 5/5 laboratory isolates (Rowe et al. 1997),
including Malayan Camp which rosettes through CD36- perhaps pointing to a
synergistic interaction between CD36 and CR1.
All other members of human-infective plasmodium family also rosette, for example
almost all P. vivax isolates show some degree of rosetting (Udomsanpetch et al.
1995; Angus et al. 1996; Chotivanich et al. 1998; Lowe et al. 1998). However, it is
only in P. falciparum that rosetting is linked to severe disease, probably because of
the additional cytoadhesion property which may act in concert with rosetting to cause
vessel obstruction (Rowe 2005) as demonstrated in a rat model (Kaul et al. 1991).
Human erythrocyte polymorphisms such as CR1 deficiency in Asia (Cockburn et al.
2004; Thomas et al. 2005) and blood group O (Rowe et al. 2007) in malaria-endemic
areas have been postulated to be selected for because of their protective effect in
malaria due to reduced rosetting, and a resulting inverse association with severe
malaria. It has not so far been possible to prove a causative link between rosetting
and severe malaria, but the evidence is compelling.
6.2.3 Rosette disruption by heparin and heparan sulfate (HS)
Heparan sulfate (HS) and heparin are members of the sulfated glycosaminoglycan
(GAG) family. HS and heparin are both composed of alternating glycosamine and
uronic acids, linked 13 or 1  4  (Fig. 6.1). The glucosamine can be N-sulfated or
N-acetylated and can contain O-sulfate ester on the second carbon. The uronic acids
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can be glucuronic acid or iduronic acid and may also be O-sulfated. Binding
properties of distinct GAGs are associated with the sulfate and carboxyl groups.  As
sulfation states of heparin and HS vary, the two can be very similar, but in general
heparin is a highly sulfated form of HS, with a more uniform sulfation across the
molecule and more extensive modification. HS is found on almost all cells including
endothelial cells, whereas heparin is only present in granules of connective tissue,
mast cells and basophils. HS was reported to be present on erythrocytes in 2004
(Vogt et al. 2004), confirming HS as a potential rosetting receptor.
Fig. 6.1 Glycosaminoglycan (GAG) structures: Rosette disrupting GAGs;
heparin/heparan sulfate (HS), and the main component of fucoidan, sulfated fucose.
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Non-rosette disrupting GAGs; hyauluronic acid (HA) and chondroitin sulfate A
(CSA).
Previous work has shown that rosettes can be disrupted by glycosaminoglycans or
sulfated glycoconjugate compounds such as heparin and fucoidan in a strain
dependent manner (Carlson et al. 1992; Rowe et al. 1994; Barragan et al. 1999).
Heparin and HS consistently disrupt rosettes in approximately 50% of rosetting field
isolates (Carlson et al. 1992; Rowe et al. 1994; Chen et al. 1998a; Barragan et al.
1999). Fucoidan has a more wide ranging action than heparin (9/10 isolates sensitive
to fucoidan, compared to 5/10 sensitive to heparin in Rowe et al.  1994). Some
isolates are more resistant to rosette disruption, e.g. PAR+ is more sensitive to
heparin and fucoidan than TM284+ (Carlson et al. 1992; Rowe et al. 1994).
Heparin was a promising candidate for adjuvant therapy for severe disease, and
clinical trials with heparin have shown some success (Munir et al. 1980; Rampengan
1991). However, a high level of heparin-induced intracranial bleeding has led to this
treatment being discouraged and the anti-coagulant effects of these drugs prevent
their use as treatment for severe malaria (WHO 2000).
6.2.4 Reducing anticoagulant activity of rosette disrupting compounds
The anticoagulant properties of GAGs are an intrinsic chemical property of each
individual GAG, based on the chemical structure, size and modifications. The
different members of the family show a range of anticoagulant activity, so it is
possible to design molecules with reduced anticoagulant activity, whilst retaining
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rosette disruption ability. A number of ways have been attempted to reduce the
anticoagulant activity of heparin-based derivatives (Fig. 6.2).
Fractionation
Heparin   Disruption to depolymerised GAGs
Modification by N-sulfation
Fig. 6.2. Strategies for reducing anticoagulant activity of rosette disrupting heparin
derivatives.
Firstly, fractionation can be used to separate heparin according to molecular weight
or affinity for antithrombin III, resulting in heparin-derived fractions with varying
rosette disruption ability and anticoagulant properties (Carlson and Wahlgren 1992).
The rosette inhibition activity was not associated with anti-coagulant properties,
suggesting it should be possible to find a fraction with the optimum combination of
high anti-rosette activity but low anticoagulant nature.
Secondly, depolymerisation of heparin results in reduction to composite ‘building
blocks’ of novel depolymerised glycosaminoglycans (dGAGs). These lack anti-
coagulant activity but still disrupt rosettes and inhibit merozoite invasion (Vogt et al.
2006). Rosette disruption with small disaccharides as well as with monomer and long
polymers had previously been reported (Barragan et al. 1999). There was evidence of
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reduced sequestration in macaques and rats, but so far without convincing
extrapolation to humans (Vogt et al. 2006).
Thirdly, modifications of heparin/HS based compounds can drastically alter their
chemical properties. The N-sulfate groups on heparin/HS are important for rosette
disruption activity and the extent of N-sulfation further increases rosette disruption
activity (Barragan et al. 1999). This is supported by chemical data showing the
sulfation state of polysaccharides is responsible for anti-coagulant activity
(Chaidedgumjorn et al. 2002). All sulfated carbohydrate-based heparin derivatives
have some degree of anti coagulant and antithrombin activity, but this differs
between compounds, and is due to specific interactions rather than to the general
anionic character (Alban and Franz 2000).  1  3 linked polysaccharides exhibit
75% reduction in plasma mediated antithrombin activity compared to heparin
activity, and the 6-sulfate group largely determines the level of anticoagulant activity
(Chaidedgumjorn et al. 2002).
6.2.5 Curdlan sulfate has low anticoagulant properties
Curdlan sulfate (CRDS, Fig. 6.3) is a sulfated 1->3 β-D glucan; MW: 402.329.
CRDS was predicted to have rosette disruption properties (Havlik et al. 2005) due to
its polyanionic nature and chemical similarities to other sulfated polysaccharides
(Xiao et al. 1996), see structure in Fig. 6.1.  CRDS has a much more favourable
toxicity profile than heparin as it has 10-fold lower anticoagulant activity, measured
as activated partial thromboplastin time (APTT) compared to heparin (Kaneko et al.
1990).
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Fig. 6.3. Structure of curdlan sulfate (CRDS), a sulfated glycosaminoglycan with
rosette disrupting potential.
The exact mechanism of CRDS anticoagulant activity is unclear. Unlike heparin,
CRDS does not accelerate thrombin inactivation by anti-thrombin but there is
evidence it may bind to fibrinogen, causing steric hindrance preventing interaction
between thrombin and fibrinogen and preventing fibrin deposition (Alban and Franz
2000).
6.2.6 Curdlan sulfate is safe to use
CRDS is safe to use, and completed phase 1 clinical trials in HIV therapy over 10
years ago (Gordon et al. 1994; Gordon et al. 1997). In HIV, CRDS appears to block
HIV adsorption on target CD4+ T cells (Kaneko et al. 1990; Aoki et al. 1992), via
binding to the V3 loop of gp120 (Jagodzinski et al. 1994), therefore preventing virus
invasion. A similar adsorption mechanism exists in merozoite invasion of P.
falciparum, and CRDS almost completely blocks merozoite invasion (Havlik et al.
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1994). CRDS may act as an analogue of the glycophorin sialic acid which is required
for merozoite invasion (Orlandi et al. 1992; Evans et al. 1998). A similar mechanism
may cause heparin-induced invasion disruption (Kulane et al. 1992). CRDS may also
inhibit sporozoite invasion of hepatocytes, as reported for other sulfated glycans
(Pancake et al. 1992). CRDS does not affect trophozoite maturation but does delay
schizont rupture (Evans et al. 1998).
6.2.7 Curdlan sulfate and malaria
A clinical trial of the effect of CRDS in severe/cerebral P. falciparum malaria by
Havlik et al. (2005) suggested that CRDS may be able to reduce disease severity, as
fever clearance time was reduced as was coma resolution time, though the trial was
not conclusive, probably due to the small number of patients in the trial (Havlik et al.
2005).
As CRDS inhibits merozoite invasion but does not affect trophozoite development
(Havlik et al. 1994; Evans et al. 1998), it is likely that the CRDS modifies
erythrocyte surface proteins. A role in rosette disruption has also been postulated,
due to its polyanionic character (Havlik et al. 2005). Because of the chemical
similarities between CRDS and heparin, and the 10 fold lower anticoagulant effects
of CRDS (Kaneko et al. 1990), it was hypothesised that CRDS might be effective
against P. falciparum rosetting and could form the basis of an adjunctive treatment
for severe malaria (Havlik et al. 2005).
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CRDS is also active against Babesia, a tick-borne parasite which is an economically
important infection of cattle in the tropics and sub tropics. The mechanism is unclear
but Babesia has a similar mechanism of infection as P. falciparum  (Igarashi et al.
1998).
CRDS thus has the chemical properties that suggest it may disrupt rosettes and is
safe for clinical use (Kaneko et al. 1990; Jagodzinski et al. 1994; Havlik et al. 2005).
This study tested the ability of CRDS to inhibit rosetting in P. falciparum field
isolates, and shows universal rosette inhibition at therapeutic doses of CRDS. CRDS
disrupted rosettes in 18/18 P. falciparum field isolates tested in addition to 7/7
laboratory isolates previously examined in the laboratory. The combined data present
CRDS as a strong candidate for adjunct therapy in severe malaria from rosetting P.
falciparum.
6.3 Aim of chapter
The aim of the chapter was to assess the ability of curdlan sulfate (CRDS) to disrupt
rosettes in field isolates of P. falciparum, to complement in vitro work on laboratory
isolates carried out in the Rowe laboratory. The ultimate aim of this work was to
examine CRDS as a potential therapeutic agent against severe malaria among
African children caused by rosetting strains of P. falciparum.
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6.4 Materials and methods
Materials and methods that are specific to chapter 6 are listed below. General
materials and methods and a list of suppliers are given in chapter 2.
6.4.1 Parasites
Wild isolates were collected from Kilifi District Hospital, Kenya. Fresh isolates were
cultured by standard methods (chapter 2) for at least 18 hours in vitro to the mature
pigmented trophozoite stage. Frozen rings and trophozoites had been cryopreserved
in glycerolyte and stored in liquid nitrogen, before thawing for either immediate use
(frozen trophs), or culturing to the mature pigmented trophozoite stage (frozen
rings). Cryopreservation of mature trophozoites does not affect the surface antigens
of the trophozoite-infected erythrocytes (Kinyanjui et al. 2004). Thus the rosetting
frequency of a single isolate does not change significantly pre-freezing and post-
thawing (Kyriacou et al. 2007). Two sets of field isolates were used; those collected
Jan-March 2006, and those which had been previously collected and cryopreserved
(J.A. Rowe) in 1993. Summary of field isolates used: Collected Jan-March 2006:
6566Fztr, RF48; 6394Fztr, RF15; 6399Fztr, RF12; 6547Fztr, RF5; 6542Fztr, RF52;
6794Fzrng, RF33; 6921Fsh, RF27.5; 6962Fsh, RF24.5; 6908Fsh, RF27 and collected
in 1993: KR1Fzr, RF53.5; KR7Fzr, RF68; KR9Fzr, RF14; KR10Fzr, RF25;
KR11Fzr, 27; KR14Fzr, RF37.5, KR17Fzt, RF61; KR18Fzt, 28; KR20Fzr, RF6
(Fsh, fresh trophs; Fztr, frozen trophs, Fzrng, frozen rings. RF, pretreatment rosette
frequency).
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Rosetting laboratory strains used were TM284+, TM180, Muz12R+, HB3, R29, A4R
and PAR+. Laboratory strains were cultured by standard methods and rosetting was
regularly selected by percoll treatment (see chapter 2).
6.4.2 Assessment of Rosette Frequency
All rosette assays were performed on mature pigmented trophozoites, determined
using a Giemsa smear (details in chapter 2). Rosette frequency (RF) varies from
cycle to cycle, but is stable within a given cycle (Rowe et al. 1994). Parasites were
resuspended at 1-2% haematocrit in complete binding medium (Bicarbonate-free
RPMI, supplemented as RPMI), as this has a more stable pH when ungased. The
culture suspension was pre-stained with ethidium bromide (EtBR), or acridine
orange (AO), to identify infected erythrocytes. These staining methods did not alter
rosette frequency (PAR+: EtBr staining: mean RF 69.0%, SE 1.1%; AO staining:
mean RF 68.8%, SE 0.8%).
6.4.3 Curdlan sulfate drug rosetting inhibition assay
Curdlan suphate (CRDS) was dissolved in sterile phosphate buffered saline (PBS)
and added to 18 µl pigmented trophozoites (RF > 50%) culture suspension to give
final concentrations 0, 10, 50 and 100 µg/ml. Final concentrations of 100 µg/ml
fucoidan and 100 µg/ml hyaluronic acid (both from Sigma, UK) were used as
positive and negative controls for rosette inhibition (Rowe et al. 1994).
All aliquots of P. falciparum were incubated for 30 min. Field isolates were rotated
for 30 min at room temperate. Laboratory isolates were incubated at 37 °C, and cells
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were resuspended every 15 min by flicking the tubes. These methods do not alter the
rosette frequency (PAR+: Incubation with EtBr 30 min rotation, RT, RF 69.0% SE
1.1; incubation with EtBr 30 min not rotating, but “flicking” at 0, 15 and 30 min, RF
68.5%, SE 0.65). Wet preparation slides of the parasites were prepared and viewed
under fluorescence. Two hundred infected erythrocytes were counted, and scored for
number of rosettes; at least two uninfected red blood cells bound constitutes a
rosette. Rosette frequency was then expressed as a percentage of total infected
erythrocytes. All slides were counted blind.  For laboratory strains, data were
collected at least three times for every culture and condition used. For field isolates,
isolates were only counted once for each condition.
6.4.4 Kinetics of curdlan sulfate rosette disruption
CRDS was dissolved in sterile phosphate buffered saline (PBS) and added to 180 µl
culture suspension of PAR+ or TM284+ pigmented trophozoites to give final
concentration of 50 µg/ml or 0 µg/ml (PBS control). Cultures were incubated at
37°C, and RF recorded after 0, 2, 5, 30, 60 and 120 min. The assay was repeated 5
times.
6.4.5 Rosette reformation after curdlan sulfate rosette disruption
Two 36 µl aliquots of culture suspension of PAR+ pigmented trophozoites were
incubated at 37°C with a final concentration of 50 µg/ml CRDS, 100 µg/ml fucoidan,
100 µg/ml hyaluronic acid or with 2 µl PBS. After 30 min one culture for each
condition was washed 4 times with 750 µl incomplete binding media, to wash away
the CRDS, fucoidan, hyauluronic acid or PBS, and the culture was resuspended in
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complete binding media and incubated at 37 °C. RF was recorded after 0, 2, and 120
min (after washing) and 120 min (without washing). The assay was repeated 4 times.
6.4.6 Statistics
Relative rosette frequency was calculated as a proportion of post-treatment rosette
frequency, and given as mean ± SD or SE as appropriate. Paired t-tests were used to
compare RF in different treatment groups of time points as the data were normally
distributed. Combined data for field isolate RF after treatment was also analysed
using ANOVA.
6.5 Previous work: CRDS-mediated inhibition of rosetting in laboratory
strains
The following laboratory work (section 6.5 only) was carried out by Ahmed Raza
and Katie E Steen (Edinburgh), but data analysis, statistics and production of the
figures was carried out personally.
The effect of CRDS was tested in eight different laboratory parasite strains. Cultures
were pigmented trophozoites (RF > 50%). Three doses of CRDS were used (10, 50,
100 µg/ml), alongside a PBS control (i.e. 0 µg/ml CRDS). Positive and negative
controls for rosette inhibition, fucoidan and hyaluronic acid, were also included.
Rosette frequency was significantly reduced (t-test, P<0.05) by CRDS at the highest
dose (100 µg/ml) in all parasites (7/7). At 50 µg/ml CRDS, rosetting was
significantly reduced in all parasites apart from TM284+ (6/7). At 10 µg/ml CRDS,
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rosette frequency was reduced (t-test, P<0.05) in 3/8 parasites. Data for each
laboratory isolate is given in Fig. 6.4, and a summary table is shown in Fig. 6.5.
The mean RF for all parasites combined at each treatment were 62.3% for PBS
(Standard Error (SE) 2.8), 21.9% for 10 µg/ml CRDS (SE:6.6), 14.6% for 50 µg/ml
CRDS (SE:4.6) and 8.7% for 100 µg/ml CRDS (SE:2.7). As expected hyaluronic
acid provided a reliable negative control for rosette inhibition (mean RF 65.2%, SE
2.8) and fucoidan a reliable positive control (mean RF 5.4%, SE 1.0).
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Fig. 6.4. Individual data for inhibition of rosette frequency in 7 laboratory strains of
P. falciparum by 0, 10, 50 and 100 µg/ml CRDS in PBS. Each assay was counted
blind and performed in triplicate. Post-treatment RF, calculated as proportion of pre-
treatment RF, were logged to normalise the data then compared to pre-treatment RF
using paired t-tests. p values are indicated with asterisks as *P<0.05 and **P<0.005.
 *
 *
** **  **  **
** **** ** ****
**
** **







Fig. 6.5. Summary table for rosette disruption in laboratory strains of P. falciparum
by 0, 10, 50 and 100 µg/ml CRDS in PBS. Each assay was counted blind and
performed in triplicate. Post-treatment RF, calculated as proportion of pre-treatment
RF, is indicated by shading as >96%, 51-95%, 11-50% and 0-10%. Post-treatment
RFs were logged to normalise the data then compared to pre-treatment RF using
paired t-tests. p values are indicated with asterisks as *P<0.05 and **P<0.005.
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Parasites responded to CRDS in a dose dependent manner, though there was
variation in the response of the parasite strains to CRDS. Some isolates, such as
PAR+, are very sensitive to CRDS, with significant inhibition at only 10 µg/ml (Fig.
6.4, 6.5 and 6.6). This may be due to differences in the strength of the rosettes,
depending on the precise molecular interactions involved, as seen for fucoidan and
heparin fucoidan (Rowe et al. 1994).
Fig. 6.6. 10µg/ml CRDS significantly reduced rosetting in P. falciparum laboratory
strain PAR+ compared to a control culture. Live wet-preparation images taken with
40x objective lens on a bright field microscope. Infected erythrocytes can be
identified by the presence of malaria pigment, seen as black dots within the
erythrocytes. Images taken by Alex Rowe.
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6.6 Results 1: CRDS inhibition of rosetting in laboratory strains
After the initial rosette disruption experiments described above (section 6.5), I
wanted to further define the rosette-disrupting ability of CRDS.
6.6.1 CRDS inhibition of rosetting in laboratory strains: kinetics of
CRDS
The kinetics of CRDS rosette disruption was assessed in PAR+ (very CRDS
sensitive; Fig. 6.4) and TM284+ (less CRDS sensitive; Fig. 6.4) over 2 hr with 50
µg/ml CRDS.
PAR+ (mean RF 67.6%, SE:2.6%) was treated with 50 µg/ml CRDS and rosette
frequency recorded over 2 hours. Rosettes were disrupted within 2 min (relative RF
11.9%, SE:3.3%). After 2 hr no rosettes were present in the CRDS treated samples
(relative RF 0%, SE 0%). The PBS control samples showed high RF (relative RF
95.9%, SE 1.9%). Fig. 6.7A shows mean relative rosette frequencies for 5 repeats of
the 6 time points.
TM284+ (mean RF 67.6%, SE:2.6%) was also treated with 50 µg/ml CRDS and
rosette frequency recorded over 2 hours. Rosettes were also disrupted within 2 min,
but to a lesser extent that for PAR+, reflecting the reduced sensitivity of TM284+
rosettes to CRDS treatment (at 2 min: relative RF 55.4%, SE:2.9%). Rosettes were
still present in the CRDS treated samples after 2 hr (at 2 hr: mean RF 32.9%, SE
0.6%).Rosetting in the PBS control samples remained high (PBS at 2 hr: mean RF
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87.3%, SE 6.7%). Fig. 6.7B shows mean relative rosette frequencies for 5 repeats of
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Fig. 6.7. Speed of action of CRDS. PAR+ parasites were treated with 0 or 50 µg/ml
CRDS. The RF was assessed at 0, 2,5, 30, 60 and 120 min post treatment.  RF given
as proportion of pre-treatment RF, as mean ± SE for 5 repeats of the experiment.
** ** ** **
**
**
** ** ** **
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Post-treatment RFs were compared to pre-treatment RF using paired t-tests. p values
are indicated with asterisks as **P<0.005.
6.6.2 CRDS inhibition of rosetting in laboratory strains: Rosette
reformation after CRDS treatment
The ability of rosettes to reform after CRDS disruption was also investigated.
Rosette reformation assays were also carried out on PAR+ parasites. After 30 min
CRDS treatment (maximum disruption), the CRDS was thoroughly washed out with
incomplete binding medium (as binding medium, but with no added serum), and the
erythrocytes re-suspended in fresh complete binding medium. Rosette frequency
returned to 102% (SE:6.5%) original RF (Fig. 6.8). This shows similar kinetics to
fucoidan (Rowe et al. 1994), which I found to return to 100% (SE:8.2%) original RF
after washing.
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Fig. 6.8. Rosette reformation assay. PAR+ were incubated at 37°C with final
concentration of 50 µg/ml CRDS, 100 µg/ml fucoidan, 100 µg/ml hyaluronic acid or
with 2 µl PBS. After 30 min the drug treatment was washed out. RF was recorded
after 0, 2, and 120 min (after washing) and 120 min (without washing). The assay
was repeated 4 times. RF is given as proportion of pre-treatment RF as mean ± SE
for 4 repeats of the experiment.
6.7 Results 2: CRDS-mediated rosette disruption in rosetting field
isolates
To validate the use of CRDS in a clinical trial, the same four concentrations of
CRDS (0, 10, 50 and100 µg/ml), alongside fuciodan and hyaluronic acid, were used

































6.7.1 CRDS-mediated rosette disruption in rosetting field isolate
samples from Kilifi, Kenya collected Jan-March 2006
Nine rosetting isolates were cultured to mature trophozoite stage. CRDS consistently
disrupted rosetting in a concentration dependent manner in all parasites (Fig. 6.9).
Fucoidan and hyaluronic acid were used for positive and negative controls for rosette
inhibition in all isolates.
CRDS seems to be at least as effective at rosette disruption as fucoidan, reported to
be active against 9/10 isolates in a previous study (Rowe et al. 1994), and to have a
wider range of action than heparin, which was effective in only 50% isolates in that
same study and in others (Carlson et al. 1992; Rowe et al. 1994; Chen et al. 1998a;
Barragan et al. 1999).
As with laboratory isolates there is evidence for high and low responders to CRDS,
with some isolates reacting strongly to a low dose, whereas others required the
highest dose for effective rosette inhibition. This may have implications for dose
needed for therapy.
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Fig. 6.9. CRDS-mediated rosette disruption in 9 rosetting field isolates from Kilifi,
Kenya, collected Jan-March 2006. RF shown as proportion of pre-treatment RF for
comparison: Relative rosette frequency, Y-axis. Summary of field isolates used:
6566Fztr, RF48; 6394Fztr, RF15; 6399Fztr, RF12; 6547Fztr, RF5; 6542Fztr, RF52;
6794Fzrng, RF33; 6921Fsh, RF27.5; 6962Fsh, RF24.5; 6908Fsh, RF27. (Number,
Clinical Brady Number from Kilifi District Hospital; Fsh, fresh trophs; Fztr, frozen





















































































































































































































































































































Rosette frequency was expressed relative to initial (pre-treatment) rosette frequency,
so that all nine field isolates could be compared (Fig. 6.10). There was a significant
inhibition (P < 0.05) across all field isolates combined at 10 µg/ml CRDS, and this
rose in significance (P < 0.005) for 50 and 100 µg/ml CRDS conditions. Difference
in RF compared to PBS control for all concentrations was significant by ANOVA
(P<0.0001).
Fig. 6.10. Combined data for 9 field isolates of P. falciparum from Kilifi, Kenya,
collected Jan-March 2006 treated with 0, 10, 50, 100 µg/ml CRDS in PBS, 100
µg/ml fucoidan or with 100 µg/ml hyaluronic acid. Mean + SD is shown. * p < 0.05.
** p < 0.005 for paired t-tests compared to 0 µg/ml CRDS (PBS control). Relative



























































6.7.2 CRDS-mediated rosette disruption in rosetting field isolate
samples from Kilifi, Kenya 2- samples collected and cryopreserved in
1993
It was not possible to examine any more field isolate in Kenya due to the lack of
malaria during Jan-March 2006 because of a severe drought. However, in order to
increase the sample size, further field isolates from Kenya that had been frozen in
1993 (J.A. Rowe) were thawed and cultured to mature trophozoite stage as above.
Consistent with the previous Kenya field isolate samples (section 6.7.1), CRDS
consistently disrupted rosetting in a concentration dependent manner in all parasites
(Fig. 6.11), again showing evidence for high and low responders to CRDS.
As for the previous field isolate samples, rosette frequency was expressed relative to
initial (pre-treatment) rosette frequency, so that all nine field isolates could be
compared (Fig. 6.12). There was a significant inhibition (P = 0.006) across all field
isolates combined at 10 µg/ml CRDS, and this rose to (P < 0.005) significance for 50
and 100 µg/ml CRDS conditions. Difference in RF compared to PBS control for all
concentrations was significant by ANOVA (P<0.0001).
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Fig. 6.11. CRDS-mediated rosette disruption in 9 rosetting field isolates from, Kilifi
Kenya, collected 1993. RF shown as proportion of pre-treatment RF for comparison:
Relative rosette frequency, Y-axis. Summary of field isolates used: KR1Fzr, RF53.5;
KR7Fzr, RF68; KR9Fzr, RF14; KR10Fzr, RF25; KR11Fzr, 27; KR14Fzr, RF37.5,
KR17Fzt, RF61; KR18Fzt, 28; KR20Fzr, RF63  (Fztr, frozen trophs, Fzrng, frozen






















































































































































































































































































































Fig. 6.12. Combined data for 9 field isolates of P. falciparum from Kilifi, Kenya
collected in 1993 treated with 0, 10, 50, 100 µg/ml CRDS in PBS, 100 µg/ml
fucoidan or with 100 µg/ml hyaluronic acid. Mean + SD is shown. * p < 0.05. ** p <
0.005 for paired t-tests compared to 0 µg/ml CRDS (PBS control). Relative rosette
































































6.7.3 CRDS-mediated rosette disruption in rosetting field isolates:
combined data
Rosette frequency was expressed relative to initial (pre-treatment) rosette frequency,
so that all 18 field isolates could be compared (Fig. 6.13). There was a significant
inhibition (P<0.005) across all field isolates combined at each CRDS condition
compared to PBS. The effect of CRDS was also significant by ANOVA (P<0.0001).
Fig. 6.13. Combined data for all 18 field isolates of P. falciparum from Kilifi, Kenya
treated with 0, 10, 50, 100 µg/ml CRDS in PBS, 100 µg/ml fucoidan or with 100
µg/ml hyaluronic acid. Mean + SD is shown. * p < 0.05. ** p < 0.005 for paired t-
tests compared to 0 µg/ml CRDS (PBS control). Relative rosette frequency was
calculated as a proportion of each isolate’s own pre-treatment rosette frequency.
 































































6.7.4 PfEMP1 expression in rosetting field isolates
Attempts were made to analyse the var gene transcription in the Kenyan rosetting
field isolates, by separating the rosetting and non-rosetting infected erythrocytes
using percoll (Fig. 6.14, details in chapter 2).
Fig. 6.14. Pigmented trophozoite infected erythrocytes can be separated from
uninfected and ring stage parasite infected erythrocytes using a percoll gradient, as
trophozoite infected erythrocytes have a lower density, and form a discrete layer
above the 60% percoll after spinning (4000 rpm, 15 min). However, rosettes sink
beneath the percoll due to the weight of uninfected erythrocytes, causing rosetting
pigmented trophozoite infected erythrocytes to remain with the uninfected or ring
stage infected cells. Rosetting and non-rosetting pigmented trophozoite infected



















Unfortunately, the small packed cell volume of the field isolates which was available
meant that only a few microlitres of non-rosetting parasites were retrieved, and so
there was not enough for RNA extraction, cDNA preparation and RT-PCR for a
control (non-rosetting) set of var gene transcripts for comparison. Without this
control group, analysis of the var gene transcripts from the remainder of the culture
would be hard to interpret, as the contributions of the different PfEMP1 to rosetting
would not be clear. An interesting follow-up study to this would be to examine the
link between rosetting and expressed PfEMP1 in field isolates, and between
expressed PfEMP1 and efficiency of CRDS action.
6.8 Discussion
CRDS was found to disrupt rosettes in 18/18 field isolates at doses suitable for
clinical use, showing a significant effect on rosette frequency in two groups of
Kenyan field isolates. The analysis of CRDS on field isolates discussed in this
chapter complements data on laboratory clones (outlined in section 6.5), together
showing that CRDS effectively and consistently disrupts rosettes in a wide range of
strains.
At present we cannot prevent infection, or predict severe disease manifestation, so a
key area of therapy is to reduce severe disease complications. High levels of
rosetting (>30% RF) are estimated to occur in approximately 25% of severe malaria
cases in Kenya, and around 50% of severe malaria cases in Mali (Alex Rowe,
personal communication). If these figures are representative across the whole of sub-
Saharan Africa, rosetting may play a role in an estimated 500,000 P. falciparum
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malaria deaths per year in sub-Saharan Africa (Rowe 2005). Rosette inhibiting drugs
could thus have a substantial impact on malaria mortality and morbidity. The strong
ability to reduce rosetting suggests CRDS may be able to reduce the severe
complications and lower mortality of P. falciparum malaria.
Who would CRDS therapy be for? A clinical trial of CRDS in severe and cerebral
malaria reported a moderate decrease in fever and coma resolution time (Havlik et al.
2005). However, the patients studied were from Thailand, where rosetting is not
associated with disease severity, possibly due to the CR1 deficiency across Asia (al-
Yaman et al. 1995; Cockburn et al. 2004). Rosette disruption via CRDS treatment
might not be appropriate in Asia. Rosette-disruption via CRDS therapy is also not
relevant where P. vivax is the dominant infective Plasmodium. Although rosetting is
a common property of P. vivax field isolates, and heparin (and therefore potentially
also CRDS) reverses P. vivax rosettes, rosetting of P. vivax is not associated with
severe disease (Chotivanich et al. 1998). As such there may not be any therapeutic
benefit from disrupting the P. vivax rosettes.
However, in Africa, and especially in African children, there is compelling evidence
that rosetting is involved in the pathogenesis of severe disease (Carlson et al. 1990;
Rowe et al. 1995; Rowe et al. 2002c)and also reported in chapter 3). In the case of
cerebral malaria, parasitized erythrocytes adhering to the cerebral endothelium are
associated with coma which is fatal in up to 30% of cases (MacPherson et al. 1985;
White 1987; Brewster et al. 1990; Berendt et al. 1994a; Newton et al. 1998; Silamut
et al. 1999). However, if the infected cells are cleared, a full recovery is made with
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neurological impairment in only 12% of survivors (Brewster et al. 1990). A s
rosetting parasites are associated with cerebral malaria (Carlson et al. 1990; Rowe et
al. 1995; Rowe et al. 2002c), it seems logical to conclude that the rosettes participate
in the obstruction of the cerebral capillaries. Thus, disruption of rosettes may quicken
the clearance of infected erythrocytes from the cerebral vasculature. This may
reverse the coma more rapidly and reduce chance of focal lesions, or ring
haemorrhages, within the cerebral hemisphere which can lead to neurological
sequelae (Brewster et al. 1990; Newton et al. 1998). Ideally CRDS treatment could
be targeted towards isolates with a high rosette frequency, though the 24 hr culturing
required to mature peripheral ring parasites to pigmented trophozoites would be
inappropriate for field situations. Furthermore, many patients do no have 24 hr to
wait before treatment as most malaria deaths occur within 24 hr of admission (Jaffar
et al. 1997), before standard anti-malarial drugs are effective. Thus there is an urgent
need for drugs to tackle phenomena causing severe malaria disease symptoms within
this short time window. As rosetting is consistently associated with all forms of
severe disease in Africa (though not in Asia) (Carlson et al. 1990; al-Yaman et al.
1995; Rowe et al. 1995; Rowe et al. 2002b) CRDS could be given to all patients
showing severe complications in Africa.
In addition to rosetting, it is possible CRDS may have a direct effect on
sequestration. HS can also mediate sequestration, as HS is present on endothelial
cells although the possibility of HS as a ligand for sequestration for infected
erythrocytes has been controversial. Xiao et al. (1993) reported HS does not
influence cytoadherence to HMEC or C2 melanoma cells, as heparinase treatment
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did not abolish adhesion. However, the heparinase treatment used may not have
completely digested the heparin, leaving enough HS chains on the endothelium to
support IE adhesion. Vogt et al. (2003) reported adhesion of FCR3 and wild type
clinical isolates to HUVEC and HLEC cells lines via hepain/HS, through a
DBLα:HS interaction, and field isolates with affinity for HS have been reported
(Heddini et al. 2001). Sporozoite invasion of hepatocytes is via CSP adhesion to
heparan sulfate proteoglycans on the hepatocyte surface (Frevert et al. 1993). This
may also be disrupted by CRDS.
Even if CRDS does not directly inhibit sequestration, removal of rosettes is likely to
reduce vascular blockage. For example disruption of Malayan Camp rosettes
dramatically decreased microvascular obstruction and cytoadherence in a rat
mesocaecum vasculature model with P. falciparum infected sequestered erythrocytes
(Kaul et al. 1991), though the rosetting ligand in this case was CD36, a common
endothelial sequestration receptor, and not affected by CRDS (Evans et al. 1998).
However, CD36 binding is associated with sequestration in non-vital organs, and
with PfEMP1 expressed in non-severe malaria, as discussed in chapter 3.
Other ligands present on cell types such as endothelium or platelets, which may aid
sequestration by bridging IE and activated endothelium, may also be affected by
CRDS. Chondroitin sulfate A and hyaluronic acid, implicated in placental malarial
sequestration, as discussed in chapter 4, are both sulfated glycoconjugates and thus
chemically similar to heparin. Though these molecules do not inhibit rosetting (Rowe
et al. 1994), it remains possible that CRDS may disrupt their use as adhesion
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receptors for infected erythrocytes. Thus it is possible CRDS may also play a role in
reversal of adhesion in placental malaria.
Further experiments characterising the effect of CRDS on laboratory isolates
revealed that rosettes were able to reform after CRDS was removed. The short half-
life (2-3 hr;(Gordon et al. 1994) and rosette reformation after washing has
implications for administration of drug, suggesting that the drug should be
administered regularly throughout treatment. The effect on merozoite invasion was
not examined in this study, but it has previously been reported that CRDS can inhibit
merozoite invasion (Havlik et al. 1994; Evans et al. 1998), as can many sulfated
glycoconjugates (Kulane et al. 1992; Xiao et al. 1996).
At present there is no data on whether GAGs influence commitment to
gametocytogenesis, which is an important consideration for any drug administered to
infected individuals, as reducing the asexual parasitaemia can sometimes be
associated with an increase in sexual stage parasites, and thus an overall increase in
transmission, such as has been observed with chloroquine (Buckling et al. 1999).
It is important to emphasise that CRDS has already been shown to be well tolerated
in clinical trials and was able to reduce fever clearance time in a recent clinical trial
of P. falciparum malaria (Havlik et al. 2005). CRDS is able to inhibit P. falciparum
growth in vitro, through inhibiting merozoite invasion (Havlik et al. 1994; Evans et
al. 1998). In addition CRDS has also been shown to down-modulate cytokine effects
in HIV infection (Naito et al. 2001). This is promising for auxiliary therapy for
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severe malaria treatment, as some of the clinical symptoms may be due to the
immune response to infection (Grau et al. 1989; Kwiatkowski et al. 1990), making
CRDS an even more potent agent against severe disease symptoms of clinical
malaria. This data, together with previous reports, suggests that CRDS is a strong
candidate for adjunctive therapy in severe malaria, and support further clinical trials






The general aim of the thesis was to investigate the hypothesis that PfEMP1
expression influences clinical malaria disease due to P. falciparum infection. The
work presented in the thesis focussed on conserved PfEMP1 subgroups and clinical
disease presentation in African field isolates, and development of a drug that could
use this information to prevent onset of severe symptoms due to P. falciparum
infection. In the case of childhood malaria, I have shown that there was a
significantly higher frequency of group A var gene transcripts in cerebral malaria
field isolates compared to isolates from children with equally high parasite burdens
but no symptoms or signs of severe malaria (hyperparasitaemia), suggesting that
group A var genes are important determinants of parasite virulence (chapter 3). In
work on placental malaria, I detected var2csa transcripts in all 6 placental malaria
field isolates examined, but not in a control group of 10 childhood malaria isolates,
suggesting that var2csa expression is a critical factor in the onset of clinical malaria
disease in pregnant women (chapter 4), consistent with other recent studies (Tuikue
Ndam et al. 2005; Duffy et al. 2006a). I also found that type 3 var genes, an
atypically small and conserved subset of group A var genes, were commonly
transcribed in blood-stage parasites, showing a possible association with
hyperparasitaemia rather than cerebral malaria field isolates, and sequence analysis
confirmed a very high level of conservation across this var gene subfamily (chapter
5). In addition, I found a non-toxic compound, curdlan sulfate, to be effective at
disrupting rosettes in all rosetting field isolates examined (chapter 6), suggesting
potential for use in treatment of severe malaria due to rosetting P. falciparum
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isolates. This final chapter aims to link together these findings and discuss the role of
conserved PfEMP1 and clinical malaria disease.
The link between group A var gene expression and severe malaria (chapter 3) is
consistent with data from previous field isolate studies (Kirchgatter and Portillo Hdel
2002; Rottmann et al. 2006) and with upregulation of group A var gene transcription
in 3D7 after selection for severe malaria-type VSA (Jensen et al. 2004). Severe
malaria has also been linked to “common” var genes through sera agglutination
studies (Bull et al. 1999), and the resistance to severe malaria which develops
throughout childhood suggests common epitopes are present in severe malaria-
causing parasites, allowing protective cross-reactive antibodies to develop. Group A
var genes tend to have more cross-reacting epitopes than group B or C (Joergensen et
al. 2006), and transcripts that were present in multiple isolates in the chapter 3
analysis were more frequently DBLα1 than DBLα0. Thus the association between
group A PfEMP1 and severe malaria is consistent with a link between “common”
PfEMP1 and severe malaria.
Multiple adhesive phenotypes can be associated with severe malaria (Heddini et al.
2001).  Group A PfEMP1 tend to have more domains than group B and C PfEMP1
(Gardner et al. 2002; Kraemer et al. 2007), and thus have an increased binding
potential, for example for ligands such as ICAM-1 (Smith et al. 2000a; Springer et
al. 2004) or IgM (Semblat et al. 2006). Furthermore, binding to molecules on
uninfected erythrocytes, such as CR1 (Rowe et al. 1997; Rowe et al. 2000), ABO
blood group antigens (Carlson and Wahlgren 1992; Chen et al. 1998a; Barragan et
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al. 2000) or heparan sulfate (Carlson et al. 1992), causes rosetting, which is a
phenomenon associated with severe malaria in African field isolates (Carlson et al.
1990; Rowe et al. 1995; Rowe et al. 2002c). Rosetting is more commonly a property
of group A var genes (Rowe, JA, unpublished data), and many field studies observe
a correlation of higher rosette frequency with group A/DBLα1 domain expression
(chapter 3;(Bull et al. 2005a; Kaestli et al. 2006; Rottmann et al. 2006; Normark et
al. 2007). This provides another consistent link between group A PfEMP1 and severe
disease.
Rosetting interactions may cause rosetting PfEMP1 to have conserved structural or
sequence features which may provide common epitopes for recognition by cross-
reactive antibodies. Natural rosetting-disrupting antibodies can form upon infection,
and have been associated with protection from cerebral malaria (Carlson et al. 1990).
Antibodies raised against the rosetting DBLα domains of FCR3S1.2 (the rosetting
PfEMP1 of FCR3) disrupt FCR3 rosettes (Chen et al. 2004) and also show cross-
reactive rosette disruption against R29 rosettes (Moll et al. 2007). These antibodies
also showed recognition of a panel of Ugandan field isolates, with increased
recognition of those causing severe disease (Normark et al. 2007) suggesting
common antibody epitopes are present across diverse rosetting PfEMP1. The
interaction of many diverse rosetting PfEMP1 with host rosetting ligands can also be
inhibited by drugs such as heparin (Carlson et al. 1992; Rowe et al. 1994) and
curdlan sulfate (chapter 6), also suggesting common features are present between
many rosetting interactions.
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Conversely, group B and C PfEMP1 are commonly expressed in non-severe malaria
(this study chapter 3, (Kaestli et al. 2006; Rottmann et al. 2006). Group B and C
PfEMP1 commonly bind to CD36, which is associated with non-severe malaria, and
with immunosuppression (Urban et al. 1999) and sequestration in non-vital organs
(Serghides et al. 2003). Group B and C PfEMP1 are commonly expressed in
individuals who have reached a high level of immunity to clinical disease
(asymptomatic adults e.g. Kaestli et al. 2006, or hyperparasitaemia; this study)
suggesting cross-reactive protective antibodies are rare.  Parasites from clinically
immune individuals, or patients with mild or asymptomatic malaria infection, are
less likely to be agglutinated by heterologous sera (Bull et al. 2000), also indicating a
lower level of epitope cross-reactivity. Cross-reactive epitopes between group B and
C PfEMP1 of 3D7 are uncommon (Joergensen et al. 2006), and few DBLα0 were
found in multiple isolates in the Mali childhood malaria isolates discussed in this
thesis (chapter 3). Thus DBLα0 domains or group B and C PfEMP1, though present
in the majority of PfEMP1, are not promising vaccine candidates, as they are
associated with non-severe malaria and do not share a high number of cross-reactive
epitopes.
If a vaccine were to be raised to PfEMP1, then this data suggests group A PfEMP1
should be targeted. Immunisation of Aotus monkeys with the CIDR domain of
Malayan Camp caused protection against subsequent infection with the same strain,
showing PfEMP1 domains can be immunogenic and elicit a protective antibody
response (Baruch et al. 2002). As all known group A PfEMP1 have a DBLα1
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domain, cross-reactive epitopes within DBLα1 domains might be a promising focus
for vaccine design. DBLα0 domain immunisation in Sprague Dawley rats also
elicited a protective immune response against rosetting and sequestration, with some
degree of cross-reactivity to other strains, providing evidence that DBLα domain
immunisation can be effective (Chen et al. 2004; Moll et al. 2007; Normark et al.
2007). Normark et al. (2007) also suggested certain motifs are common between
PfEMP1 associated with rosetting and severe malaria isolates, and using structural
modelling predicted that some of these motifs lie within a pocket of the DBLα1
domain that is homologous to the fold used by Pk-DBLα for DARC-recognition.
This fold is also conserved in EBA-175 and may be a conserved area for receptor
binding that could provide a cross-reactive structural antibody target. However, there
was little overall cross-reactivity of antibodies raised against various domains of 3D7
(Joergensen et al. 2006) and the question remains whether PfEMP1 is too
polymorphic to be an effective vaccine candidate.
The type 3 PfEMP1 are a special case of group A PfEMP1, having only 2
extracellular domains and an atypically short intron which appears to be without a
regulatory promoter. Theoretically, the type 3 PfEMP1 subfamily makes an excellent
vaccine candidate as type 3 PfEMP1 are highly conserved. However, though most or
many P. falciparum strains encode a type 3 var gene, and most field isolates show
type 3 var gene expression (chapter 5), there is no evidence that they are expressed
on the infected erythrocyte surface, or that their expression is essential, and as such a
vaccine might not be effective. Furthermore, the surprising observation of greater
diversity of type 3 var gene expression in hyperparasitaemia isolates compared to
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cerebral malaria isolates suggests that these atypical group A PfEMP1 may not be
commonly involved in severe disease pathogenesis (chapter 5).
At present the only PfEMP1 which shows potential as a vaccine target is VAR2CSA
specifically in the context of placental malaria, as discussed in chapter 4. There is a
strong association between var2csa transcription and placental malaria field isolates
(chapter 4, and e.g.(Tuikue Ndam et al. 2005; Duffy et al. 2006a). In addition,
VAR2CSA has affinity for CSA, which is associated with placental sequestration
(Fried and Duffy 1996; Reeder et al. 2000; Muthusamy et al. 2007). The rise in anti-
VAR2CSA antibodies, which coincides with protection from placental malaria upon
subsequent pregnancies (Salanti et al. 2004; Tuikue Ndam et al. 2006), suggests a
VAR2CSA vaccine could effectively mimic this natural immunity. Not all peptide
stretches of VAR2CSA are targets of natural antibodies (Dahlback et al. 2006), and
so high sequence homology appears to be insufficient to ensure an protective
antibody response. A motif EIEKD within a variable region (V2) was noted by
Dahlback et al. (2006) to be common in VAR2CSA from primigravidae and was
predicted to lie within a surface exposed loop, and thus provide a promising vaccine
target. The motif EIEKD is uncommon in multigravidae where GIEGE is found at
this position (Dahlback et al. 2006). Although this suggests EIEKD-VAR2CSA
variants may be more virulent or more efficient at sequestration and thus a good
vaccine target, loss of these variants may simply result in selection of GIEGE-
VAR2CSA variants and would not necessarily result in an overall decrease of
placental infection. As discussed in chapter 4, there still remains some sequence
diversity between var2csa homologues, and there is evidence of surprisingly low
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cross-reactivity between antibodies raised against different VAR2CSA
(e.g.(Bockhorst et al. 2007; Oleinikov et al. 2007). In addition, the contribution of
other PfEMP1 is unclear, and there is evidence of a high number of non–var2csa var
genes being transcribed at similar or higher frequency to var2csa (chapter 4).
Furthermore, other (non-PfEMP1) proteins have also been associated with placental
malaria (Francis et al. 2007). If VAR2CSA is not the only protein responsible for
placental sequestration, then the relative contributions of other proteins must also be
taken into account in order to determine the efficacy of an anti-VAR2CSA vaccine.
In addition to vaccines, drugs can also be used to target sequestration in malaria. At
present there are no drugs designed to directly target sequestration of P. falciparum-
infected erythrocytes. However, advances in the development of a drug to target
rosetting (curdlan sulfate, as described in chapter 6) are promising. The benefits of a
rosette-disrupting drug are that it is quick acting and may have an immediate effect
in reducing microvascular obstruction due to rosetting and help to relieve symptoms
of anaemia by releasing bound uninfected erythrocytes back into the circulation.
Curdlan sulfate could be administered to all patients with severe malaria disease in
Africa, where rosetting is associated with all forms of severe disease (Rowe et al.
1995; Rowe 2005), and so patients would not require expensive or time-consuming
tests to assess rosette frequency before drug administration. As many parasite
isolates do not rosette, there may be little pressure for drug resistance to develop
against this anti-rosetting drug, as is seen with more conventional antimalarials,
which aim to eradicate the parasite. Thus drug resistance to curdlan sulfate may be
slow to build up in a population. The effect of curdlan sulfate on other
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glycosaminoglycan interactions, such as sequestration to CSA in placental malaria, is
at present unknown, and would be an interesting follow-up study. There is also
recent evidence that CSA is involved in ookinete invasion in the anopheles mosquito
(Dinglasan et al. 2007). In addition to disrupting placental sequestration via CSA,
this may provide another opportunity for any drugs which can disrupt CSA-binding,
whether developed from the VAR2CSA/placental malaria perspective, or from
research on CSA/proteoglycans and rosetting.
The links between conserved PfEMP1 and clinical disease are not independent.
Interactions between the major associations discussed above can be represented in a
network of relationships between PfEMP1 group and clinical disease (Fig. 7.1). This
highlights the connections between various factors associated with severe/cerebral
clinical disease and group A PfEMP1, such as “commonness”, rosetting and
multiple-binding phenotypes, as distinct from factors associated with non-severe
clinical disease/hyperparasitaemia, such as CD36-binding and group B or C
PfEMP1. VAR2CSA, CSA-binding and placental malaria form a separate triangle,
with a possible link to group A PfEMP1 due to DBLγ domain interactions. The
possible therapeutic interventions with curdlan sulfate are also indicated in Fig. 7.1.
These include rosette inhibition, a general role in severe malaria treatment for
example through other roles such as merozoite inhibition (Havlik et al. 1994; Evans
et al. 1998), and the possibility of inhibition of other interactions such as CSA-
binding, as discussed in chapter 6. The putative link between type 3 PfEMP1 and
non-severe malaria/hyperparasitaemia discussed in chapter 5 is also included.
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Fig. 7.1. Relationships between PfEMP1 group and clinical disease. Positive
associations between factors associated with severe or clinical disease and group A
PfEMP1 (red), between non-severe clinical disease/hyperparasitaemia and group B
or C PfEMP1 (blue), between VAR2CSA, CSA binding and placental malaria
(green) and possible therapeutic interventions with curdlan sulfate (purple) are
indicated. Dotted lines show negative associations. Bold arrows between group A
PfEMP1 and severe/cerebral malaria, between group B/C PfEMP1 and non-severe
malaria, between VAR2CSA and placental malaria and between type 3 PfEMP1
(orange) and non-severe malaria, and the bold line between curdlan sulfate and



































This network highlights the associations between multiple factors and raises
questions about intervention strategies. For example, does knocking out a bridging
point between group A PfEMP1 and severe malaria (such as rosetting or other
binding phenotypes) reduce the strength of the link between group A PfEMP1
expression and severe disease?
In conclusion, the data presented in this thesis demonstrate significant relationships
between var gene/PfEMP1 expression and clinical outcome in P. falciparum malaria
disease pathogenesis. Research on malaria is highly multidisciplinary, and benefits
from all areas of research working collectively towards the common goal of malaria
disease control and eradication. This work highlights the need for continued research
on var gene/PfEMP1 expression involvement in clinical disease in the effort to
reduce the severity of complications due to P. falciparum infection, in the fight
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Appendix 1. Table of Mali childhood malaria field isolate details
Data on the 26 Mali isolates for clinical disease manifestation, age, parasitaemia,
rosette frequency, platelet-mediated clumping and multiplicity of infection is given,
along with percentage of DBLα transcripts detected that were of the DBLα1-type
(discussed in chapter 3), and the estimated number of type 3 transcripts present
(discussed in chapter 5).
Appendix 2. Phylogenetic network of DBLα  transcripts in Mali
childhood field isolates (discussed in chapter 3)
A phylogenetic network was created by Dr Graham Stone (University of Edinburgh)
to replace the phenogram of childhood isolate DBLα domain transcripts (chapter 3,
Fig. 3.13). The network was produced from an initial Clustal W alignment of the
amino acid sequences, converted to a nucleotide alignment. The network and
phenogram both show separation of sequences into two clades, signifying DBLα1
versus DBLα0-like sequences. Sequences from the cerebral malaria patients (red in
network; appendix 2) are significantly concentrated into a ‘cerebral malaria clade’
(P<0.001, chi-squared test). Sequences from the hyperparasitaemia patients (blue)
are significantly concentrated in a ‘hyperparasitaemia clade’ (P<0.025, Chi-squared
test). Sequences from the uncomplicated malaria patients (green) showed no bias in
distribution between the two main clades of the network.
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1: Arising from the work presented in chapter 3
Title: Differential var gene transcription in Plasmodium falciparum isolates from
patients with cerebral malaria compared to hyperparasitaemia.
Authors: Helen M. Kyriacou, Graham N. Stone, Richard J. Challis, Ahmed Raza,
Kirsten E. Lyke, Mahamadou A. Thera, Abdoulaye K. Koné, Ogobara K. Doumbo,
Christopher V. Plowe and J. Alexandra Rowe.
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Publisher: Elsevier
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CM1 Cerebral 28 6.0 19 0 1 83.3 1
CM2 Cerebral 15 9.2 28 0 3 78.6 1
CM3 Cerebral 27 15.0 20 5 3 92.9 1
CM4 Cerebral 79 13.0 22 0 5 5.9 1
CM5 Cerebral 52 10.0 96 0 1 72.2 1
CM6 Cerebral 15 24.0 64 8 3 100.0 1
CM7 Cerebral 28 7.4 20 0 1 100.0 2
CM8 Cerebral 18 20.0 0 53 1 94.7 1
CM9 Cerebral 55 6.0 41 0 2 100.0 0
HYP1 Hyperp 49 18.5 0 0 4 0.0 4
HYP2 Hyperp 51 12.0 16 0 3 6.7 3
HYP3 Hyperp 15 10.0 4 13 1 27.8 1
HYP4 Hyperp 64 11.4 20 0 2 100.0 2
HYP5 Hyperp 39 15.0 15 0 3 40.0 3
HYP6 Hyperp 52 12.0 20 0 3 25.0 3
HYP7 Hyperp 20 11.4 0 0 3 6.3 3
HYP8 Hyperp 50 5.0 0 ND 2 0.0 2
U1 Uncomp 27 5.4 14 0 4 60.0 4
U2 Uncomp 25 3.8 8 0 3 6.7 3
U3 Uncomp 39 5.6 8 0 3 100.0 3
U4 Uncomp 36 3.0 21 0 3 5.6 3
U5 Uncomp 15 1.2 2 0 3 73.7 3
U6 Uncomp 39 3.2 23 ND 1 100.0 1
U7 Uncomp 49 3.0 0 0 3 6.7 3
U8 Uncomp 102 2.8 0 ND 1 5.3 1
U9 Uncomp 80 1.6 0 0 1 83.3 1
Appendix 1: Table showing isolate name, clinical disease manifestation, age (mo:
months), parasitaemia (Pt, %), rosette frequency (RF, %) platelet-mediated clumping
(PMC, %), multiplicity of infection (genotypes), percentage of amplified DBLα
transcripts that were of the DBLα1-type (DBLα1%), and the estimated number of
type 3 transcripts present (type 3 transcripts) for the 26 Mali childhood malaria
isolates discussed throughout the thesis.
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Appendix 2. Phylogenetic network produced by Dr Graham Stone from a Clustal W
alignment of Mali isolate DBLα  domain transcripts described in chapter 3.
Relationships between var gene DBLα sequence tags transcribed by P. falciparum
isolates, generated using Neighbour-Net (Bryant and Moulton 2004). Sequences
transcribed by isolates from African children with cerebral malaria (CM, red),
hyperparasitaemia (HYP, blue), and uncomplicated malaria (U, green) are compared
to a selection of var genes from the laboratory clone 3D7.  For the 3D7 genes, the
gene name is preceded by A, B, C, BA or BC to indicate the group to which the gene
belongs. The sequences fall into 2 major clades, with the DBLα0-like sequences to
the left of the dotted line and the DBLα1-like sequences to the right. For the
predominant gene from 9 of the Malian isolates, the var gene upstream region was
determined by PCR and is indicated as a boxed letter.
